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Targeted  drug  delivery  to  solid  tumors  aims  to  increase  the  accumulation  of  
drug  at  the  site  of  disease  while  limiting  accumulation  in  healthy  tissues.  Thus,  targeted  
delivery  serves  to  enhance  therapeutic  efficacy  while  minimizing  off-­‐‑target  side  effects.  
Targeting  drug  to  the  site  of  disease  is  especially  important  for  many  current  anti-­‐‑cancer  
therapeutics  whose  cytotoxic  effects  are  not  exclusive  to  cancer  cells.  Drug  carriers  can  
improve  tumor  targeting  of  drug  cargo  by  either  passive  or  active  mechanisms.  Passive  
targeting  of  drug  carriers  occurs  by  the  enhanced  permeability  and  retention  effect,  
whereby  long  circulating  drug  carriers  can  accumulate  in  the  tumor  by  extravasation  
from  the  tumor’s  leaky  vasculature  and  be  retained  in  the  tumor  due  to  the  lack  of  an  
organized  tumor  lymphatic  system.  Alternatively,  active  targeting  can  improve  drug  
delivery  to  the  tumor  by  means  of  functionalizing  a  drug  carrier  such  that  it  interacts  
specifically  with  the  tumor  tissue.  Traditionally,  actively  targeted  drug  carriers  rely  on  
intrinsic  features  of  the  tumor  such  as  upregulated  cell  receptors,  overexpressed  
extracellular  enzymes,  or  depressed  tissue  pH.  These  intrinsic  targets,  however,  are  
heterogeneous  across  cancer  classes  and  between  patients  with  a  single  tumor  type.  
Therefore  traditional  active  targeting  cannot  be  applied  to  a  breadth  of  cancers  or  
patients  without  prior  knowledge  of  the  cancer  phenotype.  
    
v  
Active  targeting  can  alternatively  be  achieved  by  an  extrinsic  trigger,  
independent  of  the  characteristics  of  the  tumor.  This  approach  could  thereby  achieve  
targeted  drug  delivery  in  a  breadth  of  tumor  types  and  cancer  patients.  This  dissertation  
describes  one  such  approach  that  exploits  cell-­‐‑penetrating  peptides  (CPPs)  to  achieve  
receptor-­‐‑independent  and  non-­‐‑specific  uptake  in  a  variety  of  cancer  cells.  The  function  
of  this  non-­‐‑specific  CPP  is  controlled  by  an  extrinsic  trigger  by  means  of  the  modulation  
of  its  local  interfacial  density  with  temperature-­‐‑triggered  micelle  assembly.  Elastin-­‐‑like  
polypeptide  diblock  copolymers  (ELPBCs)  were  used  as  the  drug  carrier  platform,  as  
their  lower  critical  solution  temperature  phase  transition  behavior  permits  their  
controlled  self-­‐‑assembly  from  unimer  to  micelle  in  response  to  a  thermal  stimulus.  CPP-­‐‑
ELPBCs  were  recombinantly  synthesized  in  E.  coli  with  CPP-­‐‑functionalization  at  their  
hydrophilic  terminus,  such  that  temperature-­‐‑triggered  micelle  assembly  would  result  in  
the  decoration  of  CPP  on  the  micelle  corona.  The  CPP-­‐‑ELPBC  design  was  carefully  
optimized  to  permit  micelle  self-­‐‑assembly  in  response  to  the  clinically  relevant  trigger  of  
mild  hyperthermia.  
Temperature-­‐‑triggered  micelle  assembly  of  CPP-­‐‑ELPBCs  achieved  controlled  
cellular  uptake  in  vitro  by  means  of  their  CPP  density  modulation,  such  that  cellular  
uptake  was  minimized  at  physiologic  temperature  and  was  greatly  enhanced  at  
conditions  of  mild  hyperthermia.  This  effect  was  achieved  in  multiple  cell  lines,  albeit  
with  variable  magnitude.  Controlled  uptake  of  the  CPP-­‐‑ELPBC  carrier  could  control  the  
    
vi  
intracellular  delivery  of  appended  drug  cargo.  This  controlled  intracellular  delivery  was  
translated  to  controlled  therapeutic  effect  when  the  CPP-­‐‑ELPBC  was  genetically  
appended  to  a  proapoptotic  peptide  drug  cargo.  These  drug-­‐‑loaded  CPP-­‐‑ELPBCs  
achieved  controlled  cytotoxicity  in  cancer  cells,  whereby  significant  cell  death  was  
induced  at  conditions  of  mild  hyperthermia,  but  cells  at  physiologic  temperature  were  
spared.    
For  use  as  targeted  drug  carriers  in  vivo,  CPP-­‐‑ELPBCs  would  be  systemically  
administered  and  circulate  throughout  the  body  in  their  soluble  state.  It  would  only  be  
at  the  site  of  the  solid  tumor  that  local  mild  hyperthermia  would  be  applied  and  induce  
the  self-­‐‑assembly  of  CPP-­‐‑ELPBC  micelles  that  could  induce  internalization  into  cancer  
cells.  Translation  of  CPP-­‐‑ELPBC  function  from  in  vitro  to  in  vivo  environments  proved  to  
be  quite  challenging.  Issues  such  as  perturbation  of  temperature-­‐‑triggered  assembly  in  
serum  and  interference  of  CPP-­‐‑ELPBC  internalization  by  serum  proteins  likely  played  a  
role  in  preventing  the  extrinsically  targeted  accumulation  of  CPP-­‐‑ELPBCs  in  
hyperthermia  treated  tumors,  as  investigated  by  intravital  tumor  microscopy  and  
biodistribution  studies.  Further  optimization  of  the  CPP-­‐‑ELPBC  platform  is  thus  required  
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Figure  27:  Alexa  Fluor  488  labeling  at  the  N-­‐‑terminal  cysteine  abolished  micelle  
assembly  of  second  generation  Arg5-­‐‑ELPBC.  Temperature-­‐‑regulated  turbidimetry  
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construct  at  approximate  45  °C.  Temperature-­‐‑regulated  turbidimetry  measurement  was  
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micelle  assembly  as  evident  by  temperature-­‐‑regulated  turbidimetry.  Attachment  of  
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Figure  30:  Second  generation  Arg5-­‐‑ELPBC  achieved  mild  hyperthermia-­‐‑controlled  cellular  
uptake,  as  visualized  by  live  cell  fluorescence  microscopy.  Minimal  cellular  uptake  was  
seen  for  all  constructs  at  the  “off”  state  of  37  °C  (A-­‐‑C).  Enhanced  cellular  uptake  at  42  °C  
was  seen  for  Arg5-­‐‑ELPBC  (D),  but  not  for  controls  ELPBC  (E)  or  Arg5-­‐‑ELP  (F).  Green—ELP;  
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uptake,  as  quantified  by  live  cell  flow  cytometry.  Only  Arg5-­‐‑ELPBC  demonstrated  an  
enhanced  cellular  uptake,  as  measured  by  cellular  fluorescence,  at  42  °C  as  compared  to  
37  °C  at  10  µμM  ELP  (A),  achieving  a  4-­‐‑fold  increase  in  uptake  between  thermal  
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SF-­‐‑media,  for  Arg5-­‐‑ELPBC  at  42  °C.  Uptake  of  Arg5-­‐‑ELPBC  at  37  °C  or  ELPBC  at  either  
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ELPBC  at  25  °C.  ...........................................................................................................................  103	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visualized  by  live  cell  fluorescence  microscopy.  Minimal  cellular  uptake  was  observed  
for  all  constructs  at  the  “off”  condition  of  37  °C  (A-­‐‑C).  Only  Arg5-­‐‑ELPBC  exhibited  
enhanced  cellular  uptake  at  the  “on”  state  of  42  °C  (D)  while  the  cellular  uptake  of  non-­‐‑
functionalized  ELPBC  (E)  and  soluble  Arg5-­‐‑ELP  (F)  remained  unchanged.  The  
internalized  Arg5-­‐‑ELPBC  localized  to  the  perinuclear  space  (D,  box).  Green—ELP;  red—
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and  Arg5-­‐‑ELP  (C)  showed  slight  increase  in  cellular  fluorescence  when  treated  with  non-­‐‑
enzymatic  dissociator.  Cells  treated  with  Arg5-­‐‑ELP  and  trypsin  at  37  °C  were  not  
measured  (NM).  Flow  cytometry  measurements  from  each  ELP  treatment  were  
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increase  in  cellular  fluorescence  (A)  and  increasing  the  incubation  volume  enhanced  the  
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Figure  36:  Fold  increase  in  cellular  uptake  of  Arg5-­‐‑ELPBC  was  maximized  within  the  time  
scale  of  mild  clinical  hyperthermia.  Cellular  uptake,  as  quantified  by  flow  cytometry,  of  
Arg5-­‐‑ELPBC  (A),  ELPBC  (B),  and  Arg5-­‐‑ELP  (C)  increased  over  the  course  of  1  hour,  but  
only  Arg5-­‐‑ELPBC  exhibited  an  enhanced  rate  of  uptake  at  42  °C,  maximizing  the  fold  
increase  in  uptake  at  42  °C,  as  compared  to  37  °C,  within  1  hour.  Reproduced  from  [149].
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MCF7  breast  cancer  cells,  and  primary  endothelial  HUVEC  cells  confirmed  that  
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uptake,  however,  was  cell-­‐‑dependent  and  greatest  for  cancer  cells.  Reproduced  from  
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Figure  38:  TAT-­‐‑ELPBC  achieved  enhanced  cellular  uptake  at  both  thermal  conditions,  as  
compared  to  Arg5-­‐‑ELPBC.  TAT-­‐‑ELPBC  achieved  greater  uptake  at  37  °C  (B),  as  compared  
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was  greatly  enhanced  for  TAT-­‐‑ELPBC  (E),  as  compared  to  Arg5-­‐‑ELPBC  (B).  Visualized  
uptake  was  confirmed  by  flow  cytometry  at  37  °C  and  42  °C  (C  and  F).  Green—ELP;  
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“off”  and  “on”  conditions,  as  visualized  by  fluorescence  microscopy.  HeLa  cells  were  
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compared  to  37  °C,  while  the  non-­‐‑functionalized  ELPBC  showed  no  difference  in  uptake  
between  thermal  conditions  (A).  *Indicates  p  <  0.01  between  thermal  conditions  (two-­‐‑
way  ANOVA,  Bonferroni  posthoc  test  for  multiple  comparisons).  Fold  increase  in  
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cellular  uptake  that  was  dependent  on  CPP  functionalization  (B).  *Indicated  p  <  0.0125  
versus  ELPBC  control  (ANOVA,  Bonferroni  posthoc  test  for  multiple  comparisons).  Flow  
cytometry  data  represents  mean  of  3  measurements  ±  SEM.  Reproduced  from  [152].  ..  121	  
Figure  41:  Inhibition  of  endocytosis  pathways  suggested  the  role  of  macropinocytosis  in  
the  uptake  of  second  generation  Arg5-­‐‑ELPBC.  Changes  in  uptake  of  Arg5-­‐‑ELPBC  at  42  °C  
were  visualized  with  fluorescence  microscopy  (A)  and  quantified  by  flow  cytometry  (B).  
Decreased  uptake  in  the  presence  of  amiloride,  but  not  chlorpromazine  or  filipin,  
suggested  macropinocytosis  was  the  major  pathway  of  Arg5-­‐‑ELPBC  uptake.  However,  
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and  caveolae-­‐‑mediated  endocytosis  in  the  uptake  of  third  generation  Arg5-­‐‑ELPBC.  
Cellular  uptake  of  Arg5-­‐‑ELPBC  at  42  °C,  as  measured  by  cellular  fluorescence,  
significantly  decreased  with  genistein  or  amiloride  treatment,  but  not  with  
dansylcadaverine  treatment  (A).  Fluorescence  microscopy  confirmed  that  cellular  
uptake  of  Arg5-­‐‑ELPBC  in  the  absence  of  inhibitor  (B)  was  largely  unperturbed  in  the  
presence  of  dansylcadaverine  (C),  but  greatly  decreased  in  the  presence  of  genistein  (D)  
or  amiloride  (E).  Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  scale  bars  25  µμm.  
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with  mild  hyperthermia  alone.  Absorbance  was  normalized  to  untreated  cells  incubated  
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Figure  45:  Gemcitabine  conjugation  increased  the  CMT  of  Arg8-­‐‑ELPBC.  Temperature-­‐‑
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greatest  fold  increase  in  cell  death  between  thermal  conditions.  Absorbance  was  
normalized  to  untreated  cells  at  37  °C.  Data  represents  mean  of  3  measurements  ±  SEM.
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ELPBC-­‐‑cBH3  (C),  Arg8-­‐‑ELPBC-­‐‑BH3  (D),  and  Arg8-­‐‑ELPBC-­‐‑RVRR  maintained  a  CMT  
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kDa,  where  furin  cleaves  at  the  C-­‐‑terminus  of  the  RVRR  linker  producing  the  fragment  
MGQVGRQLAIIGDDINRRYRVRR)  from  the  CPP-­‐‑ELPBC  (approximate  MW:  40  kDa,  
depending  on  CPP  functionalization)  (A).  CuCl2  staining  visualized  all  CPP-­‐‑ELPBCs  with  
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°C  were  spared.  Absorbance  was  normalized  to  untreated  cells  at  37  °C.  Data  represents  
mean  of  3  experiments  ±  SEM.  *Indicates  p  <  0.005  between  thermal  conditions  (two-­‐‑way  
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1. Background and motivation  
1.1 Cancer 
1.1.1 Morbidity, mortality, and cost to society 
Cancer  is  an  incredibly  diverse  disease  characterized  by  the  uncontrolled  
proliferation  of  abnormal  cells.  Although  cancer  can  manifest  in  a  variety  of  pathologies,  
cancer  cells  in  solid  tumors  are  generally  distinguished  from  normal  healthy  cells  due  to  
genetic  aberrations  that  can  change  their  rate  of  proliferation  and  capacity  for  excessive  
replication,  their  ability  to  recruit  vascularization  and  migrate  to  invade  other  tissues,  
and  their  evasion  of  cell  death  by  check  points  like  apoptosis  and  immunological  
monitoring  [1].  Furthermore,  cancer  is  manifest  from  abnormal  interaction  of  these  cells  
with  their  local  environment,  be  it  interactions  in  the  tissue  with  other  cell  types  or  
interaction  with  the  extracellular  matrix  [2].  These  aspects  of  the  cancer  cell,  in  
combination  with  their  abnormal  interaction  with  their  environment,  result  in  
malignancies  of  localized  primary  tumors  or  the  spread  of  metastasized  disease  
throughout  the  body.  
The  cause  of  many  cancers  may  not  be  precisely  defined,  but  a  variety  of  factors  
can  contribute  to  the  incidence  of  cancer  including  environmental  exposure  to  mutagens  
and  genetic  predisposition.  For  this  reason,  great  efforts  are  made  in  the  prevention  and  
screening  for  cancer,  as  well  as  the  development  of  effective  anti-­‐‑cancer  treatments.  
Although  many  cancers  are  similar  due  to  their  characteristics  caused  by  neoplasia,  the  
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variability  between  each  type  and  instance  of  cancer  has  made  this  a  particularly  
difficult  disease  to  treat.  Due  to  the  diversity  of  cancer  the  approaches  to  prevent,  
diagnose,  and  treat  tumors  must  often  be  tailored  to  each  classification  of  the  disease.  
Cancer  is  one  of  the  leading  causes  of  death  in  the  United  States  with  585,720  
individuals  expected  to  die  as  a  result  of  cancer  in  2014.  In  2012,  approximately  13.7  
million  living  individuals  in  the  United  States  had  been  diagnosed  with  cancer  in  their  
lifetimes,  with  1,665,540  new  cases  of  cancer  expected  to  be  diagnosed  in  the  year  2014.  
The  magnitude  of  this  disease  burden  leads  to  a  substantial  cost,  approximated  to  be  
$216.6  billion  for  the  United  States  in  2009  alone  [3].  The  morbidity,  mortality,  and  
extreme  cost  of  healthcare  to  prevent,  diagnose,  and  treat  cancer  have  made  this  disease  
target  a  major  topic  in  the  medical  research  community.  
1.1.2 Standards of cancer treatment 
Conventional  treatments  for  solid  tumors  include  surgical  resection,  radiation  
therapy,  chemotherapy,  or  some  combination  thereof.  Surgery  to  remove  abnormal  
tissue  has  remained  a  prominent  approach  in  cancer  therapy  for  hundreds  of  years.  
Physical  removal  of  the  cancer  can  provide  relief  of  the  noxious  effects  of  the  tumor  and  
prevent  spread  of  the  disease,  provided  that  no  cancer  cells  are  left  behind  whose  
continued  growth  can  lead  to  a  repopulation  of  the  tumor.  Surgery  is  a  feasible  option  
only  in  tumors  deemed  resectable,  that  is,  tumors  that  are  well  localized  in  the  body,  not  
excessively  infiltrating  their  surrounding  tissue,  and  not  adjacent  to  critical  tissues  or  
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organs.  These  factors,  for  instance,  limit  the  ability  to  surgically  remove  tumors  that  
have  spread  widely  throughout  the  body,  although  some  measures  can  be  taken  to  
remove  migrating  cancer  cells  from  areas  such  as  proximal  lymph  nodes.  Additionally,  
there  is  a  limited  feasibility,  or  increased  complexity,  of  removing  tumors  in  some  
critical  organs,  for  example  the  brain,  where  surgical  resection  must  be  balanced  with  
the  risk  of  altering  critical  biological  functions.  Furthermore,  surgical  resection  is  limited  
by  the  realistic  risk  associated  with  residual  tumor  margins,  whereby  cancer  cells  left  
behind  after  surgery  can  lead  to  relapse  of  disease.  Thus,  surgery  must  often  be  paired  
with  orthogonal  treatments  to  address  those  cancers  cells  that  may  be  left  behind.  
Radiation  therapy  is  an  alternative  means  of  eliminating  large  populations  of  
cancer  cells.  Exposure  of  cancer  cells  to  x-­‐‑rays  or  gamma  rays  can  induce  DNA  damage  
that  will  lead  to  cell  death.  Radiation  can  be  applied  from  external  sources,  such  as  
focused  x-­‐‑ray  beams,  or  from  internal  sources,  such  as  implanted  materials  impregnated  
with  radioactive  isotopes  known  as  brachytherapy  seeds.  There  is  some  preferential  
killing  of  cancer  cells  with  radiation  therapy  as  their  vulnerability  to  DNA  damage-­‐‑
induced  cell  death  is  enhanced  due  to  their  accelerated  division,  as  compared  to  most  
healthy  cells  [4].  However,  there  are  aspects  of  the  tumor  environment,  such  as  hypoxia,  
that  can  lead  to  radiation  resistance  in  cancer  cells  [5].  The  cytotoxic  effects  of  radiation  
are  not  specific  to  cancer  cells,  however,  and  therefore  normal  healthy  cells  surrounding  
the  tumor  are  susceptible  to  damage  from  extraneous  radiation.  Therefore  radiation  is  
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often  administered  in  fractionated  doses,  to  allow  repair  of  radiation-­‐‑induced  damage  in  
normal  tissue,  and  with  local  precision  directed  by  tumor  imaging  for  planning  of  either  
external  beam  irradiation  or  surgical  placement  of  brachytherapy  seeds.  
Chemotherapy  is  a  third  common  approach  in  eliminating  tumors  by  inducing  
cancer  cell  death.  This  therapeutic  method  has  the  advantage  of  an  ease  of  
administration,  as  compared  to  surgical  intervention  or  radiation  therapy,  as  
chemotherapeutics  can  often  be  delivered  systemically  by  intravenous  or  oral  dosing.  
There  are  many  types  of  chemotherapy  drugs,  which  can  be  classified  by  the  means  in  
which  they  induce  cell  death,  often  by  their  interaction  with  DNA  and  their  interference  
with  cellular  machinery  critical  to  cell  division.  These  drugs  can  achieve  a  degree  of  
apparent  therapeutic  targeting  in  the  tumor  as  their  action  is  usually  amplified  in  cancer  
cells  due  to  their  rapid  turnover,  as  compared  to  many  normal  healthy  cells.  However,  
the  cytotoxicity  of  most  of  these  chemotherapeutics  is  not  completely  restricted  to  cancer  
cells.  Even  novel  targeted  agents,  such  as  those  directed  at  HER2  and  EGFR,  induce  off-­‐‑
target  effects  including  dermatologic  and  cardiac  toxicities,  respectively  [6].  Therefore  
systemic  administration  of  these  drugs  comes  at  the  risk  of  off-­‐‑target  toxicity  that  limits  
the  application  of  chemotherapeutics,  as  their  use  must  balance  anti-­‐‑tumor  efficacy  with  
dose-­‐‑limiting  side  effects.    
Although  not  considered  a  primary  treatment  for  anti-­‐‑cancer  therapy  in  the  
United  States,  the  application  of  heat  can  be  used  as  a  tool  to  improve  outcomes  in  
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combination  with  orthogonal  treatments.  In  the  context  of  oncology  heat  may  be  applied  
at  extreme  temperatures  to  ablate  tumors,  thereby  eliminating  large  numbers  of  cancer  
cells.  This  technique,  for  example,  has  been  used  to  locally  treat  liver  metastases  from  
breast  cancers  [7].  Alternatively,  a  much  milder  application  of  heat,  just  slightly  above  
body  temperature,  can  be  used  to  treat  the  whole  body,  defined  regions  of  the  body,  or  
specific  targets  in  the  body,  like  solid  tumors.  Mild  hyperthermia  of  solid  tumors  
typically  involves  heating  to  approximately  40-­‐‑44  °C  [8].  Localized  mild  hyperthermia  is  
achieved  in  the  clinic  with  externally  focused  microwaves,  radiofrequency,  or  
ultrasound  [9-­‐‑11]  applied  in  a  variety  of  tumor  sites  [12].    Mild  hyperthermia  can  be  
effectively  contained  within  tumors  without  significant  spillover  into  adjacent  normal  
tissue  because  tumors  are  poor  heat  exchangers  compared  to  normal  tissues.  The  
disorganized  vasculature  and  recirculating  blood  flow  cause  heat  to  be  further  retained  
within  the  tumor  mass  [13].  A  typical  session  of  mild  hyperthermia  may  involve  1  hour  
of  treatment  in  which  the  tumor  tissue  is  maintained  at  approximately  42  °C  [14],  
resulting  in  minimal  side  effects  that  are  generally  well  tolerated  by  patients  [15-­‐‑17].  
Application  of  mild  hyperthermia  is  most  feasible  for  surface  tumors,  easily  
accessible  to  heating  methods.  Treatment  of  breast  cancer  recurrence  on  the  chest  wall  
[18]  and  melanoma  [19]  are  examples  of  superficial  targets  in  which  hyperthermia  is  
combined  with  radiation  therapy.  However,  success  has  also  been  achieved  with  
regional  heating  of  internal  tumors  including  retroperitoneal  soft-­‐‑tissue  sarcomas  (in  
    6  
combination  with  chemotherapy)  [20],  cervical  cancers  (in  combination  with  radiation  
therapy)  [21],  and  internal,  albeit  superficial,  bladder  carcinomas  (in  combination  with  
chemotherapy)  [22].  
In  contrast  to  the  high  temperatures  utilized  for  destruction  of  tumors  by  thermal  
ablation,  mild  hyperthermia  in  itself  is  not  considered  to  be  cytotoxic,  however  it  has  
been  proven  useful  as  an  adjuvant  therapy  to  improve  the  efficacy  of  other  anti-­‐‑cancer  
treatments  such  as  radiation  and  chemotherapy  [9,  11,  23].    Effects  of  mild  clinical  
hyperthermia  that  may  synergize  the  action  of  other  treatment  modalities  may  include  
increased  blood  flow  [24],  increased  cellular  uptake  [25],  and  decreased  cellular  repair  of  
therapy-­‐‑induced  toxicities  [26].  Furthermore,  for  novel  therapeutics  delivered  by  drug  
carriers,  hyperthermia  may  improve  delivery  by  enhanced  extravasation  of  
nanoparticles  in  heated  tumors  by  means  of  increased  tumor  vascular  pore  cutoff  size  
[27].  Tumor  heating  at  42  °C  for  1  hour  has  been  shown  to  specifically  increase  the  pore  
size  in  tumor  vasculature  to  allow  extravasation  of  400  nm  liposomes  from  tumor  
vessels  that  would  otherwise  exclude  extravasation  of  liposomes  greater  than  100  nm  at  
physiologic  conditions  [28].  Heating  appears  to  create  a  prolonged  effect  on  vascular  
permeability  lasting  6-­‐‑8  hours  after  treatment  [27,  29],  suggesting  its  applicability  
toward  long  circulating  drug  carriers  that  can  accumulate  in  the  tumor  by  means  of  this  
temporary  enhanced  permeability  and  retention  effect.  
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Finally,  hyperthermia  can  be  used  not  only  as  an  adjuvant  therapy,  but  also  as  a  
trigger  to  influence  the  delivery  of  stimulus-­‐‑responsive  drug  carriers  and  their  cargo.  
Local  heat  at  the  site  of  cancer  can  influence  aggregation  of  drug  carriers  to  enhance  
accumulation  in  the  tumor  [30,  31],  or  alternatively,  local  heat  can  influence  the  stability  
of  drug  carriers  to  trigger  drug  release  only  in  the  tumor  [32-­‐‑34].  Local  heat  can  thereby  
provide  advantages  by  manipulating  the  drug  carrier  for  improved  drug  targeting  and  
confer  its  advantageous  effects  on  the  tumor  physiology  that  may  improve  efficacy  of  
the  delivered  drug  cargo.  
1.2 Systemically delivered tumor-targeted drug carriers 
1.2.1 Passive targeting 
Advances  in  the  systemic  delivery  of  anti-­‐‑cancer  therapeutics  to  solid  tumors  
have  aimed  to  increase  the  accumulation  of  drug  at  the  disease  site  while  limiting  the  
accumulation  in  healthy  tissues.  This  is  of  particular  importance  when  delivering  
cytotoxic  anti-­‐‑cancer  drugs  whose  therapeutic  action  culminates  in  cell  death.  Exposure  
of  healthy  tissues  to  these  drugs  can  result  in  toxic  side  effects  that  limit  drug  dosage  
and  thus  compromise  therapeutic  efficacy.  Improving  the  specificity  with  which  the  
drug  can  reach  the  tumor  allows  the  delivery  of  increased  drug  dose  while  minimizing  
side  effects  to  achieve  improved  outcomes  of  treatment.  Delivering  therapeutics  by  
means  of  drug  carriers  can  serve  to  achieve  these  goals  by  manipulating  the  
pharmacokinetics  and  biodistribution  of  the  drug  cargo.  
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Systemic  delivery  of  anti-­‐‑cancer  therapeutics  provides  an  ease  of  administration,  
as  compared  to  local  delivery  at  the  site  of  disease,  but  presents  the  challenge  of  
directing  drug  to  the  tumor  while  preventing  its  accumulation  in  off-­‐‑target  tissues.  
Inherent  characteristics  of  many  cancers  are  proposed  to  achieve  passive  tumor  
targeting  by  accumulation  via  the  enhanced  permeability  and  retention  (EPR)  effect.  The  
abnormal  vasculature  produced  by  the  rapid  angiogenesis  accompanying  tumor  growth  
often  exhibits  an  enhanced  permeability,  such  that  the  leakiness  of  these  vessels  permits  
the  extravasation  of  drug  carriers  into  the  tumor  tissue  [35].  Normal  vasculature,  
however,  exhibits  tight  endothelial  junctions,  which  prevent  this  extravasation  in  
healthy  tissues.  Furthermore,  the  lack  of  well-­‐‑organized  lymphatics  in  the  tumor  tissue  
prevents  the  clearance  of  drug  carriers  once  they  have  accumulated  in  the  extravascular  
space  of  the  tumor.  This  lack  of  clearance  thus  permits  the  retention  of  drug  carriers  at  
the  disease  site.  
The  permeability  of  tumor  vasculature  results  from  the  creation  of  pores  due  to  
the  aberrant  architecture  of  the  tumor  vessels.  It  is  therefore  important  to  consider  the  
size  of  the  tumor  vascular  pores,  in  relation  to  the  size  of  a  drug  carrier,  to  exploit  the  
EPR  phenomenon.  Pore  sizes  of  400-­‐‑600  nm,  for  example,  were  evaluated  in  a  human  
colon  adenocarcinoma  xenograft  in  mice,  which  allowed  the  accumulation  of  400  nm  
liposomes  in  the  tumor,  but  excluded  600  nm  liposomes  from  escaping  the  vasculature  
[36].  This  pore  size  is,  of  course,  heterogeneous  across  tumor  types,  but  a  range  of  380-­‐‑
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780  nm  pores  has  been  evaluated  in  many  tumors  [37].  If  relying  on  bigger  pore  size  to  
extravasate  larger  drug  carriers  it  is  important  to  consider  that  those  outliers  may  be  
present  only  infrequently  along  the  tumor  vasculature.  Thus  many  drug  carriers  exploit  
the  EPR  effect  at  size  ranges  well  below  the  pore  size.  
Prolonged  circulation  of  the  drug  carrier  is  an  important  factor  in  exploiting  the  
EPR  effect.  When  high  concentrations  of  the  drug  carrier  are  maintained  in  the  
circulation,  a  greater  accumulation  in  the  tumor  can  be  achieved  over  time,  whereas  
healthy  tissues  are  continually  spared  by  their  normal  vasculature.  Drug  carriers  whose  
size  exceeds  that  of  the  renal  filtration  cutoff,  while  staying  below  the  pore  size  of  tumor  
vasculature,  can  best  exploit  the  EPR  effect  to  passively  accumulate  in  the  tumor  tissue.  
As  such,  an  incredible  number  of  macromolecule  and  nanoparticle  drug  carriers  have  
been  designed  to  exploit  the  EPR  effect  as  a  primary  means  of  accumulation  in  the  
tumor.  However,  these  systems  often  take  for  granted  that  EPR  will  result  in  sufficient  
accumulation  in  the  tumor,  without  adequate  evaluation  of  this  outcome.  There  are  
factors  in  tumor  physiology  that  can  work  against  the  EPR  effect,  such  as  enhanced  
tumor  interstitial  fluid  pressure,  caused  also  by  the  leaky  tumor  vasculature.  Enhanced  
tumor  interstitial  fluid  pressure  leads  to  equal  fluid  pressure  between  the  vascular  and  
extravascular  space  of  the  tumor,  thus  providing  little  driving  force  for  extravasation  of  
drug  carrier  despite  the  presence  of  pores  in  the  tumor  vasculature.  The  propensity  of  
each  tumor  to  exhibit  the  EPR  effect  should  therefore  be  included  in  the  list  of  
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heterogeneous  features  of  tumor  physiology,  whereby  the  type,  size,  and  location  of  
tumors  can  be  expected  to  influence  the  effect  of  EPR  on  tumor-­‐‑targeted  accumulation  of  
drug  carriers  [38].  
1.2.2 Active targeting 
Alternative  to  passive  targeting  via  the  EPR  effect,  tumors  can  be  actively  
targeted  when  drug  carriers  are  functionalized  in  such  a  way  as  to  interact  specifically  
with  the  cancer  cells  or  tumor  tissue.  Traditional  active  targeting  relies  on  unique  
aspects  of  the  tumor  that  are  upregulated  as  compared  to  normal  healthy  tissues.  These  
intrinsic  tumor  targets  are  most  often  upregulated  cell  receptors,  overexpressed  
enzymes,  or  depressed  pH  in  the  tumor  tissue.  Increased  tumor  accumulation  may  not  
be  the  ultimate  measure  of  success  for  actively  targeted  drug  carriers,  particularly  if  
their  accumulation  is  dominated  by  the  EPR  effect.  However,  their  specific  interaction  
with  the  tumor  may  cause  other  advantages  such  as  prolonged  retention  at  the  site  of  
disease  or  internalization  of  drug  into  the  targeted  cancer  cells.  
Active  targeting  requires  both  a  valid  target  specific  to  the  tumor  and  a  means  of  
interacting  with  high  specificity  to  that  target.  Antibody-­‐‑functionalization  is  one  
approach  to  active  targeting  where  the  antibody  provides  highly  specific  recognition  of  
its  binding  partner,  typically  a  receptor  that  is  upregulated  on  the  cancer  cell.  HER2,  
upregulated  on  some  breast  cancer  cells  [39],  and  transferrin  [40],  upregulated  on  a  
variety  of  cancer  cells,  are  two  examples  of  cell  surface  receptors  targeted  by  antibodies  
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or  antibody-­‐‑functionalized  carriers.  Ligand  binding  is  an  alternative  approach  to  achieve  
specific  interactions  between  drug  carrier  and  cancer  cells.  For  example,  
functionalization  of  nanoparticles  with  transferrin  can  selectively  interact  with  cancer  
cells  overexpressing  the  transferrin  receptor  [41].  As  an  additional  example,  
functionalization  of  nanoparticles  with  small  molecule  substrates  can  be  recognized  
specifically  by  cell  surface  enzymes  upregulated  on  the  cancer  cell,  such  as  PSMA  on  
prostate  cancer  cells  [42].  Finally,  tissue-­‐‑specific  features  can  be  utilized  to  target  
accumulation  of  drug  in  the  tumor,  often  by  exploiting  features  of  overexpressed  
enzymes  and  depressed  tumor  pH.  These  unique  features  of  the  tumor  are  often  used  to  
induce  a  change  in  the  drug  carrier  that  can  improve  drug  accumulation  or  distribution  
in  the  tumor.  Release  of  small  molecule  drugs  from  macromolecular  carriers  via  
enzyme-­‐‑degradable  linkers  [43,  44],  or  disassembly  and  drug  release  from  ionizable  
nanoparticles  in  the  low  tumor  pH  [45,  46]  are  both  mechanisms  of  active  targeting  that  
serve  to  increase  drug  accumulation  in  the  tumor  while  encouraging  distribution  of  
small  drug  molecules  throughout  the  tumor.  
As  an  alternative  to  targeting  intrinsic  features  of  the  tumor,  active  targeting  can  
also  be  achieved  by  stimulus-­‐‑responsive  drug  carriers  that  are  controlled  by  extrinsic  
triggers.  Provided  these  external  stimuli  can  be  applied  with  local  precision  at  the  site  of  
the  tumor,  these  alternative  means  of  targeting  can  improve  delivery  of  drug  carriers  to  
tumors  without  prior  knowledge  of  the  tumor  phenotype.  Heat  is  an  external  trigger  
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that  can  be  used  to  induce  tumor  accumulation  of  drug  carriers  that  exhibit  lower  critical  
solution  temperature  phase  transition  behavior.  Drug  carriers  that  aggregate  in  response  
to  an  increase  in  temperature  can  be  accumulated  in  the  vasculature  of  heated  tumors.  
When  the  heat  is  removed  the  resolubilization  of  drug  carriers  in  the  vasculature  creates  
a  concentration  gradient  that  drives  the  carrier  into  the  extravascular  tumor  space  [30,  
31].  Alternatively,  interaction  of  a  drug  carrier  with  cancer  cells  can  be  controlled  by  
extrinsic  triggers  such  as  light.  Light-­‐‑labile  molecules  on  a  nanoparticle  can  be  released  
in  response  to  UV  illumination,  revealing  active  targeting  moieties  on  the  nanoparticle  
surface.  This  approach  has  shown  UV-­‐‑triggered  cellular  uptake  by  controlled  
presentation  of  folic  acid  to  cells  overexpressing  the  folate  receptor  [47].  Finally,  external  
stimuli  can  also  provide  means  for  local  drug  release,  as  has  been  shown  with  focused  
ultrasound  and  its  destabilization  of  drug-­‐‑loaded  micelles.  Ultrasound-­‐‑triggered  
disruption  of  drug-­‐‑loaded  micelles  has  achieved  improved  anti-­‐‑tumor  efficacy,  likely  by  
both  the  local  release  of  drug  and  its  improved  distribution  in  the  tumor  [48].  
1.3 Cell-penetrating peptides 
1.3.1 Non-specific cellular uptake 
Cell-­‐‑penetrating  peptides  (CPPs)  are  a  family  of  peptides  that  can  achieve  
receptor-­‐‑independent  and  non-­‐‑specific  cellular  internalization  [49,  50].  HIV’s  
transactivator  of  transcription  (TAT)  was  the  first  to  be  discovered  to  achieve  efficient  
cellular  uptake  by  apparent  penetration  of  the  cell  membrane.  Other  peptides  such  as  
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Antennapedia,  a  transcription  factor  from  drosophila  [49],  and  bactenecin,  an  anti-­‐‑
microbial  peptide  derived  from  bovine  neutrophils  [51],  were  discovered  to  exhibit  
similar  behavior,  and  thus  CPPs  were  classified  as  a  family  of  peptides  that  achieve  
uptake  in  a  variety  of  cell  types.  The  family  of  CPPs  has  expanded  beyond  natural  
peptides  to  include  biologically  inspired  CPPs,  such  as  arginine  oligomers  [52-­‐‑54],  and  
synthetic  CPP  derivatives  [55-­‐‑57].  
Many  CPPs  are  cationic  due  to  the  contribution  of  either  lysine  or  arginine  
residues.  Arginine  is  believed  to  play  an  important  role  in  the  function  of  CPPs  due  to  
their  electrostatic  interaction  and  bidendate  hydrogen  bonding  with  components  on  the  
cell  membrane,  including  anionic  lipids  and  proteoglycans  [58,  59].  Although  the  exact  
mechanism  of  cationic  CPP  uptake  is  not  completely  elucidated,  it  is  likely  that  these  
interactions  initiate  the  events  leading  to  internalization.  For  the  many  types  of  CPPs,  
there  are  a  number  of  proposed  additional  mechanisms  that  participate  in  the  
internalization  of  these  materials,  whether  they  are  charged,  amphiphilic,  or  
hydrophobic:  pore  formation  [60,  61],  inverted  micelle  formation  [62],  and  endocytosis  
[63,  64].  CPPs  may  therefore  directly  access  the  cytoplasm,  by  their  apparent  penetration  
across  the  cell  membrane,  or  they  may  be  internalized  into  intracellular  compartments.  
This  distinction  for  some  CPPs  has  been  strongly  debated,  particularly  when  CPP  charge  
has  the  potential  to  induce  confounding  artifacts  depending  on  the  protocol  of  
evaluating  internalization.  
    14  
Arginine  oligomers,  whose  design  is  inspired  by  the  arginine-­‐‑rich  CPPs  like  TAT,  
are  an  interesting  class  of  CPPs  in  that  their  internalization  is  controlled  by  the  number  
of  sequential  arginine  residues  that  make  up  the  peptide.  Below  6  consecutive  arginine  
residues  is  not  sufficient  to  induce  significant  uptake,  whereas  above  6  residues  is  
adequate  to  induce  enhanced  internalization  [55,  65].  Pure  arginine  oligomers  are  
commonly  used,  but  it  has  been  shown  that  arginine  residues  do  not  have  to  be  
arranged  sequentially  to  achieve  efficient  cellular  uptake.  Rather,  arginine  residues  can  
be  spaced  along  a  peptide  sequence  without  compromising  cellular  uptake  [66].    
1.3.2 CPP-assisted intracellular delivery of drug carriers 
The  true  utility  of  CPPs  in  the  field  of  drug  delivery  is  that  the  non-­‐‑specific  
internalization  attributed  to  the  CPP  can  be  conferred  to  large  covalently  conjugated  
cargo.  Peptides  and  proteins  [67],  liposomes  [68],  micelles  [69,  70],  and  metallic  
nanoparticles  [71,  72]  are  all  carriers  whose  intracellular  uptake  has  been  facilitated  by  
CPP  functionalization.  The  mechanism  of  cellular  uptake  for  these  large  CPP-­‐‑conjugates,  
however,  tends  to  differ  from  that  of  the  CPPs  alone.  Though  some  CPPs  appear  to  cross  
the  cell  membrane  and  achieve  diffuse  distribution  throughout  the  cytosol,  CPP-­‐‑
conjugates  typically  exhibit  a  punctate  accumulation  within  the  cell,  suggesting  their  
uptake  by  an  endocytic  mechanism  that  leads  to  their  localization  within  intracellular  
vesicle  compartments.  These  differences  in  uptake  between  CPPs  and  their  CPP-­‐‑
conjugates  have  been  shown  with  cargo  whose  size  ranges  from  peptides  to  proteins  [63,  
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73].  The  sensitive  nature  of  this  transition  in  the  mechanism  of  uptake  has  been  
demonstrated  with  fluorescently  labeled  Arg7  with  increasing  addition  of  amino  acid  
residues  as  its  cargo  [73].  Arg7  alone,  or  when  appended  with  a  single  tryptophan,  
directly  traversed  the  membrane  of  osteosarcoma  cells  as  evident  by  their  diffuse  
fluorescence  throughout  the  cell.    However,  the  addition  of  9  to  11  amino  acid  residues  
resulted  in  uptake  by  an  endocytic  mechanism  as  suggested  by  their  punctate  
fluorescence  in  the  cell.    
The  exact  endocytic  mechanism  that  a  CPP-­‐‑conjugate  might  exploit  for  
internalization  is  likely  dependent  on  the  type  and  density  of  CPP  as  well  as  the  size  and  
composition  of  the  cargo.  Arg8,  for  example,  has  been  shown  to  elicit  macropinocytosis  
when  decorating  liposomal  carriers  at  a  high  density  [74].  With  functionalization  at  
lower  density,  however,  Arg8  decorated  liposomes  were  shown  to  enter  cells  via  
clathrin-­‐‑mediated  endocytosis.  The  internalization  pathway  associated  with  
macropinocytosis  is  believed  to  be  less  degradative  than  that  of  clathrin-­‐‑mediated  
endocytosis,  as  the  former  can  avoid,  to  some  extent,  the  trafficking  to  harsh  
environments  of  the  lysosome  [75],  as  is  typical  for  the  latter.  Thus  in  this  case,  a  high  
density  of  CPP-­‐‑functionalization  could  provide  an  advantage  to  the  drug  carrier  by  
improving  its  ability  to  prevent  degradation  of  its  cargo  in  hopes  of  delivering  intact  and  
active  drug  to  its  intracellular  target.  Due  to  the  variation  in  their  mechanisms  of  uptake,  
each  CPP-­‐‑functionalized  carrier  system  should  therefore  be  individually  evaluated  to  
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elucidate  their  mechanism  of  entry  in  the  cell,  which  may  inform  decisions  about  the  
design  of  the  carrier  to  improve  function  based  on  the  intracellular  environments  it  is  
likely  to  encounter  on  its  route  of  internalization.  
Despite  the  variability  in  the  mechanism  of  uptake  of  CPP-­‐‑conjugates,  these  CPP-­‐‑
functionalized  carriers  have  been  exploited  for  their  non-­‐‑specific  uptake  into  a  variety  of  
cell  types.  Due  to  this  non-­‐‑specific  uptake,  CPPs  were  initially  used  for  local  delivery.  
PenetratinTM  1  Peptide  (Q-­‐‑Biogene)  [76]  and  ChariotTM  Protein  Delivery  Reagent  (Active  
Motif)  [77]  are  CPP-­‐‑functionalized  laboratory  reagents  developed  for  in  vitro  
intracellular  delivery.  In  vivo,  local  application  of  CPP-­‐‑functionalized  carriers  has  been  
used  for  transdermal  drug  delivery  for  scarring  [78],  wrinkles  [79],  and  psoriasis  [80].  
Beyond  local  applications,  preliminary  use  of  CPP-­‐‑functionalized  conjugates  for  
systemic  delivery  has  been  investigated  for  the  treatment  of  myocardial  infarction  [81]  
and  stroke  [82].  
1.3.3 Targeted delivery with activatable CPP-functionalized drug 
carriers 
To  use  CPPs  in  systemically  administered  anti-­‐‑cancer  drug  carriers  the  function  
of  the  CPP  must  be  carefully  controlled  to  provide  targeted  tumor  uptake  while  
avoiding  uptake  in  off-­‐‑target  tissues.  To  achieve  this  control,  stimulus-­‐‑responsive  
materials  have  been  used  to  selectively  display  CPPs  on  drug  carriers  in  response  to  
tumor-­‐‑specific  triggers,  such  as  overexpressed  enzymes  or  depressed  pH,  or  extrinsic  
triggers,  such  as  light.  This  general  approach  to  control  CPP  function  on  drug  carriers  
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has  been  investigated  with  four  major  mechanisms:  1)  controlled  display  of  CPPs  after  
removal  of  stealth  polymers,  2)  triggered  display  of  CPPs  using  actuated  molecular  
tethers,  3)  controlled  display  of  CPPs  by  dissociation  from  ionic  inhibitors,  and  4)  
manipulation  of  CPP  charge  by  ionizable  residues.  
Decoration  of  drug  carriers  with  a  high  density  of  CPPs  would  lead  to  their  
efficient  uptake  in  many  types  of  cells.  If  such  a  carrier  were  delivered  systemically,  it  
could  be  taken  up  non-­‐‑specifically  into  any  tissue  it  encountered.  Hiding  CPP-­‐‑
functionalization  beneath  a  coating  of  stealth  polymer,  such  as  polyethylene  glycol  
(PEG),  can  prevent  interaction  of  the  CPP  with  cell  surfaces  and  thus  shield  the  drug  
carrier  from  non-­‐‑specific  cellular  uptake.  Recovery  of  the  CPP  function  can  then  occur  
when  the  stealth  polymers  are  removed.  This  can  provide  targeted  uptake  if  removal  of  
the  stealth  coating  only  occurs  in  the  tumor.  Thus,  mechanisms  of  removal  have  been  
designed  into  PEGylated  drug  carriers  to  release  their  PEG  in  response  to  tumor-­‐‑specific  
intrinsic  triggers.  For  example,  PEG  attached  to  TAT-­‐‑functionalized  liposomes  via  
hydrazone  linkers  can  be  released  by  pH-­‐‑sensitive  cleavage  of  the  linker  in  the  acidic  
conditions  of  the  tumor.  After  removal  of  the  PEG,  TAT-­‐‑functionalized  liposomes  could  
efficiently  deliver  their  cargo,  such  as  chemotherapeutic  doxorubicin,  into  cancer  cells  
[83].  Alternatively,  PEG  attached  to  CPP-­‐‑functionalized  nanoparticles  by  enzyme-­‐‑
cleavable  peptide  linkers  can  release  their  protective  coating  by  digestion  of  the  linker  in  
the  enzymatically  rich  tumor  environment.  PEG  linkers  cleaved  by  matrix  
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metalloprotease-­‐‑2  have  been  used  in  such  designs  to  achieve  controlled  cellular  uptake  
of  drug  carriers  such  as  TAT-­‐‑functionalized  liposomes  [84],  or  imaging  agents  such  as  
CPP-­‐‑functionalized  quantum  dots  [85]  and  iron  oxide  nanoparticles  [86].  
When  using  stealth  coatings  to  selectively  shield  CPPs,  the  function  of  CPPs  can  
alternatively  be  triggered  by  actuation  of  a  molecular  tether  that  allows  the  presentation  
of  CPPs  beyond  the  protective  stealth  corona.  Using  an  ionizable  tether  can  provide  
actuation  in  response  to  tumor  acidity  using  a  self-­‐‑assembled  diblock  copolymer  micelle  
as  a  carrier.  When  the  CPP-­‐‑functionalized  tether  is  neutral  at  pH  7  it  prefers  to  sequester  
itself  near  the  hydrophobic  core  of  the  micelle,  such  that  it  is  buried  within  the  stealth  
corona  and  prevents  the  interaction  of  the  appended  CPP  with  non-­‐‑specific  targets.  Only  
in  the  acidic  conditions  of  the  tumor  can  the  tether  be  ionized  and  its  increased  
hydrophilicity  can  encourage  the  stretching  of  the  tether  across  the  stealth  corona,  to  
ultimately  display  CPP  on  the  surface  of  the  nanoparticle.  This  mechanism  has  been  
used  with  TAT-­‐‑functionalized  micelles  to  achieve  targeted  delivery  of  doxorubicin  to  
improve  tumor  regression  of  a  drug  resistant  xenograft  in  mice  [87].  This  unique  
approach  has  the  advantage  of  being  reversible,  whereby  the  tether  could  potentially  
return  the  CPP  to  its  hidden  position  beneath  the  stealth  coating  if  it  were  to  escape  the  
acidic  conditions  in  the  tumor  and  return  to  conditions  of  normal  pH.      
For  those  CPPs  that  are  rich  in  cationic  charge,  their  function  can  alternatively  be  
controlled  by  electrostatic  interactions.  Pairing  a  cationic  CPP  with  an  anionic  inhibitor  
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can  electrostatically  preoccupy  the  CPP,  such  that  it  will  not  prematurely  interact  with  
off-­‐‑target  tissues.  This  is  commonly  achieved  with  hairpin-­‐‑like  structures  in  which  the  
CPP  and  anionic  inhibitor  are  attached  by  a  short  linker  that  strongly  encourages  their  
interaction  due  to  their  forced  proximity.  Selective  recovery  of  the  CPP  function  can  be  
achieved  when  interaction  with  the  inhibitor  is  disrupted.  This  is  most  often  achieved  by  
use  of  a  peptide  linker  that  is  cleaved  by  tumor  specific  enzymes,  such  as  matrix  
metalloprotease-­‐‑2.  Overexpression  of  this  enzyme  in  the  tumor  leads  to  local  cleavage  of  
the  linker,  dissociation  of  the  CPP  and  inhibitor,  and  internalization  of  the  functional  
CPP  in  the  tumor.  This  approach  has  been  extensively  developed  using  arginine-­‐‑rich  
CPPs  for  delivery  of  imaging  agents  such  as  dyes  for  fluorescent  imaging  [88-­‐‑90]  and  
gadolinium  for  magnetic  resonance  imaging  [91,  92].  Their  use  as  tumor-­‐‑specific  
imaging  agents  has  been  employed  as  a  tool  for  improved  tumor  resection,  where  
intraoperative  visualization  of  accumulated  CPP-­‐‑functionalized  markers  could  direct  
surgical  decisions  that  improved  the  removal  of  tumor  margins  [92].  
The  function  of  many  CPPs  relies,  at  least  in  part,  on  their  charge  content.  A  final,  
although  less  common,  approach  to  controlling  CPP  function  is  to  control  its  inherent  
charge  by  the  use  of  ionizable  residues.  An  example  of  this  approach  was  shown  with  a  
mutated  transportan  CPP.  This  lysine-­‐‑rich  CPP  was  mutated  such  that  all  lysine  residues  
were  substituted  with  histidine  residues,  whose  pKa  near  physiologic  pH  makes  then  
suitable  ionizable  residues  in  the  context  of  biological  systems.  The  neutral  charge  of  this  
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mutated  CPP  at  pH  7.4  eliminated  uptake,  while  the  ionization  to  positive  charge  at  pH  
6.0  increased  internalization.  This  triggered  uptake  in  low  pH,  typical  of  acidic  tumors,  
could  increase  the  in  vitro  cytotoxicity  caused  by  chemotherapeutic  cargo,  such  as  
camptothecin  [93].  This  is  another  approach  that  provides  the  advantage  of  reversibility,  
whereby  charge  of  the  CPP  can  change  as  it  either  enters  or  exits  the  acidic  conditions  of  
the  tumor.  
The  activation  of  the  CPP  function  in  most  of  these  approaches  relies  on  intrinsic  
triggers  characteristic  to  the  tumor  tissue,  such  as  overexpression  of  extracellular  
enzymes  and  tumor  tissue  acidity.  While  these  alternative  approaches  have  their  
respective  merits,  they  will  likely  remain  limited  by  three  important  factors.  First,  these  
approaches  remain  reliant  on  the  intrinsic  characteristics  of  the  tumor  tissue  as  their  
CPP-­‐‑activating  trigger  and  thus  will  remain  limited  by  the  heterogeneity  of  tumors.  
Second,  the  reliance  on  enzyme  and  pH-­‐‑mediated  reactions  presents  a  challenge  of  slow  
reaction  kinetics,  where  the  slow  activation  of  CPPs  by  these  processes  may  hinder  their  
function  in  the  time  frame  of  their  accumulation  in  the  tumor  tissue.  And  third,  the  loss  
of  shielding  polymers  or  ionic  inhibitors  means  some  of  these  approaches  to  CPP  
activation  are  irreversible,  and  thus  present  concern  for  the  re-­‐‑entry  of  activated  CPPs  
into  the  systemic  circulation  from  which  they  may  accumulate  in  any  tissue  within  the  
body.  
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1.4 Elastin-like polypeptides as drug carriers 
1.4.1 Elastin-like polypeptides  
Elastin-­‐‑like  polypeptides  (ELPs)  are  a  class  of  materials  inspired  from  human  
elastin  [94],  which  are  composed  of  a  repeating  pentapeptide  (VPGXG)n  ,  where  X,  the  
guest  residue,  is  any  amino  acid  other  than  proline,  and  n  indicates  the  number  of  
pentapeptide  repeats  that  defines  the  length  of  the  ELP  chain.    ELPs  exhibit  a  lower  
critical  solution  temperature  (LCST)  phase  transition  behavior,  such  that  they  are  soluble  
below  a  characteristic  transition  temperature  (Tt)  and  coacervate  into  micron-­‐‑scale  
aggregates  above  this  Tt  [95].  For  many  ELPs  this  transition  occurs  on  a  short  timescale  
over  a  few  degrees  Celsius  and  is  fully  reversible  when  the  solution  is  return  to  
temperatures  below  the  Tt.  This  reversibility  of  the  ELP  transition  makes  it  a  useful  
behavior  that  can  be  exploited  for  the  purification  of  ELPs  by  a  technique  termed  inverse  
transition  cycling  [96].  
ELPs  are  typically  expressed  recombinantly  in  E.  coli,  but  have  also  been  
successfully  synthesized  in  yeast,  fungi,  and  plant  expression  systems.  Due  to  their  
repetitive  nature,  their  genetic  design  requires  specialized  cloning  techniques  to  create  
repeating  genes  of  specific  length.  Such  cloning  techniques  include  recursive  directional  
ligation  (RDL)  [97],  recursive  directional  ligation  by  plasmid  reconstruction  (PRe-­‐‑RDL)  
[98],  and  overlap  extension  rolling  circle  amplification  (OERCA)  [99].  
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As  stimuli-­‐‑responsive  materials,  ELPs  are  particularly  useful  because  of  the  
tunability  of  their  behavior.  The  characteristic  Tt  of  an  ELP  is  dependent  both  on  intrinsic  
parameters  of  the  ELP  design  and  extrinsic  parameters  of  the  ELP  environment.  Intrinsic  
parameters,  including  sequence  and  length,  are  most  commonly  used  to  manipulate  the  
ELP  Tt.  The  ELP  sequence  is  manipulated  by  changing  the  guest  residue,  where  more  
hydrophilic  guest  residues  raise  the  Tt  and  more  hydrophobic  guest  residues  lower  the  
Tt  [100,  101].  The  ELP  length  is  inversely  related  to  ELP  Tt,  such  that  the  longer  the  chain  
length,  the  more  depressed  the  Tt  [102].  Extrinsic  parameters  that  affect  the  Tt  include  the  
ELP  concentration  and  cosolutes,  such  as  salts.  ELP  concentration  is  inversely  related  to  
Tt,  such  that  higher  concentrations  result  in  lower  Tts,  in  a  logarithmic  relationship  [102].  
The  presence  of  kosmotropic  anions  (Cl-­‐‑  and  higher  on  the  Hofmeister  series)  lowers  the  
ELP  Tt,  where  increasing  concentration  of  salt  amplifies  this  effect  [103].  Tuning  these  
intrinsic  and  extrinsic  parameters  allows  exceptional  control  over  the  ELP  Tt,  such  that  
the  stimulus-­‐‑response  of  an  ELP  can  be  engineered  precisely  for  its  specific  application.  
As  biopolymers,  ELPs  have  distinct  material  advantages  for  use  in  biological  
applications.  First,  since  the  ELP  sequence  and  length  are  controlled  by  a  genetic  
template,  ELP  products  are  perfectly  monodisperse.  Maintaining  consistent  composition  
and  size  provides  predictability  in  material  performance  in  vivo,  in  which  these  material  
characteristics  influence  pharmacokinetics  and  biodistribution.  Second,  since  ELPs  are  
polymers  composed  of  natural  amino  acids  they  are  biocompatible  and,  despite  their  
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synthesis  in  bacterial  hosts,  illicit  minimal  inflammatory  and  immune  responses  when  
locally  or  systemically  injected  in  animal  models  [104-­‐‑106].  Finally,  this  natural  
composition  also  provides  biodegradability,  such  that  an  ELP  can  be  broken  down  into  
amino  acid  building  blocks,  which  are  safely  cleared  from  the  body.    
The  rate  of  degradation  of  ELPs  has  been  approximated  with  systemically  
administered  14C-­‐‑labeled  ELP  in  mice.  These  ELPs  exhibited  a  degradation  rate  of  
approximately  2.5  weight  %/day  after  systemic  administration  [30],  demonstrating  that  
ELPs  remain  intact  within  timescales  typical  of  applications  for  drug  delivery,  but  also  
degrade  within  weeks  of  administration  to  be  safely  cleared  from  the  body.  It  is  
important,  however,  to  consider  the  effect  of  ELP  Tt  on  the  degradation  rate,  as  the  
degradability  of  ELPs  by  some  enzymes  has  been  shown  to  be  inhibited  when  the  ELP  is  
coacervated  in  micron-­‐‑scale  aggregates  or  coacervated  and  sequestered  within  the  core  
of  ELP  block  copolymer  micelles  [107].  
Due  to  their  controlled  synthesis,  biocompatibility,  and  tunable  stimulus-­‐‑
response,  ELPs  have  been  used  for  a  number  of  biological  applications  including  
biosensing  [108,  109],  tissue  engineering  [110],  and  drug  delivery  [111].  Furthermore,  
their  qualities  as  biocompatible  and  stimulus-­‐‑responsive  materials  have  been  extensively  
exploited  in  the  delivery  of  therapeutics  to  cancers,  be  it  as  macromolecular  and  
nanoparticle  carriers,  hyperthermia-­‐‑targeted  vehicles,  or  temperature-­‐‑triggered  depots  
[112].  
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1.4.2 CPP-ELPs as drug carriers 
Pseudorandom  ELPs  have  been  functionalized  with  CPPs  such  as  antennapedia  
and  TAT  as  a  means  to  increase  their  cellular  uptake  and  thereby  increase  
internalization  of  drug  cargo  [113].  When  the  Tt  of  the  CPP-­‐‑ELP  was  tuned  between  37  
°C  and  42  °C,  it  could  be  used  to  further  enhance  uptake  by  means  of  hyperthermia-­‐‑
triggered  aggregation,  whereby  the  ELP  transition  alone  had  been  shown  to  increase  
cellular  uptake,  likely  by  means  of  increased  endocytosis  of  the  portion  of  aggregates  
that  are  nano-­‐‑scale  [114].  Increased  cellular  uptake  of  CPP-­‐‑ELPs,  assisted  by  mild  
hyperthermia,  has  enhanced  the  delivery  of  a  number  of  genetically  appended  
therapeutics  in  vitro,  including  peptide  drugs  like  H1  c-­‐‑Myc  inhibitor  [115],  p21  kinase  
inhibitor  [116],  and  L12  cancer  cell  lytic  peptide  [117].  Alternatively,  CPP-­‐‑ELPs  have  also  
been  covalently  conjugated  with  small  molecule  chemotherapeutics  such  as  doxorubicin  
[118,  119]  and  paclitaxel  [120].  In  vivo,  these  CPP-­‐‑ELPs  have  been  shown  to  exhibit  anti-­‐‑
tumor  efficacy  when  delivering  peptide  drugs  [121]  or  small  molecule  
chemotherapeutics  [122,  123]  by  systemic  administration  in  combination  with  local  
tumor  hyperthermia.  
However,  the  use  of  pseudorandom  or  homopolymer  ELPs  to  control  the  CPP  
function  by  ELP  coacervation  is  not  an  idealized  approach,  in  that  the  presentation  of  
CPPs  in  the  ELP  aggregate  is  disorderly  and  not  necessarily  displayed  in  a  manner  that  
would  increase  uptake  by  enhanced  interaction  with  the  cell  surface.  However,  the  
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aggregation  of  the  ELP  alone  has  been  shown  to  increase  cellular  uptake  and  the  
contribution  of  this  effect  may  compensate  for  non-­‐‑optimal  presentation  of  CPP  by  the  
aggregate.  Furthermore,  aggregation  of  CPP-­‐‑ELPs  may  also  present  complications  of  
toxicity,  as  not  all  CPP-­‐‑ELPs  discussed  above  were  found  to  be  suitable  materials  as  
drug  carriers  due  to  their  inherent  toxicity  in  some  cell  lines  [115,  124].  
1.4.3 ELP diblock copolymers 
ELP  diblock  copolymers  (ELPBCs)  are  created  by  the  genetic  fusion  of  two  ELP  
sequences.  When  the  two  blocks  are  composed  of  a  hydrophilic  ELP  (containing  more  
hydrophilic  guest  residues)  and  a  hydrophobic  ELP  (containing  more  hydrophobic  
guest  residues),  the  ELPBC  can  undergo  temperature-­‐‑triggered  self-­‐‑assembly  into  higher  
order  structures,  provided  the  two  ELP  sequences  impart  a  Tt  on  each  block  that  is  
sufficiently  different  than  the  other.    Raising  the  solution  temperature  above  the  Tt  of  the  
hydrophobic  block  leads  to  the  desolvation  of  a  nanoparticle  core,  while  the  hydrophilic  
block  creates  a  solvated  nanoparticle  corona.  Raising  the  solution  temperature  further,  
above  the  Tt  of  the  hydrophilic  block,  leads  to  complete  aggregation  of  the  ELPBCs  into  
micron-­‐‑scale  aggregates.  
This  behavior  has  been  extensively  characterized  for  ELPBCs  that  self-­‐‑assemble  
into  spherical  micelles.  The  first  ELPBC  to  exhibit  temperature-­‐‑triggered  micelle  assembly  
was  composed  of  a  hydrophilic  [VPGEG(IPGAG)4]14  block  and  a  hydrophobic  
[VPGFG(IPGVG)4]16  block  [125].  The  extreme  difference  in  the  hydrophilicty  of  guest  
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residues  glutamic  acid  and  alanine  as  compared  to  the  hydrophobicity  of  the  guests  
residues  phenylalanine  and  valine  drove  the  temperature-­‐‑triggered  self-­‐‑assembly  of  this  
construct  into  spherical,  and  sometimes  cylindrical,  micelles  when  above  approximately  
25  °C,  the  Tt  attributed  to  the  hydrophobic  block.  
Systematic  design  of  several  ELPBCs,  composed  of  a  hydrophilic  (VPGXG)n  
[X=V1A8G7;  n=64,  96,  or  128]  block  and  a  hydrophobic  (VPGVG)m  [m=60,  90,  or  120]  
block,  shed  light  on  the  design  parameters  that  control  temperature-­‐‑triggered  micelle  
assembly  [126].  The  combinatorial  pairing  of  these  two  blocks  demonstrated  that  any  
ratio  of  block  sizes  (n:m)  between  1:2  and  2:1  was  capable  of  temperature-­‐‑triggered  self-­‐‑
assembly,  whereby  straying  significantly  from  this  ratio  resulted  only  in  unimer-­‐‑to-­‐‑
aggregate  transition.  Furthermore,  the  variation  in  hydrophobic  block  size  demonstrated  
that  the  thermal  property  of  this  domain  controlled  the  critical  micellization  temperature  
(CMT),  the  temperature  at  which  the  unimer-­‐‑to-­‐‑micelle  transition  occurs.  The  size  of  the  
self-­‐‑assembled  micelles  depended  not  only  on  the  overall  size  of  the  ELPBC,  but  also  on  
the  hydrophilic-­‐‑to-­‐‑hydrophobic  block  ratio  (n:m).  Beyond  this  basic  investigation  of  
ELPBC  design  parameters  for  micelle  self-­‐‑assembly  further  elucidation  has  recently  been  
achieved  with  modeling  of  the  ELPBC  transitions,  such  that  the  CMT  and  micelle-­‐‑to-­‐‑
aggregate  transition  of  an  ELPBC  can  be  predicted  by  the  Tts  of  the  individual  blocks  
from  which  the  ELPBC  is  composed  [127].  Although  this  predictive  power  is  limited  only  
to  those  ELP  components  used  to  make  such  a  model,  it  is  a  step  in  the  right  direction  
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toward  developing  procedures  for  the  rational  design  of  ELPBCs  with  precisely  predicted  
thermal  properties.    
1.4.4 ELPBCs as drug carriers 
ELPBCs  have  been  proposed  as  suitable  drug  carriers  both  as  stable  self-­‐‑
assembled  micelles  and  as  dynamic  systems  that  exploit  the  temperature-­‐‑triggered  
unimer-­‐‑to-­‐‑micelle  transition.  With  the  goal  of  tumor  targeted  delivery,  ELPBCs  have  been  
functionalized  at  their  hydrophilic  terminus  with  peptides  [126,  128,  129]  and  proteins  
[130,  131]  that  target  upregulated  cancer  cell  receptors  to  induce  cell-­‐‑specific  
internalization.  In  some  instances,  the  thermal  properties  of  the  ELPBC  were  appropriate  
for  temperature-­‐‑triggered  density  modulation  of  the  functionalized  entity,  whereby  
temperature-­‐‑triggered  micelle  assembly  could  influence  internalization  in  those  cell  
types  that  overexpressed  the  target  receptor.  Very  few  functionalized  ELPBCs,  however,  
have  been  optimized  to  achieve  temperature-­‐‑triggered  micelle  assembly  in  response  to  
conditions  of  clinically  relevant  mild  hyperthermia.  
The  use  of  ELPBCs  has  advantages  over  the  use  of  homopolymer  ELPs  to  control  
the  activity  of  functionalized  targeting  moieties  due  to  the  spatial  organization  of  the  
functionalization  on  the  self-­‐‑assembled  micelle,  as  opposed  to  the  disordered  aggregate  
created  by  homopolymer  coacervation.  The  orderly  display  of  RGD,  for  example,  on  an  
ELPBC  micelle  corona  was  crucial  for  amplifying  uptake  above  the  CMT  in  targeted  
cancer  cells,  as  compared  to  the  ELPBC  unimer  below  the  CMT.  RGD-­‐‑functionalized  ELP  
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above  its  Tt  could  not  achieve  increased  cellular  uptake,  by  means  of  its  triggered  
aggregation,  of  comparable  magnitude  to  the  ELPBC  by  means  of  its  triggered  micelle  
assembly  [128].  
Despite  efforts  to  design  ELPBCs  suitable  as  drug  carriers,  there  is  very  little  
evidence  in  the  literature  that  these  materials  have  been  used  to  successfully  deliver  
drug  cargo.  In  fact,  only  one  instance  is  reported  in  which  ELPBC  functionalized  at  the  
hydrophilic  terminus  with  FK506  binding  protein  12  (FKBP),  a  binding  partner  to  the  
small  molecule  drug  rapamycin,  self-­‐‑assembled  into  a  stable  micelle  at  37  °C  and  carried  
drug  cargo,  both  bound  to  the  micelle  corona  and  sequestered  in  the  micelle  core  by  
means  of  the  hydrophobic  effect.  The  immunosuppressant  and  anti-­‐‑proliferative  
properties  of  this  drug  provided  efficacy  in  suppressing  autoimmune  effects  in  a  
Sjogren’s  syndrome  mouse  model  [132]  and  in  regressing  tumor  growth  of  a  breast  
cancer  xenograft  in  mice  [131].  Delivery  of  the  drug  by  means  of  the  ELPBC  served  to  
reduce  toxic  side  effects  as  compared  to  free  drug  alone.  
1.5 Manipulation of CPP density with ELPBC self-assembly for 
controlled cellular uptake 
The  success  of  anti-­‐‑cancer  drugs  relies  heavily  on  their  delivery  to  the  tumor  
target.  The  toxicity  of  anti-­‐‑cancer  drugs  caused  by  their  effects  in  off-­‐‑target  tissues  has  
significantly  limited  their  safe  dosage  and  thus  hindered  their  therapeutic  success.  
Development  of  macromolecule  and  nanoparticle  drug  vehicles  has  improved  the  
accumulation  of  drug  cargo  in  the  tumor  with  passive  targeting  by  the  EPR  effect.  
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Furthermore,  a  number  of  active  targeting  strategies  have  been  investigated  that  exploit  
distinct  features  of  the  tumor  such  as  overexpressed  receptors,  upregulated  enzymes,  
and  depressed  pH.  These  approaches,  however,  are  limited  by  the  heterogeneity  of  the  
intrinsic  tumor  targets.  Due  to  the  vast  diversity  of  cancer  types,  these  methods  of  active  
targeting  are  applicable  only  to  specific  cancers  likely  to  possess  the  required  target  
[133].  Their  efficacy  is  also  limited  by  tumor  heterogeneity  among  individual  patients,  
such  that  all  instances  of  a  single  cancer  type  cannot  be  successfully  targeted  by  these  
approaches  [134-­‐‑137].    
Development  of  a  novel  carrier  capable  of  targeted  accumulation  at  the  tumor  
site  independent  of  the  tumor  characteristics,  while  simultaneously  avoiding  uptake  in  
healthy  tissue,  would  provide  a  delivery  method  applicable  to  a  wide  range  of  cancer  
types  and  would  circumvent  the  need  for  a  prior  knowledge  of  the  tumor  phenotype.  
Such  a  therapeutic  carrier  has  yet  to  be  realized  in  the  clinic  and  would  likely  find  
benefits  in  the  systemic  treatment  of  a  variety  of  solid  tumors.  
To  attain  this  goal,  the  method  described  here  exploits  CPPs  as  a  means  of  
achieving  non-­‐‑specific  and  receptor-­‐‑independent  cellular  uptake.  Because  of  their  non-­‐‑
specific  activity,  the  function  of  CPPs  must  be  carefully  controlled  to  achieve  the  desired  
uptake  at  the  tumor  site,  regardless  of  tumor  characteristics,  while  avoiding  uptake  in  
healthy  tissues  throughout  the  body.  To  create  “on”  and  “off”  states  of  CPP  uptake,  a  
CPP-­‐‑functionalized  ELPBC  has  been  designed  whose  temperature-­‐‑triggered  micelle  
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assembly  can  modulate  the  density  of  CPPs  in  the  presence  of  mild  clinical  
hyperthermia  (Figure  1).  In  the  simplest  approach,  the  density  of  arginine  residues—
important  to  CPP  function  due  to  their  unique  guanidinium  headgroup—can  be  
modulated  between  unimer  and  micelle  states  of  the  ELPBC.  The  threshold  of  6  arginine  
residues  required  to  achieve  uptake  can  prevent  the  cellular  internalization  of  unimers  
containing  fewer  than  6  arginines.  Only  when  assembled  into  micelles  in  the  presence  of  
heat  can  this  threshold,  as  sensed  by  the  target  cell  surface,  be  overcome  by  the  

















Figure  1:  CPP-­‐‑ELPBCs  control  cellular  uptake  by  modulation  of  CPP  density.  The  low  
density  of  arginines  on  each  unimer—below  the  threshold  necessary  for  uptake—
limits  their  internalization  into  cells  in  their  soluble  “off”  state  at  37  °C.  When  the  
temperature  is  increased  above  the  CMT,  the  ELPBC  self-­‐‑assembles  into  micelles  with  
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increased  density  of  CPP  on  the  micelle  corona.  This  increased  density  of  CPP—above  
the  threshold  necessary  for  uptake—permits  enhanced  internalization  in  their  self-­‐‑
assembled  “on”  state  at  42  °C.    
CPP-­‐‑ELPBCs,  by  means  of  their  temperature-­‐‑triggered  micelle  assembly,  can  
thereby  control  cellular  uptake  by  manipulation  of  CPP  density  using  an  extrinsic  
trigger.  Parameters  of  controlled  uptake,  including  the  magnitude  of  internalization  at  
both  “off”  and  “on”  conditions,  can  be  tuned  by  the  CPP-­‐‑functionalization  beyond  
arginine  oligomers.  Creation  of  a  family  of  CPP-­‐‑ELPBCs  thus  permits  the  exploration  of  
variable  levels  of  uptake.  This  is  particularly  convenient  in  the  context  of  delivering  
variable  drug  cargo,  where  the  suitable  “off”  and  “on”  levels  of  intracellular  delivery  
necessary  to  induce  controlled  therapeutic  effect  at  “on”  conditions  and  spare  cells  at  
“off”  conditions  is  likely  to  be  dependent  on  drug  characteristics,  such  as  potency.  This  
modular  drug  carrier  system,  capable  of  extrinsically  targeting  cellular  internalization,  
thus  provides  a  platform  of  materials  that  may  be  suitable  for  the  delivery  of  a  breadth  
of  drug  classes  to  a  variety  of  cell  types  with  controlled  therapeutic  effect.  
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2. Design, synthesis, and thermal characterization of 
CPP-ELPBCs  
2.1 Motivation 
The  temperature-­‐‑triggered  self-­‐‑assembly  of  ELPBCs  was  first  established  for  
constructs  composed  purely  of  two  distinct  ELP  domains  [126].  It  has  since  been  
demonstrated  that  ELPBCs  can  be  functionalized  with  additional  components  and  retain  
their  temperature-­‐‑triggered  self-­‐‑assembly.  Tumor-­‐‑targeting  peptides,  such  as  NGR  and  
RGD,  have  been  genetically  appended  to  the  hydrophilic  terminus  of  ELPBCs  and  
resulted  in  minimal  perturbation  of  the  CMT  of  functionalized  ELPBC,  as  compared  to  
non-­‐‑functionalized  ELPBC  [126,  128].  Furthermore,  tumor-­‐‑targeting  protein fibronectin  
type  III  domain,  despite  its  size  and  hydrophobicity,  has  been  successfully  appended  to  
ELPBCs  that  self-­‐‑assemble  into  micelles  and  display  the  protein  on  the  micelle  corona  
[130].  Thus,  it  is  highly  feasible  that  ELPBCs  can  also  be  genetically  appended  to  CPPs  at  
their  hydrophilic  terminus  and  retain  their  temperature-­‐‑triggered  self-­‐‑assembly.  
There  are  three  important  requirements  that  must  be  met  when  genetically  
appending  a  new  peptide  entity  to  an  ELPBC.  First,  the  fusion  must  be  sufficiently  
expressed  in  E.  coli.  The  sequence  and  structure  of  the  peptide,  as  well  as  its  mRNA  
template,  can  influence  the  efficiency  of  expression.  Furthermore,  the  site  of  peptide  
fusion,  at  the  N-­‐‑  or  C-­‐‑terminus  of  the  ELPBC,  can  also  affect  successful  expression  and  
sufficient  yield  of  the  ELP  fusion.    
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Second,  the  fusion  must  be  adequately  purified  from  the  E.  coli  lysate.  Typically,  
ELPs  are  easily  purified  from  the  E.  coli  lysate  by  means  of  their  LCST  behavior.  
However,  peptides  that  are  highly  charged,  such  as  cationic  CPPs,  can  introduce  
additional  challenges  in  the  purification  process  by  electrostatically  binding  to  
contaminants  that  can  then  be  unintentionally  co-­‐‑purified  with  the  ELP.  Modifications  in  
the  purification  process  many  therefore  be  necessary  to  produce  pure  peptide  ELPBC  
fusions.    
Third,  the  peptide-­‐‑functionalized  ELPBC  must  display  the  desired  thermal  
properties  required  for  its  specific  application.  For  applications  requiring  mild  
hyperthermia-­‐‑targeted  self-­‐‑assembly,  the  CMT  must  be  between  37  °C  (corresponding  to  
normal  body  temperature)  and  42  °C  (corresponding  to  mild  clinical  hyperthermia)  over  
an  acceptable  range  of  ELP  concentration.  The  ELP  transition  is  sensitive  to  its  local  
environment,  including  those  entities  that  are  synthetically  or  genetically  appended  to  
the  polypeptide  chain,  creating  what  is  known  as  a  ΔTt  effect,  in  which  the  Tt  of  the  ELP  
fusion  differs  from  the  ELP  alone  [138].  Thus,  it  is  not  unexpected  that  some  peptides  
will  perturb  the  Tt  of  the  appended  ELP  and  thereby  perturb  the  ELPBC’s  CMT  and  
micelle-­‐‑to-­‐‑aggregate  Tt.  Characteristics  such  as  the  size,  charge,  and  hydrophobicity  of  
the  peptide  are  likely  to  influence  the  magnitude  of  the  peptide’s  effect  on  the  ELP  Tt.  
Although  CPPs  are  generally  short  peptides,  the  high  charge  content  of  cationic  CPPs  
may  induce  changes  in  the  thermal  properties  of  the  ELPBCs  to  which  they  are  appended.  
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Keeping  in  mind  the  potential  challenges  presented  by  CPP-­‐‑functionalization  in  
meeting  the  requirements  discussed  above,  novel  CPP-­‐‑ELPBCs  were  genetically  
designed,  recombinantly  expressed,  and  purified.  Their  thermal  behavior  was  then  
characterized  with  temperature-­‐‑regulated  turbidimetry,  dynamic  light  scattering,  and  
zeta  potential  measurements.  ELPBC  design  parameters  were  manipulated  to  optimize  
the  thermal  behavior  of  these  systems,  such  that  they  would  exist  as  soluble  unimers  at  
37  °C  and  self-­‐‑assemble  into  micelles  at  42  °C.  The  behavior  of  these  optimized  
constructs  would  best  permit  the  future  investigation  of  controlled  cellular  uptake  by  
means  of  modulating  CPP  density  with  temperature-­‐‑triggered  ELPBC  self-­‐‑assembly  in  
response  to  the  clinically  relevant  stimulus  of  mild  hyperthermia.  
2.2 Methods 
Two  cloning  methods  were  utilized  in  the  design  of  CPP-­‐‑ELPBCs:  recursive  
directional  ligation  (RDL)  and  RDL  by  plasmid  reconstruction  (PRe-­‐‑RDL).  First  and  
second  generation  CPP-­‐‑ELPBCs  were  designed  by  RDL,  whereas  third  and  fourth  
generation  CPP-­‐‑ELPBCs  were  designed  by  PRe-­‐‑RDL.  Transition  to  the  PRe-­‐‑RDL  cloning  
system  provided  additional  ease  of  genetic  design  due  to  the  modular  nature  of  this  
technique,  which  facilitates  the  variation  of  N-­‐‑  and  C-­‐‑terminal  functionalization  of  the  
ELPBC  genes.  Each  method  utilized  its  own  cloning  vector  with  unique  enzyme  
restriction  sites  for  the  insertion  of  ELP,  leader,  and  trailer  genes.  Once  genetically  
encoded,  ELPBCs  designed  with  either  cloning  method  were  similarly  expressed,  
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purified,  and  characterized.  Design  parameters,  such  as  ELP  sequence  and  length,  were  
manipulated  to  optimize  the  thermal  behavior  of  CPP-­‐‑ELPBCs  for  hyperthermia-­‐‑
triggered  self-­‐‑assembly.  
2.2.1 RDL cloning method 
RDL  is  one  method  for  oligomerizing  repetitive  genes  with  precisely  controlled  
sequence  and  length  [97].  This  method  exploits  a  cloning  vector  that,  when  cut  at  a  
unique  restriction  site,  can  receive  a  gene  insert  digested  out  of  a  separate  vector.  This  
method  can  thereby  predictably  build  the  length  of  an  ELP  by  the  addition  of  the  gene  in  
the  receiving  vector  and  the  gene  insert.  Digestion  at  the  unique  restriction  site  in  the  
receiving  vector  results  in  asymmetric  sticky  ends  that  serve  two  purposes:  first,  to  
recognize  the  insert  only  in  its  correct  5’-­‐‑to-­‐‑3’  directionality  and  second,  to  prevent  
concatemerization  of  multiple  copies  of  the  insert.  These  features  ensure  that  the  ELP  
gene  sequence  and  length  are  precisely  controlled  with  each  oligomerization  step.  
Functionalization  of  the  N-­‐‑  and  C-­‐‑terminus  of  the  ELP  gene  is  accomplished  by  ligating  
the  complete  ELP  gene  into  an  expression  vector  at  a  unique  restriction  site  designed  at  
the  junction  between  the  leader  and  trailer-­‐‑encoding  genes.  RDL  cloning  of  ELPBCs  was  
performed  in  a  pUC19  vector,  while  modification  of  the  N-­‐‑  and  C-­‐‑terminal  
functionalization  of  ELPBCs  was  performed  in  a  pET-­‐‑25b(+)  vector.  Both  vectors  encoded  
antibiotic  resistance  to  ampicillin.  
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2.2.1.1  Synthesis  of  ELPBC  genes  by  RDL  cloning  
First  and  second  generation  ELPBCs  synthesized  by  RDL  cloning  were  composed  
of  two  ELP  sequences:  E4  and  E2.  E4  is  a  hydrophobic  ELP  with  the  sequence  (VPGVG)n,  
where  the  guest  residue  is  valine.  E2  is  a  hydrophilic  ELP  with  the  sequence  (VPGXG)n  
where  the  guest  residue,  X,  is  valine,  glycine,  or  alanine  in  a  ratio  of  1:7:8.  The  sequence  
and  length  of  an  ELP  is  denoted  with  the  nomenclature  E-­‐‑n,  where  E  denotes  the  type  of  
ELP    (ex.  E4,  E2,  etc.)  and  n  denotes  the  length,  in  pentapeptides.  Genes  encoding  both  
E4  and  E2  were  readily  available  in  the  Chilkoti  laboratory,  and  therefore  did  not  
require  synthesis  beginning  at  oligomer  concatemerization.  Only  the  combination  of  E4  
and  E2  genes  was  required  in  the  creation  of  new  ELPBCs  using  this  RDL  cloning  
method.  The  oligonucleotide  and  peptide  sequence  of  ELPs  designed  with  RDL  cloning  
are  listed  in  Table  1.  
Table  1:  Genetic  design  of  ELPs  for  RDL  cloning.  
ELP:  (VPGXG)n   Peptide  and  gene  sequence  
E4:  (VPGVG)30,  60,  
or  90  
    (V      G        V        P      G        V        G        V        P        G      V        G        V        P        G        V      G        
(gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt  gtg  ggc  gta  ccg  ggc  gtt  ggt    
  
  V      P        G        V      G        V        P        G)6,  12,  or  18  
gtt  cct  ggt  gtc  ggc  gtg  ccg  ggc)6,  12,  or  18  
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E2:  (VPGXG)64  or  96  
X=V:G:A=1:7:8  
    (V      G        V        P        G        A        G        V        P        G      G        G        V        P        G        A        G    
(gtg  ggt  gtg  ccg  ggc  gca  ggt  gtt  ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  
ggt    
  
    V      P        G        G        G        V        P        G        A        G      V        P        G        G        G        V        P    
gtt  ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  ggt  gtt  ccg  ggt  ggc  ggt  gtg  ccg    
  
    G        A        G      V        P      G        G        G        V        P          G        A        G      V        P        G      G  
ggc  gca  ggt  gtt  ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  ggt  gtt  ccg  ggt  ggc    
  
  G        V        P          G        A      G        V        P      G        G        G        V        P        G        A      G        V  
ggt  gtg  ccg  ggc  gca  ggt  gtt  ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  ggt  gtt    
  
    P        G        G        G      V        P          G        A        G      V          P        G)4  or  6  
ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  ggt  gtg  ccg  ggc)4  or  6  
  
Genes  encoding  ELPBCs  were  synthesized  by  genetic  fusion  of  E4  and  E2.  The  
ELP  destined  for  the  N-­‐‑terminus  of  the  block  copolymer  was  identified  as  the  insert,  and  
the  ELP  destined  for  the  C-­‐‑terminus  of  the  block  copolymer  was  identified  as  the  
receiving  vector.  The  receiving  vector  was  digested  with  PflMI,  dephosphorylated  with  
calf  intestinal  alkaline  phosphatase  (CIP),  and  purified  from  the  reaction  using  a  PCR  
purification  kit.  The  insert  was  prepared  by  digestion  with  PflMI  and  BglI,  creating  4  
distinct  fragments:  1377,  1186,  and  164  base  pairs  in  length,  in  addition  to  a  band  
corresponding  to  the  length  of  the  encoded  ELP  gene.  These  fragments  were  separated  
by  gel  electrophoresis  and  the  band  corresponding  to  the  ELP  fragment  was  excised  
from  the  gel  and  recovered  using  a  gel  extraction  purification  kit.  The  receiving  vector  
and  insert  were  then  ligated  and  transformed  into  competent  TOP10  E.  coli.  Successful  
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ligation  was  screened  with  diagnostic  digestion  using  HindIII  and  EcoRI  restriction  
enzymes  and  then  confirmed  with  plasmid  DNA  sequencing  using  T7  promoter  and  
terminator  primers.  
2.2.1.2  N-­‐‑  and  C-­‐‑terminal  functionalization  of  ELPBC  genes  by  RDL  cloning  
To  functionalize  the  N-­‐‑  and  C-­‐‑terminus  of  the  ELPBC,  a  vector  was  designed  to  
encode  the  leader  sequence  that  would  precede  the  ELP  and  the  trailer  sequence  that  
would  succeed  the  ELP.  A  pET-­‐‑25b(+)  cloning  vector  was  digested  with  NdeI  and  EcoRI,  
dephosphorylated  by  incubation  with  CIP,  and  purified  from  the  excised  96  base  pair  
fragment  using  a  PCR  purification  kit.  Oligonucleotides  encoding  the  leader  and  trailer  
sequences  were  designed  with  5’  and  3’  sticky  ends  complementary  to  the  NdeI  and  
EcoRI  cut  sites  and  contained  a  distinct  SfiI  cut  site  to  allow  the  insertion  of  the  ELP  
between  the  leader  and  trailer  sequences.  Annealed  oligonucleotides  and  digested  
vector  were  ligated  and  transformed  into  competent  TOP10  E.  Coli.  Successful  
functionalization  of  the  vector  was  screened  by  colony  PCR  and  diagnostic  digestion  
with  SfiI  and  then  confirmed  with  plasmid  DNA  sequencing  using  the  T7  promoter  
primer.  Oligonucleotide  and  peptide  sequences  of  leaders  and  trailers  for  those  ELPs  
designed  with  RDL  are  listed  in  Table  2,  where  pertinent  residues  of  the  leader  and  
trailer  are  noted,  functionalizing  the  N-­‐‑  and  C-­‐‑terminus  of  the  ELP,  respectively.  
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Table  2:  Genetic  design  of  leaders  and  trailers  for  RDL  cloning.  
  
The  vector  encoding  the  leader  and  trailer  sequence  was  digested  with  SfiI,  
dephosphorylated  with  CIP,  and  purified  from  the  reaction  using  a  PCR  purification  kit.  




    (M)    G        R        R        R        G          P        G        W      P        C        .          .  
t  atg  ggc  cgc  cgt  cgc  ggg  ccg  ggc  tgg  ccg  tgc  tga  t            




    (M)    G        C        G        W      P        G        G          P        G        G          S          .          .  
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  tga  t          




    (M)    G        C        G        W      P        G          G        P        G        G          S        K          .          .  
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  aaa  tga  t          




  (M)    G      C        G        W        P        G        G          P        G        G          S        R          .          .    
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  cgc  tga  t        




    (M)    G        C        G        W      P        G        G          P        G        G        S          R        R        R          .          .  
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  cgc  cgt  cgc  tga  t        




    (M)    G        C      G        W        P        G        G          P        G        G          S        R        R        R        R        .          .    
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  cgc  cgt  cgc  cgt  tga  t          




    (M)    G      C        G        W        P        G        G          P        G        G          S        R        R          R        R        R          .    
t  atg  ggc  tgc  ggg  tgg  ccg  ggc  ggg  ccg  ggc  ggt  agc  cgc  cgt    cgc  cgt  cgc  tga  
        ac  ccg  acg  ccc    acc  ggc  ccg    ccc  ggc    ccg  cca  tcg  gcg  gca  gcg  gca  gcg  act    
  
    .  
t  
att  aa  
    40  
The  vector  encoding  the  ELPBC  was  digested  with  PflMI  and  BglI,  resulting  in  sticky  
ends  that  are  compatible  with  the  SfiI  cut  site.  The  desired  fragment  that  included  the  
ELP  sequence  was  separated  by  gel  electrophoresis  and  purified  with  a  gel  extraction  
kit.  The  vector  and  insert  were  then  ligated  and  transformed  into  competent  BLR  E.  coli.  
Successful  ligation  was  screened  with  diagnostic  digestion  using  AvaI  and  XbaI  
restriction  enzymes  and  then  confirmed  by  sequencing  with  T7  promoter  and  T7  
terminator  primers.  
2.2.2 PRe-RDL cloning method 
PRe-­‐‑RDL  is  a  modular  cloning  method  that  is  well  suited  for  the  creation  and  
functionalization  of  ELPBCs  [98].  Unlike  RDL,  which  uses  a  single  restriction  site  as  the  
point  of  inserting  an  ELP  gene,  PRe-­‐‑RDL  uses  three  restriction  enzymes  to  deconstruct  
two  plasmids  encoding  the  ELP  sequences  to  be  combined.  After  purification  of  the  
desired  fragments  from  digestion  of  the  two  plasmids,  the  fragments  are  ligated  to  
reconstruct  a  functional  vector  while  combining  the  desired  genes  from  either  original  
plasmid.  A  functional  plasmid  is  only  recovered  by  successful  ligation  of  the  desired  
fragments,  thus  eliminating  colony  background  from  undesirable  ligation  events.  This  
approach  therefore  greatly  improves  cloning  efficiency,  as  compared  to  RDL,  by  
reducing  the  chances  of  vector  self-­‐‑ligation  prior  to  ELP  gene  insertion.  Furthermore,  
PRe-­‐‑RDL  allows  independent  attachment  of  leader  and  trailer  sequences  at  the  N-­‐‑  and  
C-­‐‑terminus  of  the  ELP  gene,  which  provides  greater  freedom  of  gene  functionalization.  
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This  is  particularly  useful  for  the  addition  of  a  family  of  CPPs  at  the  C-­‐‑terminus  of  the  
ELPBC  while  the  N-­‐‑terminal  functionalization  sequence  remains  the  same.  
2.2.2.1  Modification  of  pET-­‐‑24a(+)  vector  for  PRe-­‐‑RDL  cloning  
For  third  and  fourth  generation  ELPBCs,  PRe-­‐‑RDL  cloning  was  performed  using  a  
modified  pET-­‐‑24a(+)  vector  [98].  This  modification  was  added  between  XbaI  and  BamHI  
restriction  sites  and  contained  the  ribosomal  binding  site  and  restriction  enzyme  
recognition  sites  for  BseRI  and  AcuI  that  are  necessary  for  the  PRe-­‐‑RDL  cloning  method  
(Figure  2).    
  
  
Figure  2:  The  pET-­‐‑24a(+)  vector  was  modified  for  PRe-­‐‑RDL  cloning.  Insertion  of  this  
oligomer  conferred  the  restriction  enzyme  recognition  sites  for  BseRI,  NdeI,  and  AcuI  
enzymes  (grey),  a  ribosomal  binding  site  (capitalized),  and  a  short  leader  and  trailer  
sequence  (MGY).  The  cut  site  for  NdeI  (dotted  line)  results  in  ta-­‐‑5’  overhangs,  while  
the  overlapping  cut  site  for  BseRI  and  AcuI  (dotted  line)  results  in  gg-­‐‑3’  overhangs.  
Reproduced  from  [139].  
2.2.2.2  Oligomerization  of  ELP  genes  and  synthesis  of  ELPBC  genes  with  PRe-­‐‑RDL  
cloning  
The  ELP  sequences  used  to  design  ELPBCs  with  PRe-­‐‑RDL  differed  slightly  from  
those  utilized  in  RDL  cloning.  The  hydrophobic  domain  was  still  composed  of  E4  with  
the  sequence  (VPGVG)n,  where  the  guest  residue  was  valine.  The  hydrophilic  ELP  was  
composed  of  a  modified  E2,  identified  as  E2*,  with  the  sequence  (VPGXG)n  where  the  
    42  
guest  residue,  X,  is  alanine  or  glycine  at  a  1:1  ratio.  The  oligonucleotide  and  peptide  
sequences  of  ELPs  used  for  PRe-­‐‑RDL  cloning  are  listed  in  Table  3.  
Table  3:  Genetic  design  of  ELPs  for  PRe-­‐‑RDL  cloning.  
ELP:  VPGXGn   Peptide  and  oligonucleotide  sequence  
E4:  (VPGVG)30,  
35,  or  40  
  (V        G        V        P        G        V      G        V        P      G        V        G        V        P        G        V        G      V    
(gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt  gtg  ggc  gta  ccg  ggc  gtt  ggt  gtt    
  
    P      G        V      G        V        P        G)6,  7,  or  8    
cct  ggt  gtc  ggc  gtg  ccg  ggc)6,  7,  or  8  
E2*:  (VPGXG)60  
X=A:G=1:1  
    (A      G        V        P      G        G        G        V        P        G        A        G        V        P        G        G        G  
(gca  ggt  gtt  ccg  ggt  ggc  ggt  gtg  ccg  ggc  gca  ggt  gtc  ccg  ggt  ggc  ggt    
  
    V        P        G        A        G      V        P        G        G        G        V      P        G        A        G        V        P      G          
gtg  ccg  ggc  gca  ggt  gtc  ccg  ggt  ggc  ggt  gtt  ccg  ggc  gca  ggt  gtc  ccg  ggt    
  
  G        G        V          P        G        A        G        V        P        G        G        G        V        P        G)30  
ggc  ggt  gtg  ccg  ggc  gca  ggt  ggt  ccg  ggt  ggc  ggg  gtg  ccg  ggc)30  
  
E4  and  E2*  genes  for  PRe-­‐‑RDL  cloning  were  previously  synthesized  in  the  
Chilkoti  lab  in  a  variety  of  lengths.  For  the  creation  of  new  ELP  genes  (primarily  the  
synthesis  of  (VPGSG)80  discussed  in  Section  5.2.6)  oligomers  encoding  five  pentapeptide  
repeats  of  an  ELP  were  concatemerized  in  a  modified  pET-­‐‑24a(+)  vector  (Figure  3).  ELP  
oligomers  were  designed  with  sticky  ends  compatible  with  the  restriction  site  created  by  
BseRI  digestion.  Sense  and  anti-­‐‑sense  single  stranded  oligomers  were  annealed  by  
mixing,  heating  to  95  °C  for  1  minute  on  a  heat  block,  and  cooling  slowly  to  room  
temperature  over  several  hours.  The  pET-­‐‑24a(+)  vector  was  digested  with  BseRI  and  
dephosphorylated  by  incubation  with  CIP.    The  vector  and  an  excess  of  annealed  ELP  
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oligomers  were  ligated  and  transformed  into  competent  EB5α  E.  coli.  Colonies  were  
screened  for  variable  insertion  of  the  oligomers  by  colony  PCR,  in  which  the  inserted  
genes  were  amplified  using  T7  promoter  and  T7  terminator  primers.  PCR  products  were  
observed  by  DNA  electrophoresis,  which  directed  the  selection  of  colonies  to  be  grown,  
sequenced,  and  saved  for  further  cloning.  This  concatemerization  procedure  typically  
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Figure  3:  Preliminary  synthesis  of  ELP  genes  was  performed  by  concatemerization.  
Modified  pET-­‐‑24a(+)  vector  was  digested  with  BseRI  and  ligated  with  an  excess  of  
ELP  oligomers  designed  with  sticky  ends  complimentary  to  the  BseRI  cut  site.  A  
library  of  vectors  was  created  in  which  the  ELP  gene  length  varied  from  1-­‐‑4  
oligonucleotide  inserts,  equivalent  to  5-­‐‑20  pentapeptide  repeats.  Adapted  from  [139].    
The  PRe-­‐‑RDL  cloning  procedure  was  used  to  build  an  ELP  of  precisely  
increasing  length  or  combine  two  ELP  sequences  to  create  an  ELPBC  (Figure  4).  The  ELP  
sequence  intended  for  the  N-­‐‑terminus  of  the  combined  construct  was  used  to  create  an  
“A  cut”  by  digestion  with  AcuI  and  BglI  restriction  enzymes.  The  ELP  sequence  
intended  for  the  C-­‐‑terminus  of  the  combined  construct  was  used  to  create  a  “B  cut”  by  
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digestion  with  BseRI  and  BglI  restriction  enzymes.  The  reaction  mixtures  of  the  “A  cut”  
and  “B  cut”  were  then  separated  by  gel  electrophoresis.  The  “A  cut”  produced  DNA  
fragments  with  lengths,  in  base  pairs,  of  1586,  1821,  and  1891  +  the  length  of  the  ELP  
insert.  The  “B  cut”  produced  DNA  fragments  with  lengths,  in  base  pairs,  of  1891  and  
3407  +  the  length  of  the  ELP  insert.  In  each  case,  the  largest  band  was  excised  from  the  
gel  and  the  fragments  were  purified  prior  to  their  ligation  and  transformation  into  
competent  EB5α  E.  coli.  Colonies  were  screened  by  diagnostic  digestion  with  XbaI  and  
BamHI  restriction  enzymes.  Successful  oligomerization  or  ELPBC  synthesis  was  




Figure  4:  ELPBC  genes  were  synthesized  by  PRe-­‐‑RDL  cloning.  Vectors  containing  the  
hydrophobic  ELP  domain  (red)  and  hydrophilic  ELP  domain  (blue)  were  combined  to  
form  the  desired  ELPBC.  The  vector  containing  the  hydrophobic  domain  was  digested  
    45  
with  AcuI  and  BglI  to  form  an  “A  cut”,  while  the  vector  containing  the  hydrophilic  
domain  was  digested  with  BseRI  and  BglI  to  form  a  “B  cut”  (A).  The  desired  
restriction  products  were  separated  by  gel  electrophoresis  and  purified  prior  to  
ligation  to  combine  the  ELP  domains  and  form  the  ELPBC  (B).  Adapted  from  [139].  
2.2.2.3  N-­‐‑  and  C-­‐‑terminal  functionalization  of  ELPBC  genes  with  PRe-­‐‑RDL  cloning  
The  leader  sequence  applied  to  all  ELPBCs  for  thermal  characterization  and  
evaluation  of  controlled  cellular  uptake  was  MGCGWPG,  where  methionine  initiated  
polypeptide  expression,  cysteine  provided  a  reactive  amino  acid  for  the  conjugation  of  a  
fluorophore  label,  and  tryptophan  provided  an  optically  active  amino  acid  for  peptide  
quantification  by  absorbance  at  280  nm.  The  oligonucleotide  and  peptide  sequence  of  the  
leader  used  for  ELPBCs  created  with  PRe-­‐‑RDL  cloning  is  listed  in  Table  4,  where  
pertinent  residues  of  the  leader  are  noted,  functionalizing  the  N-­‐‑terminus  of  the  ELP.  
Table  4:  Genetic  design  of  the  leader  sequence  for  PRe-­‐‑RDL  cloning.  
N-­‐‑   Peptide  and  oligonucleotide  sequence  
Cys,  
Trp  
    (M)    G        C        G        W      P          
t  atg  ggc  tgc  ggg  tgg  ccg  gg  
        ac  ccg  acg  ccc    acc  ggc  
  
The  oligonucleotides  encoding  the  leader  sequence  were  designed  with  sticky  
ends  compatible  to  those  created  from  vector  digestion  with  BseRI  and  NdeI  and  
annealed  as  described  previously.  The  pET-­‐‑24a(+)  vector  was  digested  first  with  BseRI  
alone,  and  then  NdeI  was  added  to  the  reaction  mixture.  This  sequential  digestion  was  
necessary  to  create  the  desired  overhangs  in  the  digested  vector,  since  the  NdeI  cut  site  
lies  between  the  BseRI  recognition  site  and  the  BseRI  cut  site.  The  plasmid  fragments  
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were  dephosphorylated  with  the  addition  of  CIP  and  the  vector  fragment  was  purified  
by  PCR  purification  kit.  The  annealed  oligonucleotides  and  restricted  vector  were  
ligated  and  transformed  into  competent  EB5α  E.  coli.  Successful  insertion  of  the  
oligonucleotides  was  screened  with  colony  PCR  or  diagnostic  digest  using  XbaI  and  
BamHI  enzymes.  The  creation  of  leader-­‐‑encoding  vectors  was  confirmed  with  plasmid  
DNA  sequencing  using  T7  promoter  primer.    
All  trailer  sequences  encoded  a  brief  flexible  spacer  of  PGGS  followed  by  a  CPP  
sequence  and  stop  codons  to  terminate  peptide  synthesis.  The  oligonucleotide  and  
peptide  sequences  of  the  trailers  used  for  ELPBCs  created  with  PRe-­‐‑RDL  cloning  are  
listed  in  Table  5,  where  pertinent  residues  of  the  trailer  are  noted,  functionalizing  the  C-­‐‑
terminus  of  the  ELP.  
Table  5:  Genetic  design  of  trailer  sequences  for  PRe-­‐‑RDL  cloning.  
C-­‐‑   Peptide  and  oligonucleotide  sequence  
-­‐‑  
                  P        G        G          S          .          .  
        g  ccg  ggc  ggt  agc  tga  taa  gg  
ccc  ggc    ccg  cca    tcg  act  att  
Arg5  
                  P        G        G        S          R        R          R        R        R        .            .  
        g  ccg  ggc  ggt  agc  cgc  cgt    cgc  cgt  cgc  tga  taa  gg  
ccc  ggc    ccg  cca  tcg  gcg  gca  gcg  gca  gcg  act  att  
Arg8  
                  P        G        G        S          R        R          R        R        R        R          R        R        .            .  
        g  ccg  ggc  ggt  agc  cgc  cgt    cgt  cgc  cgc    cgt    cgc  cgt  tga  taa  gg  
ccc  ggc  ccg    cca  tcg  gcg  gca  gca  gcg  gcg  gca  gcg  gca  act  att  
TAT47-­‐‑57  
                  P        G        G          S      Y        G        R        K        K        R        R        Q        R        R          R        .            .  
        g  ccg  ggc  ggt  agc  tat  ggc  cgt  aaa  aaa  cgt  cgt    cag  cgt  cgc    cgt  tga  taa  gg  
ccc  ggc  ccg    cca  tcg  ata  ccg  gca    ttt      ttt    gca  gca  gtc  gca  gcg  gca  act  att  
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RTAT47-­‐‑57  
                  P        G          G        S        Y      G        R        G        G        R      R        G          R        R        R        .            .  
        g  ccg  ggc  ggt  agc  tat  ggc  cgt  ggc  ggt  cgt  cgt  ggc    cgt  cgc  cgt  tga  taa  gg  
ccc  ggc  ccg    cca  tcg  ata  ccg  gca  ccg  cca  gca  gca  ccg  gca  gcg  gca  act  att  
  
Oligonucleotides  encoding  the  trailer  sequences  were  designed  with  sticky  ends  
compatible  to  those  created  from  vector  digestion  with  BseRI  alone.  The  pET-­‐‑24a(+)  
vector  was  digested  with  BseRI,  dephosphorylated  with  the  addition  of  CIP,  and  
purified  by  PCR  purification  kit  prior  to  ligation  with  the  annealed  oligonucleotides  
encoding  the  trailer  sequences  and  transformation  into  competent  EB5α  E.  coli.  
Successful  insertion  of  the  oligonucleotides  was  screened  with  colony  PCR  or  diagnostic  
digest  using  XbaI  and  BamHI  enzymes.  The  creation  of  trailer-­‐‑encoding  vectors  was  
confirmed  with  plasmid  DNA  sequencing  using  T7  promoter  primer.    
PRe-­‐‑RDL  was  again  performed  to  functionalize  the  N-­‐‑  or  C-­‐‑terminus  of  the  
ELPBC  gene.  For  functionalization  of  the  N-­‐‑terminus,  a  vector  encoding  the  desired  
leader  sequence  would  be  digested  to  create  an  “A  cut”,  while  the  vector  encoding  the  
ELPBC  would  be  digested  to  create  a  “B  cut”  (Figure  5A).  The  desired  restriction  
fragments  were  separated  by  gel  electrophoresis,  purified,  and  ligated  to  create  a  leader-­‐‑
ELPBC  gene  (Figure  5B).  For  functionalization  of  the  C-­‐‑terminus,  the  vector  encoding  the  
leader-­‐‑ELPBC  would  be  digested  to  create  an  “A  cut”  and  the  vector  encoding  the  desired  
trailer  sequence  would  be  digested  to  create  a  “B  cut”  (Figure  5C).  The  desired  
restriction  fragments  were  separated  by  gel  electrophoresis,  purified,  and  ligated  to  
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create  the  fully  functionalized  ELPBC  (Figure  5D).  The  final  gene  was  confirmed  by  
plasmid  DNA  sequencing  using  T7  promoter  and  terminator  primers  and  transformed  
into  competent  BL21  E.  coli,  appropriate  for  overexpression  of  the  ELP  product.  
  
  
Figure  5:  N-­‐‑  and  C-­‐‑terminal  functionalization  of  ELPBCs  was  achieved  with  PRe-­‐‑RDL  
cloning.  The  vector  encoding  the  leader  (L)  was  digested  to  create  an  “A  cut”  while  
the  vector  encoding  the  ELPBC  was  digested  to  create  a  “B  cut”  (A).  Ligation  of  desired  
restriction  fragments  resulted  in  the  leader-­‐‑ELPBC  gene  (B).  The  vector  encoding  the  
leader-­‐‑ELPBC  gene  was  digested  to  create  an  “A  cut”  while  the  vector  encoding  the  
trailer  (T)  was  digested  to  create  a  “B  cut”  (C).  Ligation  of  the  desired  restriction  
fragments  created  the  fully  functionalized  ELPBC  gene  (D).  Adapted  from  [139].  
2.2.3 Recombinant expression of CPP-ELPBCs in E. coli 
E.  coli  cells  suitable  for  expression  (BLR  or  BL21)  were  transformed  with  the  
complete  plasmid  encoding  the  desired  ELP  functionalized  with  a  leader  and  trailer  
sequence,  under  control  of  the  T7-­‐‑lac  promoter.  These  cells  were  grown  in  50  mL  Terrific  
Broth  (TB)  media  with  appropriate  antibiotic  overnight  at  37  °C  while  shaking  at  200  
RPM.  E.  coli  cells  were  collected  by  centrifugation  at  2,000  x  g  for  10  minutes,  the  
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supernatant  waste  was  discarded,  cells  were  resuspended  in  PBS,  and  used  to  inoculate  
1  L  of  TB  media  with  appropriate  antibiotic.  Cultures  were  grown  for  24  hours  at  37  °C  
while  shaking  at  200  RPM.  
The  T7-­‐‑lac  system  exhibits  leaky  background  expression  that  results  from  growth  
at  37  °C  over  the  course  of  24  hours.  This  background  expression  level  was  sufficient  for  
the  synthesis  of  most  ELPs  discussed  in  this  dissertation,  particularly  of  those  ELPBCs  in  
which  a  more  hydrophobic  sequence  (ex.  (VPGVG)n)  was  expressed  proximal  to  the  N-­‐‑
terminus.  However,  when  background  expression  was  not  sufficient,  overexpression  
was  induced  with  the  addition  of  0.2  mM  isopropyl-­‐‑beta-­‐‑D-­‐‑thiogalactoside  (IPTG)  at  
approximately  10  hours  after  initiating  the  culture  growth.    
2.2.4 Purification of CPP-ELPBCs from E. coli lysate 
E.  coli  cells  were  collected  by  centrifuging  the  culture  in  a  1  L  bottle  at  2,000  x  g  
for  10  minutes  at  4  °C.  The  supernatant  was  discarded  and  the  cell  pellet  was  
resuspended  with  20  mL  phosphate  buffered  saline  (PBS).  Cells  were  lysed  by  sonication  
in  9  minute  cycles  of  10  seconds  “on”  and  20  seconds  “off”  at  an  output  power  of  85  W.  
To  condense  genomic  contaminants,  2  mL  of  10%  (w/v)  polyethylenimine  (PEI)  was  
added  to  the  lysate.  Insoluble  contaminants  were  collected  by  centrifugation  at  16,000  x  
g  for  15  minutes  at  4  °C.  The  supernatant  was  transferred  to  a  clean  tube  and  ELP  
purification  proceeded  by  inverse  transition  cycling  (ITC)  [96],  in  which  the  sample  was  
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centrifuged  above  and  below  the  ELP  Tt  to  remove  soluble  and  insoluble  contaminants,  
respectively  (Figure  6).    
  
ITC Purification
1) Start with E. coli lysate
2) Induce ELP coacervation and centrifuge  
    (hot spin)
3) Retain ELP pellet (a) and discard             
    soluble supernatant contaminants (b)
4) Resuspend ELP pellet in cold buffer
5) Centrifuge (cold spin)
6) Discard insoluble pellet contaminants (a)  
    and retain soluble ELP supernatant (b)





















Figure  6:  CPP-­‐‑ELPBCs  were  purified  from  E.  coli  lysate  by  ITC.  Repeated  
centrifugation  above  and  below  the  ELP  Tt  removed  soluble  and  insoluble  
contaminants,  respectively.  Reproduced  from  [140].  
The  ELP  transition  was  induced  with  the  addition  of  heat  (a  water  bath  was  used  
at  37  °C)  and/or  salt  (crystalline  NaCl  was  used  at  less  than  3  M).  The  ELP  coacervate  
was  collected  by  centrifugation  at  16,000  x  g  for  10  minutes  at  room  temperature—this  
step  is  termed  a  “hot  spin”.  Soluble  contaminants  were  discarded  and  the  ELP  pellet  
was  resuspended  in  cold  PBS.  The  solubilized  ELP  sample  was  then  centrifuged  at  
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16,000  x  g  for  10  minutes  at  4  °C—this  step  is  termed  a  “cold  spin”.  The  ELP  solution  
was  then  transferred  to  a  clean  tube,  and  the  insoluble  contaminant  pellet  was  
discarded.  Four  rounds  of  ITC  with  alternating  “hot”  and  “cold”  spins  generally  
produced  ELPs  of  sufficient  purity,  as  determined  by  SDS-­‐‑PAGE.  Purified  ELPs  were  
separated  on  4-­‐‑20%  Tris-­‐‑HCL  polyacrylamide  gels  run  at  180  V  for  approximately  45  
minutes.  ELPs  were  visualized  by  negative  staining  of  the  gel  using  0.5  M  CuCl2.  As  
typical  for  ELPs,  some  CPP-­‐‑ELPBCs  ran  at  an  apparent  molecular  weight  (MW)  up  to  
20%  higher  than  the  theoretical  MW  dictated  by  their  genetic  design  [97].  
2.2.5 Thermal characterization of CPP-ELPBCs 
2.2.5.1  Temperature-­‐‑regulated  turbidimetry  
The  thermal  behavior  of  ELPs  can  be  quickly  evaluated  over  a  wide  range  of  
temperatures  using  temperature-­‐‑regulated  turbidimetry.  A  Cary  300  Bio  UV-­‐‑Visible  
spectrophotometer  was  used  to  measure  the  optical  density  (OD)  at  350  nm  of  ELP  
solutions  at  5-­‐‑100  µμM  over  a  range  of  temperatures  (ex.  20-­‐‑90  °C).  OD  measurements  
were  recorded  at  every  0.33  °C  as  the  solution  temperature  was  heated  at  1  °C/minute.  
Reversibility  of  the  ELP  transition  was  confirmed  by  the  return  of  OD  to  baseline  as  the  
solution  was  cooled  at  1  °C/min.  Typically,  as  the  solution  temperature  is  raised,  a  
drastic  increase  in  OD  (>  2.0  OD  units)  is  indicative  of  the  ELP  transition  from  unimer  to  
micron-­‐‑scale  aggregate  (Figure  7A-­‐‑B).  The  ELP  Tt  can  be  defined  as  the  temperature  at  
which  the  maximum  of  the  first  derivative  of  OD,  with  respect  to  temperature,  occurs.  
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For  ELPBCs  that  exhibit  temperature-­‐‑triggered  self-­‐‑assembly  a  subtle  increase  in  OD  
(~0.1-­‐‑0.5  OD  units)  as  the  solution  temperature  is  raised  is  typically  indicative  of  the  
transition  of  ELP  unimer  to  ELP  nanoparticle  (Figure  7C).  Further  increasing  the  
solution  temperature  will  lead  to  a  drastic  increase  in  OD  (>  2.0  OD  units)  that  signifies  
































































































































Figure  7:  Temperature-­‐‑regulated  turbidimetry  and  dynamic  light  scattering  
demonstrate  representative  thermal  behavior  of  ELP  homopolymers  and  ELPBCs.  
Rapid  increase  in  OD  is  indicative  of  ELP  unimer-­‐‑to-­‐‑aggregate  transition  (A),  which  is  
typically  reversible  (B).  Representative  ELP  homopolymer:  SKGPG-­‐‑(VGVPG)80-­‐‑Y  (A-­‐‑
B).  Subtle  increase  in  OD  is  indicative  of  nano-­‐‑scale  ELPBC  assembly  prior  to  complete  
aggregation  (C),  which  can  be  confirmed  by  DLS  measurements  (D).  Representative  
ELPBC:  GCGWPG-­‐‑(VGVPG)60-­‐‑(AGVPGGGVPG)30-­‐‑PGGS  (C-­‐‑D).  Adapted  from  [140].  
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2.2.5.2  Dynamic  light  scattering  
Dynamic  light  scattering  (DLS)  was  used  to  corroborate  the  results  from  
turbidimetry  measurements  and  to  determine  the  size  of  self-­‐‑assembled  ELP  
nanoparticles.  Samples  were  filtered  prior  to  analysis  by  DLS  using  filters  with  pore  
sizes  of  20,  100,  or  200  nm,  depending  on  the  ELP  sample.  The  hydrodynamic  radius  (Rh)  
was  measured  on  a  Wyatt  Technology  DynaPro  temperature  controlled  microsampler  or  
Wyatt  DynaPro  plate  reader  over  a  temperature  range  of  interest,  as  directed  by  
turbidimetry  results.  ELP  unimers  typically  exhibit  an  Rh  ≤  10  nm,  ELP  nanoparticle  
assemblies  typically  exhibit  an  Rh  ~  20-­‐‑40  nm,  and  ELP  aggregates  typically  exhibit  an  Rh  
>  500  nm  (Figure  7D).  To  confirm  Rh  measurements  at  specific  thermal  conditions,  for  
instance  37  °C  and  42  °C,  3  samples  were  evaluated  by  DLS  and  an  average  Rh  ±  
standard  deviation  (SD)  or  standard  error  of  the  mean  (SEM)  was  reported.    
2.2.5.3  Zeta  potential  
The  surface  charge  of  self-­‐‑assembled  CPP-­‐‑ELPBC  micelles  was  investigated  by  
zeta  potential  measurements.  Due  to  the  need  to  eliminate  buffer  salts  for  zeta  potential  
measurements,  the  thermal  behavior  of  ELPBCs  was  re-­‐‑evaluated  in  H2O,  due  to  the  
dependence  of  ELP  Tt  on  the  presence  of  salts.  This  characterization  defined  the  
increased  concentration  and  temperature  at  which  the  measurements  must  be  taken  to  
ensure  the  self-­‐‑assembly  of  ELPBCs  in  water.  Solution  temperature  was  allowed  to  
equilibrate  for  10  minutes  prior  to  obtaining  zeta  potential  measurements  on  a  Malvern  
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Zetasizer  Nano  ZS90  for  CPP-­‐‑ELPBC  or  a  non-­‐‑functionalized  ELPBC  control.  Zeta  
potential  measurements  were  repeated  with  3  samples  and  an  average  zeta  potential,  in  
mV,  was  reported  ±  SD.  
2.3 Results and discussion 
2.3.1 CPP-ELPBC design 
Toward  the  goal  of  achieving  controlled  cellular  uptake  with  modulation  of  CPP  
density  on  self-­‐‑assembled  ELPBCs,  an  initial  CPP-­‐‑ELPBC  design  was  proposed  to  meet  the  
needs  of  minimizing  uptake  in  the  soluble  “off”  state  and  maximizing  uptake  in  the  self-­‐‑
assembled  “on”  state.  Selection  of  the  first  CPP  to  investigate  with  this  ELPBC  system  
was  based  on  two  existing  factors  in  the  CPP  literature:  1)  the  threshold  of  CPP  function  
of  arginine  oligomer  CPPs,  dependent  on  the  number  of  arginine  residues,  and  2)  the  
charge  density  typical  of  existing  CPP-­‐‑functionalized  drug  carrier  nanoparticles.  
Due  to  the  high  arginine  content  in  many  cationic  CPPs,  and  the  important  role  
of  arginines  in  CPP  function,  biologically  inspired  arginine  oligomers  have  been  studied  
as  a  model  CPP  system  capable  of  receptor-­‐‑independent  internalization.  The  cellular  
uptake  of  arginine  oligomers  demonstrates  a  functional  threshold  dependent  on  the  
arginine  number,  where  less  than  6  consecutive  arginine  residues  are  insufficient  to  
achieve  uptake,  while  greater  than  6  consecutive  arginine  residues  are  sufficient  to  
achieve  internalization  [55,  65].  Although  arginine  oligomers  are  often  employed  due  to  
their  simplicity,  it  has  been  shown  that  arginine  residues  do  not  have  to  be  arranged  
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sequentially  to  achieve  efficient  cellular  uptake;  arginine  residues  can  be  spaced  to  some  
extent  along  a  peptide  backbone  without  compromising  internalization  [66].  These  
characteristics  of  arginine  oligomer  CPPs  present  two  distinct  advantages  for  the  
proposed  CPP-­‐‑ELPBC  platform.  First,  the  arginine  oligomer  length  appended  to  each  
ELPBC  can  be  selected  below  the  functional  threshold  to  minimize  uptake  in  the  “off”  
state.  Second,  the  resulting  presentation  of  high  arginine  density  on  the  corona  of  self-­‐‑
assembled  CPP-­‐‑ELPBC  micelles  is  likely  to  provide  CPP-­‐‑mediated  cell  uptake,  since  
arginine  proximity  on  the  peptide  chain  is  not  a  direct  requirement  for  arginine  oligomer  
CPP  function.  
To  further  direct  the  choice  of  arginine  oligomer  length  for  ELPBC  
functionalization  in  preliminary  experiments,  while  remaining  below  the  functional  
threshold  of  6  arginine  residues,  we  looked  at  the  standards  in  the  literature  of  CPP-­‐‑
functionalized  nanoparticle  drug  carriers  that  successfully  deliver  drug  cargo  to  
intracellular  targets.  TAT-­‐‑decorated  liposomes,  extensively  utilized  in  the  laboratory  of  
Vladimir  Torchilin  at  Northeastern  University,  are  one  such  example  of  a  standard  in  the  
field.  These  TAT-­‐‑functionalized  liposomes,  approximately  100  nm  in  radius,  were  
decorated  with  the  YGRKKRRQRRR  peptide  with  an  efficiency  of  approximately  500  
TAT  peptides  per  liposome  [141].  Comparing  the  charge  density  on  this  liposomal  
platform  to  that  of  an  ELP  micelle,  approximated  to  have  a  radius  of  30  nm  and  
coordination  number  of  100  ELPBC  unimers  per  micelle,  gives  us  the  charge  balance:  
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8( ) 500( )
4! 100( )2
=
X( ) 100( )
4! 30( )2
  
where  X  is  3.6  net  positive  charge  per  ELPBC  to  create  a  nanoparticle  with  equivalent  
surface  charge  density  to  that  of  the  TAT-­‐‑functionalized  liposome.  This  approximation  
directed  the  choice  to  first  explore  this  system  with  an  ELPBC  carrying  3  arginines  per  
unimer,  in  hopes  that  rounding  down  to  3  positive  charges  per  unimer  would  minimize  
uptake  in  the  unimer  “off”  state,  while  still  achieving  enhanced  uptake  at  the  micelle  
“on”  state.  
2.3.2 CPP-ELPBC syntax 
The  first  generation  ELPBCs  synthesized  by  Dreher  et  al.  [126]  were  designed  such  
that,  from  N-­‐‑to-­‐‑C  terminus,  the  hydrophilic  block  was  expressed  first,  followed  by  the  
hydrophobic  block.  This  ELPBC  syntax  thus  required  that  any  functionalization  of  the  
hydrophilic  block,  which  would  decorate  a  micelle  corona  upon  self-­‐‑assembly,  must  be  
expressed  at  the  N-­‐‑terminus  of  the  ELPBC  gene.  N-­‐‑terminal  functionalization  had  
previously  been  successful  for  genetically  appending  ELPBCs  with  both  peptides  [126]  
and  proteins  [130].  This  ELPBC  syntax  was  therefore  also  explored  for  CPP  
functionalization.  Unfortunately,  with  the  addition  of  three  arginines  at  the  N-­‐‑terminus  
of  the  ELPBC,  no  recombinant  product  could  be  purified  from  the  E.  coli  lysate.  SDS-­‐‑
PAGE  analysis  of  the  cell  lysate  confirmed  that  the  Arg3-­‐‑ELPBC  was  not  overexpressed,  
as  compared  to  bacterial  proteins.    
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In  retrospect,  it  was  not  surprising  that  this  diblock  syntax  was  inappropriate  
when  it  required  the  N-­‐‑terminal  expression  of  arginine  oligomers.  Arginines  are  known  
to  have  a  destabilizing  effect  when  present  at  the  N-­‐‑terminus  of  proteins  expressed  in  E.  
coli,  leading  to  a  short  half-­‐‑life  in  the  bacteria  as  they  are  quickly  degraded  [142].  
Therefore  to  successfully  functionalize  the  hydrophilic  domain  of  ELPBCs  with  arginine  
oligomers,  the  syntax  of  the  ELPBC  had  to  be  reversed,  such  that  the  hydrophobic  block  
was  expressed  first,  followed  by  the  hydrophilic  block  and  finally  the  C-­‐‑terminal  
expression  of  arginine-­‐‑rich  CPPs.  
Prior  to  the  creation  of  CPP-­‐‑ELPBCs  in  this  alternative  syntax,  a  non-­‐‑
functionalized  ELPBC  was  designed  and  synthesized  with  both  possible  syntax  to  
determine  the  effect,  if  any,  that  ELPBC  expression  order  had  on  temperature-­‐‑triggered  
self-­‐‑assembly.  Surprisingly,  the  thermal  behavior  of  the  ELPBC  changed  significantly  
depending  on  its  syntax,  such  that  the  ELPBC  with  hydrophobic-­‐‑to-­‐‑hydrophilic  syntax,  
necessary  for  CPP-­‐‑functionalization,  had  a  decreased  CMT  and  increased  micelle-­‐‑to-­‐‑
aggregate  Tt,  as  compared  to  the  ELPBC  with  hydrophilic-­‐‑to-­‐‑hydrophobic  syntax  (Figure  
8).    
  











































































Figure  8:  Syntax  influences  thermal  properties  of  ELPBCs  as  measured  by  temperature-­‐‑
regulated  turbidimetry.  Both  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  are  affected  by  the  
expression  order  of  the  ELPBC  as  evident  in  comparing  an  ELPBC  with  hydrophobic-­‐‑to-­‐‑
hydrophilic  expression  order  (A:  MGCGWPG-­‐‑E4-­‐‑60/E2-­‐‑96-­‐‑PGGSK)  to  an  ELPBC  with  
hydrophilic-­‐‑to-­‐‑hydrophobic  expression  order  (B:  MSKGPG-­‐‑E2-­‐‑96/E4-­‐‑60-­‐‑WPC).  
Temperature-­‐‑regulated  turbidimetry  measurements  were  taken  in  PBS  at  5-­‐‑100  µμM.  
Arg3-­‐‑functionalized  ELPBCs  were  then  synthesized  in  the  hydrophobic-­‐‑to-­‐‑
hydrophilic  syntax,  where  the  Arg3  was  appended  to  the  C-­‐‑terminus,  and  were  
successfully  overexpressed  in  E.  coli.  Reversing  the  ELPBC  syntax  therefore  provided  
efficient  expression  for  constructs  genetically  appended  to  an  arginine-­‐‑rich  CPP  at  the  
terminus  of  the  hydrophilic  domain.  Arg3-­‐‑ELPBCs,  despite  their  additional  charge,  were  
sufficiently  purified  by  means  of  the  ELP  LCST  behavior,  without  any  modification  to  
the  standard  ITC  protocol.  This  ease  of  purification  held  true  for  all  variations  of  CPP-­‐‑
ELPBC  functionalization,  as  demonstrated  by  SDS-­‐‑PAGE  analysis  of  CPP-­‐‑ELPBCs  that  
exhibited  good  agreement  of  recombinant  product  MW  with  theoretical  MW  and  good  
purity  by  lack  of  contaminating  bands  (Figure  9).  
  


















Figure  9:  ELPBCs  with  various  CPP-­‐‑functionalization  were  overexpressed  and  
sufficiently  purified  from  E.  coli  lysate  when  designed  in  a  hydrophobic-­‐‑to-­‐‑
hydrophilic  ELPBC  syntax.  SDS-­‐‑PAGE  and  CuCl2  staining  of  CPP-­‐‑ELPBC  products  
demonstrated  agreement  of  measured  and  theoretical  MW,  where  the  expected  MWs  
varied  slightly  due  to  CPP  functionalization  and  were,  by  lane:  1)  39.72  kDa,  2)  40.05  
kDa,  3)  40.97  kDa,  4)  41.26  kDa,  and  5)  41.05  kDa.  
2.3.3 Characterization of first generation CPP-ELPBCs  
Three  ELPBCs  were  synthesized  with  a  hydrophobic-­‐‑to-­‐‑hydrophilic  syntax  and  
functionalized  with  Arg3  at  the  hydrophilic  terminus.    These  diblock  copolymers  had  a  
hydrophobic/hydrophilic  block  size  ratio  of  E4-­‐‑90/E2-­‐‑64,  E4-­‐‑60/E2-­‐‑96,  or  E4-­‐‑60/E2-­‐‑64,  
which  in  their  opposite  syntax  had  been  designed  previously  by  Dreher  et  al.  [126].  The  
addition  of  Arg3  to  any  of  these  diblock  configurations  did  not  perturb  the  temperature-­‐‑
triggered  micelle  assembly  (Figure  10).  However,  the  reversed  syntax  of  these  diblocks  
caused  a  drop  in  CMT  below  37  °C,  such  that  these  materials  would  not  be  suitable  for  
hyperthermia-­‐‑targeted  self-­‐‑assembly  between  normal  body  temperature  and  conditions  
of  mild  hyperthermia.  Although  not  ideal  in  achieving  our  ultimate  goal  of  utilizing  a  
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clinically  relevant  extrinsic  thermal  stimulus  to  trigger  micelle  assembly,  these  first  
generation  materials  would  still  permit  us  to  investigate  the  proof-­‐‑of-­‐‑concept  of  
controlled  cell  uptake  with  CPP  density  modulation  on  self-­‐‑assembled  nanoparticles  
using  thermal  conditions  of  25  °C  and  37  °C  as  the  “off”  and  “on”  conditions,  
respectively.  Indeed,  these  conditions  may  inadvertently  provide  an  advantage  of  
evaluating  our  hypothesis  in  the  absence  of  the  hyperthermia  parameter,  which  could  
have  its  own  confounding  effects  on  cellular  uptake  of  drug  carriers.  
  































































































































































Figure  10:  Functionalization  of  the  hydrophilic  terminus  with  Arg3  CPP  did  not  
perturb  temperature-­‐‑triggered  self-­‐‑assembly  of  ELPBCs  E4-­‐‑90/E2-­‐‑64  (A-­‐‑B),  E4-­‐‑60/E2-­‐‑96  
(C-­‐‑D),  or  E4-­‐‑60/E2-­‐‑64  (E-­‐‑F),  as  determined  by  temperature-­‐‑regulated  turbidimetry  (A,  
C,  and  E)  and  DLS  (B,  D,  and  F).  However,  changes  in  behavior  due  to  ELPBC  syntax  
precluded  the  use  of  these  materials  for  triggered  self-­‐‑assembly  between  body  
temperature  and  conditions  of  mild  clinical  hyperthermia.  Temperature-­‐‑regulated  
turbidimetry  measurements  were  taken  in  PBS  at  5-­‐‑100  µμM.  DLS  data  represent  mean  
of  three  measurements  taken  in  PBS  at  25  µμM  ±  SD.  
Successful  self-­‐‑assembly  was  also  evident  by  the  change  in  surface  charge,  
measured  by  zeta  potential,  with  respect  to  temperature-­‐‑triggered  micelle  formation.  As  
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a  CPP-­‐‑ELPBC  solution  is  heated,  an  increase  in  zeta  potential  is  expected  when  the  
unimer  self-­‐‑assembles  into  micelles,  transitioning  from  a  low  density  of  cationic  CPP  on  
the  unimer  to  high  density  cationic  CPP  on  the  micelle  surface.  Indeed  this  was  true  for  
Arg3-­‐‑functionalized  E4-­‐‑60/E2-­‐‑96  whose  zeta  potential  increased  as  the  solution  
temperature  was  raised  from  25  °C,  to  37  °C,  to  42  °C  (Figure  11).  The  change  in  zeta  
potential  with  micelle  assembly  and  the  magnitude  of  the  zeta  potential  in  the  micelle  
state  is  reasonable  when  compared  to  other  CPP-­‐‑functionalized  carriers.  For  example,  an  
increase  in  zeta  potential  from  0  to  6  mV  has  been  reported  for  the  deshielding  of  
activatable  TAT-­‐‑functionalized  micelles  [143].  Thus  the  change  in  zeta  potential  from  2  
to  6  mV  with  self-­‐‑assembly  of  Arg3-­‐‑ELPBCs  is  feasible  since  these  materials  have  some  
inherent  charge  in  their  unassembled  state,  in  contrast  to  shielded  TAT-­‐‑functionalized  
micelles,  and  will  likely  display  less  charge  on  the  nanoparticle  corona  as  Arg3  CPP  has  
less  net  charge  than  TAT.  Interestingly,  non-­‐‑functionalized  ELPBC  showed  the  opposite  
trend,  whereby  its  zeta  potential  became  increasingly  more  negative  as  temperature  was  
increased.  This  is  logical,  however,  in  that  this  construct  has  a  negatively  charged  
carboxyl  group  on  the  C-­‐‑terminus  that  will  decorate  the  micelle  surface  upon  self-­‐‑
assembly.    
  


























Figure  11:  Change  in  zeta  potential  is  indicative  of  temperature-­‐‑triggered  micelle  
assembly  of  E4-­‐‑60/E2-­‐‑96  diblocks.  Increasingly  positive  zeta  potential  was  measured  
for  Arg3-­‐‑ELPBC  as  it  was  heated  from  below  its  CMT  at  25  °C  to  above  its  CMT  at  37  °C  
and  42  °C.  Non-­‐‑functionalized  ELPBC  exhibited  an  increasingly  negative  zeta  potential  
with  micelle  assembly,  likely  due  to  the  negatively  charged  carboxyl  terminus  
decorating  the  surface  of  this  control  micelle.  Data  represents  mean  of  3  
measurements  taken  in  low  ionic  strength  buffer  at  50  µμM  ±  SD.  
Of  the  three  block  copolymers  investigated,  E4-­‐‑60/E2-­‐‑96  was  chosen  for  further  
study,  as  it  achieved  stable  micelle  assembly  over  the  largest  temperature  range  and  its  
CMT  was  well  positioned  to  be  centrally  located  between  the  “off”  and  “on”  conditions,  
25  °C  and  37  °C  respectively,  to  investigate  the  effects  of  self-­‐‑assembly  of  this  non-­‐‑
optimized  CPP-­‐‑ELPBC  family.  Functionalization  of  this  block  copolymer  with  arginine  
oligomers  of  1,  3,  or  5  arginine  residues  demonstrated  that  the  micelle-­‐‑to-­‐‑aggregate  Tt  
was  affected  by  changes  in  functionalization,  but  the  CMT  remained  relatively  
unperturbed  such  that  “off”  and  “on”  conditions  of  25  °C  and  37  °C  could  be  used  
consistently  for  all  E4-­‐‑60/E2-­‐‑96  diblocks,  regardless  of  CPP-­‐‑functionalization  (Figure  12).  
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Interestingly,  as  the  functionalization  was  increased  from  1,  to  3,  to  5  arginines,  the  
micelle-­‐‑to-­‐‑aggregate  Tt  decreased.  This  is  somewhat  surprising  given  the  charge  of  the  
arginine  residues,  which  one  would  assume  would  impart  an  enhanced  hydrophilicity  
to  the  ELPBC  that  would  increase  the  micelle-­‐‑to-­‐‑aggregate  Tt.  However,  this  effect  likely  
stems  from  the  relative  hydrophobicity  of  the  arginine  residue,  despite  its  cationic  





























Figure  12:  CPP-­‐‑functionalization  affects  the  micelle-­‐‑to-­‐‑aggregate  Tt,  without  
perturbing  the  CMT  of  ELPBCs,  as  demonstrated  by  temperature-­‐‑regulated  
turbidimetry.  E4-­‐‑60/E2-­‐‑96  was  functionalized  with  Arg1,  Arg3,  and  Arg5  CPPs  and  
demonstrated  a  decreasing  micelle-­‐‑to-­‐‑aggregate  transition  as  more  arginine  residues  
were  added  to  the  hydrophilic  terminus.  The  CMT,  however,  did  not  change  
significantly  based  on  CPP  functionalization,  allowing  all  constructs  to  be  examined  
in  “off”  and  “on”  states  of  25  °C  and  37  °C,  respectively.  Temperature-­‐‑regulated  
turbidimetry  measurements  were  taken  in  PBS  at  25  µμM.  
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2.3.4 Characterization of second generation CPP-ELPBCs  
To  achieve  materials  with  the  desired  response  to  mild  clinical  hyperthermia,  the  
block  copolymer  design  was  manipulated  with  the  goal  of  a  CMT  between  37  °C  and  42  
°C.  Although  the  rules  for  predictable  ELPBC  design  are  growing  [127],  there  remains  a  
need  to  intrinsically  verify  the  thermal  behavior  of  ELPBCs  whose  design  is  guided  by  
educated  hypotheses,  based  largely  on  the  knowledge  gleaned  from  the  behavior  of  the  
homopolymer  ELPs  from  which  the  ELPBC  is  composed.  Therefore,  knowledge  of  the  
ELP  Tt’s  dependence  on  intrinsic  parameters  of  sequence  (ex.  guest  residue)  and  length  
directed  the  manipulation  of  the  existing  CPP-­‐‑ELPBC  design  to  raise  the  CMT.  
Manipulation  of  these  design  parameters—sequence  and  length—among  other  changes,  
may  be  made  to  the  ELPBC  to  achieve  a  desirable  thermal  behavior,  as  outlined  in  the  
flow  chart  of  Figure  13.  
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Figure  13:  An  iterative  design  process  was  used  to  optimize  the  ELPBC  thermal  
behavior,  as  measured  by  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt.  Manipulation  of  the  
ELPBC  design  was  performed  to  achieve  temperature-­‐‑triggered  self-­‐‑assembly  in  
response  to  conditions  of  mild  clinical  hyperthermia.  
The  CMT  is  largely  dependent  on  the  hydrophobic  block  whose  transition  
initiates  self-­‐‑assembly  and  forms  the  micelle  core.  To  increase  the  Tt  of  the  hydrophobic  
block  the  length  of  this  segment  was  decreased,  while  the  ELP  sequence  was  kept  
constant.  This  new  hydrophobic  block  was  E4-­‐‑30.  The  shorter  hydrophilic  block,  E2-­‐‑64,  
was  utilized  as  it  should  have  a  higher  Tt  than  the  larger  E2-­‐‑96  block  used  previously.  
Combination  of  these  new  hydrophobic  and  hydrophilic  blocks  yielded  an  ELPBC  of  E4-­‐‑
30/E2-­‐‑64  that  achieved  the  target  CMT  between  37  °C  and  42  °C,  as  confirmed  by  
temperature-­‐‑regulated  turbidimetry  and  DLS  (Figure  14).  Manipulation  of  the  
    67  
hydrophobic  block  also  slightly  increased  the  micelle-­‐‑to-­‐‑aggregate  Tt,  as  compared  to  the  


































Figure  14:  Second  generation  Arg5-­‐‑ELPBC  achieved  self-­‐‑assembly  in  response  to  mild  
hyperthermia.  Decreasing  the  size  of  the  hydrophobic  block  achieved  a  CMT  between  
37  °C  and  42  °C  for  E4-­‐‑30/E2-­‐‑64  as  determined  by  temperature-­‐‑regulated  turbidimetry  
(line)  and  DLS  (dots).  This  ELPBC,  however,  exhibited  a  limited  self-­‐‑assembly  range  
(<10  °C),  which  would  ultimately  prevent  it  from  being  a  broadly  applicable  construct  
for  the  purpose  of  targeted  uptake  and  drug  delivery.  Temperature-­‐‑regulated  
turbidimetry  and  DLS  measurements  were  acquired  in  PBS  at  25  µμM.  
The  increase  in  CMT  in  combination  with  the  less  significant  change  in  the  
micelle-­‐‑to-­‐‑aggregate  Tt  of  the  optimized  E4-­‐‑30/E2-­‐‑64  diblock  effectively  decreased  the  
range  of  temperatures  over  which  stable  micelle  assembly  was  attained  (this  range  is  
defined  as  that  between  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt)  (Figure  15).  Although  a  
minimum  micelle  assembly  range,  and  thus  an  implied  minimum  micelle-­‐‑to-­‐‑aggregate  
Tt,  was  not  an  initial  requirement  of  ELPBC  optimization,  it  would  become  an  important  
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design  parameter  when  the  ELPBC  was  further  modified  in  ways  that  affected  its  thermal  
behavior,  such  as  the  attachment  of  fluorescent  labels.  For  this  reason  the  E4-­‐‑30/E2-­‐‑64  
diblock  would  not  be  the  optimal  construct  for  application  as  a  drug  delivery  vehicle,  
but  it  did  provide  the  properties  that  allowed  the  initial  evaluation  of  controlled  cellular  
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Figure  15:  Raising  the  CMT  in  second  generation  ELPBCs  decreased  the  temperature  
range  over  which  stable  micelle  assembly  occurred.  Comparison  between  first  
generation  Arg3-­‐‑ELPBCs  (A)  and  second  generation  Arg5-­‐‑ELPBC  (B)  demonstrated  the  
decreased  micelle  range  that  resulted  from  the  increase  in  the  CMT,  that  was  greater  
than  the  increase  in  the  micelle-­‐‑to-­‐‑aggregate  Tt.  CMTs  and  micelle-­‐‑to-­‐‑aggregate  Tts  
were  obtained  from  temperature-­‐‑regulated  turbidimetry  measurements  in  PBS  at  5-­‐‑
100  µμM.  
2.3.5 Characterization of third generation CPP-ELPBCs  
To  further  optimize  the  thermal  response  of  CPP-­‐‑ELPBCs,  a  new  ELP  sequence  
was  investigated  to  raise  the  Tt  of  the  hydrophilic  domain.  These  third  generation  ELPBCs  
were  synthesized  with  PRe-­‐‑RDL  cloning.  The  hydrophilic  domain  was  composed  of  60  
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pentapeptides  of  E2*,  whose  sequence  (VPGXG)60  where  X=A1G1  is  more  hydrophilic  
than  the  previous  hydrophilic  domain  of  E2,  which  alternatively  replaced  a  hydrophilic  
glycine  guest  residue  with  a  hydrophobic  valine  guest  residue  in  every  16th  
pentapeptide.  The  hydrophobic  domain  was  still  composed  of  E4,  but  three  lengths  of  
this  domain  were  investigated—30,  35,  or  40  pentapeptides—to  fine-­‐‑tune  the  thermal  
response  by  their  increasing  hydrophobicity.  The  hydrophobic  and  hydrophilic  genes  
were  fused  to  create  diblocks  of  E4-­‐‑30/E2*-­‐‑60,  E4-­‐‑35/E2*-­‐‑60,  and  E4-­‐‑40/E2*-­‐‑60  which  
were  functionalized  with  Arg5  CPP  and  characterized  by  temperature-­‐‑regulated  






















Figure  16:  Third  generation  Arg5-­‐‑ELPBCs  achieved  self-­‐‑assembly  in  response  to  mild  
hyperthermia  and  increased  the  micelle  assembly  range.  A  more  hydrophilic  domain,  
composed  of  E2*,  increased  the  micelle-­‐‑to-­‐‑aggregate  Tt.  Three  hydrophobic  block  
sizes,  composed  of  E4  with  30,  35,  or  40  pentapeptides,  provided  fine-­‐‑tuning  of  the  
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CMT  between  37  °C  and  42  °C.  Temperature-­‐‑regulated  turbidimetry  measurements  
were  taken  in  PBS  at  25  µμM.  
The  more  hydrophilic  E2*  sequence  increased  the  micelle-­‐‑to-­‐‑aggregate  Tt  as  
much  as  5  °C,  as  compared  to  previous  constructs  using  E2.  This  new  hydrophilic  block,  
in  combination  with  all  three  hydrophobic  block  lengths  tested,  achieved  a  desired  CMT  
between  37  °C  and  42  °C  at  25  µμM.  As  expected,  the  CMT  was  fine-­‐‑tuned  by  the  subtle  
changes  in  the  hydrophobic  block  size,  such  that  the  CMT  increased  slightly  as  the  
hydrophobic  block  decreased  in  length  (Table  6).  The  effect  of  the  hydrophobic  block  
size  was  also  reflected  in  the  micelle-­‐‑to-­‐‑aggregate  Tt,  which  decreased  slightly  with  
increasing  hydrophobic  block  length.  
Table  6:  Fine-­‐‑tuning  of  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  of  third  generation  Arg5-­‐‑
ELPBCs.  
Arg5-­‐‑ELPBC   CMT   Micelle-­‐‑to-­‐‑aggregate  Tt  
E4-­‐‑30/E2*-­‐‑60   40.5  °C   55.3  °C  
E4-­‐‑35/E2*-­‐‑60   38.8  °C   54.1  °C  
E4-­‐‑40/E2*-­‐‑60   37.5  °C   53.1  °C  
  
DLS  of  the  Arg5-­‐‑ELPBCs  with  the  two  extremes  in  hydrophobic  block  length  
further  demonstrated  the  fine-­‐‑tuned  temperature-­‐‑triggered  self-­‐‑assembly  of  
nanoparticles  approximately  20  nm  in  radius  (Figure  17).  This  library  of  ELPBCs  with  
finely  tuned  CMT  would  be  particularly  important  when  these  constructs  were  further  
modified  to  serve  their  function  as  carriers  for  controlled  cellular  uptake  and  drug  
delivery.  Addition  of  moieties  such  as  fluorescent  labels  and  drug  cargo  are  expected  to  
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slightly  perturb  the  thermal  properties  of  the  ELPBCs,  and  thus  this  library  of  materials  
was  useful  to  pull  from  to  conform  to  those  perturbations  and  maintain  an  appropriate  

























































































Figure  17:  Third  generation  Arg5-­‐‑ELPBCs  finely  tune  the  temperature-­‐‑triggered  
behavior,  as  confirmed  by  DLS.  Arg5-­‐‑functionalized  E4-­‐‑30/E2*-­‐‑60  (A)  and  Arg5-­‐‑
functionalized  E4-­‐‑40/E2*-­‐‑60  (B)  demonstrate  CMTs  between  37  °C  and  42  °C  that  
differ  by  only  2  °C,  as  controlled  by  the  length  of  their  hydrophobic  domain.  
Temperature-­‐‑regulated  turbidimetry  (lines)  and  DLS  (dots)  measurements  were  taken  
in  PBS  at  25  µμM.  
Zeta  potential  measurements  also  confirmed  the  self-­‐‑assembly  of  third  
generation  CPP-­‐‑ELPBCs.  To  improve  the  quality  of  zeta  potential  measurements,  these  
ELPBCs  were  investigated  in  water  to  circumvent  the  negative  effects  of  salt  on  this  
technique.  These  CPP-­‐‑ELPBCs  were  thus  measured  at  an  elevated  concentration  (100  µμM)  
and  elevated  temperature  (50  °C)  that  achieved  micelle  assembly  while  considering  the  
change  in  thermal  properties  due  to  the  absence  of  salts.  At  these  conditions,  Arg5-­‐‑
functionalized  E4-­‐‑40/E2*-­‐‑60  and  non-­‐‑functionalized  E4-­‐‑40/E2*-­‐‑60  micelles  exhibited  zeta  
potentials  of  14.3  ±  0.5  mV  and  -­‐‑4.8  ±  0.8  mV  (average  of  three  measurements    ±  SEM),  
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respectively.  Arg5-­‐‑ELPBC  exhibited  a  positive  zeta  potential,  indicative  of  the  high  
density  of  cationic  CPP  on  the  micelle  corona.  The  negative  zeta  potential  of  the  non-­‐‑
functionalized  ELPBC  was  likely  due  to  the  presentation  of  the  negatively  charged  ELP  C-­‐‑
terminus  on  the  corona  of  this  control  micelle.  
The  role  of  alternative  CPPs  was  investigated  by  the  functionalization  of  third  
generation  E4-­‐‑40/E2*-­‐‑60  block  copolymer.  This  block  copolymer  was  functionalized  with  
Arg8,  TAT  (residues  47-­‐‑57),  and  a  mutation  of  TAT,  termed  RTAT,  in  which  the  
architecture  of  arginine  could  be  evaluated  without  contribution  from  other  charged  
residues,  as  achieved  by  mutation  of  all  non-­‐‑arginine  residues  to  neutral  glycine  
residues.  The  thermal  behavior  of  Arg5-­‐‑ELPBC  as  compared  to  Arg8-­‐‑ELPBC  confirmed  that  
third  generation  ELPBCs  could  be  functionalized  with  new  CPPs  without  significantly  
perturbing  the  CMT.  Altering  the  functionalization  at  the  corona  does,  however,  
influence  the  micelle-­‐‑to-­‐‑aggregate  transition  (Figure  18).  Yet,  the  conserved  transition  
from  unimer  at  37  °C  to  micelle  at  42  °C,  despite  changes  in  the  charge  of  functionalized  
CPP  at  their  most  extreme,  supported  the  choice  of  this  third  generation  ELPBC  as  a  
platform  for  the  investigation  of  a  variety  of  CPPs  in  the  pursuit  of  controlled  cellular  
uptake  by  modulation  of  CPP  density  with  temperature-­‐‑triggered  micelle  assembly.  
  
























Figure  18:  The  CMT  was  conserved  between  third  generation  E4-­‐‑40/E2*-­‐‑60  block  
copolymers  despite  variation  in  CPP-­‐‑functionalization.  Functionalization  of  E4-­‐‑
40/E2*-­‐‑60  with  Arg5  or  Arg8  did  not  significantly  perturb  the  CMT  as  compared  to  a  
non-­‐‑functionalized  ELPBC  control,  confirming  the  utility  of  this  platform  to  produce  
various  CPP-­‐‑ELPBCs  for  controlled  cellular  uptake  and  drug  delivery.  Temperature-­‐‑
regulated  turbidimetry  measurements  were  taken  in  PBS  at  15  µμM.  
2.4 Conclusions 
Significant  changes  in  the  design  of  ELPBCs  were  made  to  accommodate  the  
addition  of  CPPs  on  the  hydrophilic  terminus  and  compensate  for  resulting  changes  in  
the  ELPBC  thermal  properties,  with  the  goal  of  achieving  a  unimer-­‐‑to-­‐‑micelle  transition  
between  body  temperature  and  a  temperature  typical  of  mild  clinical  hyperthermia.  
Prior  to  CPP-­‐‑functionalization,  the  ELPBC  syntax  was  reversed  to  allow  the  expression  of  
residues  typical  to  cationic  CPPs  (ex.  arginines)  on  the  hydrophilic  terminus  of  the  
ELPBC.  In  this  syntax,  CPP-­‐‑functionalization  of  ELPBCs  did  not  destroy  the  temperature-­‐‑
triggered  self-­‐‑assembly.  However,  the  syntax  did  influence  the  thermal  properties  of  the  
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ELPBC,  such  that  first  generation  constructs  displayed  a  CMT  below  37  °C,  which  did  not  
meet  the  goal  of  achieving  triggered  self-­‐‑assembly  in  response  to  mild  clinical  
hyperthermia.    
Iterative  manipulation  of  CPP-­‐‑ELPBC  design  parameters  was  performed  to  
improve  the  thermal  behavior,  with  the  goal  of  achieving  a  CMT  between  37  °C  and  42  
°C.  Decreasing  the  length  of  the  hydrophobic  domain  achieved  this  goal  with  an  E4-­‐‑
30/E2-­‐‑64  block  copolymer,  albeit  at  the  negative  side-­‐‑effect  of  decreasing  the  
temperature  range  over  which  stable  micelle  assembly  occurred.  This  would  eventually  
become  a  limitation  of  this  block  copolymer  when  additional  manipulation  of  the  
construct  (ex.  fluorophore  conjugation)  would  further  limit  the  micelle  range  and  
eventually  destroy  micelle  assembly.    
Further  optimization  of  the  block  copolymers  was  thus  necessary  to  increase  the  
micelle-­‐‑to-­‐‑aggregate  transition  and  thereby  increase  the  temperature  range  over  which  
stable  micelle  assembly  was  achieved.  This  was  accomplished  with  a  hydrophilic  
domain  composed  of  a  new  ELP  sequence,  E2*,  with  an  increased  Tt.  This  adjustment  of  
the  ELPBC  design  created  a  construct  that  achieved  both  a  CMT  between  37  °C  and  42  °C  
and  an  extended  micelle  assembly  range  that  could  accommodate  the  perturbations  
typical  of  fluorophore  conjugation  and  drug  loading.  This  third  generation  ELPBC  
displayed  a  consistent  CMT,  regardless  of  CPP-­‐‑functionalization,  demonstrating  its  
strength  as  a  platform  material  to  test  the  function  of  various  CPPs  for  controlled  
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cellular  uptake  by  modulation  of  CPP  density  with  temperature-­‐‑triggered  micelle  
assembly.  
Successful  design  of  CPP-­‐‑ELPBCs  was  primarily  measured  by  the  ability  to  
achieve  temperature-­‐‑triggered  micelle  assembly  between  conditions  of  37  °C  and  42  °C.  
However,  additional  aspects  of  the  self-­‐‑assembled  micelles  may  be  influenced  by  the  
CPP-­‐‑ELPBC  design  and  have  an  effect  on  the  performance  of  CPP-­‐‑ELPBCs  as  drug  
carriers.  The  aggregation  number  (number  of  CPP-­‐‑ELPBC  chains  per  micelle),  for  
instance,  may  vary  with  CPP-­‐‑functionalization  or  ELPBC  design  and  influence  the  
valency  of  CPP  on  each  micelle.  This  could  lead  to  changes  in  cellular  uptake  depending  
on  the  number  of  CPPs  on  each  micelle  that  are  capable  of  interacting  with  the  cell  
surface.  More  thorough  characterization  of  the  CPP-­‐‑ELPBC  micelle  structure  and  
morphology  may  shed  greater  light  on  the  relationship  between  the  design  and  function  
of  CPP-­‐‑ELPBCs.  
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3. Controlled cellular uptake of CPP-ELPBCs in vitro 
3.1 Motivation 
Temperature-­‐‑triggered  CPP-­‐‑ELPBC  micelle  assembly  provides  the  mechanism  to  
control  the  density  of  CPPs  by  means  of  an  extrinsic  stimulus.  CPP-­‐‑ELPBCs  below  their  
CMT  exist  as  soluble  unimers  whose  low  CPP  density  (ex.  a  limited  number  of  arginine  
residues  per  ELPBC)  does  not  strongly  encourage  cellular  uptake  as  conferred  by  the  CPP  
moiety.  CPP-­‐‑ELPBCs  above  their  CMT,  however,  present  a  high  density  of  CPPs  on  the  
self-­‐‑assembled  micelle  corona,  which  encourages  enhanced  cellular  uptake  as  defined  by  
the  CPP  component.  CPP-­‐‑ELPBCs  synthesized  in  the  previous  section  were  characterized  
to  determine  “on”  and  “off”  state  thermal  conditions  at  which  the  ELPBC  was  a  unimer  
(T  <  CMT)  or  a  micelle  (CMT  <  T  <  micelle-­‐‑to-­‐‑aggregate  Tt).  This  defined  the  
experimental  conditions  used  to  evaluate  the  controlled  cellular  uptake  as  triggered  by  
an  external  thermal  stimulus.  
To  best  evaluate  controlled  cellular  uptake,  the  CPP-­‐‑ELPBCs  were  labeled  with  a  
fluorescent  dye  to  allow  them  to  be  visualized  by  microscopy  and  quantified  by  flow  
cytometry.  Comparing  internalization  below  and  above  the  CMT  provided  a  
preliminary  understanding  of  cellular  uptake,  as  controlled  by  the  temperature-­‐‑
triggered  self-­‐‑assembly  of  CPP-­‐‑ELPBCs.  As  the  mechanism  of  uptake  is  known  to  depend  
on  both  the  CPP  and  its  appended  cargo,  common  routes  of  endocytosis  were  
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investigated  for  their  role  in  the  uptake  of  CPP-­‐‑ELPBCs  by  inhibition  and  colocalization  
studies.    
3.2 Methods 
3.2.1 Fluorophore labeling of CPP-ELPBCs 
CPP-­‐‑ELPBCs  and  controls  were  fluorescently  labeled  with  Alexa  Fluor  488.  The  
reactive  cysteine  residue  at  the  ELP  N-­‐‑terminus  permitted  conjugation  of  fluorophore  
via  maleimide  chemistry.  Purified  ELP  was  reacted  with  an  excess  of  Alexa  Fluor  488  
C5-­‐‑maleimide  in  3  mM  TCEP-­‐‑HCl  and  10  mM  sodium  phosphate  for  2  hours  at  room  
temperature.  ELP  was  collected  from  the  reaction  solution  by  the  addition  of  NaCl  to  
induce  ELP  coacervation  and  centrifugation  for  10  minutes  at  16,000  x  g.  Free  
fluorophore  in  the  supernatant  was  discarded  and  the  ELP  pellet  was  resuspended  in  
PBS.  Resuspended  ELP  was  passed  through  a  desalting  column  to  remove  remaining  
free  fluorophore.  Labeling  efficiency  was  determined  by  absorbance  at  495  nm,  
compensating  for  fluorophore  absorbance  occurring  at  the  280  nm  protein  peak.  Labeled  
ELP  was  mixed  with  respective  unlabeled  ELP  to  achieve  a  labeling  efficiency  that  was  
equivalent  across  all  CPP-­‐‑ELPBCs  and  controls  compared  in  an  experiment.  A  labeling  
efficiency  of  50%  was  typical  for  most  experiments.  
3.2.2 Cell culture 
HeLa  cells  were  grown  in  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  
supplemented  with  10%  fetal  bovine  serum  (FBS),  0.1  M  non-­‐‑essential  amino  acids,  1.0  
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mM  sodium  pyruvate,  100  units/mL  penicillin,  and  100  µμg/mL  streptomycin.  MCF7  cells  
were  grown  in  Minimum  Essential  Medium  Eagle  with  Earle’s  salts,  supplemented  with  
10%  FBS,  0.01  mg/mL  bovine  insulin,  0.1  M  non-­‐‑essential  amino  acids,  1.0  mM  sodium  
pyruvate,  100  units/mL  penicillin,  and  100  µμg/mL  streptomycin.  HUVEC  cells  were  
cultured  in  EBM-­‐‑2  media  supplemented  with  EGM-­‐‑2MV  SingleQuots  and  5%  FBS.  All  
cells  were  maintained  at  37  °C  and  5%  CO2.  
3.2.3 Visualization of CPP-ELPBC uptake with live cell microscopy 
Cells  were  seeded  on  8  well  coverglass  slides  and  allowed  to  attach  for  24  hours,  
after  which  the  media  was  removed  and  replaced  with  serum-­‐‑free  media  (SF-­‐‑media)  
containing  Alexa  Fluor  488-­‐‑labeled  CPP-­‐‑ELPBCs  or  controls  at  concentrations  of  10-­‐‑25  
µM.  The  slides  were  incubated  at  37  °C  or  42  °C  for  1  hour  after  which  the  media  was  
replaced  with  Hank’s  balanced  salt  solution  (HBSS)  containing  5  µμg/mL  Alexa  Fluor  594  
wheat  agglutinin  and  2  µμM  Hoechst  33342  to  stain  the  cell  membrane  and  cell  nuclei,  
respectively.  After  10  minutes,  cells  were  washed  3  times  with  PBS  before  the  addition  of  
HBSS.  The  cells  were  imaged  immediately  on  a  Nikon  Eclipse  TE2000  widefield  
fluorescence  microscope,  using  a  60x  oil  immersion  objective,  or  on  a  Leica  SP5  confocal  
microscope,  using  a  63x  water  immersion  objective.    
3.2.4 Quantification of CPP-ELPBC uptake with live cell flow cytometry 
HeLa,  MCF7,  or  HUVEC  cells  were  seeded  in  12-­‐‑well  tissue  culture  polystyrene  
plates.  After  24  hours  the  media  was  removed  and  replaced  with  SF-­‐‑media  containing  10  
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-­‐‑25  µM  of  Alexa  Fluor  488-­‐‑labeled  CPP-­‐‑ELPBC  or  controls.  The  plates  were  incubated  at  
37  °C  or  42  °C  for  1  hour  after  which  the  cells  were  washed  once  with  PBS  and  removed  
from  the  culture  surface  with  0.05%  trypsin/EDTA.  The  cells  were  washed  by  
centrifugation  for  3  minutes  at  1,200  RPM  once  with  complete  media  and  twice  more  
with  PBS  before  immediate  analysis  on  a  BD  LSR  II  flow  cytometer.  Cells  were  gated  on  
the  live  population  by  forward  and  side  scatter  and  no  less  than  10,000  cells  were  
evaluated  to  determine  cellular  uptake  by  measure  of  mean  cellular  fluorescence,  
corrected  for  autofluorescence  of  untreated  cells.  
3.2.5 Investigation of uptake mechanism and intracellular localization 
of CPP-ELPBCs  
3.2.5.1  Inhibition  of  endocytosis  pathways  
To  evaluate  the  contribution  of  endocytosis  pathways  on  the  cellular  uptake  of  
CPP-­‐‑ELPBCs,  HeLa  cells  were  co-­‐‑incubated  with  CPP-­‐‑ELPBCs  or  controls  at  20  µμM  in  SF-­‐‑
media  in  combination  with  inhibitors  for  clathrin-­‐‑mediated  endocytosis  
(chlorpromazine  (10  µμM)  or  dansylcadaverine  (50  µμM)),  caveolae-­‐‑mediated  endocytosis  
(filipin  (0.5  µμg/mL)  or  genistein  (100  µμM)),  or  macropinocytosis  (amiloride  (50  µμM)).  
Following  1  hour  of  incubation  at  42  °C,  cells  were  analyzed  by  confocal  microscopy  or  
flow  cytometry,  as  described  previously.    The  effect  of  inhibitors  on  temperature-­‐‑
triggered  micelle  assembly  was  evaluated  with  DLS.    
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3.2.5.2  Colocalization  with  endocytosis  markers  
To  evaluate  the  intracellular  localization  of  CPP-­‐‑ELPBCs,  HeLa  cells  were  
coincubated  with  20  µμM  CPP-­‐‑ELPBC  in  combination  with  markers  of  macropinocytosis  
(Lucifer  yellow,  0.5  mg/mL)  [147]  or  receptor-­‐‑mediated  endocytosis  into  lysosomes  
(Lysotracker  Red,  75  nM)  [148].  The  excitation/emission  of  Lucifer  yellow  (488/532)  
corresponded  too  closely  to  the  Alexa  Fluor  488  used  previously  for  ELP  labeling.  
Therefore  ELP  was  alternatively  labeled  with  Alexa  Fluor  594  to  use  in  combination  with  
Lucifer  yellow.  The  excitation/emission  of  Lysotracker  Red  (577/590)  permitted  the  use  
of  Alexa  Fluor  488-­‐‑labeled  ELP,  as  usual.  HeLa  cells  were  co-­‐‑incubated  with  CPP-­‐‑ELPBC  
and  endocytosis  markers  at  42  °C  for  1  hour  and  then  visualized  by  fluorescence  
microscopy,  as  previously  described.  
3.3 Results and discussion 
3.3.1 Controlled cellular uptake of first generation CPP-ELPBCs: Proof-
of-concept with non-optimized temperature-triggered assembly 
First  generation  CPP-­‐‑ELPBCs  exhibited  thermal  behavior  that  was  not  optimized  
for  our  ultimate  goal  of  temperature-­‐‑triggered  CPP-­‐‑ELPBC  micelle  assembly  in  response  
to  mild  clinical  hyperthermia.  These  constructs  displayed  unique  thermal  behavior  due  
to  their  reversed  ELPBC  syntax,  as  compared  to  the  original  ELPBCs  synthesized  in  the  
Chilkoti  lab  [126].  The  changes  in  thermal  behavior  that  accompanied  the  change  in  
ELPBC  syntax  included  a  decrease  in  the  CMT,  precluding  the  use  of  these  constructs  for  
hyperthermia-­‐‑triggered  self-­‐‑assembly.  However,  these  materials  were  still  useful  to  
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probe  our  hypothesis  regarding  controlled  CPP  density,  by  defining  “off”  and  “on”  
conditions  appropriate  for  these  constructs.  At  25  °C  these  first  generation  CPP-­‐‑ELPBCs  
were  soluble  unimers  in  their  “off”  state  and  at  37  °C  were  self-­‐‑assembled  into  spherical  
micelles  in  their  “on”  state.    
In  order  to  visualize  or  quantify  the  cellular  uptake  of  the  CPP-­‐‑ELPBCs  they  had  
to  be  labeled  with  a  traceable  tag.  Alexa  Fluor  488  C5  maleimide  was  chosen  to  stably  
label  the  ELP  with  a  fluorescent  tag  that  would  allow  visualization  by  fluorescence  
microscopy  and  quantification  by  flow  cytometry.  This  fluorophore  derivative  was  
reacted  with  the  cysteine  residue  genetically  engineered  at  the  N-­‐‑terminus  of  the  CPP-­‐‑
ELPBC,  proximal  to  the  hydrophobic  domain  of  the  block  copolymer,  such  that  the  
fluorophore  would  be  sequestered  into  the  micelle  core  upon  self-­‐‑assembly.    
Due  to  the  sensitivity  of  ELPs  to  their  local  environment,  the  effect  of  this  
covalent  attachment  on  the  thermal  properties  of  the  ELPBC  was  investigated  before  its  
use  for  in  vitro  experiments.  The  Alexa  Fluor  488-­‐‑labeled  non-­‐‑functionalized  ELPBC  
demonstrated  a  change  in  thermal  properties  with  fluorophore  attachment  that  was  also  
evident  in  all  CPP-­‐‑ELPBCs.  The  effects  of  Alexa  Fluor  488  attachment  included  a  slight  
increase  in  the  CMT  and  a  more  significant  decrease  in  the  micelle-­‐‑to-­‐‑aggregate  Tt  
(Figure  19).  These  changes  are  likely  caused  by  the  relatively  hydrophilic  nature  of  the  
fluorophore  and  its  forced  sequestration  in  the  hydrophobic  micelle  core,  leading  to  a  
decreased  stability  of  micelle  assembly  apparent  in  a  decreased  temperature  range  over  
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which  stable  micelle  assembly  is  achieved.  The  changes  in  thermal  behavior  with  
fluorophore  labeling  for  first  generation  CPP-­‐‑ELPBCs  did  not  interfere  with  their  
intended  behavior  at  their  “off”  and  “on”  thermal  conditions  and  thus  these  labeled  
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Figure  19:  Alexa  Fluor  488  labeling  affects  the  thermal  properties  of  first  generation  
ELPBC.  Attaching  Alexa  Fluor  488  to  the  N-­‐‑terminal  cysteine  on  the  hydrophobic  
domain  of  the  ELPBC  raised  the  CMT  and  lowered  the  micelle-­‐‑to-­‐‑aggregate  Tt.  
Temperature-­‐‑regulated  turbidimetry  measurements  were  acquired  in  PBS  at  25  µμM.  
Although  much  of  the  in  vitro  testing  would  be  performed  in  SF-­‐‑media  (a  
standard  in  the  CPP  literature),  the  behavior  of  first  generation  Alexa  Fluor  488-­‐‑labeled  
CPP-­‐‑ELPBCs  was  evaluated  in  cell  culture  media  to  confirm  that  serum  proteins  did  not  
perturb  temperature-­‐‑triggered  self-­‐‑assembly.  Arg3-­‐‑ELPBC,  Arg1-­‐‑ELPBC,  and  a  non-­‐‑
functionalized  ELPBC  control  all  displayed  nearly  identical  thermal  behavior  in  either  
PBS  or  cell  culture  media  containing  10%  FBS  (Figure  20).  
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positively  charged  arginine  residues  per  CPP-­‐‑ELPBC  did  not  interact  significantly  with  
additional  serum  proteins,  permitting  temperature-­‐‑triggered  micelle  assembly  in  cell  
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Figure  20:  Cell  culture  media  did  not  affect  temperature-­‐‑triggered  micelle  assembly  of  
first  generation  CPP-­‐‑ELPBCs.  For  Alexa  Fluor  488-­‐‑labeled  Arg3-­‐‑ELPBC,  Arg1-­‐‑ELPBC,  and  
non-­‐‑functionalized  ELPBC  there  was  no  significant  difference  between  thermal  
behavior  in  PBS  or  cell  culture  media  supplemented  with  10%  FBS.  Temperature-­‐‑
regulated  turbidimetry  measurements  were  acquired  at  25  µμM.  
Arg3-­‐‑ELPBCs  labeled  with  Alexa  Fluor  488  were  first  evaluated  for  uptake  in  
HeLa  cells  at  their  self-­‐‑assembled  “on”  state  of  37  °C.  Specific  intracellular  uptake  of  
Arg3-­‐‑ELPBC  micelles  was  difficult  to  visualize  and  distinguish  from  non-­‐‑specific  
adsorption  of  CPP-­‐‑ELPBC  (Figure  21).  Failure  to  identify  significant  uptake  by  
fluorescence  microscopy  with  this  construct  likely  culminated  from  several  factors:  1)  
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the  nature  of  the  membrane  stain  (Cell  Tracker  Orange),  2)  the  influence  and  possible  
repulsion  from  the  cell  culture  surface  (lysine-­‐‑functionalized  polystyrene),  and  3)  the  
insufficiency  of  Arg3  to  provide  the  CPP  density  necessary  to  significantly  enhance  




Figure  21:  Intracellular  uptake  of  first  generation  CPP-­‐‑ELPBCs  was  not  obviously  
apparent  in  live  cell  fluorescence  microscopy  after  1  hour  at  37  °C,  at  which  the  ELPBCs  
were  self-­‐‑assembled  into  micelles.  Specific  uptake  of  Arg3-­‐‑ELPBC  (A)  as  compared  to  
Arg1-­‐‑ELPBC  (B)  or  non-­‐‑functionalized  ELPBC  (C)  was  not  easily  distinguished  from  
non-­‐‑specific  adsorption  in  the  cell  culture  environment.  Green—ELP;  red—cell  
tracker;  acquired  at  60x.  
Increasing  the  valency  of  arginine  on  the  ELPBC  from  Arg3  to  Arg5  significantly  
enhanced  uptake.  Visualization  of  uptake  was  likely  also  improved  by  the  modified  
identification  of  cell  membrane  with  wheat  agglutinin  Alexa  Fluor  594,  in  addition  to  
nuclear  staining  with  Hoechst.  First  generation  Arg5-­‐‑ELPBC  qualitatively  demonstrated  
temperature-­‐‑controlled  cellular  uptake  by  visualization  of  cells  treated  with  Arg5-­‐‑ELPBC  
at  either  25  °C  or  37  °C  for  1  hour  (Figure  22A,D).  Very  little  intracellular  signal  was  
apparent  in  HeLa  cells  treated  with  Arg5-­‐‑ELPBC  at  25  °C,  but  significant  intracellular  
localization  of  Arg5-­‐‑ELPBC  was  present  at  37  °C.  Two  controls  were  also  visualized  to  
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ensure  that  this  effect  was  not  due  to  micelle  assembly  (independent  of  CPP-­‐‑
functionalization)  or  changes  in  temperature  alone.  A  non-­‐‑functionalized  ELPBC  showed  
minimal  intracellular  uptake  that  did  not  appear  to  change  between  25  °C  and  37  °C  
(Figure  22B,E),  suggesting  that  a  change  in  size  from  unimer  to  micelle  did  not  
significantly  affect  uptake.  An  Arg5-­‐‑functionalized  unimer  control,  Arg5-­‐‑ELP,  incapable  
of  temperature-­‐‑triggered  assembly  also  showed  minimal  uptake  that  was  not  dependent  
on  thermal  conditions  (Figure  22C,F).  These  results  confirmed  that  the  enhanced  uptake  
was  caused  by  the  change  in  CPP  presentation  by  Arg5-­‐‑ELPBC,  from  low  CPP  density  on  










Figure  22:  First  generation  Arg5-­‐‑ELPBC  achieved  controlled  cellular  uptake  as  
visualized  by  live  cell  fluorescence  microscopy.  Punctate  intracellular  accumulation  
was  enhanced  for  Arg5-­‐‑ELPBC  at  37  °C  (D),  as  compared  to  25  °C  (A).  Minimal  
internalization  was  evident  for  ELPBC  (B,  E)  or  Arg5-­‐‑ELP  (C,  F)  controls  at  either  
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thermal  condition.  Cells  were  treated  with  20  µμM  ELP  in  SF-­‐‑media.  Green—ELP;  
red—cell  membrane;  blue—cell  nuclei;  acquired  at  60x.  
Controlled  cellular  uptake  was  then  quantified  by  live  cell  flow  cytometry.  Mean  
fluorescence  of  live  cells  was  compared  between  treatment  with  Arg5-­‐‑ELPBC,  non-­‐‑
functionalized  ELPBC,  or  Arg5-­‐‑ELP  unimer  at  either  25  °C  or  37  °C  in  SF-­‐‑media.  
Histograms  of  the  flow  cytometry  data  demonstrate  the  shift  in  cellular  fluorescence  for  
Arg5-­‐‑ELPBC  between  25  °C  and  37  °C  (Figure  23A).  This  shift  was  less  exaggerated  for  
non-­‐‑functionalized  ELPBC  and  insignificant  for  Arg5-­‐‑ELP  unimer.  Quantification  of  
uptake  corroborated  the  results  visualized  by  microscopy,  such  that  the  internalization  
of  Arg5-­‐‑ELPBC  increased  significantly  at  37  °C,  as  compared  to  25  °C  (Figure  23B).  By  
flow  cytometry  measurements  uptake  of  the  ELPBC  control  also  increased  at  37  °C,  as  
compared  to  25  °C,  albeit  less  dramatically  than  for  Arg5-­‐‑ELPBC,  supporting  that  micelle  
assembly  alone  is  at  least  not  the  major  factor  driving  the  function  of  Arg5-­‐‑ELPBCs.  
However,  any  change  in  uptake  between  thermal  conditions  for  the  non-­‐‑functionalized  
ELPBC  was  not  expected.  This  result  may  be  indicative  of  changes  in  endocytosis  
between  25  °C  and  37  °C,  particularly  for  these  nanoparticle  targets  of  cellular  uptake.  
Although  a  greatly  decreased  thermal  condition  of  4  °C  is  typically  employed  to  stop  
energy-­‐‑dependent  mechanisms  of  endocytosis,  it  may  be  that  there  is  some  decrease  in  
endocytosis  at  even  25  °C  that  causes  this  change  in  uptake  between  the  thermal  
conditions  used  for  these  non-­‐‑optimized  first  generation  ELPBCs.  The  uptake  of  the  
soluble  Arg5-­‐‑ELP  control,  however,  did  not  change  significantly  between  either  thermal  
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condition,  confirming  that  heat  alone  was  not  responsible  for  the  Arg5-­‐‑ELPBC  function  at  
37  °C.  Furthermore,  although  Arg5-­‐‑ELPBC  significantly  increased  uptake  in  its  “on”  state  
at  37  °C,  it  did  not  greatly  exceed  the  uptake  of  controls  at  its  “off”  state  at  25  °C  (Figure  
23C),  demonstrating  that  the  low  density  of  CPP  on  the  soluble  Arg5-­‐‑ELPBC  achieved  
desirable  “off”  state  behavior,  limiting  uptake  to  that  which  is  characteristic  of  the  ELPBC  
platform  alone.  Additionally,  this  result  agrees  well  with  the  threshold  of  arginine  
oligomer  CPPs  reported  in  the  literature  [55,  65],  suggesting  that  those  peptides  with  
less  than  6  arginine  residues  do  not  display  significant  CPP  functionality.  
  





















































































































































































































Figure  23:  First  generation  Arg5-­‐‑ELPBC  achieved  controlled  cellular  uptake,  as  
quantified  by  live  cell  flow  cytometry.  Histograms  of  flow  cytometry  measurements  
at  25  °C  and  37  °C  demonstrated  a  large  shift  in  cellular  fluorescence  for  Arg5-­‐‑ELPBC  
that  was  less  significant  for  ELPBC  and  insignificant  for  Arg5-­‐‑ELP  (A).  Quantification  
of  mean  fluorescence  confirmed  that  greatly  enhanced  cell  uptake,  measured  by  
cellular  fluorescence,  was  evident  at  37  °C  for  Arg5-­‐‑ELPBC,  as  compared  to  25  °C  (B).  
This  enhanced  uptake  was  achieved  while  still  maintaining  an  “off”  state  uptake  that  
did  not  greatly  exceed  that  of  Arg5-­‐‑ELP  control  (C).  Cells  were  treated  with  10  µμM  ELP  
in  SF-­‐‑media.  Flow  cytometry  measurements  were  normalized  to  the  uptake  of  Arg5-­‐‑
ELPBC  at  25  °C.  
Cellular  uptake  of  first  generation  Arg5-­‐‑ELPBC  was  next  evaluated  in  cell  culture  
media,  to  determine  the  effect  of  serum  on  the  internalization  of  this  CPP-­‐‑ELPBC.  
Expected  temperature-­‐‑triggered  self-­‐‑assembly  of  Arg5-­‐‑ELPBC,  despite  its  increased  
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charge  content,  was  confirmed  with  temperature-­‐‑regulated  turbidimetry  measurement  
in  10%  FBS  (Figure  24A),  as  is  typical  for  the  culture  media  used  here.  Visualization  of  
cell  uptake  at  the  “on”  state  of  37  °C  revealed  a  decrease  in  punctate  internalization  for  
cells  treated  in  culture  media  supplemented  with  10%  FBS  (Figure  24B),  as  compared  to  
those  cells  treated  in  SF-­‐‑media  (Figure  24C).  Flow  cytometry  confirmed  this  decrease  in  
uptake  suggested  by  fluorescence  microscopy.  Uptake  of  Arg5-­‐‑ELPBC  and  Arg5-­‐‑ELP  
control  were  both  decreased  at  37  °C  when  in  the  presence  of  10%  FBS,  as  compared  to  
SF-­‐‑media  (Figure  24D).  This  decreased  internalization  in  the  presence  of  serum  could  be  
augmented,  however,  by  increasing  the  concentration  of  the  ELP.  This  suggests  that,  
although  a  decreased  cellular  uptake  should  be  expected  in  environments  more  relevant  
to  in  vivo  conditions,  there  are  controllable  parameters  of  CPP-­‐‑ELPBC  treatment,  such  as  
concentration,  that  may  be  able  to  increase  uptake  in  the  “on”  state  in  vivo,  while  
maintaining  minimal  uptake  in  the  “off”  state.      
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Figure  24:  Serum  influences  the  uptake  of  first  generation  Arg5-­‐‑ELPBCs.  Although  
temperature-­‐‑triggered  self  assembly  of  Arg5-­‐‑ELPBC  is  conserved  in  10%  FBS  (A),  its  
enhanced  cellular  uptake  at  20  µμM  and  37  °C  in  serum  free  media  (B)  was  decreased  
in  the  presence  of  10%  FBS  (C).  Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  
acquired  at  60x.  Flow  cytometry  confirmed  the  decrease  of  uptake  in  the  presence  of  
serum  for  both  Arg5-­‐‑ELPBC  and  Arg5-­‐‑ELP  control  at  10  µμM,  but  demonstrated  that  
enhanced  uptake  could  be  partially  recovered  by  increased  ELP  concentration  of  50  
µμM  (D).  Flow  cytometry  measurements  were  normalized  to  the  uptake  of  Arg5-­‐‑ELPBC  
at  25  °C.  
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An  additional  concern  about  the  apparent  uptake  of  Arg5-­‐‑ELPBC  was  that  it  was  
indeed  internalized  into  the  cell  and  not  just  accumulated  on  the  cell  surface.  This  is  a  
significant  concern,  as  the  cationic  nature  of  these  materials  would  likely  encourage  
localization  on  the  anionic  cell  surface.  In  some  instances  membrane  localization  could  
be  useful,  for  instance  to  label  cell  populations  for  tumor  imaging  and  cell  tracking  
purposes.  However,  subsequent  internalization  into  the  cell  is  an  important  function  if  
these  materials  will  be  useful  as  drug  carriers  to  deliver  cargo  to  intracellular  therapeutic  
targets.  One  approach  to  probe  the  location  of  Arg5-­‐‑ELPBC,  either  inside  or  outside  the  
cell,  is  to  wash  the  cells  in  buffer  with  high  ionic  strength  to  increase  charge  screening  
that  should  elute  any  materials  adherent  to  the  cell  surface  due  to  charge  interactions.  
Punctate  fluorescence  from  first  generation  Arg5-­‐‑ELPBC  incubated  with  cells  at  37  °C  
looked  similar  regardless  if  the  cells  were  washed  in  buffer  with  low  ionic  strength  (PBS)  
(Figure  25A)  or  high  ionic  strength  (+  2M  NaCl)  (Figure  25B).  Thus,  although  some  ELP  
may  be  localized  on  the  cell  surface,  a  significant  majority  of  Arg5-­‐‑ELPBC  was  localized  
within  the  cell  after  1  hour  of  incubation.  
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Figure  25:  Cellular  punctate  fluorescence  of  Arg5-­‐‑ELPBC  was  not  affected  by  washing  
with  high  ionic  strength  buffer.  Cells  treated  with  20  µμM  Arg5-­‐‑ELPBC  at  37  °C  
exhibited  similar  punctate  fluorescence  regardless  of  washing  at  low  ionic  strength  
(PBS—A)  or  at  high  ionic  strength  (2M  NaCl—B),  supporting  that  fluorescence  from  
Arg5-­‐‑ELPBC  was  localized  within  the  cells  and  not  on  the  cell  surface.  Green—ELP;  
red—cell  membrane;  blue—cell  nuclei;  acquired  at  60x.  
With  Arg5-­‐‑ELPBCs  confirming  our  proof-­‐‑of-­‐‑concept  of  controlled  cellular  uptake,  
the  valency  of  the  arginine  oligomer  CPP  was  revisited  to  determine  the  number  of  
arginine  residues  necessary  on  each  ELPBC  to  induce  this  effect.  The  more  sensitive  
method  of  quantification,  flow  cytometry,  was  used  to  probe  the  controlled  uptake  
achieved  by  ELPBCs  functionalized  with  1,  3,  or  5  arginine  residues  (Figure  26).  This  
uptake  was  compared  to  that  of  the  equivalently  functionalized  soluble  unimer  controls  
as  well  as  a  non-­‐‑functionalized  ELPBC.  The  “off”  state  uptake  at  25  °C  was  comparable  
for  all  constructs  with  no  apparent  trends,  suggesting  that  ELP  architecture  and  
functionalization  of  up  to  5  arginines  did  not  significantly  affect  the  uptake  when  in  a  
soluble  unimer  form.  There  was,  however,  an  apparent  trend  in  the  uptake  achieved  at  
the  “on”  state  of  37  °C,  such  that  an  increasing  number  of  arginines  induced  an  
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increasing  degree  of  uptake,  as  measured  by  cellular  fluorescence.  The  Arg5-­‐‑ELPBC  thus  




























































Figure  26:  Increasing  valency  of  the  arginine  oligomer  CPP  enhanced  the  fold  increase  
in  cellular  uptake  between  25  °C  and  37  °C.  Increasing  arginine  functionalization  of  1,  
3,  or  5  residues  increased  the  uptake  achieved  at  20  µμM  and  37  °C  without  significant  
effect  on  the  uptake  at  25  °C.  This  trend  was  less  apparent  in  CPP-­‐‑ELP  controls.  
Two  additional  details  are  notable  from  this  evaluation  of  arginine  oligomer  
valency.  First,  that  functionalization  of  the  ELPBC  with  a  single  arginine  did  not  achieve  
any  improvement  in  uptake  at  the  “on”  state,  as  compared  to  the  non-­‐‑functionalized  
ELPBC  control.  So,  greater  than  one  arginine  is  needed  to  see  a  desired  effect,  albeit  at  a  
lesser  magnitude  than  is  desirable.  Second,  in  this  study  the  non-­‐‑functionalized  ELPBC  
control,  and  to  a  lesser  extent  the  CPP-­‐‑functionalized  soluble  controls,  continued  to  
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display  an  increase  in  uptake  at  37  °C,  compared  to  25  °C.  This  again  suggested  that  the  
thermal  conditions  chosen  for  this  non-­‐‑optimized  construct  may  have  a  side-­‐‑effect  of  
decreasing  endocytosis  at  the  hypothermic  condition  of  25  °C  for  all  constructs.  This  
may,  in  effect,  exaggerate  the  apparent  controlled  uptake  achieved  with  these  first  
generation  CPP-­‐‑ELPBCs.  
3.3.2 Controlled cellular uptake of second generation CPP-ELPBCs: 
Proof-of-concept with mild hyperthermia-triggered assembly 
To  move  on  to  investigate  controlled  cellular  uptake  with  a  clinically  relevant  
trigger  of  mild  hyperthermia,  second  generation  CPP-­‐‑ELPBCs  were  prepared  with  
fluorophore-­‐‑labeling  for  their  initial  evaluation  in  vitro.  However,  as  alluded  to  in  
Section  2.3.4,  the  limited  micelle  range  of  second  generation  ELPBCs  would  become  
problematic  when  attaching  fluorophore,  due  to  the  effects  of  this  modification  
previously  gleaned  from  the  labeling  of  first  generation  ELPBCs.  Primarily,  the  slight  
increase  in  CMT  and  the  decrease  in  micelle-­‐‑to-­‐‑aggregate  Tt  that  results  from  the  
attachment  of  fluorophore  at  the  N-­‐‑terminal  cysteine  can  result  in  the  destruction  of  
micelle  assembly  if  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  are  forced  too  close  to  one  
another  and,  in  effect,  cause  the  ELPBC  to  transition  from  unimer-­‐‑to-­‐‑aggregate,  
eliminating  the  micelle  range.    
This  is  exactly  the  undesirable  effect  that  was  seen  in  the  labeling  of  second  
generation  Arg5-­‐‑ELPBC  with  Alexa  Fluor  488  C5  maleimide.  Temperature-­‐‑regulated  
turbidimetry  alluded  to  the  loss  of  micelle  assembly  (Figure  27),  which  was  further  
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confirmed  by  DLS.  In  an  effort  to  mitigate  this  undesirable  effect,  labeling  efficiency  was  
decreased  by  mixing  labeled  Arg5-­‐‑ELPBC  with  its  unlabeled  equivalent.  DLS  
measurements  of  these  mixtures  suggested  a  phase  separation  of  unlabeled  and  labeled  
Arg5-­‐‑ELPBCs,  such  that  both  a  unimer  and  micelle  population  were  evident  across  the  
temperature  range  of  interest  from  37  °C  to  42  °C.  Manipulation  of  the  labeling  efficiency  
was  therefore  not  a  feasible  solution  to  create  a  clean  transition  from  a  purely  unimer  
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Figure  27:  Alexa  Fluo   488  labeling  at  the  N-­‐‑terminal  cysteine  abolished  micelle  
assembly  of  second  generation  Arg5-­‐‑ELPBC.  Temperature-­‐‑regulated  turbidimetry  
confirmed  the  loss  of  the  micelle  region  and  complete  aggregation  of  the  labeled  
construct  at  approximate  45  °C.  Temperature-­‐‑regulated  turbidimetry  measurement  
was  acquired  at  20  µμM  in  PBS.  
It  is  imaginable  that  these  effects  are,  in  part,  dependent  on  the  characteristics  of  
the  fluorophore,  such  as  its  size,  charge,  or  hydrophobicity.  Therefore  a  number  of  other  
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fluorophores  with  maleimide  reactive  groups  were  attached  to  second  generation  Arg5-­‐‑
ELPBC  to  determine  if  the  desirable  thermal  properties  of  this  construct  could  be  
maintained  when  fluorescently  labeled  at  the  cysteine  residue.  Alternative  fluorophores  
including  Alexa  Fluor  594  (Figure  28A),  Oregon  Green  (Figure  28B),  and  fluorescein  
(Figure  28C)  had  the  same  deleterious  effects  as  Alexa  Fluor  488  and  destroyed  micelle  
assembly  of  the  Arg5-­‐‑ELPBC.  However,  one  fluorophore  alternative,  BODIPY  FL,  did  not  
perturb  micelle  assembly,  likely  due  to  its  hydrophobic  nature  (Figure  28D).  However,  
this  fluorophore  is  a  poor  choice  for  our  intended  purpose  as  the  inherent  self-­‐‑quenching  
of  this  molecule  leads  to  a  decreased  fluorescence  in  the  assembled  micelle  state  when  
fluorophores  are  packed  into  close  proximity  in  the  micelle  core.  Preliminary  in  vitro  
studies  of  both  live  cell  microscopy  and  live  cell  flow  cytometry  confirmed  that  
BODIPY-­‐‑labeled  Arg5-­‐‑ELPBC  micelles  precluded  measurement  of  controlled  cellular  
uptake  at  37  °C  due  to  a  lack  of  punctate  fluorescence  in  cells  when  observed  by  
microscopy  and  low  fluorescent  signal  of  cells  when  quantified  by  flow  cytometry.  
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Figure  28:  BODIPY  was  the  only  alternative  fluorophore  to  maintain  micelle  assembly  
of  second  generation  Arg5-­‐‑ELPBC  with  attachment  at  the  N-­‐‑terminal  cysteine.  
Maleimide  derivatives  of  Alexa  Fluor  594  (A),  Oregon  green  (B),  and  fluorescein  (C)  
abolished  micelle  assembly  as  evident  by  temperature-­‐‑regulated  turbidimetry.  
Attachment  of  BODIPY  FL  did  not  perturb  self-­‐‑assembly,  maintaining  a  CMT  at  
approximately  40  °C  and  a  micelle-­‐‑to-­‐‑aggregate  Tt  at  approximately  50  °C  (D).  
Temperature-­‐‑regulated  turbidimetry  measurements  were  acquired  at  20  µμM  in  PBS.  
While  the  characteristics  of  the  fluorophore  may  be  one  factor  in  this  undesirable  
effect  on  micelle  assembly,  another  factor  may  the  residue  to  which  the  fluorophore  is  
being  attached.  Although  the  reactive  cysteine  was  included  in  the  block  copolymer  
design  for  the  purpose  of  fluorophore  attachment,  it  may  also  serve  an  unintended  
purpose  of  stabilizing  micelle  formation  by  means  of  inter-­‐‑molecular  disulfide  bonds  
that  could  potentially  be  formed  in  the  micelle  core.  If  this  were  to  play  a  role  in  the  
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stability  of  the  self-­‐‑assembled  micelles,  then  occupying  these  cysteine  residues  with  
fluorophore  would  thereby  prevent  their  function,  as  such.  To  investigate  this  
hypothesis,  the  N-­‐‑terminal  amine  on  the  hydrophobic  domain,  as  opposed  to  the  
cysteine  residue,  was  targeted  for  fluorophore  conjugation  with  Alexa  Fluor  488  SDP  
ester.  This  approach  was  feasible,  as  the  ELP  contains  no  other  amines,  allowing  the  
fluorophore  to  label  the  hydrophobic  terminus  and  be  buried  in  the  micelle  core  upon  
self-­‐‑assembly.  Temperature-­‐‑regulated  turbidimetry  and  DLS  of  this  labeled  variant  
revealed  successful  preservation  of  the  thermal  properties,  whereby  pure  unimer  
population  was  maintained  at  37  °C  and  pure  micelle  population  was  achieved  at  42  °C  
(Figure  29).  This  alternative  labeling  strategy  would  allow  this  construct  to  serve  for  
initial  analysis  of  controlled  cellular  uptake  in  response  to  mild  clinical  hyperthermia.  
However,  it  was  evident  from  the  sensitivity  of  this  construct  to  functionalization  that  
this  second  generation  ELPBC  was  not  well  suited  as  the  ultimate  platform  for  our  drug  
delivery  strategy.  
  











































Figure  29:  Alexa  Fluor  488  labeling  at  the  N-­‐‑terminal  amine  of  second  generation  
Arg5-­‐‑ELPBC  maintained  a  desired  thermal  behavior  as  confirmed  by  temperature-­‐‑
regulated  turbidimetry  (line)  and  DLS  (dots).  Temperature-­‐‑regulated  turbidimetry  
and  DLS  measurements  were  acquired  at  20  µμM  in  PBS.  
With  fluorescently  labeled  second  generation  CPP-­‐‑ELPBC,  the  controlled  cellular  
uptake  could  be  investigated  under  the  trigger  of  mild  clinical  hyperthermia.  Uptake  
was  first  visualized  by  live  cell  microscopy,  in  which  HeLa  cells  were  incubated  with  
Arg5-­‐‑ELPBC,  or  appropriate  controls,  for  1  hour  at  37  °C  or  42  °C  (Figure  30).  At  the  “off”  
condition  of  37  °C  all  constructs  exhibited  minimal  uptake.  However,  at  the  “on”  
condition  of  42  °C  Arg5-­‐‑ELPBC  displayed  significantly  increased  uptake  as  evident  by  
punctate  cellular  fluorescence.  No  such  uptake  was  seen  with  the  non-­‐‑functionalized  
ELPBC  or  soluble  Arg5-­‐‑ELP  control.  These  preliminary  results  confirmed  that  controlled  
cellular  uptake  by  means  of  CPP  density  manipulation  on  self-­‐‑assembled  micelles  could  
indeed  be  translated  to  clinically  relevant  conditions,  whereby  the  CPP-­‐‑ELPBC  minimizes  
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cell  uptake  at  normal  physiologic  temperature,  but  induces  enhanced  cellular  uptake  at  










Figure  30:  Second  generation  Arg5-­‐‑ELPBC  achieved  mild  hyperthermia-­‐‑controlled  
cellular  uptake,  as  visualized  by  live  cell  fluorescence  microscopy.  Minimal  cellular  
uptake  was  seen  for  all  constructs  at  the  “off”  state  of  37  °C  (A-­‐‑C).  Enhanced  cellular  
uptake  at  42  °C  was  seen  for  Arg5-­‐‑ELPBC  (D),  but  not  for  controls  ELPBC  (E)  or  Arg5-­‐‑ELP  
(F).  Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  acquired  at  60x.  
Controlled  internalization  of  second  generation  Arg5-­‐‑ELPBC  was  then  quantified  
by  flow  cytometry.  The  controlled  cellular  uptake  of  Arg5-­‐‑ELPBC  was  confirmed,  where  
cellular  fluorescence  was  much  greater  at  the  “on”  state  of  42  °C,  as  compared  to  the  
“off”  state  of  37  °C  (Figure  31A).  No  change  in  cellular  fluorescence  between  thermal  
conditions  was  observed  for  the  controls  of  ELPBC  or  Arg5-­‐‑ELP.  Arg5-­‐‑ELPBC  achieved  a  4-­‐‑
fold  increase  in  fluorescence,  quantified  as  the  quotient  of  cellular  fluorescence  at  42  °C  
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and  37  °C  (Figure  31B).  It  is  of  interest  to  note  that,  unlike  the  previous  studies  with  first  
generation  CPP-­‐‑ELPBCs,  this  family  of  materials  did  not  exhibit  a  fold-­‐‑increase  in  
fluorescence  of  the  non-­‐‑functionalized  ELPBC  alone.  This  suggests  that  the  effects  of  
hypothermia  on  endocytosis,  as  were  suspected  for  the  thermal  condition  of  25  °C,  were  
not  experienced  at  the  physiologic  “off”  state  of  37  °C  for  these  optimized  second  
generation  materials.  Furthermore,  the  controls  here  also  confirmed  that  the  conditions  
of  mild  clinical  hyperthermia  alone—heating  to  42  °C  for  1  hour—did  not  appear  to  
have  a  general  effect  on  endocytosis.  Although  mild  hyperthermia  has  the  potential  to  
induce  effects  on  the  cell  membrane  and  cytoskeleton  that  can  influence  uptake  of  
nanoparticles,  the  hyperthermia  treatment  in  the  context  of  these  assays  did  not  result  in  
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Figure  31:  Second  generation  Arg5-­‐‑ELPBC  achieved  mild  hyperthermia-­‐‑controlled  
cellular  uptake,  as  quantified  by  live  cell  flow  cytometry.  Only  Arg5-­‐‑ELPBC  
demonstrated  an  enhanced  cellular  uptake,  as  measured  by  cellular  fluorescence,  at  42  
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°C  as  compared  to  37  °C  at  10  µμM  ELP  (A),  achieving  a  4-­‐‑fold  increase  in  uptake  
between  thermal  conditions,  above  that  of  the  ELPBC  or  Arg5-­‐‑ELP  controls  (B).  
Finally,  the  effect  of  serum  on  the  controlled  uptake  of  second  generation  Arg5-­‐‑
ELPBC  was  examined.  Flow  cytometry  confirmed  that  the  uptake  of  second  generation  
Arg5-­‐‑ELPBC  micelles  with  the  addition  of  10%  FBS  was  similarly  influenced  by  the  
presence  of  serum  proteins  as  was  first  generation  Arg5-­‐‑ELPBC  micelles.  However,  a  
decrease  in  uptake  with  the  addition  of  10%  FBS  was  seen  only  for  Arg5-­‐‑ELPBC  at  42  °C,  
whereas  no  significant  change  in  uptake  was  measured  for  Arg5-­‐‑ELPBC  at  37  °C  or  for  
non-­‐‑functionalized  ELPBC  at  either  thermal  condition  (Figure  32).  The  controlled  cellular  
uptake  of  second  generation  Arg5-­‐‑ELPBC  appeared  to  be  less  affected  by  the  presence  of  
serum,  as  compared  to  first  generation  Arg5-­‐‑ELPBC.  It  is  not  clear  whether  this  is  an  effect  
of  culture  conditions,  such  as  “off”  and  “on”  temperatures,  or  parameters  of  the  ELPBC,  
such  as  size  or  coordination  number.  Regardless  of  the  degree  of  the  effect,  these  results  
confirmed  that  controlled  cellular  uptake  could  likely  still  be  achieved  in  in  vivo  
environments,  but  at  a  decreased  magnitude.  
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Figure  32:  Serum  influenced  the  uptake  of  second  generation  Arg5-­‐‑ELPBCs.  Flow  
cytometry  confirmed  the  decrease  of  uptake  in  the  presence  of  10%  FBS,  as  compared  
to  SF-­‐‑media,  for  Arg5-­‐‑ELPBC  at  42  °C.  Uptake  of  Arg5-­‐‑ELPBC  at  37  °C  or  ELPBC  at  either  
thermal  condition  appeared  unchanged  with  the  addition  of  FBS.  Cells  were  treated  
with  20  µμM  ELP  and  flow  cytometry  measurements  were  normalized  to  the  uptake  of  
ELPBC  at  25  °C.  
3.3.3 Controlled cellular uptake of third generation CPP-ELPBCs: 
Optimized mild hyperthermia-triggered assembly 
Ultimately,  it  is  the  third  generation  ELPBCs  that  will  provide  a  robust  material  
platform  for  the  evaluation  of  various  CPP-­‐‑ELPBCs  as  extrinsically  targeted  carriers.  
Three  variants  were  designed  and  characterized  in  Section  2.3.5:  E4-­‐‑30/E2*-­‐‑60,  E4-­‐‑35/E2*-­‐‑
60,  and  E4-­‐‑40/E2*-­‐‑60.  Unlike  the  second  generation  CPP-­‐‑ELPBC,  these  third  generation  
constructs  could  be  labeled  at  their  N-­‐‑terminal  cysteine  with  Alexa  Fluor  488  without  
detrimental  effect  to  their  self-­‐‑assembly.  This  improvement  was  likely  due  to  the  
increased  micelle  range  of  the  third  generation  ELPBCs,  created  by  an  increase  in  the  
micelle-­‐‑to-­‐‑aggregate  Tt.  This  prevented  the  effects  of  fluorophore  conjugation  from  
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driving  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  so  close  to  one  another  as  to  eliminate  the  
micelle  assembly  range.    
Although  fluorophore  conjugation  did  not  destroy  micelle  assembly  for  these  
constructs,  it  did  increase  the  CMT  slightly,  as  evident  with  previous  generations  of  
ELPBCs.  This  change  called  into  play  the  advantage  of  having  three  constructs,  with  
varying  hydrophobic  block  lengths,  and  thus  varying  CMTs,  to  fine-­‐‑tune  the  desired  
CMT  following  fluorophore  conjugation.  In  the  case  of  E4-­‐‑30/E2*-­‐‑60  and  E4-­‐‑35/E2*-­‐‑60,  
fluorophore  conjugation  caused  the  CMT  to  rise  too  close  to  42  °C,  at  20  µμM,  to  be  useful  
in  the  intended  thermal  conditions.  Due  to  the  dependence  of  the  ELP  Tt  on  
concentration,  the  CMT  will  decrease  with  increasing  concentration.  Thus,  it  is  feasible  
to  find  a  concentration  range  at  which  each  of  these  three  diblocks  can  function  with  a  
desirable  CMT.  DLS  measurements  of  Alexa  Fluor  488-­‐‑labeled  Arg5-­‐‑ELPBCs,  including  
E4-­‐‑30/E2*-­‐‑60,  E4-­‐‑35/E2*-­‐‑60,  and  E4-­‐‑40/E2*-­‐‑60,  across  a  range  of  concentrations  confirmed  
the  solution  conditions  at  which  the  desired  CMT  was  achieved  for  each  construct,  such  
that  a  population  of  pure  unimers  was  present  at  37  °C  and  a  population  of  pure  
micelles  was  present  at  42  °C.  For  E4-­‐‑30/E2*-­‐‑60  with  the  shortest  hydrophobic  block  of  
the  highest  Tt,  a  concentration  of  greater  than  45  µμM  was  necessary  to  lower  the  CMT  
into  a  usable  range  between  37  °C  and  42  °C.  For  E4-­‐‑35/E2*-­‐‑60,  a  concentration  of  greater  
than  25  µμM  was  necessary.  Finally,  for  E4-­‐‑40/E2*-­‐‑60,  a  concentration  greater  than  only  5  
µμM  was  required.  Preferred  conditions  for  in  vitro  evaluation  of  cellular  uptake,  
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determined  from  preliminary  results  with  first  and  second  generation  CPP-­‐‑ELPBCs,  were  
at  ELP  concentrations  of  10-­‐‑20  µμM.  Therefore  E4-­‐‑40/E2*-­‐‑60  was  the  construct  most  
suitable  to  carry  forward  for  thorough  characterization  of  controlled  cellular  uptake.  
Following  Alexa  Fluor  488  labeling  of  E4-­‐‑40/E2*-­‐‑60,  this  third  generation  Arg5-­‐‑
ELPBC  was  evaluated  by  DLS  to  confirm  the  unimer  and  micelle  population  at  37  °C  and  
42  °C,  respectively  (Table  7).  Arg5-­‐‑ELPBC  was  indeed  a  unimer  at  37  °C  with  an  Rh  of  
approximately  5  nm,  and  a  micelle  at  42  °C  with  an  Rh  of  approximately  21  nm.  The  
arginine  functionalization  did  not  appear  to  greatly  influence  the  Rh  at  either  thermal  
condition,  as  the  non-­‐‑functionalized  ELPBC  control  had  similar  Rh  measurements  of  
unimer  and  micelle  at  37  °C  and  42  °C,  respectively.  The  Rh  of  the  soluble  control  Arg5-­‐‑
ELP,  of  approximately  5  nm  at  both  37  °C  and  42  °C,  confirmed  that  it  was  a  unimer  at  
both  thermal  conditions.  
Table  7:  Characterization  of  Alexa  Fluor  488-­‐‑labeled  third  generation  Arg5-­‐‑ELPBC  and  
controls  by  DLS  at  10  µμM  in  PBS.  
Construct   ELP   MW  (kDa)   Rh  (nm)  at  37  °C   Rh  (nm)  at  42  °C  
Arg5-­‐‑ELPBC   E4-­‐‑40/E2*-­‐‑60   40.6   5.5  ±  0.1   21.0  ±  1.3  
ELPBC   E4-­‐‑40/E2*-­‐‑60   39.8   5.8  ±  0.2   20.5  ±  0.6  
Arg5-­‐‑ELP   E2*-­‐‑100   39.2   5.4  ±  0.2   5.2  ±  0.1  
  
The  controlled  cellular  uptake  of  third  generation  CPP-­‐‑ELPBC  was  then  
visualized  with  live  cell  fluorescence  confocal  microscopy.  Again,  limited  cellular  uptake  
of  Arg5-­‐‑ELPBC  and  controls  was  observed  at  37  °C,  while  only  Arg5-­‐‑ELPBC  achieved  
enhanced  cellular  uptake  at  42  °C  (Figure  33).  The  cellular  uptake  of  non-­‐‑functionalized  
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ELPBC  and  soluble  Arg5-­‐‑ELP  did  not  appear  to  change  between  thermal  conditions,  
confirming  that  micelle  assembly  and  hyperthermia  alone  were  not  accountable  for  the  
controlled  cellular  uptake  achieved  by  Arg5-­‐‑ELPBC.  In  this  experiment  it  was  particularly  










Figure  33:  Third  generation  Arg5-­‐‑ELPBC  achieved  controlled  cellular  uptake,  as  
visualized  by  live  cell  fluorescence  microscopy.  Minimal  cellular  uptake  was  
observed  for  all  constructs  at  the  “off”  condition  of  37  °C  (A-­‐‑C).  Only  Arg5-­‐‑ELPBC  
exhibited  enhanced  cellular  uptake  at  the  “on”  state  of  42  °C  (D)  while  the  cellular  
uptake  of  non-­‐‑functionalized  ELPBC  (E)  and  soluble  Arg5-­‐‑ELP  (F)  remained  
unchanged.  The  internalized  Arg5-­‐‑ELPBC  localized  to  the  perinuclear  space  (D,  box).  
Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  scale  bars  25  µμm.  Reproduced  
from  [149].  
The  sectioning  ability  of  confocal  microscopy  provided  a  vote  of  confidence  in  
the  localization  of  Arg5-­‐‑ELPBC  within  the  cells,  as  opposed  to  on  the  cell  surface.  
Nonetheless,  the  effect  of  cell  washing  on  cellular  uptake  was  investigated  to  further  
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confirm  the  internalization  of  the  Arg5-­‐‑ELPBC.  Flow  cytometry  was  used  to  quantify  
cellular  uptake,  as  measured  by  cellular  fluorescence,  after  incubation  with  Arg5-­‐‑ELPBC  
and  controls  and  detachment/washing  of  cells  with  trypsin,  non-­‐‑enzymatic  cell  
dissociator,  or  non-­‐‑enzymatic  cell  dissociator  followed  by  a  heparin  wash.  These  three  
conditions  were  chosen  due  to  their  distinct  differences  in  how  surface  peptides  may  be  
removed  from  the  cell  during  their  preparation  for  analysis  by  flow  cytometry.    
Trypsin  is  an  enzyme  that  dissociates  cells  by  digesting  their  attachments  to  the  
culture  surface.  Trypsin  is  also  likely  to  be  efficient  at  removing  cell  surface-­‐‑bound  
arginine-­‐‑functionalized  ELPs.  Since  the  trypsin  cleaves  at  the  carboxyl  side  of  an  
arginine  residue  it  should  cut  the  CPP  and  release  the  appended  ELP,  as  well  as  its  
attached  fluorophore,  from  the  cell  surface.  Non-­‐‑enzymatic  cell  dissociator  is  a  chelator  
that  interrupts  cellular  interactions  responsible  for  cell  surface  attachment  and  thereby  
does  not  directly  remove  surface  bound  materials.  However,  non-­‐‑enzymatic  dissociator  
in  combination  with  a  heparin  wash  should  remove  surface  bound  arginine-­‐‑
functionalized  ELPs  by  electrostatic  interactions  and  hydrogen  bonding  that  compete  
with  the  cell  surface  to  interact  with  the  cationic  CPPs.  
Arg5-­‐‑ELPBC  and  controls  were  incubated  with  HeLa  cells  at  37  °C  or  42  °C  as  
usual  and  then  removed  from  the  cell  culture  surface  and/or  washed  with  these  three  
conditions,  after  which  the  cellular  fluorescence  was  quantified  by  flow  cytometry.  
Surprisingly,  for  Arg5-­‐‑ELPBC  there  was  hardly  any  change  in  cellular  fluorescence  at  
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either  thermal  condition  between  the  three  dissociation/washing  conditions  (Figure  
34A).  This  suggested  that  the  significant  majority  of  Arg5-­‐‑ELPBC  was  internalized  and  
any  portion  that  remained  on  the  surface  was  likely  to  be  removed  by  the  standard  
procedure  of  PBS  washing.  For  both  non-­‐‑functionalized  ELPBC  (Figure  34B)  and  Arg5-­‐‑
ELP  (Figure  34C)  there  was  a  slight  increase  in  cellular  fluorescence  detected  for  non-­‐‑
enzymatic  dissociation  with  and  without  heparin  washing,  as  compared  to  the  cells  
processed  with  trypsin.  This  suggested  that  for  these  controls  there  was  a  small  portion  
that  existed  on  the  cell  surface  that  was  removed  efficiently  by  trypsin,  but  not  by  
heparin  washing.  These  materials  are  therefore  likely  to  be  adsorbed  to  the  cell  by  means  
other  than  electrostatic  effects,  such  as  hydrophobic  interactions.  This  experiment  
confirmed  that  the  use  of  trypsin  as  the  dissociator,  and  PBS  as  a  standard  washing  


























































































Figure  34:  Third  generation  Arg5-­‐‑ELPBC  was  sufficiently  internalized,  as  evident  from  
dissociator/washing  conditions  prior  to  flow  cytometry.  Arg5-­‐‑ELPBC  showed  no  
difference  in  cellular  fluorescence  between  dissociator/washing  conditions  (A).  ELPBC  
(B)  and  Arg5-­‐‑ELP  (C)  showed  slight  increase  in  cellular  fluorescence  when  treated  
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with  non-­‐‑enzymatic  dissociator.  Cells  treated  with  Arg5-­‐‑ELP  and  trypsin  at  37  °C  were  
not  measured  (NM).  Flow  cytometry  measurements  from  each  ELP  treatment  were  
normalized  to  fluorescence  at  42  °C  with  trypsin  treatment.  
Prior  to  the  thorough  quantification  of  cellular  uptake  of  Arg5-­‐‑ELPBC  and  its  
controls,  the  conditions  pertaining  to  flow  cytometry  measurements  were  optimized.  In  
vitro,  the  ratio  of  CPP:cell  has  been  known  to  be  an  important  parameter  affecting  the  
internalization  of  CPPs,  were  a  greater  amount  of  CPP  per  cell,  independent  of  CPP  
concentration,  can  improve  uptake  [150].  Thus  there  are  advantages  of  manipulating  the  
cell  density  and  incubation  volume  to  influence  this  CPP:cell  ratio,  while  maintaining  a  
constant  ELP  concentration  that  fulfills  our  desired  thermal  behavior.    
The  effect  of  cell  density  was  first  investigated  by  incubating  10  µμM  Arg5-­‐‑ELPBC  
at  37  °C  or  42  °C  with  cells  plated  at  25,000,  50,000,  or  100,000  cells  per  well  on  a  12-­‐‑well  
plate.  The  fold  increase  in  fluorescence  (the  quotient  of  uptake  at  42  °C  compared  to  37  
°C)  revealed  decreasing  controlled  uptake  as  the  cell  density  was  increased  (Figure  35A).  
Although  25,000  cells  demonstrated  the  best  performance,  the  limited  number  of  cells  in  
this  case  made  it  difficult  to  collect  the  signal  from  10,000  cells  after  cell  processing,  as  
was  standard  for  the  flow  cytometry  protocol.  Therefore,  50,000  cells  per  well  would  be  
used  to  improve  the  fold  increase  in  cellular  fluorescence,  without  burden  on  the  
procedures  of  the  flow  cytometry  measurements.    
Next,  the  effect  of  incubation  volume  was  investigated  by  treating  50,000  cells  
per  well  at  37  °C  or  42  °C  with  either  400  or  600  µμL  of  Arg5-­‐‑ELPBC  at  10  µμM.  Lower  
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volumes  were  not  feasible,  as  they  would  not  provide  sufficient  surface  coverage  of  the  
wells,  while  larger  volumes  were  undesirable  as  they  consumed  a  greater  amount  of  
precious  Alexa  Fluor  488-­‐‑labeled  Arg5-­‐‑ELPBC.  The  fold  increase  in  fluorescence  increased  
with  increasing  incubation  volume  (Figure  35B),  supporting  the  choice  of  600  µμL  as  the  
incubation  volume  for  subsequent  flow  cytometry  experiments.  These  results  confirmed  
those  suggestions  found  in  the  literature  that  increasing  the  CPP:cell  ratio,  independent  











































Figure  35:  Increasing  the  CPP:cell  ratio  optimized  controlled  cellular  uptake  of  Arg5-­‐‑
ELPBC,  as  measured  by  flow  cytometry.  Decreasing  the  cell  density  enhanced  the  fold  
increase  in  cellular  fluorescence  (A)  and  increasing  the  incubation  volume  enhanced  
the  fold  increase  in  cellular  fluorescence  (B).  
Using  these  optimized  conditions,  the  cellular  uptake  of  Arg5-­‐‑ELPBC  and  controls  
was  quantified  by  flow  cytometry  over  the  course  of  1  hour.  Measurements  at  5,  15,  30,  
and  60  minutes  revealed  increasing  cellular  internalization  over  time  for  Arg5-­‐‑ELPBC  at  
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both  37  °C  and  42  °C  (Figure  36A).  Uptake  at  42  °C,  however,  increased  much  faster  than  
at  37  °C,  after  5  minutes  of  incubation.  The  fold  increase  in  uptake  at  42  °C,  compared  to  
37  °C,  reached  its  maximum  by  30  minutes  but  was  approximately  retained  until  1  hour.  
This  result  is  encouraging,  to  see  that  the  maximum  difference  in  uptake  between  “off”  
and  “on”  state  conditions  is  achieved  within  the  time  limitations  typical  of  mild  clinical  
hyperthermia  (1  hour  at  42  °C  [14]).  ELPBC  and  Arg5-­‐‑ELP  controls  also  revealed  an  
increase  in  uptake,  albeit  modest,  over  the  course  of  1  hour,  but  this  increase  did  not  
differ  between  37  °C  and  42  °C  for  either  control  (Figure  36B-­‐‑C).  
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Figure  36:  Fold  increase  in  cellular  uptake  of  Arg5-­‐‑ELPBC  was  maximized  within  the  
time  scale  of  mild  clinical  hyperthermia.  Cellular  uptake,  as  quantified  by  flow  
cytometry,  of  Arg5-­‐‑ELPBC  (A),  ELPBC  (B),  and  Arg5-­‐‑ELP  (C)  increased  over  the  course  of  
1  hour,  but  only  Arg5-­‐‑ELPBC  exhibited  an  enhanced  rate  of  uptake  at  42  °C,  
maximizing  the  fold  increase  in  uptake  at  42  °C,  as  compared  to  37  °C,  within  1  hour.  
Reproduced  from  [149].  
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Due  to  their  non-­‐‑specific  mechanism  of  uptake,  CPPs  should  achieve  efficient  
internalization  in  a  variety  of  cell  types.  To  investigate  this  feature  of  CPP-­‐‑ELPBCs,  the  
cellular  uptake  of  Arg5-­‐‑ELPBC  and  controls  was  evaluated  in  three  cell  lines:  HeLa  
cervical  cancer  cells,  MCF7  breast  cancer  cells,  and  primary  endothelial  HUVEC  cells.  
All  cell  lines  demonstrated  the  effect  of  controlled  cellular  uptake  with  CPP-­‐‑density  
manipulation,  such  that  the  fold  increase  in  fluorescence,  between  42  °C  and  37  °C,  was  
greatest  for  Arg5-­‐‑ELPBC  in  all  cases  and  minimized  for  ELPBC  and  Arg5-­‐‑ELP  controls  
(Figure  37).  However,  controlled  uptake,  as  measured  by  fold  increase  in  fluorescence,  
was  best  achieved  in  HeLa  cells  and  to  a  lesser  extent  in  MCF7  and  then  HUVEC  cells,  
demonstrating  that  the  level  of  uptake  should  not  be  expected  to  be  consistent  between  
cell  lines.  The  differences  detected  here  suggest  that  uptake  is  achieved  to  a  higher  level  
in  cancer  cells,  as  opposed  to  non-­‐‑cancerous  primary  endothelial  cells,  perhaps  due  to  
exaggerated  endocytosis  of  malignant  cells  [151].  These  differences  in  performance  
could  suggest  an  advantage  in  targeting  cancerous  cells  over  normal  cells.  However,  
comparison  in  uptake  between  two  cancer  cell  lines  and  one  variant  of  endothelial  cells  
does  not  yet  provide  strong  support  of  this  variable  uptake.  Furthermore,  the  uptake  in  
HUVECs  may  vary  considerably  from  other  endothelial  cell  types,  such  as  those  found  
in  the  microvasculature,  causing  uptake  in  the  endothelial  cell  layer  to  vary  in  different  
types  of  vasculature.  Finally,  although  the  uptake  is  diminished  in  the  endothelial  cell  
line  investigated  here,  it  is  important  to  remember  that  the  endothelial  cells  will  
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encounter  the  highest  concentration  of  CPP-­‐‑ELPBC  as  it  circulates  throughout  the  body,  
such  that  even  a  lower  degree  of  uptake  in  endothelial  cells  may  result  in  important  
biological  effects  that  could  be  either  advantageous  or  detrimental  to  the  function  of  










































Figure  37:  Quantification  of  the  fold  increase  in  cellular  fluorescence  achieved  with  
Arg5-­‐‑ELPBC,  ELPBC,  and  Arg5-­‐‑ELP  between  42  °C  and  37  °C  in  HeLa  cervical  cancer  
cells,  MCF7  breast  cancer  cells,  and  primary  endothelial  HUVEC  cells  confirmed  that  
controlled  cellular  uptake  was  achieved  regardless  of  cell  type.  The  magnitude  of  cell  
uptake,  however,  was  cell-­‐‑dependent  and  greatest  for  cancer  cells.  Reproduced  from  
[149].  
Thus  far,  CPP-­‐‑ELPBCs  for  controlled  cellular  uptake  with  temperature-­‐‑triggered  
micelle  assembly  have  focused  on  arginine-­‐‑functionalized  constructs  where  each  unimer  
was  functionalized  with  5  arginine  residues,  below  the  threshold  necessary  for  uptake,  
to  prevent  cellular  internalization  in  the  soluble  “off”  state  at  37  °C.  Thus,  only  when  the  
Arg5-­‐‑ELPBC  assembled  into  micelles  at  their  “on”  state  of  42  °C,  could  the  cell  perceive  
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that  the  arginine  density  was  above  the  threshold  necessary  for  uptake.  This  design  
therefore  took  advantage  not  only  of  the  changing  density  of  arginine  residues  with  
micelle  assembly,  but  of  the  special  threshold  of  arginine  content  necessary  for  uptake.  
The  investigation  of  CPP-­‐‑functionalized  ELPBCs  was  next  expanded  beyond  the  case  of  
arginine  oligomers  below  their  functional  threshold  to  include  more  complex  CPP  
sequences  and  utilize  only  the  modulation  of  CPP  density  with  temperature-­‐‑triggered  
micelle  assembly  to  achieve  enhanced  cellular  uptake  at  conditions  of  mild  
hyperthermia.  
The  first  expansion  of  the  CPP-­‐‑ELPBC  library  involved  the  extrapolation  of  
arginine  oligomers  to  the  biological  peptide  from  which  they  were  inspired,  leading  to  
the  creation  of  a  TAT-­‐‑functionalized  ELPBC  bearing  residues  47-­‐‑57  from  the  trans-­‐‑
activator  of  transcription  (TAT)  of  HIV.  As  each  TAT-­‐‑ELPBC  contains  a  single  fully  
functional  CPP,  it  is  no  longer  expected  that  cellular  uptake  will  be  significantly  
inhibited  at  the  “off”  condition  of  37  °C.  However,  increasing  TAT  density  with  
temperature-­‐‑triggered  micelle  assembly  will  still  likely  increase  cellular  uptake,  thus  
separating  the  levels  of  cellular  internalization  at  “off”  and  “on”  conditions.  
Preliminary  evaluation  of  TAT-­‐‑ELPBC  was  performed  with  confocal  microscopy  
and  flow  cytometry  and  compared  to  the  performance  of  Arg5-­‐‑ELPBCs  (Figure  38).  As  
hypothesized,  TAT-­‐‑ELPBC  was  visualized  to  have  a  much  greater  degree  of  uptake  at  the  
“on”  state  of  42  °C,  as  compared  to  Arg5-­‐‑ELPBC  (Figure  38B,E),  but  at  the  cost  of  also  
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increasing  uptake,  to  a  lesser  extent,  at  the  “off”  state  of  37  °C  (Figure  38A,D).  
Histograms  of  cellular  fluorescence  acquired  by  flow  cytometry  confirmed  the  
microscopy  results,  such  that  there  was  a  greater  increase  in  cellular  fluorescence  for  
TAT-­‐‑ELPBC  between  thermal  conditions,  but  this  effect  was  shifted  to  higher  levels  of  




























































Figure  38:  TAT-­‐‑ELPBC  achieved  enhanced  cellular  uptake  at  both  thermal  conditions,  
as  compared  to  Arg5-­‐‑ELPBC.  TAT-­‐‑ELPBC  achieved  greater  uptake  at  37  °C  (B),  as  
compared  to  Arg5-­‐‑ELPBC  (A),  likely  due  to  its  fully  functional  CPP  on  each  ELPBC.  
Uptake  at  42  °C  was  greatly  enhanced  for  TAT-­‐‑ELPBC  (E),  as  compared  to  Arg5-­‐‑ELPBC  
(B).  Visualized  uptake  was  confirmed  by  flow  cytometry  at  37  °C  and  42  °C  (C  and  F).  
Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  scale  bars—25  µμm.  
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These  interesting  differences  in  cellular  uptake  at  “off”  and  “on”  states,  as  well  as  
their  implication  in  the  fold-­‐‑increase  in  uptake  from  normothermic  to  hyperthermic  
conditions,  was  further  investigated  by  manipulating  the  CPP  sequence  appended  to  the  
ELPBC.  Additional  CPP-­‐‑ELPBCs  were  added  to  the  library  of  third  generation  ELPBCs  to  
expand  the  available  levels  of  “off”  and  “on”  state  cellular  uptake  that  can  maximize  
internalization  at  conditions  of  mild  hyperthermia  while  minimizing  uptake  at  normal  
body  temperature.  These  additional  constructs  included  functionalization  with  Arg8,  
above  the  threshold  necessary  for  uptake  of  arginine  oligomer  CPPs,  and  RTAT,  a  
variant  of  TAT  in  which  the  architecture  of  arginine  was  explored  by  mutating  all  non-­‐‑
arginine  residues  to  neutral  glycine  residues.  This  complete  family  of  CPP-­‐‑ELPBCs  was  
labeled  with  Alexa  Fluor  488  and  characterized  by  DLS  to  confirm  that  all  constructs  
existed  as  unimers  (Rh  ~  5-­‐‑6  nm)  at  37  °C  and  micelles  (Rh  ~  20-­‐‑21  nm)  at  42  °C  (Table  8).  
Table  8:  Characterization  of  the  extended  library  of  Alexa  Fluor  488-­‐‑labeled  third  
generation  CPP-­‐‑ELPBCs  by  DLS  at  10  µμM  in  PBS.  
Construct   MW  (kDa)   Rh  (nm)  at  37  °C   Rh  (nm)  at  42  °C  
Arg5-­‐‑ELPBC   40.50   5.7  ±  0.3   20.8  ±  1.0  
Arg8-­‐‑ELPBC   40.97   5.4  ±  0.4   21.2  ±  0.3  
TAT-­‐‑ELPBC   41.26   5.7  ±  0.3   21.4  ±  0.3  
RTAT-­‐‑ELPBC   41.05   6.5  ±  0.2   21.8  ±  0.3  
ELPBC   39.72   6.2  ±  0.1   20.3  ±  0.3  
  
Controlled  cellular  uptake  of  these  CPP-­‐‑ELPBCs  was  visualized  in  HeLa  cells.  
Non-­‐‑functionalized  ELPBC  showed  no  visible  uptake  at  either  thermal  condition  (Figure  
39A,B),  confirming  the  function  of  this  control  as  in  previous  results  and  demonstrating  
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that  the  ELPBC  is  a  useful  platform  since  its  function  is  subsequently  conferred  entirely  
by  its  appended  CPP  moiety.  Arg5-­‐‑ELPBC  demonstrated  minimal  uptake  at  37  °C  in  its  
unimer  state,  but  did  achieve  greater  internalization  at  42  °C  (Figure  39C,D),  again  
consistent  with  previous  studies.  In  contrast,  ELPBCs  appended  with  Arg8  (Figure  39E,F),  
TAT  (Figure  39G,H),  and  RTAT  (Figure  39I,J)  all  exhibited  some  level  of  uptake  at  the  
“off”  condition  of  37  °C,  consistent  with  the  known  ability  of  these  CPPs  as  single  copies  
to  induce  cellular  uptake.  Internalization  of  these  constructs  was  then  dramatically  
enhanced  at  the  “on”  state  of  42  °C.  All  constructs  achieved  a  punctate  intracellular  
fluorescence,  suggesting  an  endocytic  route  of  cellular  entry.  
  


































Figure  39:  The  extended  family  of  CPP-­‐‑ELPBCs  achieved  a  breadth  of  cellular  uptake  at  
“off”  and  “on”  conditions,  as  visualized  by  fluorescence  microscopy.  HeLa  cells  were  
incubated  for  1  hour  at  37  °C  or  42  °C  with  ELPBC  (A,B),  Arg5-­‐‑ELPBC  (C,D),  Arg8-­‐‑ELPBC  
(E,F),  TAT-­‐‑ELPBC  (G,H),  or  RTAT-­‐‑ELPBC  (I,J).  All  CPP-­‐‑ELPBCs  demonstrated  an  
increased  internalization  at  42  °C,  as  compared  to  37  °C.  The  magnitude  of  the  
difference  in  uptake  between  thermal  conditions  was  controlled  by  the  appended  
CPP  moiety.  Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  scale  bars—50  µμm.  
Reproduced  from  [152].  
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Quantification  of  uptake  by  flow  cytometry  confirmed  the  tunable  internalization  
of  these  CPP-­‐‑ELPBCs.  All  CPP-­‐‑ELPBCs  achieved  amplified  uptake  at  42  °C,  as  compared  
to  37  °C,  while  the  control  non-­‐‑functionalized  ELPBC  showed  no  difference  in  uptake  
between  “off”  and  “on”  conditions  (Figure  40A).  Although  amplification  of  uptake  was  
apparent  for  all  CPP-­‐‑ELPBCs,  the  amplitude  of  uptake  at  “off”  and  “on”  conditions  
varied  significantly  as  a  function  of  the  CPP  potency.  The  fold  increase  in  cellular  
fluorescence  at  42  °C,  as  compared  to  37  °C,  demonstrated  the  control  of  cellular  uptake  
afforded  by  each  CPP-­‐‑ELPBC  and  also  shed  light  on  the  variation  in  CPP-­‐‑ELPBC  
performance,  dependent  on  the  CPP-­‐‑functionalization  (Figure  40B).  
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ELPBC Arg5-ELPBC Arg8-ELPBC TAT-ELPBC RTAT-ELPBC   
Figure  40:  The  magnitude  of  controlled  cellular  uptake  was  highly  tunable  by  means  
of  the  CPP-­‐‑functionalization.  All  CPP-­‐‑ELPBCs  achieved  greater  uptake  at  42  °C,  as  
compared  to  37  °C,  while  the  non-­‐‑functionalized  ELPBC  showed  no  difference  in  
uptake  between  thermal  conditions  (A).  *Indicates  p  <  0.01  between  thermal  
conditions  (two-­‐‑way  ANOVA,  Bonferroni  posthoc  test  for  multiple  comparisons).  
Fold  increase  in  cellular  uptake  between  42  °C  and  37  °C  demonstrated  variability  in  
the  controlled  cellular  uptake  that  was  dependent  on  CPP  functionalization  (B).  
*Indicated  p  <  0.0125  versus  ELPBC  control  (ANOVA,  Bonferroni  posthoc  test  for  
multiple  comparisons).  Flow  cytometry  data  represents  mean  of  3  measurements  ±  
SEM.  Reproduced  from  [152].  
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3.3.4 Mechanism of uptake and intracellular localization of CPP-
ELPBCs 
Although  small  CPPs  on  their  own  have  been  suggested  to  penetrate  directly  
across  the  cell  membrane,  the  internalization  of  CPPs  appended  to  the  macromolecular  
ELP  carrier  should  not  be  expected  to  do  the  same.  Visualization  of  internalized  CPP-­‐‑
ELPBCs  revealed  uptake  predominantly  characterized  by  punctate  fluorescence,  
suggesting  an  endocytic  route  of  entry  that  leads  to  the  entrapment  of  CPP-­‐‑ELPBCs  in  
discrete  compartments  within  the  cell.  There  are  several  generalized  means  of  entering  a  
cell  via  endocytosis.  All  of  these  routes  of  entry  have  distinct  characteristics,  such  as  the  
local  environment  of  their  intracellular  compartments,  which  may  have  an  effect  on  how  
a  carrier  will  function  in  delivering  a  therapeutic  cargo.  For  that  reason,  the  mechanism  
of  endocytosis  exploited  by  CPP-­‐‑ELPBCs  was  investigated.  Mechanisms  of  uptake  
including  clathrin-­‐‑mediated  endocytosis,  macropinocytosis,  and  caveolae-­‐‑mediated  
endocytosis  were  investigated  as  potential  routes  for  the  internalization  of  CPP-­‐‑ELPBCs.     
Preliminary  investigation  of  the  mechanism  of  uptake  was  performed  for  second  
generation  Arg5-­‐‑ELPBC  by  observing  changes  in  cellular  uptake  in  the  presence  of  
endocytosis  inhibitors.  HeLa  cells  were  co-­‐‑incubated  at  42  °C  with  Alexa  Fluor  488-­‐‑
labeled  Arg5-­‐‑ELPBC  in  its  micelle  state  and  inhibitors  of  clathrin-­‐‑mediated  endocytosis  
(chlorpromazine),  macropinocytosis  (amiloride),  or  caveolae-­‐‑mediated  endocytosis  
(filipin).  Uptake  was  then  visualized  with  fluorescence  microscopy.  Punctate  
intracellular  fluorescence  was  observed  in  chlorpromazine  and  filipin  treated  cells,  but  
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very  little  uptake  was  evident  in  amiloride  treated  cells  (Figure  41A).  This  visual  result  
suggested  that  macropinocytosis  was  the  primary  route  of  uptake  for  Arg5-­‐‑ELPBC  as  
amiloride,  its  inhibitor,  had  the  greatest  negative  effect  on  uptake.  This  decrease  in  
uptake  was  confirmed  with  flow  cytometry,  which  demonstrated  the  negative  shift  in  
cellular  fluorescence  in  the  presence  of  amiloride,  as  compared  to  the  other  inhibitors  
that  achieved  6-­‐‑fold  higher  internalization  (Figure  41B).  However,  DLS  of  Arg5-­‐‑ELPBC  in  
the  presence  of  each  of  these  inhibitors  revealed  that  some  were  poor  choices  for  this  
system  as  they  had  a  tendency  to  perturb  the  micelle  self-­‐‑assembly  of  Arg5-­‐‑ELPBC  (Figure  
41C).  Chlorpromazine  appeared  to  perturb  the  unimer-­‐‑to-­‐‑micelle  transition  such  that  
larger  particles  were  formed  prior  to  the  assembly  of  stable  micelles.  More  drastically,  
filipin  led  to  a  unimer-­‐‑to-­‐‑nanoparticle  transition  in  which  the  self-­‐‑assembled  particles  
were  nearly  three  times  the  expected  size  of  the  Arg5-­‐‑ELPBCs  without  inhibitor.  Only  
amiloride  appeared  to  have  negligible  effect  on  the  temperature-­‐‑triggered  Arg5-­‐‑ELPBC  
assembly.  Thus,  the  amiloride  data  provided  useful  insight  into  the  potential  role  of  
macropinocytosis  in  Arg5-­‐‑ELPBC  uptake,  but  alternative  inhibitors  were  needed  to  better  
probe  the  roles  of  clathrin-­‐‑mediated  or  caveolae-­‐‑mediated  endocytosis.  
  















































































































































































































Figure  41:  Inhibition  of  endocytosis  pathways  suggested  the  role  of  macropinocytosis  
in  the  uptake  of  second  generation  Arg5-­‐‑ELPBC.  Changes  in  uptake  of  Arg5-­‐‑ELPBC  at  42  
°C  were  visualized  with  fluorescence  microscopy  (A)  and  quantified  by  flow  
cytometry  (B).  Decreased  uptake  in  the  presence  of  amiloride,  but  not  chlorpromazine  
or  filipin,  suggested  macropinocytosis  was  the  major  pathway  of  Arg5-­‐‑ELPBC  uptake.  
However,  DLS  of  Arg5-­‐‑ELPBC  in  the  presence  of  inhibitors  revealed  that  
chlorpromazine  and  filipin  perturbed  micelle  assembly  (C).  
To  better  characterize  the  mechanism  of  uptake  by  means  of  inhibiting  endocytic  
pathways,  alternative  inhibitors  were  screened  for  their  effect  on  temperature-­‐‑triggered  
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self-­‐‑assembly,  this  time  of  third  generation  Arg5-­‐‑ELPBC  and  controls.  DLS  confirmed  that  
the  chosen  inhibitors  did  not  perturb  assembly  as  their  Rh  at  42  °C  matched  closely  to  
that  of  their  equivalent  in  the  absence  of  inhibitor  (Table  9).  The  chosen  inhibitors  were  
dansylcadaverine,  genistein,  and  amiloride,  which  are  inhibitors  of  clathrin-­‐‑mediated  
endocytosis,  caveolae-­‐‑mediated  endocytosis,  and  macropinocytosis,  respectively.  
Table  9:  Rh  (in  nm)  for  CPP-­‐‑ELPBCs  in  the  absence  and  presence  of  endocytosis  
inhibitors,  as  measured  by  DLS.  
   Arg5-­‐‑ELPBC   ELPBC   Arg5-­‐‑ELP  
No  Treatment   24.7  ±  0.8  nm   20.7  ±  1.3  nm   5.3  ±  0.4  nm  
Dansylcadaverine   23.4  ±  0.5  nm   21.4  ±  0.4  nm   5.7  ±  0.0  nm  
Genistein   22.3  ±  0.6  nm   20.3  ±  0.4  nm   5.3  ±  0.0  nm  
Amiloride   22.7  ±  0.1  nm   21.1  ±  0.4  nm   5.6  ±  0.1  nm  
  
These  inhibitors  allowed  reliable  evaluation  of  the  effect  of  blocking  endocytosis  
pathways  on  the  uptake  of  CPP-­‐‑ELPBC.  Cellular  fluorescence,  as  measured  with  flow  
cytometry,  revealed  that  dansylcadaverine  had  little  effect  on  the  uptake  of  Arg5-­‐‑ELPBC  
or  controls  when  co-­‐‑incubated  with  HeLa  cells  at  the  “on”  state  of  42  °C  (Figure  42A).  In  
contrast,  genistein  and  amiloride  both  decreased  uptake  of  Arg5-­‐‑ELPBC  significantly,  by  
57%  and  80%,  respectively,  as  compared  to  cells  treated  with  Arg5-­‐‑ELPBC  without  
inhibitor.  These  inhibitors  did  not  have  a  significant  effect  on  the  uptake  of  ELPBC  or  
Arg5-­‐‑ELP  controls,  with  the  exception  of  the  decrease  in  uptake  by  31%  of  Arg5-­‐‑ELP  
when  co-­‐‑incubated  with  amiloride.  These  results  were  confirmed  visually  by  confocal  
microscopy  of  cells  treated  with  Arg5-­‐‑ELPBC  at  42  °C  in  combination  with  endocytosis  
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inhibitors.  Significantly  less  intracellular  fluorescence  was  evident  in  cells  treated  with  
amiloride  or  genistein,  as  compared  to  cells  treated  with  dansylcadaverine  or  treated  








































Figure  42:  Inhibition  of  endocytosis  pathways  suggested  the  role  of  macropinocytosis  
and  caveolae-­‐‑mediated  endocytosis  in  the  uptake  of  third  generation  Arg5-­‐‑ELPBC.  
Cellular  uptake  of  Arg5-­‐‑ELPBC  at  42  °C,  as  measured  by  cellular  fluorescence,  
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significantly  decreased  with  genistein  or  amiloride  treatment,  but  not  with  
dansylcadaverine  treatment  (A).  Fluorescence  microscopy  confirmed  that  cellular  
uptake  of  Arg5-­‐‑ELPBC  in  the  absence  of  inhibitor  (B)  was  largely  unperturbed  in  the  
presence  of  dansylcadaverine  (C),  but  greatly  decreased  in  the  presence  of  genistein  
(D)  or  amiloride  (E).  Green—ELP;  red—cell  membrane;  blue—cell  nuclei;  scale  bars  25  
µμm.  Reproduced  from  [149].  
The  outcomes  of  this  inhibitor  study  provided  several  insights  into  the  route  of  
entry  for  Arg5-­‐‑ELPBC  micelles.  First,  the  minimal  effect  of  dansylcadaverine  suggested  
that  clathrin-­‐‑mediated  endocytosis,  typically  associated  with  receptor-­‐‑mediated  uptake,  
was  not  an  important  route  of  internalization  for  Arg5-­‐‑ELPBC  in  its  micelle  state.  Second,  
the  strong  effect  of  amiloride  to  reduce  uptake  suggested  that  macropinocytosis  was  an  
important  pathway  for  the  uptake  of  this  CPP-­‐‑ELPBC.  This  is  consistent  with  reports  in  
the  literature  that  high  arginine  density  directs  cellular  uptake  toward  the  
macropinocytosis  pathway  [74].  Indeed,  we  see  in  our  own  system  that  the  low  arginine  
density  on  the  Arg5-­‐‑ELP  control  exploits  macropinocytosis  to  some  extent,  as  amiloride  
also  decreased  uptake  of  this  soluble  unimer  construct.  The  increase  in  arginine  density  
from  Arg5-­‐‑ELP  unimer  to  Arg5-­‐‑ELPBC  micelle  appeared  to  push  uptake  more  toward  the  
macropinocytosis  pathway,  as  evident  by  the  more  drastic  effect  of  amiloride  on  the  
cellular  uptake  of  Arg5-­‐‑ELPBC,  as  compared  to  Arg5-­‐‑ELP.  Finally,  it  is  clear  that  Arg5-­‐‑
ELPBC  exploits  more  than  one  route  of  cellular  entry  as  demonstrated  by  the  additional  
effect  of  genistein  on  Arg5-­‐‑ELPBC  uptake,  which  suggested  that  caveolae-­‐‑mediated  
endocytosis  also  plays  a  role  in  Arg5-­‐‑ELPBC  micelle  internalization.  
    128  
The  results  of  the  inhibitor  studies  were  interesting  as  they  suggested  the  Arg5-­‐‑
ELPBC  was  internalized  by  mechanisms  that  may  have  advantages  as  routes  of  
intracellular  delivery  for  drug  carriers.  Primarily,  caveolae-­‐‑mediated  endocytosis  and  
macropinocytosis  may  be  less  degradative  routes  of  cellular  entry,  as  compared  to  
clathrin-­‐‑mediated  endocytosis.  For  example,  studies  have  shown  that  caveolae-­‐‑mediated  
endocytosis  may  avoid,  to  some  extent,  lysosomal  trafficking  [153],  while  
macropinocytosis  has  been  shown  to  involve  leaky  macropinosomes  that  might  promote  
the  release  of  cargo  into  the  cytosol  or  avoid  fusion  with  lysosome  compartments  [75].  
Together,  these  pathways  present  an  opportunity  for  cellular  entry  that  may  be  less  
harmful  to  labile  therapeutic  cargo,  such  as  biologic  drugs,  as  compared  to  receptor-­‐‑
mediated  uptake  via  clathrin-­‐‑mediated  endocytosis.  
To  gain  a  modest  degree  of  insight  on  the  localization  of  Arg5-­‐‑ELPBC  micelles  in  
intracellular  compartments,  Arg5-­‐‑ELPBC  was  co-­‐‑incubated  with  HeLa  cells  at  42  °C  with  
markers  of  endocytosis  pathways.  Lucifer  yellow  was  chosen  as  a  fluorophore  that  
typically  accumulates  in  macropinosomes  and  Lysotracker  Red  was  chosen  as  a  marker  
that  localizes  to  lysosomes,  classically  associated  with  clathrin-­‐‑mediated  endocytosis.  Of  
note,  Lucifer  yellow  has  an  excitation/emission  spectrum  very  close  to  that  of  Alexa  
Fluor  488,  our  ELP  label.  Therefore,  for  analysis  with  Lucifer  yellow  the  Arg5-­‐‑ELPBC  was  
attached  to  an  alternative  fluorophore,  Alexa  Fluor  594.    
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Cellular  uptake  of  Lucifer  yellow  and  Alexa  Fluor  594-­‐‑labeled  Arg5-­‐‑ELPBC  
appeared  to  colocalize  strongly  within  the  HeLa  cells,  indicating  the  presence  of  Arg5-­‐‑
ELPBC  in  compartments  such  as  macropinosomes  (Figure  43).  In  contrast,  the  cellular  
uptake  of  Lysotracker  Red  and  Alexa  Fluor  488-­‐‑labeled  Arg5-­‐‑ELPBC  appeared  to  have  
distinct  localization  that  did  not  largely  overlap  in  some  parts  of  the  cells.  These  initial  
results  suggested  that  Arg5-­‐‑ELPBCs  might,  in  part,  avoid  the  harsh  lysosome  
environment.  However,  the  most  distinctly  separate  localization  of  Lysotracker  Red  and  
Arg5-­‐‑ELPBC  appeared  to  occur  in  the  periphery  of  the  cell,  such  that  this  lack  of  
colocalization  may  just  suggest  that  those  intracellular  compartments  simply  had  not  yet  





Figure  43:  Arg5-­‐‑ELPBC  micelles  co-­‐‑localized  with  a  macropinocytosis  marker,  but  less  
significantly  co-­‐‑localized  with  a  marker  of  lysosomes.  Arg5-­‐‑ELPBC  was  incubated  with  
HeLa  cells  at  42  °C  in  the  presence  of  markers  for  macropinocytosis  (A-­‐‑C)  or  
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lysosomes  (D-­‐‑F).  Lucifer  yellow  (A)  and  Alexa  Fluor  594-­‐‑labeled  Arg5-­‐‑ELPBC  (B)  
demonstrated  intracellular  colocalization  (C).  Lysotracker  Red  (D)  and  Alexa  Fluor  
488-­‐‑labeled  Arg5-­‐‑ELPBC  (E)  demonstrated  some  separate  localization,  particularly  in  
the  periphery  of  the  cell  (F).  Scale  bars—25  µμm.  
3.4 Conclusions 
We  hypothesized  that  manipulation  of  CPP  density,  by  means  of  temperature-­‐‑
triggered  micelle  assembly,  would  provide  an  extrinsic  trigger  to  control  cellular  uptake  
by  a  non-­‐‑specific  mechanism  that  was  thereby  applicable  to  a  variety  of  cell  types.  To  
test  this  hypothesis,  CPP-­‐‑ELPBCs  were  labeled  with  a  fluorescent  tag  such  that  their  
cellular  uptake  could  be  visualized  by  fluorescence  microscopy  and  quantified  by  flow  
cytometry.  
First  generation  CPP-­‐‑ELPBCs,  although  not  optimized  for  triggered  self-­‐‑assembly  
in  response  to  clinically  relevant  hyperthermia  conditions,  provided  a  platform  in  which  
to  investigate  controlled  uptake  between  the  “off”  condition  of  25  °C  and  the  “on”  
condition  of  37  °C.  Arg3-­‐‑ELPBC  was  the  first  CPP-­‐‑ELPBC  whose  uptake  was  investigated  
in  HeLa  cells.  Difficulty  in  detecting  uptake  of  this  construct  by  microscopy  encouraged  
the  creation  of  CPP-­‐‑ELPBCs  with  increasing  arginine  content  including  an  Arg4-­‐‑  and  
Arg5-­‐‑ELPBC.  It  is  with  the  Arg5-­‐‑ELPBC  that  a  striking  control  in  cellular  uptake  was  first  
observed  with  microscopy  and  quantified  by  flow  cytometry.  This  effect  was  greatly  
exaggerated  for  Arg5-­‐‑ELPBC,  as  compared  to  ELPBC  or  Arg5-­‐‑ELP  controls.  However,  there  
were  some  differences  in  uptake  of  these  control  constructs  between  “off”  and  “on”  
conditions,  suggesting  that  there  may  have  been  an  unintended  side  effect  of  the  “off”  
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state  of  25  °C.  It  is  possible  that  this  hypothermic  condition  generally  reduced  
endocytosis,  thus  exaggerating  the  performance  of  CPP-­‐‑ELPBCs  evaluated  between  25  °C  
and  37  °C.  
Second  generation  CPP-­‐‑ELPBCs  would  provide  the  first  evaluation  of  this  
mechanism  for  controlled  uptake  using  a  clinically  relevant  external  trigger,  such  that  
the  “off”  state  was  at  normal  physiologic  temperature  of  37  °C,  while  the  “on”  state  was  
in  agreement  with  mild  clinical  hyperthermia  at  42  °C.  However,  the  limited  micelle  
range  of  these  second  generation  CPP-­‐‑ELPBCs  made  them  highly  sensitive  to  fluorophore  
conjugation,  which  would  affect  the  thermal  characteristics  of  these  constructs  and  
abolish  temperature-­‐‑triggered  self-­‐‑assembly.  Ultimately,  it  was  best  to  label  these  
constructs  with  fluorophore  at  the  N-­‐‑terminal  amine,  as  opposed  to  the  genetically  
designed  cysteine  residue,  which  allowed  stable  self-­‐‑assembly  with  a  CMT  between  37  
°C  and  42  °C.  Alexa  Fluor  488-­‐‑labeled  second  generation  Arg5-­‐‑ELPBC  demonstrated  
controlled  cellular  uptake  in  HeLa  cells,  as  observed  with  microscopy  and  quantified  
with  flow  cytometry.  At  these  thermal  conditions  both  ELPBC  and  Arg5-­‐‑ELP  controls  
exhibited  negligible  change  in  uptake  between  37  °C  and  42  °C,  suggesting  that  micelle  
assembly  and  hyperthermia  alone  were  not  responsible  for  enhanced  uptake  of  Arg5-­‐‑
ELPBC,  confirming  that  the  change  in  CPP  density  triggered  the  drastic  increase  in  
internalization.    
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Ultimately  a  more  stable  construct,  less  sensitive  to  modifications  such  as  
fluorophore  attachment,  is  desirable  as  a  material  platform  for  drug  carriers.  Therefore  
third  generation  CPP-­‐‑ELPBCs  were  similarly  characterized  to  demonstrate  controlled  
cellular  uptake  as  visualized  by  microscopy.  Flow  cytometry  conditions  were  optimized  
prior  to  quantification  of  uptake  in  HeLa  cells  as  well  as  MCF7  and  HUVEC  cells,  
demonstrating  that  controlled  cellular  uptake  was  achievable  in  a  variety  of  cell  types,  
but  that  the  magnitude  of  uptake  was  variable  and  was  greater  in  cancerous  cell  lines  as  
compared  to  primary  non-­‐‑cancerous  cells.  Using  third  generation  ELPBCs  as  a  robust  
material  platform,  the  CPP-­‐‑ELPBC  library  was  expanded  to  include  alternative  CPP-­‐‑
functionalization  of  Arg8,  TAT,  and  RTAT  peptides  that  all  demonstrated  controlled  
cellular  uptake  with  variable  magnitudes  of  internalization  both  in  their  “off”  and  “on”  
states.  
Finally,  the  mechanism  of  uptake  for  Arg5-­‐‑ELPBCs  was  investigated  by  inhibition  
of  endocytosis  pathways  and  colocalization  with  endocytosis  markers.  Evaluation  of  
both  second  and  third  generation  Arg5-­‐‑ELPBCs  suggested  that  macropinocytosis  was  a  
major  endocytic  pathway  accountable  for  the  internalization  of  Arg5-­‐‑functionalized  
micelles.  Caveolae-­‐‑mediated  endocytosis  was  also  indicated  as  a  potential  pathway,  but  
clathrin-­‐‑mediated  endocytosis,  typical  of  receptor-­‐‑mediated  uptake,  did  not  appear  to  be  
an  important  pathway  for  Arg5-­‐‑ELPBC  internalization.  Greater  colocalization  of  Arg5-­‐‑
ELPBCs  with  a  macropinocytosis  marker,  as  compared  to  a  lysosome  marker,  suggested  
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that  the  intracellular  trafficking  of  Arg5-­‐‑ELPBCs  might,  in  part,  avoid  the  degradative  
environment  of  the  lysosome.  
Third  generation  ELPBCs  proved  to  be  a  stable  material  platform  that  could  be  
functionalized  with  a  number  of  CPPs  to  provide  controlled  cellular  uptake  that  was  
repeatable  and  applicable  to  a  number  of  cell  types.  The  tunable  levels  of  uptake  at  “off”  
and  “on”  conditions,  as  controlled  by  CPP-­‐‑functionalization,  provided  a  variable  drug  
carrier  system  that  could  potentially  be  custom-­‐‑paired  with  a  therapeutic  cargo  to  meet  
the  needs  of  that  drug  in  terms  of  minimizing  “off”  state  uptake  to  avoid  off-­‐‑target  
toxicity  while  providing  enhanced  “on”  state  uptake  sufficient  to  induce  a  therapeutic  
effect.  This  functionality  of  the  CPP-­‐‑ELPBC  platform  was  next  tested  with  two  types  of  
therapeutics  applicable  for  anti-­‐‑cancer  therapy:  small  molecule  chemotherapeutics  and  
proapoptotic  peptide  drugs.  
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4. Controlled drug delivery by CPP-ELPBCs in vitro 
4.1 Motivation 
Successful  demonstration  of  controlled  cellular  uptake  of  CPP-­‐‑ELPBCs  in  vitro  
confirmed  that  manipulation  of  CPP  density,  by  micelle  self-­‐‑assembly,  could  achieve  
selective  internalization  in  response  to  an  external  stimulus.  These  preliminary  
experiments  demonstrated  the  ability  of  CPP-­‐‑ELPBCs  as  a  carrier  alone  to  enter  cells  in  a  
controlled  manner,  suggesting  any  drug  cargo  associated  with  these  carriers  could  also  
be  delivered  into  the  cell  with  the  same  precision,  thereby  achieving  a  therapeutic  effect  
in  a  controlled  fashion.  This  hypothesis  would  be  tested  with  drug  cargo  whose  anti-­‐‑
cancer  therapeutic  effect  would  be  evaluated  based  on  its  controlled  cytotoxicity  in  
cancer  cells.    
Two  distinct  types  of  anti-­‐‑cancer  drug  cargo  were  investigated  with  this  CPP-­‐‑
ELPBC  carrier  platform:  small  molecule  chemotherapeutics  and  proapoptotic  peptide  
drugs.  Each  drug  type  had  potential  advantages  and  disadvantages  in  terms  of  ease  of  
design  and  drug  attachment  and  their  potential  for  perturbation  of  the  CPP-­‐‑ELPBC  
temperature-­‐‑triggered  self-­‐‑assembly.  Furthermore,  differences  in  the  potency  of  each  
drug  type  would  also  contribute  to  the  likelihood  of  the  cargo  to  achieve  controlled  
therapeutic  effect  based  on  the  difference  in  intracellular  drug  delivery  at  “off”  and  “on”  
conditions.    
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Small  molecule  drugs  were  investigated  as  a  potential  cargo  due  to  their  
prevalence  in  current  cancer  treatments  and  the  relative  ease  in  which  they  could  be  
appended  to  genetically  engineered  biopolymers.  Inclusion  of  cysteine  residues  at  
precisely  controlled  locations  on  the  CPP-­‐‑ELPBC  would  allow  covalent  attachment  of  
small  molecule  drugs  via  maleimide-­‐‑functionalized  linkers.  This  approach  has  been  
utilized  extensively  in  the  Chilkoti  laboratory  to  conjugate  hydrophobic  
chemotherapeutics  at  one  terminus  of  a  soluble  pseudorandom  ELP,  inducing  drug-­‐‑
loaded  nanoparticle  assembly  by  means  of  the  hydrophobic  effect  [154].  While  this  well-­‐‑
established  application  paves  the  way  in  terms  of  the  technical  details  of  small  molecule  
drug  attachment,  it  also  provides  significant  warning  of  the  effect  that  small  molecules  
can  have  on  ELP  self-­‐‑assembly.  For  this  reason,  hydrophobic  small  molecule  drugs  were  
avoided  as  cargo  for  CPP-­‐‑ELPBCs,  due  to  the  sensitive  thermal  behavior  of  this  carrier,  in  
hopes  to  not  perturb  the  optimized  CMT  of  the  carrier.  
Peptide  drugs  were  chosen  as  the  second  potential  cargo  due  to  their  specificity  
in  targeting  therapeutic  pathways  in  cancer  cells,  their  generally  poor  intracellular  
uptake  as  free  drug,  and  their  ease  with  which  they  can  be  appended  to  a  recombinant  
biopolymer  carrier.  Peptide  drugs  are  a  stringent  test  for  CPP-­‐‑ELPBCs,  as  the  delivery  of  
therapeutic  peptides  remains  a  major  challenge  in  drug  delivery,  since  peptide  drugs  
typically  suffer  from  limited  efficacy  due  to  fast  plasma  clearance,  premature  
degradation,  and  difficulty  in  crossing  the  cell  membrane  to  reach  their  intracellular  
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therapeutic  targets  [155].  The  genetic  design  of  CPP-­‐‑ELPBCs  can  be  modified  to  encode  a  
peptide  drug  cargo  and  a  cleavable  peptide  linker  can  be  embedded  between  the  drug  
and  CPP-­‐‑ELPBC  to  provide  a  mechanism  of  free  drug  release  within  the  cell.  Peptide  
drugs  also  have  the  potential  to  perturb  ELPBC  thermal  properties  if  their  sequence  
encodes  residues  with  extreme  characteristics,  be  it  hydrophilicity  or  hydrophobicity.  
Indeed  a  sufficient  number  of  hydrophobic  residues  localized  to  one  terminus  of  a  
hydrophilic  ELP  homopolymer  can  also  induce  self-­‐‑assembly  of  nanoparticles  [156],  
reminiscent  of  those  formed  with  hydrophobic  small  molecules  [154].  Thus,  careful  
attention  should  be  made  to  the  peptide  drug’s  amino  acid  sequence  in  predicting  its  
effect  on  the  CPP-­‐‑ELPBC’s  optimized  CMT.  
4.2 Methods 
4.2.1 Drug loading of small molecule therapeutics 
4.2.1.1  Genetic  modification  of  CPP-­‐‑ELPBCs  for  small  molecule  conjugation  
CPP-­‐‑ELPBCs  were  originally  designed  to  include  a  single  cysteine  within  the  N-­‐‑
terminal  leader,  proximal  to  the  hydrophobic  domain.  This  single  cysteine  could  be  used  
to  attach  small  molecule  chemotherapeutics  through  a  maleimide-­‐‑functionalized  linker.  
However,  this  single  cysteine  limited  the  potential  drug  loading  of  these  carriers  to  a  
maximum  of  one  drug  molecule  per  ELP.  To  increase  the  capacity  for  drug  loading,  
additional  cysteine  residues  were  appended  to  the  CPP-­‐‑ELPBC  via  a  new  leader  
sequence.  This  leader  included  eight  cysteine  residues,  each  separated  by  a  di-­‐‑glycine  
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spacer  intended  to  provide  space  around  each  reactive  cysteine  residue  to  prevent  
suboptimal  drug  conjugation  due  to  steric  hindrance  between  attachment  sites.  The  
genetic  design  of  this  leader  sequence  is  shown  in  Table  10,  where  pertinent  residues  at  
this  N-­‐‑terminal  functionalization  are  noted.  
Table  10:  Genetic  design  of  leader  sequence  for  attachment  of  small  molecule  
chemotherapeutics  to  CPP-­‐‑ELPBCs.  
N-­‐‑   Peptide  and  oligonucleotide  sequence  
Cys8,  
Trp  
    (M)    G        C      G        G        C        G        G      C        G        G        C      G        G        C        G        G        C      G        G  
t  atg  ggc  tgc  ggt  ggt  tgc  ggc  ggt  tgc  ggt  ggc  tgc  ggc  ggc  tgc  ggt  ggc  tgc  ggc  ggt    
        ac  ccg  acg  cca  cca  acg  ccg  cca  acg  cca  ccg  acg  ccg  ccg  acg  cca  ccg  acg  ccg  cca    
  
  C        G        G      C        G        G        W      P          
tgc  ggt  ggc  tgc  ggc  ggt  tgg  ccg  gg  
acg  cca  ccg  acg  ccg  cca  acc  ggc  
  
Oligonucleotides  encoding  this  leader  sequence  were  inserted  into  the  PRe-­‐‑RDL  
cloning  vector,  and  the  N-­‐‑terminus  of  the  CPP-­‐‑ELPBC  was  functionalized  by  PRe-­‐‑RDL  
cloning,  as  described  previously.  Successful  modification  of  the  CPP-­‐‑ELPBC  was  screened  
by  diagnostic  digestion  and  confirmed  with  plasmid  DNA  sequencing.  Although  the  
thermal  properties  of  this  functionalized  CPP-­‐‑ELPBC  allowed  typical  ITC  purification  by  
centrifugation  above  and  below  the  ELP  Tt,  these  CPP-­‐‑ELPBCs  had  the  potential  to  co-­‐‑
purify  contaminants,  likely  due  to  their  many  cysteine  residues  that  could  form  disulfide  
bonds  with  extraneous  E.  coli  proteins.  To  prevent  these  undesirable  interactions,  CPP-­‐‑
ELPBCs  appended  to  this  Cys8  leader  were  purified  in  10  mM  TCEP-­‐‑HCl/H20  at  pH  7,  to  
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break  disulfide  bonds  and  release  contaminating  proteins  to  be  cleared  as  normally  by  
ITC.  
4.2.1.2  Covalent  conjugation  of  gemcitabine  small  molecule  chemotherapeutic  
Covalent  conjugation  of  gemcitabine  to  CPP-­‐‑ELPBCs  was  performed  by  Dr.  
Jayanta  Bhattacharyya  [157].  Gemcitabine  was  conjugated  to  the  cysteine(s)  genetically  
engineered  at  the  N-­‐‑terminus  of  the  hydrophobic  domain  of  the  ELPBC  by  a  maleimide-­‐‑
functionalized  linker.  The  reactive  acid  groups,  3’-­‐‑OH  and  5’-­‐‑OH,  of  the  gemcitabine  
molecule  were  selectively  protected  with  BOC  (t-­‐‑butyloxycarbonyl)  to  permit  specific  
coupling  of  a  BMPA  (N-­‐‑β-­‐‑Maleimidopropionic  acid)  linker  only  at  the  reactive  
gemcitabine  amine.  EDC  (1-­‐‑Ethyl-­‐‑3-­‐‑[3-­‐‑dimethylaminopropyl]carbodiimide)  was  added  
with  BMPA  to  the  protected  gemcitabine  molecule,  to  attach  the  –COOH  group  of  the  
BMPA  to  the  gemcitabine  amine  via  EDC  crosslinker.  The  acid  groups  of  the  
gemcitabine  molecule  were  deprotected  with  trifluoroacetic  acid  prior  to  reaction  of  the  
gemcitabine-­‐‑BMPA  conjugate  with  the  cysteine  residue(s)  on  the  CPP-­‐‑ELPBC.    
The  cysteine(s)  on  the  CPP-­‐‑ELPBC  was  reduced  by  the  addition  of  TCEP-­‐‑HCl,  
with  excess  TCEP  in  solution  then  removed  by  phase  transition  of  the  ELP  and  
resuspension  in  sodium  phosphate  reaction  buffer,  to  which  the  reactive  gemcitabine-­‐‑
BMPA  linker,  in  methanol,  was  added.  Reaction  proceeded  overnight  to  attach  the  
maleimide  reactive  group  of  the  gemcitabine-­‐‑BMPA  to  the  sulfydryl  group(s)  on  the  
CPP-­‐‑ELPBC  cysteine(s),  after  which  methanol  in  the  reaction  buffer  was  evaporated  such  
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that  unconjugated  gemcitabine-­‐‑BMPA  could  be  removed  by  centrifugation  of  
precipitates.  The  CPP-­‐‑ELPBC-­‐‑gemcitabine  conjugate  was  then  collected  by  triggering  the  
phase  transition,  centrifuging  to  concentrate  the  ELP  pellet,  and  resuspending  the  ELP  
pellet  in  PBS  prior  to  purification  by  size-­‐‑exclusion  PD-­‐‑10  chromatography.      
This  conjugation  strategy  using  the  gemcitabine  amide  group  was  chosen  as  it  
has  been  proposed  to  improve  pharmacokinetics  compared  to  the  short  half-­‐‑life  
achieved  with  conjugation  to  the  acid  groups  of  gemcitabine  through  ester  linkages  
[158].  Attachment  at  the  amide  group  may  enhance  the  half-­‐‑life  of  the  drug  by  
protecting  against  inactivation  by  deaminase  activity.  Although  the  BMPA  linker  used  
here  does  not  impart  a  practical  mechanism  of  cleavage,  ELP-­‐‑BMPA-­‐‑gemcitabine  
conjugates  have  achieved  therapeutic  efficacy  in  vitro.  It  is  possible  that  the  inherent  
degradability  of  ELPs  provides  sufficient  breakdown  of  the  peptide  backbone  in  the  
endosome  of  the  cell  such  that  small  gemcitabine-­‐‑conjugated  peptides  are  capable  of  
inducing  therapeutic  effects,  without  the  encumbrance  of  the  intact  macromolecular  ELP  
carrier.  
4.2.2 Drug loading of peptide therapeutics 
4.2.2.1  Genetic  modification  of  CPP-­‐‑ELPBCs  for  appending  peptide  drugs  
Peptide  drugs,  due  to  their  amino  acid  composition,  can  be  genetically  encoded  
along  with  the  CPP-­‐‑ELPBC  to  create  a  drug-­‐‑loaded  macromolecular  carrier  in  a  single  
recombinant  synthesis  step.  Peptide  drugs  were  encoded  at  the  N-­‐‑terminus  of  the  CPP-­‐‑
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ELPBC,  proximal  to  the  hydrophobic  domain,  such  that  they  would  be  sequestered  into  
the  micelle  core  upon  self-­‐‑assembly.  Two  anti-­‐‑cancer  peptide  drugs  were  investigated  as  
cargo  of  the  CPP-­‐‑ELPBC  drug  carrier  platform  (Table  11).    
Table  11:  Genetic  design  of  leader  sequences  encoding  anti-­‐‑cancer  peptide  drugs.  
N-­‐‑   Peptide  and  oligonucleotide  sequence  
H1  
    (M)    G        N        E        L        K        R        A        F        A        A        L        R        D        Q        I        G        C        G        W  
t  atg  ggc  aac  gaa  ctg  aaa  cgt  gcg  ttt    gcg  gcg  ctg  cgt    gat  cag  att  ggc  tgc  ggg  tgg    
        ac  ccg    ttg    ctt    gac    ttt  gca  cgc  aaa  cgc  cgc  gac  gca  cta  gtc    taa  ccg  acg  ccc  acc    
  
    P  
ccg    gg  
ggc  
BH3  
    (M)    G      Q        V        G        R        Q        L        A        I          I        G        D        D      I        N        R        R      Y        G    
t  atg  ggt  cag  gtg  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc  tat  ggc    
        ac  cca  gtc    cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg  ata  ccg    
  
    C      G        W      P            
tgc  ggg  tgg  ccg  gg  
acg  ccc  acc  ggc  
  
The  first  drug,  the  H1  peptide,  is  a  c-­‐‑Myc  inhibitor  derived  from  helix-­‐‑1  of  the  
basic-­‐‑helix-­‐‑loop-­‐‑helix-­‐‑zipper  domain  found  in  c-­‐‑Myc  [159].  The  H1  peptide  used  here  is  
a  derivative  of  wild-­‐‑type  H1,  containing  F8A  and  S6A  mutations,  which  purportedly  
increase  c-­‐‑Myc  binding  due  to  increased  peptide  helicity.  H1  can  induce  an  anti-­‐‑cancer  
therapeutic  effect  when  it  binds  to  c-­‐‑Myc  and  prevents  the  interaction  of  this  
transcription  factor  with  its  DNA  binding  targets.  H1  can  thus  change  transcription  and  
protein  expression  controlled  by  c-­‐‑Myc,  which  is  often  upregulated  in  cancers  cells,  and  
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lead  to  cellular  instability  that  culminates  in  apoptosis.  This  drug  was  chosen  simply  to  
validate  our  drug  delivery  carrier  as  this  peptide  drug  has  functioned  successfully  with  
other  CPP-­‐‑ELP  systems  that  utilize  pseudorandom  ELPs  as  a  macromolecular  drug  
carrier  [115].    
The  second  drug,  BH3  peptide,  corresponds  to  residues  71-­‐‑89  of  the  proapoptotic  
Bak  protein  [160,  161].  The  BH3  peptide  sensitizes  cells  to  apoptosis  by  inhibiting  
prosurvival  proteins.  For  example,  this  BH3  peptide  can  bind  to  prosurvival  Bcl-­‐‑xL  [160]  
and  displace  the  proapoptotic  molecules  that  were  neutralized  by  this  Bcl-­‐‑xL  interaction.  
These  released  factors  can  then  contribute  to  triggering  the  apoptotic  cascade  [162].  This  
BH3  peptide  is  thereby  not  the  most  potent  of  its  class,  as  it  does  not  directly  activate  
apoptosis,  but  rather  primes  a  cell  toward  this  death  pathway.  However,  this  BH3  
peptide  has  demonstrated  efficacy  in  cancer  cells,  such  as  HeLa  cells,  demonstrating  that  
this  perturbation  of  prosurvival  protein  function  can  indeed  induce  apoptosis  [161].  This  
BH3  peptide  was  chosen  as  a  therapeutic  cargo  since  it  is  known  to  have  poor  activity  as  
a  free  drug,  which  is  recovered  when  it  is  delivered  in  assistance  with  CPP-­‐‑
functionalized  carriers  [161,  163,  164].    
Both  of  these  peptides  were  feasible  candidates  as  their  sequences  were  not  
dominated  by  hydrophobic  or  hydrophilic  character,  but  were  rather  a  mixture  of  both  
types  of  residues.  This  was  encouraging,  in  hopes  that  the  mixed  qualities  of  each  
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peptide  would  neutralize  their  effect  on  the  ELPBC  and  thereby  have  minimal  effect  on  
the  CMT.        
4.2.2.2  Exploring  cleavable  linkers  with  BH3  peptide  drug  
As  would  become  apparent  with  preliminary  in  vitro  testing,  BH3  peptide  drug  
cargo  would  require  release  from  the  ELP  carrier  within  the  cell  to  achieve  a  therapeutic  
effect.  For  this  reason,  a  number  of  cleavable  linkers  were  investigated  to  join  the  BH3  
peptide  and  the  ELP  carrier.  For  ease  of  design  and  synthesis,  only  peptide  linkers  were  
considered,  as  they  could  easily  be  genetically  encoded  along  with  the  peptide  cargo.  As  
peptides,  these  linkers  are  all  enzymatically  cleavable,  providing  a  mechanism  of  release  
when  encountering  enzymes  localized  in  the  endosomes.  A  number  of  linkers  were  
chosen  for  testing  to  determine  which  was  capable  of  enzyme-­‐‑mediated  free  peptide  
drug  release,  while  not  perturbing  the  CPP-­‐‑ELPBC  CMT.  For  those  linkers  with  
predominant  hydrophobic  character,  including  GFLG  and  FK  linkers,  the  GCGWPG  
portion  of  the  leader,  otherwise  included  for  consistency  with  previous  constructs,  was  
removed  to  decrease  overall  hydrophobicity.  The  design  of  peptide  drug  in  combination  




    143  
Table  12:  Genetic  design  of  leaders  encoding  BH3  peptide  drug  and  enzyme-­‐‑cleavable  
linkers.  
N-­‐‑   Linker   Peptide  and  oligonucleotide  sequence  
BH3   GFLG  
    (M)    G      Q        V      G        R        Q        L        A        I          I        G        D      D        I        N        R      R          
t  atg  ggt  cag  tgt  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc    
        ac  cca  gtc  cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg    
  
  Y        G        F        L        G        
tat  ggc    ttt    ctg  gg  
ata  ccg  aaa  gac    
BH3   FK  
    (M)    G      Q        V        G        R        Q        L        A        I          I        G        D      D        I        N        R        R    
t  atg  ggt  cag  gtg  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc  
        ac  cca  gtc    cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg  
    
  Y        F        K        G            
tat    ttt    aaa  gg  
ata  aaa  ttt  
BH3   GGGGG  
    (M)    G        Q        V        G        R      Q        L        A        I          I        G        D        D        I      N        R        R            
t  atg  ggt  cag  gtg  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc  
        ac  cca  gtc    cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg  
  
  Y        G        G        G        G        G      C        G        W        P        G      
tat  ggc  ggt  ggc  ggt  ggc  tgc  ggg  tgg  ccg  gg  
ata  ccg  cca  ccg  cca  ccg    acg  ccc  acc  ggc  
BH3   GGG  
    (M)    G      Q        V        G        R        Q        L        A        I          I        G        D        D      I        N        R        R            
t  atg  ggt  cag  gtg  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc    
        ac  cca  gtc    cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg    
  
  Y        G      G        G        C        G        W        P        G          
tat  ggc  ggt  ggc  tgc  ggg  tgg  ccg  gg  
ata  ccg  cca  ccg  acg  ccc    acc  ggc  
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Cleavage  of  the  peptide  linker  was  evaluated  in  vitro  by  incubation  with  enzymes  
that  specifically  recognized  the  linker  sequence  as  a  cut  site  and  were  localized  to  
intracellular  compartments  that  the  CPP-­‐‑ELPBC  carrier  was  likely  to  encounter.  Two  such  
enzymes  were  evaluated  in  the  cleavage  of  the  RVRR  peptide  linker:  furin  and  cathepsin  
B.  
Furin  reaction  buffer  was  prepared  with  100  mM  HEPES  containing  0.5%  
TritonX-­‐‑100,  1  mM  CaCl2,  and  1  mM  2-­‐‑mercapto-­‐‑ethanol  at  pH  7.5.  CPP-­‐‑ELPBCs  were  
incubated  with  2  units  of  Furin  in  reaction  buffer  for  6  hours  at  37  °C.  The  reaction  was  
mixed  1:1  with  tricine  sample  buffer  containing  2-­‐‑mercaptoethanol  and  heated  to  95  °C  
for  2  minutes.  Reaction  products  were  separated  on  a  SDS-­‐‑PAGE  10-­‐‑20%  Tris-­‐‑tricine  gel  
and  stained  with  CuCl2  to  visualize  the  ELP  by  negative  staining  (minimally  charged  
ELPs  do  not  stain  well  with  conventional  coomassie  staining),  washed  with  water,  and  
subsequently  stained  with  coomassie  blue  to  visualize  the  released  BH3  peptide.  
BH3   RVRR  
    (M)    G      Q        V        G        R        Q        L        A        I          I        G        D      D        I        N        R      R            
t  atg  ggt  cag  gtg  ggc  cgt  cag  ctg  gcg  att  atc  ggc  gat  gat  att  aac  cgt  cgc    
        ac  cca  gtc    cac  ccg  gca  gtc  gac  cgc  taa  tag  ccg  cta  cta  taa  ttg  gca  gcg    
  
  Y        R        V        R          R        G        C        G        W      P        G          
tat    cgt  gtg  cgc    cgt  ggc  tgc  ggg  tgg  ccg  gg  
ata  gca  cac  gcg  gca  ccg  acg  ccc  acc  ggc  
none   RVRR  
    (M)    G        R      V        R        R        G        C        G        W      P        G  
t  atg  ggt  cgt  gtg  cgc  cgt  ggc  tgc  ggg  tgg  ccg  gg  
        ac  cca  gca  cac  gcg  gca  ccg  acg  ccc  acc  ggc  
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Cathepsin  B  reaction  buffer  was  prepared  with  100  mM  potassium  phosphate,  15  
mM  sodium  phosphate,  1  mM  ethylenediaminetetraacetic  acid,  2  mM  L-­‐‑cysteine  
hydrochloride,  and  0.1%  (v/v)  Brig  35  at  pH  6.5.  CPP-­‐‑ELPBCs  were  incubated  with  50  
units  of  cathepsin  B  for  1  hour  at  37  °C.  Digestion  products  were  visualized  by  SDS-­‐‑
PAGE  as  described  above.  
4.2.3 Evaluation of controlled cytotoxicity 
4.2.3.1  Modified  in  vitro  cell  survival  assay  
Cells  were  seeded  on  96-­‐‑well  tissue  culture  treated  polystyrene  plates.  Cells  were  
allowed  to  adhere  for  24  hours  before  the  cells  were  washed  with  PBS  and  incubated  
with  drug-­‐‑loaded  CPP-­‐‑ELPBC  in  SF-­‐‑media.  Cells  were  incubated  for  1  hour  at  37  °C  or  42  
°C  after  which  the  cells  were  washed  with  PBS,  provided  complete  media,  and  returned  
to  37  °C  for  24-­‐‑72  hours.  Untreated  cells  and  cell  media  alone  were  included  as  controls  
on  each  plate.  
4.2.3.2  Quantification  of  cytotoxicity  by  MTS  assay  
Cell  survival  was  approximated  by  the  measurement  of  cell  metabolism  using  
the  MTS  assay.  24-­‐‑72  hours  after  treatment,  cell  titer  96  aqueous  non-­‐‑radioactive  cell  
proliferation  solution  (MTS)  was  diluted  in  cell  media  and  equal  amounts  were  added  to  
each  well  containing  treated  cells,  untreated  cells,  or  media  alone.  The  cell  plate  was  
returned  to  37  °C  for  15  minutes  to  1  hour,  until  a  sufficient  color  change  had  occurred.  
This  color  change,  indicative  of  reduction  of  MTS  into  formazan,  was  quantified  by  
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absorbance  at  490  nm.  Treated  cell  wells  were  corrected  for  the  signal  from  media  alone  
and  normalized  to  untreated  cells  incubated  at  37  °C.  
4.2.4 Evaluation of the mechanism of therapeutic effect 
4.2.4.1  In  vitro  apoptosis  assay  
HeLa  cells  were  seeded  on  12-­‐‑well  tissue  culture  treated  polystyrene  plates  and  
were  allowed  to  adhere  for  24  hours.  Cell  media  was  removed  and  cells  were  washed  
with  PBS  prior  to  the  addition  of  CPP-­‐‑ELPBC  drug  carrier  in  SF-­‐‑media.  Cell  plates  were  
incubated  for  1  hour  at  37  °C  or  42  °C.  The  cells  were  then  washed  with  PBS,  provided  
complete  media,  and  returned  to  37  °C  for  an  additional  5  hours.    
4.2.4.2  Quantification  of  apoptosis  by  caspase  activation  
Cells  were  gently  removed  from  the  culture  surface  with  0.05%  trypsin/EDTA  
and  analyzed  for  caspase-­‐‑3  activity  with  an  EnzChek  Caspase-­‐‑3  Assay  Kit  #2.  Cells  were  
incubated  with  lysis  buffer  on  ice  for  30  minutes  and  insoluble  cell  debris  was  removed  
by  centrifugation  at  5,000  RPM  for  5  minutes.  The  cell  lysate  was  incubated  with  Z-­‐‑
DEVD-­‐‑R110  substrate  for  1  hour  and  the  fluorescent  reaction  products  were  quantified  
by  absorbance  at  520  nm  on  a  plate  reader.  Protein  content  was  evaluated  in  each  sample  
by  BCA  assay.  Caspase-­‐‑3  activity,  as  measured  by  the  fluorescent  products  from  the  
EnzChek  assay,  was  corrected  to  protein  content  to  compensate  for  slight  variations  in  
cell  number  between  samples.  Caspase-­‐‑3  activity  was  further  normalized  to  the  level  of  
caspase-­‐‑3  activity  seen  in  untreated  cells  incubated  at  37  °C.  
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4.3 Results and discussion 
4.3.1 Cytotoxicity of CPP-ELPBC carriers alone 
Prior  to  drug  loading,  the  cytotoxicity  of  CPP-­‐‑ELPBCs  without  drug  cargo  was  
determined  by  modified  survival  assay  in  HeLa  cells  to  confirm  that  the  carrier  alone  
did  not  contribute  significantly  to  cell  death.  Third  generation  Arg5-­‐‑ELPBC  and  Arg8-­‐‑
ELPBC,  along  with  the  non-­‐‑functionalized  ELPBC  control,  were  chosen  to  evaluate  the  
cytotoxicity  of  CPP-­‐‑ELPBCs  as  these  constructs  spanned  the  breadth  of  both  CPP  charge  
and  CPP-­‐‑ELPBC  uptake  and  would  thereby  provide  insight  into  the  cytotoxicity  of  the  
complete  CPP-­‐‑ELPBC  library.    
None  of  the  CPP-­‐‑ELPBCs  or  the  ELPBC  control  induced  significant  cell  death,  as  
approximated  by  absorbance  at  490  nm,  as  compared  to  untreated  controls,  at  either  37  
°C  or  42  °C  in  this  modified  survival  assay  (Figure  44).  Additionally,  untreated  cells  
incubated  at  37  °C  or  42  °C  showed  no  significant  difference  in  cell  survival  between  
these  thermal  conditions,  confirming  that  mild  hyperthermia  alone  had  no  effect  on  
cytotoxicity  in  the  context  of  this  in  vitro  survival  assay.  These  results  confirm  that  any  
cytotoxicity  detected  from  drug-­‐‑loaded  CPP-­‐‑ELPBCs  in  the  format  of  this  assay  is  
inherent  to  the  drug  cargo  and  not  the  drug  carrier.  
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Figure  44:  CPP-­‐‑ELPBCs  alone  did  not  induce  cell  death  in  a  modified  assay  of  cell  
survival.  Cell  survival,  approximated  from  absorbance  at  490  nm,  did  not  change  
between  37  °C  and  42  °C  for  CPP-­‐‑ELPBC  carriers  without  drug  cargo  or  for  treatment  
with  mild  hyperthermia  alone.  Absorbance  was  normalized  to  untreated  cells  
incubated  at  37  °C.  Data  represents  mean  of  3  experiments  ±  SEM.  Reproduced  from  
[152].  
4.3.2 CPP-ELPBCs as drug carriers for small molecule therapeutics 
Small  molecule  therapeutics  were  investigated  as  drug  cargo  due  to  their  
applicability  to  anti-­‐‑cancer  therapy  and  their  ease  of  attachment  to  ELPs  due  to  
prerequisite  expertise  in  the  Chilkoti  laboratory.  Small  molecules,  however,  had  shown  
their  power  in  influencing  the  self-­‐‑assembly  of  ELPs  [154,  157]  and  therefore  their  effect  
on  the  thermal  behavior  of  the  optimized  CPP-­‐‑ELPBCs  was  a  primary  concern.  The  small  
molecule  chemotherapeutic  cargo  for  CPP-­‐‑ELPBCs  was  thus  carefully  chosen.  
Gemcitabine  was  chosen  to  investigate  the  feasibility  of  small  molecule  
chemotherapeutic  cargo  for  CPP-­‐‑ELPBCs  due  to  the  following  reasons.  First,  the  relative  
hydrophilicity  of  gemcitabine  (LogD  ~  -­‐‑2.2  [157])  may  not  alter  the  thermal  properties  of  
the  ELPBC,  unlike  hydrophobic  drugs  whose  conjugation  induces  the  self-­‐‑assembly  of  
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ELP  micelles  by  the  hydrophobic  effect  [154].  This  was  supported  by  previous  
experiments  by  Dr.  Jayanta  Bhattacharyya  in  which  the  conjugation  of  8  gemcitabine  
molecules  to  C-­‐‑terminal  cysteine  residues  on  a  pseudorandom  hydrophilic  ELP  did  not  
induce  premature  self-­‐‑assembly  into  ELP  micelles  nor  significantly  perturb  the  Tt  of  the  
parent  ELP  [157].  These  results  suggested  that  gemcitabine,  when  conjugated  to  the  
hydrophobic  terminus  of  an  ELPBC,  may  indeed  leave  the  thermal  properties  of  that  
ELPBC  unchanged,  maintaining  a  CMT  controlled  by  the  Tt  of  the  hydrophobic  ELPBC  
domain.      
The  second  reason  for  selecting  gemcitabine  as  a  small  molecule  
chemotherapeutic  cargo  is  due  to  its  therapeutic  action  within  the  cell.  Gemcitabine  is  a  
nucleoside  analog  whose  cytotoxicity  derives  from  its  replacement  of  cytidine  in  DNA  
replication  and  its  inhibition  of  the  enzyme  ribonucleoside  reductase,  which  interferes  
with  DNA  and  deoxyribonucleotide  synthesis,  respectively  [165].  The  cytotoxicity  of  
gemcitabine  relies  on  its  cellular  internalization  and  intracellular  activation  by  
phosphorylation  [165],  which  makes  it  an  ideal  candidate  to  be  delivered  by  efficiently  
internalized  CPP-­‐‑ELPBC  carriers.  Furthermore,  although  small  molecules  are  typically  
well  internalized  into  cells  on  their  own,  traversing  the  cellular  membrane  with  ease,  
this  may  be  less  true  for  gemcitabine  due  to  its  hydrophilic  nature,  as  compared  to  the  
many  hydrophobic  small  molecule  drugs.  Gemcitabine  may  thereby  gain  an  additional  
advantage  by  efficient  delivery  into  the  cell  by  a  CPP-­‐‑ELPBC  carrier.  
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Third,  gemcitabine  was  also  chosen  due  to  its  applicability  to  relevant  cancer  
targets.  Gemcitabine  has  been  indicated  in  the  treatment  of  pancreatic,  bladder,  and  
breast  cancers  [166-­‐‑168].  These  prospective  cancer  targets  are  particularly  suited  to  our  
proposed  system  as  they  are  all  suitable  for  concurrent  treatment  with  localized  clinical  
hyperthermia  [8].    
Finally,  gemcitabine  is  an  interesting  drug  cargo  for  temperature-­‐‑targeted  CPP-­‐‑
ELPBC  delivery  because  treatment  with  gemcitabine  in  combination  with  hyperthermia  
has  been  shown  to  synergistically  improve  the  efficacy  of  gemcitabine  both  in  vitro  [169]  
and  in  the  clinic  [170].  Therefore  the  inherent  aspect  of  heating  used  to  target  our  CPP-­‐‑
ELPBCs  may  increase  the  local  efficacy  of  a  gemcitabine  drug  cargo.  
Preliminary  investigation  of  a  CPP-­‐‑ELPBC  gemcitabine  conjugate  (CPP-­‐‑ELPBC-­‐‑
GEM)  was  investigated  in  a  simplified  drug  carrier  system.  This  carrier,  E4-­‐‑60/E2*-­‐‑60,  
was  chosen  due  to  its  CMT  below  body  temperature  and  its  incorporation  of  only  a  
single  cysteine  residue  at  its  N-­‐‑terminus.  This  CPP-­‐‑ELPBC  thereby  permitted  the  
investigation  of  drug  delivery  by  self-­‐‑assembled  micelles  at  37  °C  and  limited  the  drug  
loading  to  a  maximum  of  one  drug  molecule  per  ELP.  The  behavior  of  this  carrier  thus  
allowed  characterization  of  drug  delivery  without  involving  new  effects  of  
hyperthermia  and  high  drug  loading.  Gemcitabine  was  attached  to  Arg8-­‐‑ELPBC  with  a  
conjugation  efficiency  of  approximately  87%,  as  determined  by  MALDI-­‐‑TOF  of  carrier  
with  and  without  gemcitabine  cargo.  Thermal  characterization  of  Argg-­‐‑ELPBC-­‐‑GEM  by  
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temperature-­‐‑regulated  turbidimetry  revealed  an  increase  in  CMT  upon  drug  
conjugation  (Figure  45).  This  is  not  surprising,  in  that  the  attachment  of  hydrophilic  
drug  may  increase  the  Tt  of  the  proximal  hydrophobic  ELP  domain  and  may  also  
provide  resistance  to  self-­‐‑assembly  as  it  does  not  prefer  to  be  sequestered  into  the  
hydrophobic  micelle  core,  thereby  increasing  the  CMT.  However,  this  increase  in  CMT  
was  not  so  extreme  as  to  interfere  with  self-­‐‑assembly  at  the  thermal  condition  of  37  °C,  
therefore  this  drug  conjugate  could  be  used  to  test  the  cytotoxicity  of  Arg8-­‐‑ELPBC-­‐‑GEM  





















Figure  45:  Gemcitabine  conjugation  increased  the  CMT  of  Arg8-­‐‑ELPBC.  Temperature-­‐‑
regulated  turbidimetry  confirmed  a  change  in  thermal  behavior  between  Arg8-­‐‑ELPBC  
and  Arg8-­‐‑ELPBC-­‐‑GEM,  whereby  drug  conjugation  increased  the  CMT  and  decreased  
the  micelle-­‐‑to-­‐‑aggregate  Tt.  Turbidimetry  measurements  were  acquired  at  25  µμM  in  
PBS.  
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This  Arg8-­‐‑ELPBC-­‐‑GEM  carrier  was  evaluated  for  anti-­‐‑cancer  efficacy  by  
measurement  of  cytotoxicity  in  gemcitabine  sensitive  HCT116  colon  carcinoma  cells  
[171].  A  modified  cell  survival  assay  was  performed,  in  which  adherent  cells  were  
incubated  with  Arg8-­‐‑ELPBC-­‐‑GEM  or  free  gemcitabine  at  37  °C  for  1  hour.  After  this  
incubation  the  drug  treatment  was  removed  and  cells  were  provided  fresh  media  and  
returned  to  37  °C.  After  72  hours  cell  survival  was  approximated  by  measurement  of  cell  
metabolism  using  an  MTS  assay.  This  modified  survival  assay  includes  an  abbreviated  
exposure  to  drug  as  compared  to  typical  survival  assays  in  which  the  cells  are  exposed  
to  drug  over  a  total  of  72  hours.  Therefore  this  modified  assay  was  a  stringent  test  for  
CPP-­‐‑ELPBCs  to  deliver  drug  in  only  1  hour  to  provide  a  prolonged  therapeutic  effect,  
reminiscent  of  the  in  vivo  setting  in  which  1  hour  of  clinical  hyperthermia  will  be  used  to  
achieve  intracellular  drug  delivery  of  CPP-­‐‑ELPBCs  in  the  tumor,  after  which  extracellular  
CPP-­‐‑ELPBCs  will  be  cleared.  
In  vitro,  Arg8-­‐‑ELPBC-­‐‑GEM  achieved  increasing  cytotoxicity,  approximated  by  
absorbance  at  490  nm,  with  increasing  concentration  from  20-­‐‑100  µμM  gemcitabine  
(equivalent  CPP-­‐‑ELPBC  concentration  of  23-­‐‑115  µμM  based  on  drug  conjugation  
efficiency)  (Figure  46).  In  comparison,  free  gemcitabine  had  little  effect  on  cell  survival  
over  this  range  of  concentrations.  This  may  in  part  be  due  to  the  inefficiency  of  
intracellular  delivery  of  this  free  drug,  suggesting  this  hydrophilic  small  molecule  does  
not  traverse  the  cell  membrane  significantly  over  the  course  of  only  1  hour.  Due  to  this  
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modified  cell  survival  assay,  it  is  difficult  to  compare  the  efficacy  of  Arg8-­‐‑ELPBC-­‐‑GEM  to  
that  of  free  gemcitabine  reported  in  the  literature  (IC50  ~14  nM  [171])  and  determine  
what  effect  the  carrier  has  on  the  drug  function,  whereby  covalent  attachment  of  drug  
via  non-­‐‑cleavable  linkers  will  typically  significantly  decrease  the  drug  activity.  
However,  the  cancer  cell  death  achieved  in  even  the  limited  exposure  used  in  this  



























Figure  46:  Arg8-­‐‑ELPBC-­‐‑GEM  enhanced  cytotoxicity,  approximated  by  absorbance  at  490  
nm,  of  free  gemcitabine  in  a  modified  cell  survival  assay  in  HCT116  colon  carcinoma  
cells.  Drug  delivery  over  the  course  of  just  1  hour  produced  significant  cancer  cell  
death  with  Arg8-­‐‑ELPBC-­‐‑GEM,  but  not  free  drug.  Absorbance  was  normalized  to  
untreated  cells.  Arg8-­‐‑ELPBC-­‐‑GEM  data  represents  mean  of  3  samples  ±  SEM.  
Next,  the  third  generation  CPP-­‐‑ELPBCs  were  investigated  as  drug  carriers  for  
gemcitabine  to  determine  if  this  drug  cargo  could  achieve  controlled  cytotoxicity  by  
    154  
means  of  controlled  intracellular  delivery  with  hyperthermia-­‐‑triggered  micelle  
assembly.  Gemcitabine  was  conjugated  to  third  generation  Arg5-­‐‑ELPBC,  Arg8-­‐‑ELPBC,  and  
non-­‐‑functionalized  ELPBC,  all  with  a  single  genetically  engineered  cysteine.  Since  an  
increase  in  the  CMT  was  previously  seen  with  gemcitabine  conjugation  of  CPP-­‐‑ELPBC,  
the  thermal  behavior  of  these  third  generation  CPP-­‐‑ELPBC-­‐‑GEM  conjugates  were  
checked  by  DLS,  to  determine  the  unimer  and  micelle  populations  at  37  °C  and  42  °C,  
over  a  range  of  concentrations.  Analysis  of  the  thermal  behavior  of  ELPBC-­‐‑GEM  
confirmed  an  increase  in  CMT,  whereby  distinct  unimer  and  micelle  populations  were  
not  achieved  at  37  °C  and  42  °C,  respectively,  at  the  concentration  range  utilized  in  
previous  in  vitro  experiments  (10-­‐‑20  µμM).  At  an  increased  concentration  range  of  30-­‐‑50  
µμM,  the  ELPBC-­‐‑GEM  carrier  began  to  display  temperature-­‐‑triggered  micelle  assembly,  
but  of  a  mixed  population  of  unimer  and  micelle  at  42  °C  (Figure  47).  It  was  not  until  an  
elevated  concentration  of  60  µμM  that  a  pure  population  of  unimer  and  micelle  were  
achieved  at  37  °C  and  42  °C,  respectively.  Therefore  treatment  concentrations  of  60  µμM  
and  higher  would  be  necessary  to  truly  elucidate  the  effect  of  triggered  micelle  assembly  
on  controlled  drug  delivery  and  controlled  cytotoxicity.    
  




























Figure  47:  Gemcitabine  conjugation  increased  the  CMT  of  third  generation  ELPBC-­‐‑
GEM.  A  minimum  concentrations  of  60  µμM  was  necessary  to  achieve  a  pure  
population  of  unimer  or  micelle  at  37  °C  or  42  °C,  respectively.  DLS  data  was  acquired  
in  PBS  and  represents  the  mean  of  3  measurements  ±  SEM.  
Controlled  cytotoxicity  was  investigated  with  third  generation  CPP-­‐‑ELPBC-­‐‑GEM  
in  CFPAC-­‐‑1  cells.  This  change  in  cell  type  was  made  to  help  with  the  high  
concentrations  of  drug  carrier  necessary  to  evaluate  the  unimer  and  micelle  conditions,  
since  CFPAC-­‐‑1  cells  have  a  reported  decreased  sensitivity  to  gemcitabine  (IC50  ~  1  µμM  
[172]).  Cells  were  treated  with  60  µμM  at  37  °C  or  42  °C  for  1  hour,  per  the  modified  
survival  assay  described  previously.  No  significant  differences  in  cell  survival,  as  
approximated  from  absorbance  at  490  nm,  were  seen  between  37  °C  and  42  °C  for  Arg5-­‐‑
ELPBC-­‐‑GEM,  Arg8-­‐‑ELPBC-­‐‑GEM,  or  ELPBC-­‐‑GEM  control  (Figure  48).  Approximately  20%  of  
cells  were  surviving  at  the  end  of  this  assay,  regardless  of  treatment  type.  This  residual  
cell  population  may  represent  those  cells  with  decreased  sensitivity  to  gemcitabine  or  
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may  represent  those  cells  that  did  not  take  up  a  significant  amount  of  the  drug  carrier.  
The  72  hour  duration  of  this  assay  could  allow  either  of  such  cell  populations  to  
proliferate  and  constitute  the  signal  suggesting  a  20%  cell  survival.    
There  are  two  possible  explanations  for  the  lack  of  controlled  cytotoxicity.  The  
first  possibility  is  that  temperature-­‐‑triggered  micelle  assembly  did  not  affect  the  amount  
of  drug  delivered  into  the  cell  to  the  extent  of  producing  a  difference  in  cell  survival.  The  
second  possibility  is  that,  regardless  of  differences  in  intracellular  delivery,  the  amount  
of  drug  taken  up  into  the  cells  at  either  thermal  condition  was  enough  to  dominate  a  
cytotoxic  effect.  There  was  no  difference  in  cell  survival  between  thermal  conditions  
with  the  treatment  of  free  gemcitabine  and  in  this  cell  line  free  gemcitabine  was  
significantly  cytotoxic  at  60  µμM,  equivalent  to  the  CPP-­‐‑ELPBC  delivered  drug.  This  
suggests  that  in  the  context  of  this  modified  survival  assay  CFPAC-­‐‑1  cells  are  more  
sensitive  to  gemcitabine  than  the  HCT116  cells  used  previously,  contrary  to  their  
reported  sensitivity  in  standard  survival  assays  in  the  literature.  The  equivalence  in  
cytotoxicity  between  all  CPP-­‐‑ELPBC  drug  conjugates  and  free  drug  suggest  that  the  latter  
of  the  two  explanations  above  may  be  the  reason  for  the  lack  of  controlled  cytotoxicity  
seen  here,  where  enough  drug  was  delivered  into  the  cells  in  all  cases  that  the  cytotoxic  
effect  was  overwhelming.  This  phenomenon  sheds  light  on  the  true  disadvantage  of  the  
increased  CMT  caused  by  drug  conjugation,  forcing  the  use  of  CPP-­‐‑ELPBC-­‐‑GEM  at  high  
concentrations.    






































Figure  48:  Equivalent  cytotoxicity,  as  approximated  by  absorbance  at  490  nm,  was  
achieved  with  CPP-­‐‑ELPBC-­‐‑GEM  and  free  GEM,  regardless  of  thermal  conditions  at  60  
µμM  in  CFPAC-­‐‑1  cells.  Neither  Arg5-­‐‑ELPBC-­‐‑GEM,  Arg8-­‐‑ELPBC-­‐‑GEM,  or  ELPBC-­‐‑GEM  
achieved  controlled  cytotoxicity  with  temperature-­‐‑triggered  micelle  assembly.  
Absorbance  was  normalized  to  untreated  cells  at  37  °C.  Data  represents  mean  of  3  
samples  ±  SEM.  
To  see  if  controlled  cytotoxicity  emerged  at  other  concentrations,  the  cytotoxicity  
of  these  CPP-­‐‑ELPBC-­‐‑GEM  carriers  was  investigated  over  a  range  of  concentrations,  now  
in  HeLa  cells,  even  less  vulnerable  to  gemcitabine  (IC50  ~  26.8  µμg/mL  [173]),  in  hopes  of  
mitigating  the  necessary  use  of  high  drug  concentration.  Interestingly,  ELPBC-­‐‑GEM  
showed  little  difference  in  cytotoxicity,  approximated  from  absorbance  at  490  nm,  as  
compared  to  free  gemcitabine  and  did  not  change  significantly  between  thermal  
conditions,  suggesting  uptake  did  not  change  significantly  with  this  control  carrier  
(Figure  49).  However,  neither  Arg5-­‐‑  or  Arg8-­‐‑ELPBC-­‐‑GEM  demonstrated  a  consistent  trend  
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in  cytotoxicity  of  unimer  versus  micelle  at  37  °C  and  42  °C,  respectively.  Although  
neither  CPP-­‐‑ELPBC-­‐‑GEM  conjugate  demonstrated  consistent  controlled  cytotoxicity,  it  
was  interesting  that  Arg5-­‐‑ELPBC-­‐‑GEM  did  consistently  produce  increased  cytotoxicity  as  
compared  to  Arg8-­‐‑ELPBC-­‐‑GEM.  This  suggested  that  the  predictable  uptake,  controlled  by  
























































































Figure  49:  No  consistent  trends  in  controlled  cytotoxicity,  approximated  from  
absorbance  at  490  nm,  were  seen  with  CPP-­‐‑ELPBC-­‐‑GEM  carriers  in  HeLa  cells.  Free  
gemcitabine  and  ELPBC-­‐‑GEM  control  displayed  little  difference  in  cytotoxicity  
between  37  °C  and  42  °C,  but  controlled  cytotoxicity  did  not  emerge  for  Arg5-­‐‑ELPBC-­‐‑
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GEM  or  Arg8-­‐‑ELPBC-­‐‑GEM  between  thermal  conditions.  Absorbance  was  normalized  to  
untreated  cells  at  37  °C.  Data  represents  mean  of  3  measurements  ±  SEM.  
Despite  a  lack  of  cytotoxic  control  with  drug  loading  of  a  single  gemcitabine  
molecule  for  each  CPP-­‐‑ELPBC,  more  heavily  drug  loaded  constructs  were  characterized  
to  better  understand  the  effects  of  drug  conjugation  on  ELPBC  thermal  properties.  To  
increase  the  amount  of  drug  loading  per  ELPBC  a  new  leader  sequence—
MG(CGG)8WPG—was  genetically  appended  to  the  hydrophobic  terminus  of  the  ELPBC,  
providing  eight  reactive  cysteine  residues  for  conjugation  of  small  molecule  
chemotherapeutics.  The  effects  of  encoding  additional  cysteine  residues  at  the  CPP-­‐‑
ELPBC  hydrophobic  terminus  on  self-­‐‑assembly  were  examined  by  temperature-­‐‑regulated  
turbidimetry  measurements,  which  revealed  a  decrease  in  the  CMT  with  the  addition  of  
eight  cysteine  residues  (Figure  50).  This  was  not  surprising  as  the  interaction  between  
cysteines  likely  encouraged  the  interaction  between  ELPBCs,  which  lowered  the  
transition  temperature  of  the  hydrophobic  ELPBC  domain.  Conjugation  of  gemcitabine  to  
this  Arg5-­‐‑ELPBC  yielded  an  average  conjugation  of  5.4  gemcitabine  molecules  per  CPP-­‐‑
ELPBC,  occupying  approximately  68%  of  the  cysteine  residues  on  each  CPP-­‐‑ELPBC.  
Conjugation  of  gemcitabine  to  this  CPP-­‐‑ELPBC  did  not  greatly  perturb  the  CMT  of  the  
MG(CGG)8WPG-­‐‑functionalized  ELPBC,  suggesting  that  the  cysteines  that  remain  free  
after  drug  conjugation  (approximately  2.6  per  ELPBC)  may  continue  to  exert  their  effects  
on  self-­‐‑assembly  after  the  conjugation  reaction.  This  effect  currently  limits  the  possibility  
to  test  this  conjugate  effectively  in  our  standard  conditions,  as  in  this  state  the  drug  
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conjugate  exists  as  a  micelle  at  37  °C,  eliminating  its  useful  triggered  self-­‐‑assembly  


























Figure  50:  Genetically  appending  a  drug  conjugation  domain  with  8  cysteine  residues  
lowered  the  CMT  of  third  generation  Arg5-­‐‑ELPBC.  The  CMT  was  not  significantly  
changed  with  the  conjugation  of  approximately  5  gemcitabine  molecules  to  each  Arg5-­‐‑
ELPBC.  This  decrease  in  CMT,  below  37  °C,  precluded  the  use  of  this  carrier  with  
increased  drug  loading  for  mild  hyperthermia-­‐‑controlled  delivery.  Turbidimetry  
measurements  were  acquired  at  25  µμM  in  PBS.  
These  preliminary  results  with  CPP-­‐‑ELPBCs  and  small  molecule  cargo  suggested  
a  great  deal  of  material  optimization  was  needed  to  ensure  that  the  desired  thermal  
properties  of  the  CPP-­‐‑ELPBC  were  achieved  after  drug  loading.  This  would  be  necessary  
to  ensure  that  a  reasonable  concentration  of  CPP-­‐‑ELPBC  and  drug  cargo  could  be  
delivered  with  the  desired  thermal  behavior.  Since  extensive  optimization  was  already  
invested  in  the  third  generation  CPP-­‐‑ELPBC  constructs,  it  was  most  practical  to  turn  
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attention  to  a  different  drug  cargo  that  could  perhaps  exploit  the  CPP-­‐‑ELPBC  platform  
that  was  readily  available.  Thus,  due  to  the  complexities  of  small  molecule  conjugation  
and  the  desired  preservation  of  the  precisely  tuned  thermal  properties  of  the  ELPBC,  the  
alternative  drug  cargo  of  peptide  therapeutics  was  investigated  with  the  third  
generation  CPP-­‐‑ELPBCs.    
4.3.3 CPP-ELPBCs as drug carriers of peptide therapeutics 
Peptide  drugs  are  an  alternative  cargo  for  conjugation  to  CPP-­‐‑ELPBCs  with  
several  advantages  over  small  molecule  chemotherapeutics.  First,  peptide  drugs  are  
extremely  easy  to  conjugate  to  the  CPP-­‐‑ELPBC.  The  peptide  drug  is  simply  genetically  
encoded  at  the  N-­‐‑terminus  of  the  ELPBC  gene  and  the  drug  conjugate  can  thereby  be  
created  with  perfect  drug  loading  and  monodispersity  in  a  single  recombinant  synthesis  
step.  Second,  the  composition  of  the  peptide  drug  from  natural  amino  acid  constituents  
makes  it  easier  to  predict  the  effect  of  peptide  drug  on  ELP  properties  based  on  the  well-­‐‑
known  effects  of  each  amino  acid  on  the  ELP  thermal  behaviors,  at  least  as  guest  residue  
components  of  the  polypeptide  chain.  These  predictive  behaviors  may  be  more  reliable  
than  the  largely  unknown  effects  of  covalently  attached  molecules  based  on  their  size  
and  hydrophobicity,  as  well  as  that  of  their  intervening  linker  between  the  drug  and  
ELP.  For  these  reasons  it  is  likely  that  peptide  drug  cargo  will  be  more  amenable  to  
conserving  the  optimized  thermal  properties  of  CPP-­‐‑ELPBCs,  as  compared  to  small  
molecule  drug  cargo.  
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Preliminary  investigation  of  peptide  cargo  was  performed  with  a  drug  that  had  
been  previously  validated  by  a  CPP-­‐‑ELP  drug  delivery  system  [115].  This  H1  peptide,  a  
c-­‐‑Myc  inhibitor,  was  appended  to  third  generation  Arg5-­‐‑ELPBC.  DLS  measurements  of  
Arg5-­‐‑ELPBC-­‐‑H1  confirmed  that  a  concentration  of  greater  than  20  µμM  was  required  to  
achieve  desirable  temperature-­‐‑triggered  self-­‐‑assembly,  such  that  the  drug  carrier  was  a  
unimer  at  37  °C  and  a  micelle  at  42  °C.  The  controlled  cytotoxicity  of  this  peptide-­‐‑loaded  
construct  was  evaluated  in  MCF7  breast  cancer  cells,  in  the  same  modified  survival  
assay  employed  for  evaluation  of  small  molecule  drugs  described  above.  Arg5-­‐‑ELPBC-­‐‑H1  
demonstrated  controlled  cytotoxicity,  approximated  from  absorbance  at  490  nm,  over  
the  concentration  range  of  20-­‐‑100  µμM  (Figure  51).  Cytotoxicity  was  much  greater  at  42  
°C  with  the  delivery  of  micelle  drug  carrier,  as  compared  to  unimer  carrier  at  37  °C.  
Cytotoxicity  increased  with  concentration  at  42  °C  and  to  a  lesser  extent  at  37  °C.  The  
controlled  cytotoxic  effects  of  this  construct  confirmed  those  results  in  the  literature  for  
CPP-­‐‑ELP-­‐‑H1  carrier  [115],  although  higher  concentrations  of  the  CPP-­‐‑ELPBC  was  needed,  
likely  due  to  differences  in  CPP-­‐‑functionalization  that  led  to  both  differences  in  drug  
uptake  and  differences  in  the  inherent  toxicity  of  the  carrier  itself.  This  preliminary  
evaluation  of  peptide  drug  cargo  confirmed  that  CPP-­‐‑ELPBCs  could  indeed  control  
cytotoxicity  by  controlling  cell  uptake  of  anti-­‐‑cancer  peptide  therapeutics.    
  

























Figure  51:  Arg5-­‐‑ELPBC-­‐‑H1  achieved  controlled  cytotoxicity,  approximated  from  
absorbance  at  490  nm,  in  MCF7  breast  cancer  cells.  Cell  killing  was  enhanced  at  42  °C  
with  the  delivery  of  CPP-­‐‑ELPBC  micelles  as  compared  to  the  delivery  of  CPP-­‐‑ELPBC  
unimers  at  37  °C.  Absorbance  was  normalized  to  Arg5-­‐‑ELPBC  without  drug  cargo.  Data  
represents  mean  of  3  measurements  ±  SEM.  
An  anti-­‐‑cancer  peptide  drug  new  to  ELP  delivery  was  next  investigated  as  a  
cargo  of  CPP-­‐‑ELPBCs  to  demonstrate  the  flexibility  of  this  platform  to  accommodate  
other  peptide  therapeutics.  The  BH3  peptide,  derived  from  the  Bak  protein,  was  chosen  
as  a  proapoptotic  therapeutic  for  anti-­‐‑cancer  applications.  The  BH3  peptide  was  suitable  
for  delivery  with  CPP-­‐‑ELPBCs  for  several  reasons.  First,  its  sequence,  like  that  of  H1,  was  
a  mixture  of  residues  with  variable  qualities,  not  swayed  to  a  distinct  hydrophobic  or  
hydrophilic  content  suggesting  it  could  be  incorporated  into  the  ELPBC  design  without  
detrimental  effects  on  thermal  behavior.  Second,  this  peptide  had  shown  cytotoxicity  in  
HeLa  cells,  in  which  uptake  of  CPP-­‐‑ELPBCs  had  been  extensively  validated.  This  efficacy  
in  HeLa  cells,  however,  was  only  apparent  when  BH3  delivery  was  facilitated  with  a  
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CPP-­‐‑functionalized  carrier.  Finally,  the  internal  therapeutic  target  of  BH3  suggested  that  
this  peptide  could  be  greatly  improved  by  the  efficient  cellular  uptake  afforded  by  CPP-­‐‑
ELPBCs,  only  when  targeted  by  hyperthermia-­‐‑triggered  micelle  assembly.  
Delivery  of  BH3  peptide  drug  was  first  evaluated  with  Arg5-­‐‑ELPBC-­‐‑BH3,  similar  
to  that  for  delivery  of  H1  peptide  described  above.  Unlike  H1,  however,  the  delivery  of  
BH3,  even  up  to  80  µμM,  showed  little  controlled  cytotoxicity,  approximated  from  
absorbance  at  490  nm,  between  thermal  conditions  and  indeed  showed  little  cytotoxicity  
in  general  despite  increasing  drug  concentrations  (Figure  52).  Since  activity  of  this  drug  
against  this  cell  line  was  well  supported  in  the  literature,  this  result  suggested  two  
potential  problems  with  the  Arg5-­‐‑ELPBC  delivery  system.  The  first  potential  problem  
could  be  that  the  steric  hindrance  of  the  macromolecular  CPP-­‐‑ELPBC  carrier  disrupted  
the  interaction  of  BH3  with  its  therapeutic  target.  This  problem  could  be  alleviated  with  
the  incorporation  of  a  cleavable  linker  between  the  peptide  drug  and  the  ELP.  The  
second  potential  problem  could  be  the  delivered  amount  of  drug  if  the  extent  of  
internalized  Arg5-­‐‑ELPBC  did  not  fulfill  the  necessary  dose  to  induce  a  therapeutic  effect.  
This  problem  could  be  alleviated  by  testing  alternative  CPP-­‐‑ELPBC  carriers,  whose  
degree  of  cellular  uptake  could  be  tuned  by  their  CPP-­‐‑functionalization.  
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Figure  52:  Arg5-­‐‑ELPBC-­‐‑BH3  failed  to  achieve  significant  cytotoxicity,  approximated  
from  absorbance  at  490  nm,  in  HeLa  cells.  Neither  micelle  assembly  at  42  °C  nor  
increasing  concentration  induced  significant  changes  in  cytotoxicity.  Absorbance  was  
normalized  to  untreated  cells  at  37  °C.  Data  represents  mean  of  3  measurements  ±  
SEM.  
To  address  the  first  issue,  cleavable  linkers  were  investigated  for  use  with  this  
BH3  peptide  drug  cargo.  Peptide  linkers  were  easiest  to  employ  since  they  could  be  
genetically  engineered  between  the  peptide  drug  and  ELP.  Furthermore,  peptide  linkers  
were  appropriate  as  many  are  cleavable  by  enzymes  that  CPP-­‐‑ELPBCs  are  likely  to  
encounter  in  the  endosomal  compartment  when  internalized.  Of  common  peptide  
cleavable  linkers,  many  are  high  in  hydrophobic  character  and  it  was  unclear  whether  
the  strong  hydrophobicity  of  the  linker  would  perturb  self-­‐‑assembly  of  the  CPP-­‐‑ELPBC.  
Preliminary  incorporation  of  the  commonly  used  GFLG  [174]  and  FK  [175]  linkers,  
cleavable  by  cathepsin  B,  confirmed  that  their  hydrophobicity,  attributed  to  
phenylalanine  in  combination  with  leucine  or  alone,  did  perturb  the  self-­‐‑assembly  of  
Arg5-­‐‑ELPBC  (Figure  53).  It  is  likely  that  the  incorporation  of  these  hydrophobic  linkers  
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induced  premature  assembly,  pushing  the  CMT  below  25  °C.  This  is  not  completely  
unexpected,  as  a  higher  number  of  hydrophobic  residues  like  phenylalanine  have  been  
used  to  induce  spontaneous  self-­‐‑assembly  of  ELPs  by  asymmetric  conjugation  similar  to  





















Figure  53:  Hydrophobic  cleavable  linkers  GFLG  and  FK  significantly  changed  the  
thermal  behavior  of  Arg5-­‐‑ELPBC-­‐‑BH3.  The  hydrophobicity  of  these  linkers  perturbed  
the  CMT,  such  that  they  no  longer  achieved  unimer  and  micelle  conditions  at  37  °C  
and  42  °C,  respectively.  Turbidimetry  measurements  were  acquired  at  15  µμM  in  PBS.  
Due  to  the  significant  effect  of  hydrophobic  linkers  on  the  self-­‐‑assembly  of  Arg5-­‐‑
ELPBC-­‐‑BH3,  alternative  linkers  with  more  neutral  or  hydrophilic  character  were  
investigated.  RVRR,  cleavable  by  furin  and  cathepsin  B  [176-­‐‑178],  was  investigated  as  a  
relatively  hydrophilic  linker  and  glycine  oligomers  GGG  and  GGGGG,  cleavable  by  
cathepsin  B  [179],  were  investigated  as  relatively  neutral  linkers.  These  alternative  
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linkers  were  genetically  encoded  between  the  Arg8-­‐‑ELPBC  and  the  BH3  peptide  drug  and  
their  thermal  properties  were  evaluated  by  temperature-­‐‑regulated  turbidimetry.  
Contrary  to  the  hydrophobic  linkers  GFLG  and  FK,  these  alternative  linkers  did  not  
significantly  affect  the  thermal  behavior  of  the  Arg8-­‐‑ELPBC  (Figure  54).  Without  
perturbation  of  the  CMT,  the  RVRR,  GGG,  and  GGGGG  linkers  could  be  incorporated  
into  the  drug  carrier  design  such  that  unimers  alone  were  present  at  37  °C  and  micelle  






















Figure  54:  Hydrophilic  and  neutral  cleavable  peptide  linkers  RVRR,  GGG,  and  
GGGGG  did  not  significantly  change  the  thermal  behavior  of  Arg8-­‐‑ELPBC-­‐‑BH3.  
Preservation  of  the  CMT  would  permit  constructs  containing  these  linkers  to  achieve  
mild  hyperthermia-­‐‑triggered  self-­‐‑assembly.  Turbidimetry  measurements  were  
acquired  at  15  µμM  in  PBS.  
Since  the  RVRR,  GGG,  and  GGGGG  linkers  all  maintained  the  desirable  thermal  
properties  of  the  Arg8-­‐‑ELPBC  each  was  a  feasible  option  to  create  a  drug  carrier  capable  
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of  hyperthermia-­‐‑triggered  micelle  assembly  that  was  also  potentially  capable  of  
releasing  free  peptide  drug  within  the  cell.  These  three  linkers  were  screened  in  a  
preliminary  in  vitro  test  of  controlled  cytotoxicity.  The  Arg8-­‐‑ELPBC  carrier  was  used  here  
to  circumvent  the  additional  question  of  drug  dose,  such  that  the  maximum  intracellular  
dose  could  be  delivered  in  this  experiment  to  tease  out  only  the  effect  of  linker  on  drug  
efficacy.  In  the  modified  survival  assay  in  HeLa  cells  all  three  linkers  were  capable  of  
achieving  controlled  cytotoxicity,  measured  by  absorbance  at  490  nm,  between  37  °C  and  
42  °C  (Figure  55).  The  greatest  fold  change  in  cell  survival  was  achieved  with  the  RVRR  
linker,  which  was  therefore  chosen  for  future  use  as  the  linker  to  characterize  the  
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Figure  55:  Arg8-­‐‑ELPBC-­‐‑BH3  achieved  controlled  cytotoxicity,  approximated  from  
absorbance  at  490  nm,  with  RVRR,  GGG,  and  GGGGG  cleavable  linkers,  inducing  
cell  death  at  42  °C,  with  minimal  cell  death  at  37  °C.  RVRR  cleavable  linker  achieved  
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the  greatest  fold  increase  in  cell  death  between  thermal  conditions.  Absorbance  was  
normalized  to  untreated  cells  at  37  °C.  Data  represents  mean  of  3  measurements  ±  
SEM.  
Now  with  a  chosen  drug  linker,  a  family  of  CPP-­‐‑ELPBC  drug  carriers  was  created  
to  investigate  the  role  of  CPP-­‐‑functionalization  on  the  delivery  of  cleavable  drug  cargo  
to  achieve  controlled  cytotoxicity.  Arg5-­‐‑  and  Arg8-­‐‑ELPBCs  were  chosen  as  the  carriers  as  
they  encompass  the  breadth  of  “off”  and  “on”  levels  of  uptake  within  the  extended  CPP-­‐‑
ELPBC  family.  Drug  carriers  that  included  the  cleavable  RVRR  linker  were  designated  
CPP-­‐‑ELPBC-­‐‑cBH3.  Beyond  the  Arg5-­‐‑ELPBC-­‐‑cBH3  and  Arg8-­‐‑ELPBC-­‐‑cBH3  drug  carriers,  
three  controls  were  included  to  probe  the  effects  of  CPP-­‐‑functionalization,  cleavable  
drug  cargo,  and  linker  toxicity.  These  controls  were  non-­‐‑functionalized  ELPBC-­‐‑cBH3,  
Arg8-­‐‑ELPBC-­‐‑BH3  without  the  RVRR  linker,  and  Arg8-­‐‑ELPBC-­‐‑RVRR,  which  included  the  
RVRR  linker  without  the  BH3  peptide  drug  cargo.  All  constructs  were  efficiently  
expressed  in  E.  coli  and  sufficiently  purified  by  ITC  (Figure  56).  
  


















Figure  56:  CPP-­‐‑ELPBC  drug  carriers  and  controls  were  efficiently  expressed  and  
sufficiently  purified  from  E.  coli,  as  confirmed  by  SDS-­‐‑PAGE.  The  expected  
molecular  weight  of  the  CPP-­‐‑ELPBC  drug  carriers  varied  slightly  due  to  CPP,  drug,  and  
linker  functionalization  and  were,  by  lane,  1)  42.32  kDa,  2)  43.10  kDa,  3)  43.57  kDa,  4)  
43.00  kDa,  and  5)  41.60  kDa.  Reproduced  from  [152].  
The  thermal  behavior  of  these  drug  carriers  and  controls  was  investigated  by  
temperature-­‐‑regulated  turbidimetry  to  confirm  that  manipulation  of  CPP,  linker,  and  
drug  cargo  did  not  perturb  the  CMT  at  the  concentration  intended  for  in  vitro  
cytotoxicity  assays.  Characterization  at  15  µμM  confirmed  that  the  desired  thermal  
behavior  was  conserved  across  all  five  constructs  in  this  drug  carrier  family,  whereby  
the  CMT  did  not  change  significantly  between  constructs  although  the  micelle-­‐‑to-­‐‑
aggregate  transition  did  change  depending  on  CPP,  drug,  and  linker  functionalization  
(Figure  57).  
  





































































































Figure  57:  Desirable  thermal  behavior  was  conserved  in  this  family  of  CPP-­‐‑ELPBC-­‐‑BH3  
drug  carriers,  regardless  of  CPP,  drug,  or  linker  functionalization.  Temperature  
regulated  turbidimetry  confirmed  that  ELPBC-­‐‑cBH3  (A),  Arg5-­‐‑ELPBC-­‐‑cBH3  (B),  Arg8-­‐‑
ELPBC-­‐‑cBH3  (C),  Arg8-­‐‑ELPBC-­‐‑BH3  (D),  and  Arg8-­‐‑ELPBC-­‐‑RVRR  maintained  a  CMT  
between  37  °C  and  42  °C.  Turbidimetry  measurements  were  acquired  at  15  µμM  in  PBS.  
Reproduced  from  [152].  
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DLS  further  confirmed  that  the  desired  thermal  behavior  was  conserved  across  
this  family  of  drug  carriers  and  controls.  All  drug  carriers  and  controls  demonstrated  a  
pure  unimer  population  at  37  °C  and  a  pure  micelle  population  at  42  °C  at  15  µμM  (Table  
13).  These  results  demonstrated  the  ability  of  optimized  third  generation  CPP-­‐‑ELPBCs  to  
support  a  variety  of  functionalization  while  retaining  desirable  thermal  properties,  at  
least  for  peptide  therapeutics  and  peptide  linkers.  This  conservation  of  thermal  
properties  affords  the  opportunity  to  compare  the  role  of  CPP-­‐‑functionalization  in  
modulating  intracellular  drug  dose  and  assess  the  role  of  each  component  in  the  drug  
carrier  using  controls  to  probe  the  contribution  of  the  CPP,  drug,  and  linker  toward  the  
anti-­‐‑cancer  efficacy  of  this  drug  carrier.  
Table  13:  Characterization  of  CPP-­‐‑ELPBC-­‐‑BH3  peptide  drug  carriers  and  controls  by  
DLS  at  15  µμM  in  PBS.  Data  represents  mean  of  3  measurements  ±  SEM.  
Construct   BH3  drug   RVRR  linker   Rh  at  37  °C  (nm)   Rh  at  42  °C  (nm)  
ELPBC-­‐‑cBH3   +   +   9.7  ±  0.1   23.6  ±  0.8  
Arg5-­‐‑ELPBC-­‐‑cBH3   +   +   7.8  ±  0.2   24.1  ±  1.7  
Arg8-­‐‑ELPBC-­‐‑cBH3   +   +   8.2  ±  0.1   27.5  ±  0.3  
Arg8-­‐‑ELPBC-­‐‑BH3   +   -­‐‑   7.4  ±  0.3   22.1  ±  0.4  
Arg8-­‐‑ELPBC-­‐‑RVRR   -­‐‑   +   7.7  ±  0.3   24.4  ±  1.2  
  
Prior  to  the  in  vitro  evaluation  of  drug  delivery,  the  function  of  the  cleavable  
peptide  linker  was  verified.  Each  CPP-­‐‑ELPBC  or  control  containing  the  cleavable  BH3  
drug  via  the  RVRR  linker,  as  well  as  the  uncleavable  control,  were  incubated  with  furin  
to  mimic  the  digestion  of  these  constructs  by  this  enzyme  that  it  would  encounter  in  the  
intracellular  endosome  [176,  180,  181].  The  digestion  products  of  this  reaction  were  then  
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separated  by  SDS-­‐‑PAGE  and  visualized  by  coomassie  staining  with  comparison  to  
undigested  constructs.  Since  coomassie  staining  is  specific  to  a  handful  of  residues  (such  
as  cationic  or  aromatic  residues),  which  are  not  prevalent  in  all  constructs  investigated  
here,  the  gel  was  also  stained  by  CuCl2,  which  provides  negative  staining  to  visualize  all  
ELP  constructs.    Free  BH3  peptide  was  detected  only  for  those  constructs  exposed  to  
furin  and  for  only  those  constructs  containing  the  RVRR  linker  (Figure  58).  This  
confirmed  the  function  of  this  cleavable  linker,  at  least  with  respect  to  its  susceptibility  
of  cleavage  by  the  furin  enzyme.    
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Figure  58:  BH3  peptide  was  released  from  CPP-­‐‑ELPBCs  containing  the  RVRR  linker  
when  incubated  with  furin.  Coomassie  staining  visualized  cleaved  BH3  peptide  (MW:  
2.74  kDa,  where  furin  cleaves  at  the  C-­‐‑terminus  of  the  RVRR  linker  producing  the  
fragment  MGQVGRQLAIIGDDINRRYRVRR)  from  the  CPP-­‐‑ELPBC  (approximate  
MW:  40  kDa,  depending  on  CPP  functionalization)  (A).  CuCl2  staining  visualized  all  
CPP-­‐‑ELPBCs  with  and  without  furin  digestion  (B).  Reproduced  from  [152].  
The  RVRR  linker  is  also  a  recognition  sequence  for  cathepsin  B  cleavage,  another  
enzyme  localized  in  the  endosome  [182].  Incubation  of  CPP-­‐‑ELPBC  drug  carriers  and  
controls  with  cathepsin  B  led  to  a  much  different  digestion  product  than  was  seen  with  
furin.  The  first  difference  was  that  the  free  peptide  was  not  visualized  by  coomassie  
staining  (Figure  59).  The  second  difference  was  that  there  appeared  to  be  digestion  of  the  
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Arg8-­‐‑ELPBC-­‐‑BH3  control  lacking  the  RVRR  linker.  The  third  difference  was  seen  in  the  
CuCl2-­‐‑stained  gel,  which  revealed  a  digestion  of  each  CPP-­‐‑ELPBC  drug  carrier  and  
control  into  a  large  fragment  whose  size  was  consistent  across  all  constructs  at  
approximately  20  kDa.    
Reflecting  on  the  size  of  this  fragment  with  respect  to  the  overall  design  of  the  
ELPBC  made  it  clear  that  this  fragment  was  composed  of  the  hydrophobic  domain  of  the  
ELPBC.  In  retrospect  this  is  not  surprising  as  linkers  that  were  evaluated  for  this  system,  
such  as  GGG,  exhibit  sensitivity  to  cathepsin  B  cleavage  and  these  consensus  sequences  
are  indeed  repeated  along  the  hydrophilic  domain  of  the  ELPBC.  This  domain  has  an  
alternating  guest  residue  of  alanine  or  glycine,  and  for  each  pentapeptide  in  which  
glycine  is  the  guest  residue  a  GGG  peptide  is  created  due  to  the  VPGXG  repeat  of  the  
ELP  motif.  The  inherent  sequence  of  E2*  thus  makes  it  degradable  by  cathepsin  B.  
Without  seeing  the  free  peptide  band,  it  is  unclear  if  the  peptide  is  being  degraded  into  
smaller  fragments,  or  if  it  is  being  retained  on  the  hydrophobic  ELP  domain.  With  
plentiful  cut  sites  along  the  hydrophilic  ELP  domain  (30  fold  more  than  the  single  RVRR  
site  on  each  construct),  there  may  be  significant  competition  for  cleavage  of  the  RVRR  
sequence  if  it  is  indeed  recognized  by  cathepsin  B.  Although  conclusive  cleavage  by  
cathepsin  B  was  not  characterized,  the  release  of  free  drug  by  at  least  one  intracellular  
enzyme  confirmed  the  potential  for  this  linker  to  serve  its  ultimate  purpose  of  free  drug  
release  within  the  cell.  
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Figure  59:  BH3  peptide  drug  release  was  not  apparent  by  cathepsin  B  cleavage.  
However,  this  enzyme  did  appear  to  digest  the  hydrophilic  domain  of  the  CPP-­‐‑ELPBC.  
Coomassie  staining  of  cleavage  products  did  not  visualize  free  BH3  peptide  (MW:  2.74  
kDa,  where  furin  cleaves  at  the  C-­‐‑terminus  of  the  RVRR  linker  producing  the  
fragment  MGQVGRQLAIIGDDINRRYRVRR)  independent  of  the  CPP-­‐‑ELPBC  
(approximate  MW:  40  kDa,  depending  on  CPP  functionalization)  (A).  CuCl2  staining  
of  CPP-­‐‑ELPBCs  with  and  without  cathepsin  B  digestion  revealed  a  product  of  
approximately  20  kDa  that  was  likely  the  hydrophobic  domain  of  the  ELPBC  
(approximate  MW:  16.4  kDa  +/-­‐‑  2.74  kDa  for  drug  cargo  and  linker).  
Extensive  characterization  of  these  drug  carriers  and  control  confirmed  their  
expected  therapeutic  function.  The  in  vitro  cytotoxicity  was  evaluated  in  HeLa  cells,  
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again  using  the  modified  survival  assay  which  includes  exposure  of  the  cells  to  drug  
carrier  for  only  1  hour  at  either  37  °C  or  42  °C,  after  which  the  treatment  is  removed  and  
the  cells  are  returned  to  fresh  media  at  37  °C.  For  this  peptide  drug  cell  survival,  
approximated  from  absorbance  at  490  nm,  was  evaluated  only  24  hours  after  treatment.  
Arg8-­‐‑ELPBC-­‐‑cBH3  induced  significantly  greater  cell  death  at  42  °C,  as  compared  to  37  °C,  
while  no  significant  change  in  cell  survival  was  measured  for  Arg5-­‐‑ELPBC-­‐‑cBH3  or  non-­‐‑
functionalized  ELPBC-­‐‑cBH3  control  between  thermal  conditions  (Figure  60).  The  greater  
uptake  of  Arg8-­‐‑ELPBC  at  42  °C  was  thus  necessary  to  deliver  a  drug  dose  sufficient  to  
induce  a  therapeutic  effect,  while  the  uptake  of  Arg8-­‐‑ELPBC  at  37  °C  was  low  enough  to  
spare  cells  at  37  °C  from  a  cytotoxic  effect.    The  difference  in  cell  survival  between  37  °C  
and  42  °C  was  less  pronounced  for  Arg8-­‐‑ELPBC-­‐‑BH3,  which  lacked  the  cleavable  RVRR  
linker.  This  supports  the  importance  of  releasing  free  peptide  drug  within  the  cell  for  
this  drug  carrier  and  drug  cargo  combination.  Free  BH3  was  also  included  in  this  assay  
to  demonstrate  the  therapeutic  effect  of  this  drug  without  the  assistance  of  a  delivery  
vehicle.  Free  BH3  peptide  alone  showed  no  significant  cytotoxicity  at  either  thermal  
condition,  likely  due  to  its  poor  intracellular  delivery  caused  by  the  impermeable  barrier  
of  the  cell  membrane  to  this  drug.  
  























































































Figure  60:  Only  Arg8-­‐‑ELPBC-­‐‑cBH3  achieved  controlled  cytotoxicity  in  HeLa  cells,  as  
measured  by  absorbance  at  490  nm,  with  significant  cell  death  at  42  °C,  while  cells  at  
37  °C  were  spared.  Absorbance  was  normalized  to  untreated  cells  at  37  °C.  Data  
represents  mean  of  3  experiments  ±  SEM.  *Indicates  p  <  0.005  between  thermal  
conditions  (two-­‐‑way  ANOVA,  Bonferroni  posthoc  test  for  multiple  comparisons).  
Reproduced  from  [152].  
While  the  controls  included  in  the  experiment  above  confirmed  the  importance  
of  including  a  cleavable  linker  in  the  drug  carrier  design  to  induce  a  therapeutic  effect,  
they  did  not  examine  the  role  of  the  linker  itself  in  contributing  to  this  cytotoxic  effect.  
The  toxicity  of  the  cleavable  RVRR  linker  was  therefore  evaluated  with  the  Arg8-­‐‑ELPBC-­‐‑
RVRR  construct  using  the  same  cell  survival  assay.  Cell  survival  with  treatment  of  Arg8-­‐‑
ELPBC-­‐‑RVRR  at  42  °C  was  lower  than  those  cells  treated  at  37  °C,  as  approximated  by  
absorbance  at  490  nm,  but  this  effect  was  not  significant  (Figure  61).  However,  this  
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small,  albeit  statistically  insignificant,  effect  may  suggest  a  minor  role  of  the  RVRR  linker  
























Figure  61:  Cell  survival,  approximated  from  absorbance  at  490  nm,  did  decrease  with  
Arg8-­‐‑ELPBC-­‐‑RVRR  at  42  °C,  as  compared  to  37  °C,  but  this  effect  was  not  significant.  
Absorbance  was  normalized  to  untreated  cells  at  37  °C.  Data  represents  mean  of  3  
experiments  ±  SEM.  Reproduced  from  [152].  
Finally,  the  mechanism  of  cytotoxicity  induced  by  Arg8-­‐‑ELPBC-­‐‑cBH3  was  
investigated  by  the  contribution  of  apoptosis,  measured  by  the  activation  of  effector  
enzyme  caspase-­‐‑3.  Enzyme  activity  of  caspase-­‐‑3  was  evaluated  in  cells  treated  with  CPP-­‐‑
ELPBC  drug  carriers  and  controls  and  quantified  by  the  fluorescent  cleavage  fragments  
from  caspase-­‐‑specific  targets.  Arg8-­‐‑ELPBC-­‐‑cBH3  showed  a  significant  increase  in  caspase-­‐‑
3  activation  in  cells  treated  at  42  °C,  as  compared  to  those  treated  at  37  °C  (Figure  62).  
This  result  supports  that  the  controlled  cytotoxicity  achieved  with  this  drug  carrier  was  
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attributed  to  the  induction  of  apoptosis  by  the  BH3  peptide  drug  cargo.  The  caspase-­‐‑3  
activation  was,  however,  elevated  slightly  at  37  °C  as  well,  when  compared  to  the  other  
drug  carrier  controls.  However,  the  increased  caspase-­‐‑3  activation  triggered  at  37  °C  by  
Arg8-­‐‑ELPBC-­‐‑cBH3  did  not  correlate  to  an  increase  in  cytotoxicity,  suggesting  that  a  
threshold  of  caspase-­‐‑3  activation  was  not  met  at  this  treatment  condition  to  induce  a  
significant  cytotoxic  effect.  No  significant  changes  in  caspase-­‐‑3  activation  were  seen  
between  cells  treated  with  ELPBC-­‐‑cBH3,  Arg5-­‐‑ELPBC-­‐‑cBH3,  or  free  BH3  at  either  37  °C  or  
42  °C,  supporting  the  conclusion  that  only  the  delivery  afforded  by  Arg8-­‐‑ELPBC  was  























































































Figure  62:  Only  Arg8-­‐‑ELPBC-­‐‑cBH3  achieved  elevated  caspase-­‐‑3  activation  at  42  °C,  as  
compared  to  37  °C.  Caspase-­‐‑3  activation  was  normalized  to  untreated  cells  at  37  °C.  
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Data  represents  mean  of  3  experiments  ±  SEM.  *Indications  p  <  0.01  between  thermal  
conditions  (two-­‐‑way  ANOVA,  Bonferroni  posthoc  test  for  multiple  comparisons).  
Reproduced  from  [152].  
To  evaluate  all  factors  of  this  drug  delivery  platform,  the  role  of  hyperthermia  
alone  was  also  investigated  as  a  potential  contributor  toward  apoptosis.  Therefore  the  
effect  of  hyperthermia  on  the  induction  of  apoptosis  was  evaluated  by  quantification  of  
caspase-­‐‑3  activity  in  untreated  cells  exposed  to  37  °C  or  42  °C.  No  significant  difference  
in  caspase-­‐‑3  activity  was  detected  between  cells  incubated  at  37  °C  or  42  °C  (Figure  63),  
confirming  that  mild  hyperthermia  alone  did  not  induce  apoptosis  in  the  context  of  this  





























Figure  63:  No  significant  difference  in  caspase-­‐‑3  activity  was  detected  between  
untreated  cells  incubated  at  37  °C  or  42  °C  confirming  that  hyperthermia  alone  did  not  
contribute  to  the  induction  of  apoptosis.  Caspase-­‐‑3  activation  was  normalized  to  
untreated  cells  at  37  °C.  Data  represents  mean  of  3  experiments  ±  SEM.    Reproduced  
from  [152].  
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The  results  with  this  family  of  CPP-­‐‑ELPBC  drug  carriers  confirm  several  factors  in  
the  successful  control  of  therapeutic  effect  with  hyperthermia-­‐‑triggered  micelle  
assembly  that  drives  intracellular  drug  delivery.  For  BH3  peptide  cargo  the  critical  
parameters  included  a  drug  carrier  functionalized  with  Arg8  CPP,  capable  of  
maximizing  uptake  at  42  °C  to  cause  significant  cell  death  at  this  “on”  state,  while  
keeping  uptake  at  37  °C  low  enough  to  avoid  cytotoxicity  at  this  “off”  state.  Furthermore  
a  cleavable  peptide  linker,  such  as  RVRR,  was  critical  in  allowing  free  drug  release  in  the  
cell  that  could  perform  its  therapeutic  function.    
While  the  experiments  performed  here  confirmed  the  importance  of  these  
parameters,  there  are  likely  several  additional  factors  that  contributed  to  the  controlled  
cytotoxicity  achieved  with  the  Arg8-­‐‑ELPBC-­‐‑cBH3  drug  carrier.  First,  the  positive  charge  
contributed  to  the  BH3  peptide  by  the  residual  RVRR  linker,  following  cleavage  at  the  C-­‐‑
terminus  of  this  peptide,  could  potentially  increase  the  cytotoxicity  of  the  peptide  drug  
by  electrostatically  localizing  the  peptide  to  the  mitochondrial  membrane  [183].  This  
localization  could  either  increase  activity  of  BH3  by  increasing  its  interaction  with  
prosurvival  proteins  anchored  in  the  mitochondrial  membrane  or  could  increase  
cytotoxicity  by  directly  destabilizing  the  mitochondrial  membrane  [184].  Second,  mild  
hyperthermia  used  to  trigger  micelle  assembly  may  contribute  to  cytotoxicity  by  
influencing  components  of  the  apoptosis  cascade,  such  as  down-­‐‑regulation  of  apoptosis-­‐‑
related  proteins  [185]  or  direct  destabilization  of  the  mitochondrial  membrane  [186].  
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Since  hyperthermia  alone  did  not  induce  cytotoxicity  in  untreated  cells,  these  effects  
may  only  become  apparent  when  synergized  with  delivery  of  a  proapoptotic  signal,  
such  as  is  provided  by  the  BH3  peptide.  The  factors  of  BH3  peptide  delivery,  charge,  
and  heat  may  all  synergistically  contribute  to  a  controlled  cytotoxicity  achieved  at  
conditions  of  mild  hyperthermia,  while  sparing  cells  at  physiologic  temperatures.  
4.4 Conclusions 
Due  to  their  genetic  design,  CPP-­‐‑ELPBCs  are  well  suited  for  drug  loading,  be  it  by  
genetically  appending  biologic  drugs,  or  incorporating  unique  reactive  residues  for  
covalent  attachment  of  non-­‐‑biologic  therapeutics.  The  major  concern  in  the  attachment  
of  drug  cargo  of  all  kinds  is  the  preservation  of  the  desired  thermal  properties  of  the  
ELPBC  if  they  have  been  optimized  for  the  intended  application.  As  was  the  case  for  third  
generation  CPP-­‐‑ELPBCs,  the  desired  unimer  and  micelle  conditions  were  previously  
attained  by  careful  optimization  of  the  ELPBC  to  achieve  a  CMT  between  37  °C  and  42  °C,  
independent  of  CPP-­‐‑functionalization.  With  significant  effort  applied  in  optimizing  the  
behavior  of  the  CPP-­‐‑ELPBC,  a  drug  cargo  without  detrimental  effect  on  the  thermal  
behavior  was  sought  for  this  family  of  drug  carriers.  
Attachment  of  small  molecule  drugs  was  investigated  by  covalent  conjugation  to  
N-­‐‑terminal  cysteine  residues.  The  hydrophilic  small  molecule  gemcitabine  was  chosen  
as  the  drug  cargo  to  guarantee  that  it  would  not  induce  premature  self-­‐‑assembly  of  the  
ELP,  as  is  known  for  hydrophobic  small  molecules.  Although  the  conjugation  of  
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gemcitabine  did  not  cause  premature  self-­‐‑assembly  of  the  ELPBC,  this  drug  attachment  
did  induce  changes  in  the  CPP-­‐‑ELPBC  thermal  behavior  that  either  prevented  its  use  for  
hyperthermia-­‐‑triggered  self-­‐‑assembly  or  forced  its  use  at  high  concentrations  to  achieve  
the  desired  “off”  and  “on”  states  of  the  drug  carrier  platform.  Controlled  cytotoxicity  
with  small  molecule  drug  cargo  was  not  achievable  with  the  current  drug  carrier  design  
and  it  became  clear  that  significant  optimization  of  the  carrier  would  need  to  be  assessed  
at  each  step  in  small  molecule  drug  loading  to  truly  evaluate  the  potential  to  deliver  
small  molecule  drugs  in  a  controllable  manner  at  relevant  doses.  These  complications  
lead  to  the  search  for  alternative  drug  cargo  that  could  potentially  exploit  the  optimized  
CPP-­‐‑ELPBCs  that  were  available.  
Peptide  drug  cargo  proved  to  be  significantly  less  destructive  to  the  ELPBC  
thermal  properties.  Even  peptides  that  include  residues  with  hydrophobic  or  charged  
character  could  be  incorporated  into  the  CPP-­‐‑ELPBC  design  and  not  perturb  the  
optimized  thermal  response  of  these  carriers.  Controlled  cytotoxicity  was  achieved  with  
proapoptotic  BH3  peptide  drug  cargo  when  delivered  with  Arg8-­‐‑ELPBC  in  combination  
with  a  cleavable  linker  that  provided  release  of  free  peptide  within  the  cell.  While  this  
carrier  system  proved  suitable  for  BH3  peptide  drug  it  is  imaginable  that  for  other  
peptide  drugs  the  ideal  intracellular  drug  dose  at  “off”  and  “on”  conditions  will  likely  
vary  to  achieve  controlled  cytotoxicity  depending  on  the  drug’s  potency.  The  CPP-­‐‑ELPBC  
drug  carrier  platform  provides  the  ability  to  tune  these  delivery  parameters,  as  
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controlled  by  the  CPP-­‐‑functionalization.  This  drug  delivery  platform  may  therefore  be  
quite  tunable  depending  on  the  needs  of  the  drug  cargo.  
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5. Targeted delivery of CPP-ELPBCs in vivo  
5.1 Motivation 
CPP-­‐‑ELPBCs  successfully  controlled  cellular  uptake  and  drug  delivery  in  vitro  in  
response  to  a  trigger  of  mild  clinical  hyperthermia  that  induced  self-­‐‑assembly  of  the  
drug  carriers.  For  targeted  delivery  in  vivo  the  CPP-­‐‑ELPBCs  would  be  injected  
systemically.  At  physiologic  temperature  of  37  °C,  the  CPP-­‐‑ELPBCs  should  circulate  in  
the  blood  as  unimers  in  their  “off”  state.  This  should  minimize  the  internalization  of  
CPP-­‐‑ELPBCs  in  off-­‐‑target  tissues  that  they  encounter  as  they  circulate  throughout  the  
body.  It  is  only  in  the  solid  tumor,  to  which  local  hyperthermia  is  applied,  that  the  CPP-­‐‑
ELPBCs  should  self-­‐‑assemble  into  micelles  at  42  °C,  thereby  transitioning  to  their  “on”  
state  only  at  the  site  of  disease.  This  should  achieve  enhanced  cellular  uptake  and  
intracellular  drug  delivery  targeted  only  to  the  tumor.  
There  are  many  aspects  of  targeted  drug  carrier  delivery  that  must  be  evaluated  
to  determine  the  function  of  such  materials  in  a  living  system.  These  factors  include  the  
behavior  of  the  drug  carrier  in  blood,  the  rate  of  clearance  of  the  drug  carrier  from  
circulation,  the  interaction  of  drug  carrier  with  its  target  tissue,  and  the  biodistribution  
of  the  drug  carrier  in  both  the  target  tissue  as  well  as  off-­‐‑target  organs.  Combined,  all  of  
these  factors  contribute  to  the  success  or  failure  of  the  drug  carrier  in  vivo.  
The  hypothesis  that  drove  the  creation  of  cationic  CPP-­‐‑ELPBCs  originally  
assumed  a  relatively  low  charge  content  of  3  arginine  residues  per  ELPBC  to  achieve  
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controlled  cellular  uptake  at  42  °C  that  was  comparable  to  other  CPP-­‐‑functionalized  
systems  like  TAT-­‐‑decorated  liposomes.  However,  analysis  of  arginine  oligomer  valency  
suggested  that  greater  than  3  arginine  residues  was  necessary  to  achieve  significant  
uptake  in  the  “on”  state  of  self-­‐‑assembled  CPP-­‐‑ELPBC  micelles  at  42  °C  that  was  
enhanced  in  comparison  to  37  °C.    Indeed,  5  or  8  arginine  residues  worked  best  to  
demonstrate  controlled  cellular  uptake  with  variable  magnitudes  of  uptake  at  “off”  and  
“on”  conditions.  Furthermore,  only  Arg8-­‐‑ELPBC  was  capable  of  inducing  controlled  
cytotoxicity  of  some  drug  cargo,  suggesting  that  the  high  level  of  uptake  afforded  by  this  
CPP-­‐‑ELPBC  was  necessary  to  deliver  a  sufficient  intracellular  dose  of  some  drugs  in  
order  to  induce  a  therapeutic  effect.  Therefore,  the  CPP-­‐‑ELPBCs  we  found  to  have  useful  
behaviors  in  vitro  had  a  much  greater  cationic  content  than  we  had  originally  
anticipated.  Not  surprisingly,  this  charge  content  would  be  a  major  challenge  in  
achieving  the  desired  behavior  of  these  cationic  drug  carriers  in  vivo.    
These  challenges  would  have  the  opportunity  to  present  themselves  at  all  stages  
of  the  evaluation  of  CPP-­‐‑ELPBCs  in  vivo,  where  charge  can  have  negative  effects  on  the  
thermal  behavior  of  CPP-­‐‑ELPBCs  in  blood,  on  the  clearance  of  CPP-­‐‑ELPBCs  from  
circulation,  and  on  the  non-­‐‑specific  interaction  of  CPP-­‐‑ELPBCs  with  off-­‐‑target  organs.  It  
was  therefore  unlikely  that  these  highly  cationic  CPP-­‐‑ELPBCs  would  achieve  successful  
tumor  targeting  in  vivo.  However,  it  was  useful  to  evaluate  the  behavior  of  those  CPP-­‐‑
ELPBCs  that  were  thus  far  developed  to  perhaps  elucidate  factors  in  the  CPP-­‐‑ELPBC  
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design  that  could  be  tuned  to  achieve  successful  performance  of  temperature-­‐‑triggered  
micelle  assembly  in  vivo,  which  could  be  applicable  to  future  generations  of  
functionalized  ELPBCs.  
5.2 Methods 
5.2.1 Preparation of CPP-ELPBCs for in vivo administration 
For  visualization  and  quantification  in  vivo,  CPP-­‐‑ELPBCs  were  fluorescently  
labeled  with  Alexa  Fluor  488,  as  previously  described.  One  additional  purification  step  
was  included  for  materials  destined  for  in  vivo  administration  to  remove  residual  
endotoxin  resulting  from  the  recombinant  synthesis  of  CPP-­‐‑ELPBCs  in  E.  coli.  Labeled  
CPP-­‐‑ELPBCs  were  added  to  Pierce  high  capacity  endotoxin  removal  resin  in  a  spin  
column  and  mixed  for  1  hour  at  room  temperature  while  protected  from  light.  
Endotoxin  free  sample  was  then  collected  by  centrifugation  of  the  spin  column  at  500  x  g  
for  1  minute.  
5.2.2 Thermal characterization of CPP-ELPBCs in serum  
To  characterize  the  thermal  behavior  that  would  be  expected  of  CPP-­‐‑ELPBCs  in  
the  circulation,  temperature-­‐‑regulated  turbidimetry  was  repeated  in  fluids  that  could  
mimic  the  complex  composition  of  blood.  Mouse  serum,  90%  FBS,  and  1  mM  bovine  
serum  albumin  (BSA)  were  all  employed  to  shed  light  on  the  behavior  of  CPP-­‐‑ELPBCs  in  
buffers  beyond  that  of  PBS,  SF-­‐‑media,  and  cell  culture  media  supplemented  with  10%  
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FBS.  Turbidimetry  in  these  alternative  fluids  provided  efficient  analysis  of  changes  in  
the  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  in  the  presence  of  serum  proteins.  
5.2.3 Pharmacokinetics of systemically administered CPP-ELPBCs 
To  evaluate  the  duration  of  blood  circulation,  fluorescently  labeled  CPP-­‐‑ELPBCs  
were  administered  intravenously  via  the  tail  vein  of  balb/c  mice.  At  select  time  points  
over  the  course  of  24-­‐‑48  hours,  10  µμL  of  blood  was  sampled  from  a  tail  vein  prick.  The  
blood  sample  was  diluted  in  100  µμL  of  heparinized  PBS  and  red  blood  cells  were  
removed  by  centrifugation  at  5,000  x  g  for  5  minutes.  The  supernatant  was  loaded  onto  
black  96-­‐‑well  microplates  and  the  fluorescence  of  Alexa  Fluor  488  was  measured  on  a  
microplate  reader  and  corrected  for  background  signal  from  the  plasma  of  untreated  
mice.  The  fluorescent  signal  was  either  normalized  to  the  first  time  point  and  reported  as  
a  fraction  of  fluorescence  over  time  or  it  was  converted  to  absolute  concentration  using  
fluorescent  standard  curves  created  for  each  of  the  administered  CPP-­‐‑ELPBCs.  SAAM  II  
software  was  used  to  approximate  the  distribution  half-­‐‑life  (α  t1/2),  elimination  half-­‐‑life  
(β  t1/2),  and  area  under  the  curve  (AUC)  for  pharmacokinetic  data,  assuming  a  two  
compartment  pharmacokinetic  model.  
5.2.4 Intravital microscopy of systemically administered CPP-ELPBCs 
5.2.4.1  Surgical  implantation  of  dorsal  fold  window  chambers  
Six-­‐‑week-­‐‑old  female  nude  mice  were  used  for  the  implantation  of  dorsal  fold  
window  chambers  for  intravital  microscopy  of  CPP-­‐‑ELPBC  interactions  with  vascular  
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and  extravascular  tumor  tissue.  The  mice  were  anesthetized  for  surgery  with  
intraperitoneal  delivery  of  ketamine  (100  mg/kg)  and  xylazine  (10  mg/kg).  The  back  of  
the  mouse  was  washed  with  soap  and  then  sterilized  with  70%  alcohol.  The  dorsal  line  
of  the  mouse  was  marked  with  a  sterile  pen  and  the  mouse  was  wrapped  in  a  sterile  
drape  that  left  the  surgical  site  exposed.  Four  points  along  the  dorsal  line  were  used  to  
fix  the  mouse  skin  to  a  metal  C-­‐‑shaped  rack  using  nylon  sutures  to  stretch  the  skin.  The  
window  chamber  was  used  as  a  template  to  mark  the  area  of  skin  to  be  removed  on  one  
side  of  the  dorsal  fold  and  to  mark  the  holes  for  the  three  bolts  of  the  window  chamber.  
Holes  for  the  bolts  were  made  using  a  skin  hole  punch  and  a  circular  incision  was  made  
where  marked  on  the  dorsal  fold,  removing  the  skin  and  ensuring  that  the  fascia  from  
the  proximal  side  was  also  removed.  The  wound  was  kept  moist  by  the  application  of  
warm  saline.  One  half  of  the  window  chamber,  containing  the  bolts,  was  fit  onto  the  
dorsal  fold,  threading  through  the  three  holes  made  in  the  skin.  The  other  half  of  the  
window  chamber  was  aligned  to  the  first,  and  secured  with  three  nuts.  
FaDu  human  squamous  carcinoma  cells  were  used  to  inoculate  the  window  
chamber.  This  cell  type  was  found  to  be  best  suited  for  the  window  chamber  model  due  
to  its  slow  growth  that  allowed  tumors  to  reach  several  millimeters  in  the  course  of  10  
days  after  inoculation,  allowing  sufficient  time  for  healing  of  the  injury  caused  by  
window  chamber  implantation.  FaDu  cells  were  harvested  when  they  reached  80%  
confluence,  washed,  prepared  at  a  concentration  of  2  million  cells/mL  in  phenol-­‐‑red-­‐‑free  
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media,  and  stored  on  ice  for  the  duration  of  the  surgical  procedure.  10  µμL  of  the  tumor  
cell  suspension  (approximately  20,000  cells)  were  injected  under  the  fascia  of  the  
opposing  skin,  forming  a  bubble.  The  injection  site  was  washed  with  saline  prior  to  
fixing  a  glass  cover  slip  over  the  tissue  and  securing  it  with  an  expandable  plastic  ring.  
The  mouse  was  then  removed  from  the  C-­‐‑shaped  rack  and  the  window  chamber  was  
secured  with  sutures  at  four  total  points,  two  at  the  top  and  bottom  of  the  window  
chamber.  Antibiotic  was  applied  to  the  suture  lines  and  incision  site  and  the  animals  
were  allowed  to  recover  on  a  warmed  plate.  The  animals  were  returned  to  their  cages  
and  tumors  were  allowed  to  grow  7-­‐‑10  days  reaching  a  diameter  of  2-­‐‑3  mm  in  the  
window  chamber.  
5.2.4.2  Intravital  confocal  imaging  of  dorsal  fold  window  chambers  
For  intravital  imaging  of  the  dorsal  fold  window  chamber,  mice  were  
anesthetized  with  nembutol  and  placed  on  the  microscope  stage,  securing  the  window  
chamber  on  the  heating  element  coupled  to  a  water  bath.  The  temperature  of  the  
window  was  maintained  at  either  37  °C  or  42  °C  by  means  of  the  heated  water  bath  
circulating  through  the  heating  element  mounted  on  the  microscope  stage.  A  catheter  
was  installed  in  the  mouse  tail  vein,  enabling  ease  of  dosing  while  imaging.  To  label  the  
vascular  space,  2  MDa  rhodamine-­‐‑labeled  dextran  was  injected.  Visualization  of  the  
vasculature  helped  in  locating  an  area  of  interest  for  imaging,  preferably  in  the  tumor  as  
characterized  by  the  disorganized  and  tortuous  nature  of  the  neovasculature.  Achieving  
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this  goal  was  often  difficult  as  the  tumors  tended  to  grow  proximal  to  the  outer  diameter  
of  the  window,  where  the  window  chamber  limited  the  working  distance  of  the  
objective.  With  an  area  of  interest  identified,  Alexa  Fluor  488-­‐‑labeled  CPP-­‐‑ELPBC  was  
then  administered  via  tail  vein.  A  z-­‐‑stack  of  images  was  taken  over  the  depth  of  the  
vasculature,  as  defined  by  the  vascular  mask  signal,  every  3  minutes  over  the  course  of  1  
hour.    
This  standard  imaging  protocol  was  later  modified  due  to  concerns  about  the  
interaction  of  high  molecular  weight  dextran  with  the  CPP-­‐‑ELPBCs.  In  later  experiments  
Alexa  Fluor  488-­‐‑labeled  CPP-­‐‑ELPBC  alone  was  injected  intravenously  and  imaged  over  
time  in  the  absence  of  a  vascular  mask.  At  the  end  of  imaging,  1  hour  after  
administration,  rhodamine-­‐‑labeled  high  molecular  weight  dextran  was  added  to  help  
define  the  vascular  space  at  this  end  point.  In  these  modified  experiments  Hoechst  was  
also  administered  at  the  end  of  imaging  to  localize  the  cellular  components  of  the  tumor  
tissue.    
5.2.5 Biodistribution of systemically administered CPP-ELPBCs 
To  determine  biodistribution  of  CPP-­‐‑ELPBCs  in  the  tumor  and  other  critical  
organs,  a  FaDu  xenograft  was  used  on  the  right  hind  leg  of  nude  mice.  When  the  tumors  
reached  approximately  100  mm3  the  mice  were  assigned  to  groups  split  by  CPP-­‐‑ELPBC  
treatment  and  thermal  condition  to  normalize  the  average  tumor  volume  in  each  group.  
For  hyperthermia-­‐‑treated  tumors,  mice  were  anesthetized  with  nembutol,  catheters  were  
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installed  in  the  tail  vein,  and  rectal  temperature  probes  were  placed  in  each  mouse.  The  
mice  were  then  mounted  in  custom  holders  that  permitted  just  their  leg  bearing  the  
tumor  to  be  immersed  in  a  water  bath  that  maintained  a  tumor  temperature  of  42  °C.  
Tumors  were  preheated  for  10  minutes  to  allow  internal  temperatures  to  reach  42  °C  
prior  to  intravenous  administration  of  Alexa  Fluor  488-­‐‑labeled  CPP-­‐‑ELPBCs.  Tumor  
heating  continued  for  a  total  of  1  hour  while  monitoring  the  core  body  temperature  of  
the  mice.  After  1  hour  of  tumor  heating,  mice  were  removed  from  the  water  bath  and  
allowed  to  recover  from  anesthesia.  For  tumors  without  heat  treatment  the  mice  were  
simply  administered  CPP-­‐‑ELPBC  via  tail  vein  injection.    
2  or  24  hours  after  CPP-­‐‑ELPBC  administration,  the  mice  were  sacrificed  and  
tissues  were  collected  including  the  tumor,  muscle,  heart,  lungs,  kidney,  spleen,  and  
liver.  A  portion  of  each  organ  sample  was  homogenized  by  beating  with  zirconia  beads.  
The  homogenized  tissue  and  beads  were  centrifuged  and  the  supernatant  was  loaded  on  
a  black  96-­‐‑well  microplate.  Alexa  Fluor  488  fluorescence  was  measured  on  a  microplate  
reader.  The  fluorescent  signal  from  each  sample  was  corrected  for  the  background  
fluorescence  typical  for  each  organ  (by  mass),  measured  from  an  animal  not  receiving  
CPP-­‐‑ELPBC  treatment.  The  fluorescence  concentration  was  then  determined  from  
standard  curves,  created  for  each  CPP-­‐‑ELPBC  treatment,  and  accumulation  in  each  organ  
was  expressed  as  percent  dose  per  tissue  weight.  
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5.2.6 Optimizing material design with fourth generation CPP-ELPBCs 
It  would  become  apparent  in  preliminary  in  vivo  studies  of  third  generation  CPP-­‐‑
ELPBCs  that  a  larger  ELPBC  might  provide  advantages  in  avoiding  uptake  or  clearance  via  
the  kidney.  Increase  in  the  size  of  the  ELP  blocks  composing  the  ELPBC  would  cause  a  
drop  in  their  Tt,  due  to  the  inverse  relationship  between  ELP  length  and  Tt  [102].  
Alternative  ELP  sequences  were  thus  investigated  to  compensate  for  this  change  in  Tt  
due  to  increased  length.  A  guest  residue  of  serine  was  used  to  create  a  hydrophilic  
domain  with  increased  Tt  at  80  pentapeptides  in  length.  The  genetic  design  of  this  
hydrophilic  ELP  is  listed  in  Table  14.  
Table  14:  Genetic  design  of  an  alternative  hydrophilic  block  for  fourth  generation  
CPP-­‐‑ELPBCs.  
ELP:  VPGXGn   Peptide  and  oligonucleotide  sequence  
(SGVPG)80  
    (S        G        V        P        G        S      G      V        P        G        S        G        V        P        G          S        G      V  
(agc  ggt  gtt  ccg  ggc  tct  ggt  gtc  cca  ggt  tcc  ggc  gta  ccg  ggc  agc  ggt  gtt    
  
    P      G        S      G        V        P        G)16  
cct  ggt  tct  ggc  gtg  ccg  ggc)16  
  
Since  the  CMT  is  largely  controlled  by  the  hydrophobic  domain  of  the  ELPBC,  a  
family  of  alternative  hydrophobic  domain  sequences  were  investigated  to  aid  in  the  fine-­‐‑
tuning  of  the  CMT  between  37  °C  and  42  °C.  These  hydrophobic  domain  sequences  were  
composed  of  alanine  and  valine  guest  residues,  where  the  increasing  fraction  of  alanine  
residues  raised  the  Tt  of  these  ELP  sequences.  The  synthesis,  design,  and  
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characterization  of  most  of  these  sequences  were  performed  by  Dr.  Jon  McDaniel  [187,  
188].  The  genetic  designs  of  these  hydrophobic  ELPs  are  listed  in  Table  15.  
Table  15:  Genetic  design  of  alternative  hydrophobic  blocks  for  fourth  generation  
CPP-­‐‑ELPBCs.  
ELP:  VPGXGn   Peptide  and  oligonucleotide  sequence  
(XGVPG)80  
[X=A:V=7:3]  
    (A        G        V        P        G        A      G        V        P        G        V        G        V      P        G        A        G    
(gcc  gga  gtg  cct  ggt  gca  ggt  gtg  cca  ggc  gtg  ggt  gtt  cca  gga  gca  ggc  
    
  V        P        G      V        G        V      P      G        A        G        V        P        G        A      G        V        P        G  
gtt  cca  ggt  gtg  ggt  gtt  cct  ggc  gcc  gga  gtg  cct  ggt  gca  ggt  gtg  cca  ggc    
  
    V      G        V      P        G        A        G        V        P        G      A        G        V      P        G)8  
gtg  ggt  gtt  cca  gga  gca  ggc  gtt  cca  ggt  gcg  ggt  gtt  cct  ggc)8    
(XGVPG)80  
[X=A:V=3:2]  
    (A      G        V        P        G        A        G      V        P        G        V        G        V      P        G        A        G    
(gcc  gga  gtg  cct  ggt  gca  ggt  gtg  cca  ggc  gtg  ggt  gtt  cca  gga  gca  ggc  
    
    V      P        G        V      G        V      P        G        A      G        V        P        G        A      G        V        P        G    
gtt  cca  ggt  gtg  ggt  gtt  cct  ggc  gcc  gga  gtg  cct  ggt  gca  ggt  gtg  cca  ggc  
  
    V        G      V      P        G        A        G        V        P        G      V        G        V      P        G)8    
gtg  ggt  gtt  cca  gga  gca  ggc  gtt  cca  ggt  gtg  ggt  gtt  cct  ggc)8  
(XGVPG)80  
[X=A:V=1:1]  
    (A      G        V          P        G        V        G        V      P        G        A        G        V      P        G        V      G    
(gcc  gga  gtg  cca  ggc  gtg  ggt  gtt  cca  gga  gca  ggc  gtt  cca  ggt  gtg  ggt    
  
  V        P      G        A        G        V        P        G        V        G        V      P        G        A        G        V      P        G    
gtt  cct  ggc  gcc  gga  gtg  cca  ggc  gtg  ggt  gtt  cca  gga  gca  ggc  gtt  cca  ggt    
  
    V        G      V      P        G        A        G        V        P        G        V        G        V      P        G)8    
gtg  ggt  gtt  cct  ggc  gcc  gga  gtg  cca  ggc  gtg  ggt  gtt  cca  gga)8  
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(XGVPG)80  
[X=A:V=4:6]  
    (A      G        V        P        G        A        G      V        P        G        V        G        V      P        G          A      G    
(gcc  gga  gtg  cct  ggt  gca  ggt  gtg  cca  ggc  gtg  ggt  gtt  cca  gga  gca  ggc    
  
    V      P        G      V        G        V      P        G        V      G        V      P        G        V        G        V        P      G    
gtt  cca  ggt  gtg  ggt  gtt  cct  ggc  gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt    
  
    A        G        V        P        G        V      G        V      P      G        V        G        V      P        G)8    
gcg  ggc  gta  ccg  ggc  gtt  ggt  gtt  cct  ggt  gtc  ggc  gtg  ccg  ggc)8  
(XGVPG)80  
[X=A:V=1:4]  
    (V      G        V      P        G        V        G        V        P        G      A        G        V        P        G        V        G  
(gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt  gcg  ggc  gta  ccg  ggc  ggt  ggt    
  
    V        P      G        V      G        V        P        G        V        G        V      P        G        V        G        V      P        G  
  gtt  cct  ggt  gtc  ggc  gtg  ccg  ggc  gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt    
  
      A        G        V        P        G        V      G      V        P      G        V        G      V        P        G)8  
  gcg  ggc  gta  ccg  ggc  gtt  ggt  gtt  cct  ggt  gtc  ggc  gtg  ccg  ggc)8  
(VGVPG)80    
    (V      G        V      P        G        V        G        V        P        G      V        G        V        P        G        V        G        V  
(gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt  gtg  ggc  gta  ccg  ggc  ggt  ggt  gtt  
  
      P      G        V      G        V        P        G        V        G        V      P        G        V        G        V        P        G      V  
  cct  ggt  gtc  ggc  gtg  ccg  ggc  gtg  ggt  gtt  ccg  ggc  gta  ggt  gtc  cca  ggt  gtg  
  
      G        V        P        G        V      G      V        P      G        V      G        V        P        G)8  
  ggc  gta  ccg  ggc  gtt  ggt  gtt  cct  ggt  gtc  ggc  gtg  ccg  ggc)8  
  
The  new  hydrophilic  and  hydrophobic  blocks  were  combined  to  form  fourth  
generation  CPP-­‐‑ELPBCs.  Their  thermal  behavior  was  evaluated  in  PBS  and  mock  serum  
solutions  to  direct  the  choice  of  an  optimized  construct  to  best  test  the  mechanism  of  
temperature-­‐‑triggered  micelle  assembly  in  vivo.  
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5.3 Results and discussion 
5.3.1 Evaluation of first generation CPP-ELPBCs in vivo 
First  generation  CPP-­‐‑ELPBCs  were  not  suitable  for  mild  hyperthermia-­‐‑triggered  
self-­‐‑assembly  and  were  thus  not  appropriate  to  probe  temperature-­‐‑targeted  delivery  in  
vivo.  These  CPP-­‐‑ELPBCs  would  be  in  their  self-­‐‑assembled  “on”  state  at  37  °C,  and  
therefore  would  have  the  potential  to  interact  non-­‐‑specifically  with  any  and  all  tissues  if  
they  were  systemically  administered  in  the  blood  stream.  These  materials  should  
thereby  behave  as  non-­‐‑activatable  CPP-­‐‑functionalized  carriers  and  therefore  are  likely  to  
interact  with  off-­‐‑target  tissues  and  be  cleared  quickly  from  circulation.  It  was  unclear  
whether  these  effects  would  eliminate  any  possibility  that  these  CPP-­‐‑ELPBCs  could  also  
interact  with  the  tumor,  albeit  in  a  non-­‐‑activatable  mechanism.  Intravital  microscopy  of  
dorsal  fold  window  chamber  tissue  at  37  °C  was  performed  with  first  generation  Arg5-­‐‑
ELPBCs  and  controls  to  shed  light  on  these  questions.    
Vasculature  was  labeled  with  a  high  molecular  weight  rhodamine-­‐‑dextran  and  
Arg5-­‐‑ELPBC  and  controls  were  delivered  at  a  final  blood  concentration  of  10  µμM.  Images  
were  acquired  for  30-­‐‑60  minutes  after  administration,  depending  on  the  compliance  of  
the  mouse.  Both  Arg5-­‐‑ELPBC  and  non-­‐‑functionalized  ELPBC  appeared  to  extravasate  from  
the  vasculature  over  the  course  of  imaging,  whereas  the  signal  from  Arg5-­‐‑ELP  soluble  
unimer  only  seemed  to  fade  over  time  (Figure  64).  This  preliminary  experiment  
suggested  that  the  extravasation  with  time  at  37  °C  was  governed  by  micelle  
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nanoparticle  carriers,  not  their  CPP-­‐‑functionalization.  Although  the  exact  parameters  of  
this  experiment  and  the  characteristics  of  these  first  generation  materials  do  not  match  
with  those  investigated  in  second  generation  carriers  and  beyond,  this  information  
served  as  the  first  harbinger  that  Arg5-­‐‑functionalization  of  ELPBC  micelles  was  not  















Figure  64:  First  generation  Arg5-­‐‑ELPBC  and  ELPBC  micelles  extravasated  in  dorsal  fold  
window  chamber  tissue  at  37  °C.  Extravasation  was  less  evident  for  Arg5-­‐‑ELP  unimer.  
Green—ELP;  red—vascular  mask;  acquired  at  20x.  
5.3.2 Evaluation of second generation CPP-ELPBCs in vivo 
Second  generation  CPP-­‐‑ELPBCs  provided  the  first  opportunity  to  test  
hyperthermia-­‐‑triggered  micelle  assembly.  Once  validated  in  vitro,  their  behavior  was  
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visualized  in  vivo,  after  intravenous  administration  at  a  final  concentration  of  25  µμM  in  
the  blood  and  in  dorsal  fold  window  chambers  heated  to  37  °C  or  42  °C.  It  was  difficult  
to  identify  any  trends  in  behavior  by  this  imaging  technique  and  the  constructs  
delivered  here.  For  instance,  when  looking  at  potential  tissue  interaction  that  could  lead  
to  differences  in  extravasation,  there  did  not  seem  to  be  a  particular  pattern  dependent  
on  material  type  or  tissue  temperature.  Arg5-­‐‑ELPBC  (Figure  65)  and  Arg5-­‐‑ELP  (Figure  66)  
both  appeared  to  extravasate  over  the  course  of  1  hour  regardless  of  tissue  temperature.  
ELPBC,  however,  appeared  to  extravasate  to  a  greater  extent  at  37  °C,  as  compared  to  42  
°C  (Figure  67).  Furthermore,  there  did  not  appear  to  be  any  obvious  differences  in  the  
localization  of  fluorescent  extravasation  that  would  suggest  these  materials  were  
interacting  with  the  tissue  in  different  ways.  It  was  unclear  by  these  results  what  role  
tissue  and  vascular  heterogeneity  played  in  this  variability.    
What  was  most  important  in  looking  at  these  imaging  results  was  that  punctate  
fluorescence  from  the  Arg5-­‐‑ELPBC  was  seen  at  42  °C  in  the  vasculature  just  after  
administration  (Figure  65).  This  fluorescence  quickly  disappeared  in  the  matter  of  
minutes.  It  was  unclear  if  the  Arg5-­‐‑ELPBC  was  interacting  with  cell  or  extracellular  
components  as  it  was  injected.  In  retrospect,  however,  it  was  likely  that  this  construct  
was  aggregating  in  the  presence  of  serum  and  mild  hyperthermia.  Due  to  the  sensitivity  
of  this  construct  to  fluorophore  conjugation,  it  would  not  be  surprising  that  the  presence  
of  serum  could  disturb  its  thermal  properties  in  such  a  way  as  to  destroy  micelle  
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assembly.  The  quickness  with  which  the  punctate  fluorescence  disappeared  from  the  
vasculature  suggested  that  the  decrease  in  concentration  of  this  Arg5-­‐‑ELPBC  as  it  was  
cleared  from  circulation  likely  brought  it  below  its  critical  micelle  concentration  at  this  
hyperthermic  condition.  This  behavior  further  confirmed  the  need  for  third  generation  
CPP-­‐‑ELPBCs,  and  other  optimized  materials,  to  address  the  effects  of  the  in  vivo  
environment.  
  























Figure  65:  Second  generation  Arg5-­‐‑ELPBC  appeared  to  aggregate  upon  administration  
to  hyperthermia  treated  tissue.  Arg5-­‐‑ELPBC  accumulated  in  the  extravascular  space  
over  the  course  of  1  hour,  regardless  of  tissue  temperature.  Green—ELP;  red—vascular  
mask;  acquired  at  20x.  
  























Figure  66:  Second  generation  Arg5-­‐‑ELP  unimer  appeared  to  accumulate  in  the  
extravascular  space  over  the  course  of  1  hour,  regardless  of  tissue  temperature  and  
despite  distinct  vascular  architecture.  Green—ELP;  red—vascular  mask;  acquired  at  
20x.  
  























Figure  67:  Second  generation  non-­‐‑functionalized  ELPBC  achieved  variable  
accumulation  in  the  extravascular  space  of  tissues  at  37  °C  or  42  °C,  which  had  distinct  
vascular  architecture.  Green—ELP;  red—vascular  mask;  acquired  at  20x.  
5.3.3 Evaluation of third generation CPP-ELPBCs in vivo 
Third  generation  CPP-­‐‑ELPBCs  were  the  family  of  carriers  to  provide  reliable  and  
robust  behavior  in  vitro.  These  optimized  constructs  were  therefore  thoroughly  
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evaluated  in  vivo  to  determine  their  circulation  time,  their  interaction  with  the  tumor  
tissue,  and  their  distribution  to  the  tumor  and  other  organs.  Pharmacokinetics  of  
systemically  administered  third  generation  CPP-­‐‑ELPBC  and  controls  was  first  
investigated  to  provide  insight  into  the  clearance  of  carrier  from  the  blood  over  time.  
This  is  an  important  parameter  in  evaluating  the  function  of  the  CPP-­‐‑ELPBC  relying  on  
the  temperature-­‐‑triggered  micelle  assembly,  which  is  dependent  on  concentration.  It  is  
therefore  important  that  the  concentration  of  CPP-­‐‑ELPBC  in  the  blood  remains  above  that  
which  is  necessary  to  maintain  a  CMT  between  37  °C  and  42  °C.  To  our  advantage,  
however,  this  requirement  on  the  blood  concentration  must  only  be  achieved  over  the  
time  course  of  hyperthermia,  typically  1  hour,  in  which  triggered  micelle  assembly  is  
exploited.  Third  generation  Arg5-­‐‑ELPBC  as  well  as  non-­‐‑functionalized  ELPBC  and  soluble  
Arg5-­‐‑ELP  controls  were  fluorescently  labeled  and  systemically  administered  via  tail  vein  
injection  in  balb/c  mice.  The  blood  was  sampled  over  the  course  of  48  hours  and  the  
concentration  of  CPP-­‐‑ELPBC  or  controls  was  quantified  by  fluorescence  and  normalized  
to  the  measurement  immediately  following  administration  (40  second  time  point),  
making  a  naive  assumption  that  this  concentration  would  be  near  to  that  of  the  intended  
dose  of  100  µμM.  
  



















































Figure  68:  Arg5-­‐‑functionalization  in  third  generation  constructs  caused  more  rapid  
clearance  from  the  blood,  as  compared  to  non-­‐‑functionalized  ELPBC  control.  Yet,  
greater  than  30%  of  the  dose  of  all  constructs  was  maintained  in  the  blood  over  2  
hours  (inset).  
Both  Arg5-­‐‑ELPBC  and  Arg5-­‐‑ELP  control  were  cleared  more  quickly  from  the  blood  
when  compared  to  non-­‐‑functionalized  ELPBC.  The  effect  of  Arg5-­‐‑functionalization  to  
decrease  the  presence  in  circulation  was  evident  from  clearance  profiles  (Figure  68)  and  
pharmacokinetic  parameters  approximated  from  this  data  (Table  16).  ELPBC  achieved  the  
highest  elimination  half-­‐‑life  of  approximately  14  hours,  while  both  Arg5-­‐‑ELPBC  and  Arg5-­‐‑
ELP  had  shortened  elimination  half-­‐‑lives  of  approximately  11  hours.  Furthermore,  non-­‐‑
functionalized  ELPBC  achieved  the  largest  area  under  the  curve  (AUC),  such  that  it  
achieved  the  greatest  carrier  exposure  in  the  blood  through  its  prolonged  circulation,  as  
compared  to  Arg5-­‐‑functionalized  constructs.  This  effect  was  not  surprising  since  it  
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would  be  expected  that  the  cationic  charge,  albeit  small,  would  result  in  some  non-­‐‑
specific  interactions  that  would  lead  to  a  decreased  presence  in  the  blood.  Despite  the  
increased  clearance  of  these  Arg5-­‐‑functionalized  constructs,  they  both  greatly  
outperformed  free  arginine  oligomer  CPPs,  such  as  Arg9,  whose  circulation  half-­‐‑life  has  
been  reported  as  only  1.9  hours  [189].    
Table  16:  Pharmacokinetic  parameters  of  second  generation  Arg5-­‐‑ELPBC,  Arg5-­‐‑ELP,  and  
ELPBC  after  systemic  administration  at  100  µμM.  
Construct   α  t1/2  (min)   β  t1/2  (hour)   AUC  (µμMh)  
Arg5-­‐‑ELPBC   12.4  ±  5.5   10.7  ±  0.9   378.4  ±  27.2  
Arg5-­‐‑ELP   9.3  ±  5.8   11.0  ±  1.5   199.5  ±  23.0  
ELPBC   100.4  ±  19.1   14.2  ±  1.9   438.8  ±  22.7  
  
Most  important  to  the  CPP-­‐‑ELPBCs  was  the  clearance  of  constructs  with  respect  to  
the  time  frame  of  mild  hyperthermia.  Despite  the  increased  clearance  of  Arg5-­‐‑
functionalized  materials,  all  constructs  maintained  30%  of  their  delivered  dose  in  
circulation  over  the  course  of  2  hours  (Figure  68—inset).  Assuming  that  the  earliest  time  
point  corresponded  to  concentration  near  the  intended  does  of  100  µμM,  this  blood  
concentration  would  be  sufficiently  above  the  critical  micelle  concentration  to  achieve  a  
CMT  between  37  °C  and  42  °C.  
Pharmacokinetics  suggested  sufficient  concentration  in  the  blood  was  
maintained  by  third  generation  CPP-­‐‑ELPBC  and  controls  such  that  temperature-­‐‑triggered  
micelle  assembly  should  be  achievable  with  hyperthermia  over  the  course  of  1  hour  
following  administration.  It  was  therefore  feasible  to  investigate  the  temperature-­‐‑
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triggered  behavior  with  intravital  microscopy,  providing  insight  into  the  interaction  of  
Arg5-­‐‑ELPBC  with  the  tumor  as  a  function  of  the  “off”  or  “on”  condition  of  the  carrier  in  
either  non-­‐‑heated  or  hyperthermia-­‐‑treated  tumors  in  a  dorsal  fold  window  chamber.  
High  molecular  weight  rhodamine-­‐‑dextran  was  systemically  administered  to  provide  
visualization  of  the  vascular  space  over  the  course  of  imaging.  Alexa  Fluor  488-­‐‑labeled  
Arg5-­‐‑ELPBC  was  then  administered  via  tail  vein  at  a  final  blood  concentration  of  50  µμM.  
The  dorsal  fold  window  chamber  in  which  the  tumor  was  inoculated  was  heated  to  
either  37  °C  or  42  °C  using  a  heating  chamber  controlled  by  a  circulating  water  bath.  
This  preliminary  evaluation  of  third  generation  Arg5-­‐‑ELPBC  demonstrated  differences  in  
extravascular  accumulation  of  Arg5-­‐‑ELPBC  in  the  presence  or  absence  of  tumor  
hyperthermia  (Figure  69A)  and  revealed  an  interesting  accumulation  pattern  for  Arg5-­‐‑
ELPBC  in  tumors  heated  to  42  °C.  Enhanced  magnification  of  hyperthermia  treated  
tumors  revealed  perivascular  localization  of  Arg5-­‐‑ELPBC  after  1  hour  (Figure  69B).  The  
significance  of  this  extravasation  was  unclear  in  whether  the  CPP-­‐‑ELPBC  was  escaping  
the  vascular  space  by  means  of  hyperthermia-­‐‑induced  increased  permeability,  was  
binding  to  the  extravascular  space,  or  was  being  taken  up  by  cells  adjacent  to  the  
vasculature.  Furthermore,  it  was  unclear  if  these  visualized  differences  would  lead  to  a  
meaningful  change  in  tumor  accumulation,  as  compared  to  other  off-­‐‑target  organs.  
An  encouraging  result,  as  compared  to  second  generation  Arg5-­‐‑ELPBC,  was  that  
no  vascular  punctate  fluorescence  was  seen  with  this  third  generation  construct  
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immediately  after  administration  to  hyperthermia  treated  tumors.  This  gave  the  
impression  that  this  optimized  CPP-­‐‑ELPBC  platform  was  more  stable  in  blood  and  may  
have  avoided  the  issues  of  aggregation  that  were  detected  with  second  generation  
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Figure  69:  Mild  hyperthermia  appeared  to  influence  the  extravascular  accumulation  of  
third  generation  Arg5-­‐‑ELPBC  over  the  course  of  1  hour,  as  compared  to  non-­‐‑heated  
tissue  (A).  Perivascular  accumulation  in  hyperthermia  treated  tumors  after  1  hour  was  
revealed  by  enhanced  magnification  (B).  Green—ELP;  red—vascular  mask.  
To  probe  the  question  of  tumor  targeting  in  the  context  of  whole  body  
distribution,  the  accumulation  of  Arg5-­‐‑ELPBC  was  evaluated  in  tumors  with  or  without  
hyperthermia  as  well  as  other  critical  off-­‐‑target  organs.  Subcutaneous  tumors  were  
induced  on  the  mouse  hind  limb.  For  those  mice  receiving  tumor  hyperthermia,  their  
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hind  limb  bearing  the  tumor  was  locally  heated  with  a  water  bath  at  42  °C  for  1  hour,  
while  maintaining  the  body  temperature  of  the  mouse  at,  or  below,  37  °C.  The  tumor  
and  critical  organs  were  excised  2  hours  after  treatment  and  the  percent  dose  of  the  CPP-­‐‑
ELPBC  found  in  each  organ  was  determined  by  fluorescence.  There  was  no  significant  
difference  in  the  amount  of  Arg5-­‐‑ELPBC  or  non-­‐‑functionalized  ELPBC  that  was  found  in  
the  tumor  with  or  without  hyperthermia  treatment  (between  thermal  conditions,  two-­‐‑
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Figure  70:  No  significant  difference  in  tumor  accumulation  was  seen  with  Alexa  Fluor  
488-­‐‑labeled  Arg5-­‐‑ELPBC  or  non-­‐‑functionalized  ELPBC  in  hyperthermia-­‐‑treated  tumors  
or  tumors  receiving  no  heat.  Mice  were  administered  CPP-­‐‑ELPBC  or  control  at  a  total  
blood  concentration  of  100  µμM.  Data  represents  mean  of  3  measurements  ±  SD.  
There  were  several  interesting  aspects  of  accumulation  elsewhere  in  the  body  
when  looking  at  the  other  collected  organs  (Figure  71).  First,  little  accumulation  was  
apparent  in  the  heart,  liver,  lung,  and  spleen,  suggesting  minimal  off-­‐‑target  uptake  in  
these  tissues.  Second,  the  uptake  in  the  muscle,  which  serves  as  a  non-­‐‑heated  
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contralateral  control,  was  less  than  that  seen  in  the  tumor  with  and  without  heat  for  both  
Arg5-­‐‑ELPBC  and  ELPBC,  suggesting  a  contribution  of  passive  targeting  of  these  carriers  to  
the  tumor.  Third,  and  most  striking,  was  the  high  percent  of  the  dose  that  was  found  in  
the  kidney  for  both  Arg5-­‐‑ELPBC  and  the  ELPBC  control.  This  preliminary  result  suggested  
the  molecular  weight  of  this  CPP-­‐‑ELPBC  (approximately  40  kDa)  might  be  below  the  








































Figure  71:  Accumulation  of  Alexa  Fluor  488-­‐‑labeled  Arg5-­‐‑ELPBC  and  non-­‐‑
functionalized  ELPBC  in  critical  organs  did  not  differ  significantly  between  carriers  or  
thermal  conditions  of  the  tumor.  A  significant  fraction  of  the  dose  of  both  Arg5-­‐‑ELPBC  
and  ELPBC  was  detected  in  the  kidney.  Data  represents  mean  of  3  animals  ±  SD.  
The  results  of  the  preliminary  pharmacokinetic,  intravital  imaging,  and  
biodistribution  studies  for  third  generation  Arg5-­‐‑ELPBC  together  suggested  several  issues  
preventing  successful  tumor  targeting  in  vivo.  First,  although  the  concentration  of  CPP-­‐‑
ELPBC  in  the  circulation  appeared  to  be  sufficient  for  hyperthermia-­‐‑triggered  micelle  
assembly  over  at  least  1  hour,  it  seemed  that  a  significant  amount  of  the  carrier  was  
localized  in  the  kidney,  perhaps  suggesting  clearance  through  this  renal  pathway.  The  
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consumption  of  the  dose  present  in  the  kidney  suggested  a  large  amount  of  carrier  was  
unavailable  for  tumor  targeting,  perhaps  limiting  the  ability  of  the  carrier  to  sufficiently  
accumulate  in  the  tumor  tissue.  Second,  although  no  adverse  behavior  of  the  CPP-­‐‑ELPBC  
was  visualized  with  intravital  microscopy,  the  lack  of  hyperthermia-­‐‑controlled  tumor  
uptake  as  seen  in  the  biodistribution  study  suggested  that  the  CPP-­‐‑ELPBC  may  not  be  
behaving  as  expected  in  the  in  vivo  environment.    
It  was  only  in  retrospect  of  these  preliminary  studies  that  the  temperature-­‐‑
triggered  self-­‐‑assembly  of  third  generation  Arg5-­‐‑ELPBC  was  tested  in  mock  serum  
conditions.  Evaluation  by  temperature-­‐‑regulated  turbidimetry  in  90%  FBS  revealed  that  
Arg5-­‐‑ELPBC  self-­‐‑assembly  was  abolished  in  this  mock  serum  solution  (Figure  72),  thereby  
Arg5-­‐‑ELPBC  was  unlikely  to  function  with  its  expected  unimer-­‐‑to-­‐‑micelle  transition  in  
vivo.  It  was  interesting  that  aggregation  of  the  CPP-­‐‑ELPBC  was  not  seen  with  in  vivo  
imaging,  suggesting  several  factors  that  may  have  masked  this  effect.  First,  the  
significant  clearance  of  Arg5-­‐‑ELPBC  may  have  decreased  the  concentration  of  carrier  
reaching  the  tumor,  preventing  aggregation  at  this  temperature  and  local  concentration.  
Second,  although  unintended,  there  may  be  an  interaction  effect  between  the  dextran  
and  Arg5-­‐‑ELPBC  as  they  circulate  together  throughout  the  body.  Although  neutral  
dextran  was  utilized,  this  large  molecule  does  contain  charge  of  a  zwitterionic  nature.  
Local  concentration  of  anionic  charge  on  these  large  molecules  may  interact  with  the  
cationic  CPP-­‐‑ELPBC,  preventing  aggregation  or  preventing  its  favorable  interaction  with  
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target  cells  in  the  tumor.  Third,  this  contradiction  between  in  vivo  imaging  and  ex  vivo  
characterization  by  turbidimetry  may  simply  suggest  that  the  mock  serum  condition  of  
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Figure  72:  Temperature-­‐‑regulated  turbidimetry  revealed  the  effect  of  mock  serum  on  
the  self-­‐‑assembly  of  third  generation  Arg5-­‐‑ELPBC.  In  the  presence  of  10%  FBS,  typical  
of  cell  culture  conditions,  Arg5-­‐‑ELPBCs  self-­‐‑assembled  into  micelles  with  a  CMT  
between  37  °C  and  42  °C.  In  90%  FBS,  however,  micelle  assembly  was  abolished,  and  
Arg5-­‐‑ELPBC  appeared  to  transition  from  unimer  to  aggregate  in  response  to  mild  
hyperthermia.  Turbidimetry  measurements  were  acquired  at  25  µμM.  
5.3.4 Synthesis and characterization of fourth generation CPP-ELPBCs 
for optimized use in vivo 
Two  of  the  potential  problems  identified  by  preliminary  examination  of  third  
generation  CPP-­‐‑ELPBCs  could  be  addressed  by  further  optimization  of  the  ELPBC  design:  
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the  overall  size  of  the  carrier  and  the  stability  of  micelle  assembly  in  the  presence  of  
serum.  The  CPP-­‐‑ELPBC  design  again  went  under  iterative  optimization  to  increase  the  
molecular  weight  of  the  carrier  while  still  achieving  the  desired  thermal  properties  to  
ensure  the  transition  from  unimer  to  micelle  in  response  to  mild  hyperthermia.  A  family  
of  potential  CPP-­‐‑ELPBCs  was  then  screened  in  mock  serum  conditions  to  determine  the  
carrier  that  would  display  predictable  and  stable  triggered  micelle  assembly  in  vivo.  
To  increase  the  overall  molecular  weight  of  the  ELPBC,  an  increase  in  the  size  of  
both  domains  in  the  block  copolymer,  each  to  80  pentapeptides,  was  proposed.  Due  to  
the  inverse  relationship  of  ELP  length  and  Tt,  any  increase  in  the  ELP  size  would  result  
in  a  decrease  in  the  Tt  of  that  block.  Therefore,  simply  increasing  the  size  of  the  blocks  in  
the  existing  CPP-­‐‑ELPBC  design  would  surely  lead  to  a  carrier  that  would  display  
temperature-­‐‑triggered  micelle  assembly  well  below  37  °C,  making  it  inappropriate  for  
hyperthermia-­‐‑targeted  micelle  assembly.  The  sequence  of  each  of  the  domains  therefore  
had  to  be  changed,  such  that  a  more  hydrophilic  ELP  with  a  higher  Tt  could  compensate  
for  the  decrease  in  Tt  caused  by  the  increase  in  length.  An  ELP  with  serine  as  the  guest  
residue  (Table  14)  was  proposed  as  a  new  hydrophilic  domain,  as  the  hydrophilicity  of  
the  serine  residue  should  increase  the  Tt  as  compared  to  the  guest  residues  alanine  and  
glycine  in  E2*.  The  hydrophilicity  of  this  alternative  block  was  exemplified  in  the  
measurement  of  its  Tt  in  excess  of  100  °C  at  25  µμM  (Figure  73).  Increasing  the  Tt  of  the  
hydrophilic  domain  was  also  proposed  to  aid  in  the  stable  micelle  assembly  of  CPP-­‐‑
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ELPBCs  in  serum,  by  preventing  premature  aggregation  that  would  lead  to  a  unimer-­‐‑to-­‐‑
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Figure  73:  An  ELP  with  serine  guest  residues  was  synthesized  to  increase  the  Tt  of  the  
hydrophilic  domain  of  the  block  copolymer.  This  ELP,  at  80  pentapeptides  in  length,  
displayed  a  Tt  that  exceeded  100  °C  at  25  µμM  in  PBS,  as  determined  from  the  
extrapolation  of  Tts  measured  by  temperature-­‐‑regulated  turbidimetry  at  increasing  
concentrations  of  NaCl  in  PBS.  
The  hydrophobic  block  would  control  the  CMT  of  the  CPP-­‐‑ELPBC,  so  multiple  
sequences  were  investigated  for  this  domain.  A  family  of  ELPs  with  a  tunable  fraction  of  
alanine  and  valine  residues,  as  developed  by  Dr.  Jonathan  McDaniel  [187],  were  utilized  
to  investigate  a  range  of  Tts  to  ensure  an  optimized  CMT  could  be  achieved  for  in  vivo  
applications  (Table  15).  The  design  scheme  to  create  these  optimized  fourth  generation  
CPP-­‐‑ELPBCs  is  shown  in  Figure  74.  
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Figure  74:  The  CPP-­‐‑ELPBC  design  was  changed  to  accommodate  larger  block  sizes  
while  maintaining  an  optimized  thermal  response.  Increased  block  size  required  a  
change  in  block  sequence  to  avoid  a  decrease  in  CMT.  A  library  of  ELPs  with  varying  
fraction  of  alanine  and  valine  guest  residues  was  paired  with  an  ELP  with  serine  
guest  residues  to  create  a  family  of  fourth  generation  CPP-­‐‑ELPBCs  for  in  vivo  testing.  
The  resulting  six  ELPBCs,  all  160  pentapeptides  in  length  and  with  Arg5-­‐‑
functionalization,  were  characterized  by  temperature-­‐‑regulated  turbidimetry.  A  range  of  
CMTs  was  achieved,  among  which  some  were  potentially  useful  for  temperature-­‐‑
triggered  micelle  assembly  at  42  °C  (Figure  75).  As  expected,  increase  in  the  
hydrophobicity  of  the  hydrophobic  block,  correlating  with  the  fraction  of  valine  guest  
residues,  decreased  the  CMT  of  the  ELPBC.  Interestingly,  the  micelle-­‐‑to-­‐‑aggregate  
transition  also  changed  in  response  to  manipulating  the  hydrophobic  domain,  shedding  
light  on  the  interaction  effect  between  the  sequences  of  the  hydrophilic  and  hydrophobic  
blocks.  When  the  hydrophobic  and  hydrophilic  block  Tts  were  most  different  (ex.  
containing  100%  valine  and  100%  serine  guest  residues,  respectively),  there  appeared  to  
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be  the  least  interaction  between  blocks,  such  that  the  CMT  of  this  construct  was  the  
lowest  and  the  micelle-­‐‑to-­‐‑aggregate  Tt  was  at  its  highest  of  the  ELPBC  family  evaluated  
here.    As  alanine  was  titrated  into  the  hydrophobic  block,  the  CMT  increased  and  the  
micelle-­‐‑to-­‐‑aggregate  Tt  decreased,  leading  to  a  more  limited  temperature  range  over  
which  stable  micelle  assembly  was  achieved.  This  trend  continued  across  the  family  of  
ELPBCs,  such  that  the  ELPBC  with  the  hydrophobic  domain  containing  alanine:glycine  
guest  residues  at  a  ratio  of  7:3  only  displayed  a  unimer-­‐‑to-­‐‑aggregate  transition  that  was  
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Figure  75:  The  CMT  of  fourth  generation  CPP-­‐‑ELPBCs  was  tuned  by  manipulation  of  
the  hydrophobic  block  sequence  composed  of  alanine  and  valine  residues  (X)  in  
varying  ratios.  Temperature-­‐‑regulated  turbidimetry  confirmed  a  range  of  CMTs,  some  
of  which  could  be  feasible  for  hyperthermia-­‐‑triggered  micelle  assembly  in  vivo.  All  
ELPBCs  were  functionalized  with  Arg5  and  characterized  at  25  µμM  in  PBS.  
    217  
Of  the  six  new  CPP-­‐‑ELPBCs,  the  four  constructs  with  the  lower  CMTs  were  
chosen  for  preliminary  characterization  in  mock  serum.  All  constructs  demonstrated  a  
slight  decrease  in  CMT  and  a  more  significant  decrease  of  the  micelle-­‐‑to-­‐‑aggregate  Tt  in  
the  presence  of  90%  FBS  (Figure  76).  Although  this  result  confirmed  a  limited  micelle  
range  in  the  presence  of  serum,  it  was  encouraging  to  see  that  these  fourth  generation  
ELPBCs  could  support  the  self-­‐‑assembly  of  Arg5-­‐‑functionalized  micelles  in  the  presence  
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Figure  76:  Temperature-­‐‑regulated  turbidimetry  of  fourth  generation  Arg5-­‐‑ELPBCs  at  25  
µμM  in  90%  FBS  demonstrated  their  potential  behaviors  in  blood.  All  constructs  
demonstrated  a  decreased  CMT  and  micelle-­‐‑to-­‐‑aggregate  Tt  in  the  presence  of  serum.  
The  two  ELPBCs  who  displayed  a  CMT  closest  to  37-­‐‑42  °C  were  then  selected  
from  this  family  of  four  ELPBCs  and  their  concentration-­‐‑dependent  temperature-­‐‑
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triggered  micelle  assembly  was  measured  over  a  range  of  5-­‐‑100  µμM.  Evaluation  of  the  
CMT  with  respect  to  concentration  would  provide  insight  into  what  dose  was  best  to  
inject  in  vivo,  and  how  wide  a  concentration  range  was  permitted  in  which  the  CMT  
would  remain  between  37  °C  and  42  °C.  The  ELPBC  with  hydrophobic  block  
(XGVPG)80[X=A:V=4:6]  was  selected  as  the  ideal  candidate,  as  its  CMT  remained  
between  37  °C  and  42  °C  over  a  concentration  range  of  10  to  100  µμM  (Figure  77).  This  
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Figure  77:  Temperature-­‐‑regulated  turbidimetry  was  used  to  measure  the  thermal  
behavior  of  Arg5-­‐‑ELPBCs  whose  hydrophobic  blocks  contained  guest  residues  
X=A:V=1:4  or  X=A:V=4:6  in  90%  FBS  over  a  concentration  range  from  5-­‐‑100  µμM.  The  
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ELPBC  with  hydrophobic  guest  residues  X=A:V=4:6  was  selected  for  further  analysis  in  
vivo,  as  its  CMT  remained  between  37  °C  and  42  °C  over  a  concentration  range  of  10-­‐‑
100  µμM,  ensuring  temperature-­‐‑triggered  micelle  assembly  in  vivo  over  the  course  of  
hyperthermia  treatment  as  the  ELP  is  gradually  cleared  from  the  blood.  
With  a  chosen  ELPBC,  a  family  of  constructs  was  then  thoroughly  characterized  
prior  to  its  evaluation  in  vivo.  This  ELPBC,  MGCGWPG-­‐‑(XGVPG)80[X=A:V=4:6]-­‐‑
(SGVPG)80-­‐‑PGGSRn  was  functionalized  with  Arg5  or  Arg8  to  evaluate  those  CPPs  that  
encompassed  the  breadth  of  charge  and  the  breadth  of  cellular  uptake  as  determine  by  
in  vitro  studies.  These  CPP-­‐‑ELPBCs  and  a  non-­‐‑functionalized  control  were  first  
characterized  in  PBS  across  a  concentration  range  of  5-­‐‑100  µμM  (Figure  78A-­‐‑C).  The  
turbidimetry  curves  for  Arg8-­‐‑ELPBC  looked  different  than  those  for  Arg5-­‐‑ELPBC  or  ELPBC,  
suggesting  differences  in  the  stability  of  micelle  formation  between  these  constructs.  The  
CMT  was  approximated  from  turbidimetry  curves  and  plotted  versus  concentration  
(Figure  78D).  Arg5-­‐‑ELPBC  and  non-­‐‑functionalized  ELPBC  demonstrated  nearly  identical  
CMTs  over  the  concentration  range,  all  between  40  °C  and  45  °C  over  5-­‐‑100  µμM.  Arg8-­‐‑
ELPBC  however,  displayed  a  depressed  CMT  that  dropped  below  37  °C  at  concentrations  
above  25  µμM.  
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Figure  78:  Optimized  fourth  generation  ELPBC  was  characterized  with  Arg5  (A),  Arg8  
(B),  or  no  functionalization  (C)  across  a  range  of  concentrations  in  PBS.  While  a  CMT  
between  40-­‐‑45  °C  was  conserved  for  Arg5-­‐‑ELPBC  and  ELPBC,  the  CMT  was  depressed  
for  Arg8-­‐‑ELPBC,  dropping  below  37  °C  at  concentrations  above  25  µμM  (D).  
This  characterization  was  then  repeated,  this  time  in  90%  FBS  to  mimic  the  
environment  in  circulation.  Again  the  turbidimetry  curves  for  Arg8-­‐‑ELPBC  looked  
significantly  different  than  those  for  Arg5-­‐‑ELPBC  or  non-­‐‑functionalized  ELPBC  (Figure  
79A-­‐‑C).  However,  this  time  the  Arg8-­‐‑ELPBC  did  not  appear  to  exhibit  temperature-­‐‑
triggered  micelle  assembly,  but  rather  appeared  to  transition  from  unimer  to  aggregate  
in  the  presence  of  mock  serum.  This  suggested  that  Arg8-­‐‑ELPBC  would  not  display  the  
desired  hyperthermia-­‐‑triggered  micelle  assembly  in  vivo.  So,  although  the  optimized  
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fourth  generation  ELPBC  could  improve  stable  micelle  formation  to  support  the  assembly  
of  Arg5-­‐‑functionalized  micelles,  it  could  not  do  the  same  for  Arg8-­‐‑functionalized  
constructs.  Arg5-­‐‑ELPBC  and  non-­‐‑functionalized  ELPBC,  however,  continued  to  display  a  
well-­‐‑conserved  CMT  between  constructs  and  across  concentrations  (Figure  79D).  Each  
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Figure  79:  Optimized  fourth  generation  ELPBC  was  characterized  with  Arg5  (A),  Arg8  
(B),  or  no  functionalization  (C)  across  a  range  of  concentrations  in  90%  FBS  to  mimic  
the  environment  in  circulation.  While  a  CMT  between  37-­‐‑44  °C  was  conserved  for  
Arg5-­‐‑ELPBC  and  ELPBC  (D),  the  Arg8-­‐‑ELPBC  did  not  self-­‐‑assemble  into  micelles  in  mock  
serum,  but  rather  exhibited  a  unimer-­‐‑to-­‐‑aggregate  transition.  
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Due  to  confounding  results  with  the  third  generation  Arg5-­‐‑ELPBC  thermal  
behavior  and  its  visualization  in  vivo,  it  was  a  concern  that  perhaps  90%  FBS  was  not  an  
appropriate  solution  in  which  to  approximate  the  serum  conditions  in  vivo.  90%  FBS  has  
been  used  extensively  in  the  Chilkoti  lab  as  a  mock  serum  solution  [188]  and  has  
provided  similar  results  to  3  mM  BSA,  another  mock  serum  solution  whose  effect  on  
ELP  Tt  has  been  verified  with  comparison  to  mouse  serum.  However,  to  cross  check  the  
results  seen  in  the  mock  serum  of  90%  FBS,  thermal  characterization  was  further  
performed  in  mouse  serum.  In  this  experiment  fluorophore-­‐‑labeled  ELPBCs  were  injected  
intravenously  by  tail  vein  and  then  blood  was  collected  immediately  from  the  mouse  by  
heart  puncture.  Cells  were  removed  from  the  collected  blood  by  centrifugation  and  the  
resulting  liquid  was  characterized  by  temperature-­‐‑regulated  turbidimetry.    
The  first  attempt  to  analyze  the  ELPBC  micelle  assembly  in  mouse  serum  was  
performed  in  balb/c  mice  with  fourth  generation  Arg8-­‐‑ELPBC,  Arg5-­‐‑ELPBC,  and  an  ELPBC  
control.  The  collected  blood  was  heparinized  to  yield  serum,  which  was  diluted  with  
PBS  to  reach  the  volume  requirements  for  solution  analysis  by  temperature-­‐‑regulated  
turbidimetry.  All  three  constructs  demonstrated  turbidimetry  curves  that  suggested  a  
unimer-­‐‑to-­‐‑micelle  transition  between  40-­‐‑45  °C,  where  Arg8-­‐‑ELPBC  surprisingly  did  not  
portray  a  drastic  increase  in  absorbance  that  suggested  its  complete  aggregation  in  
serum,  contradicting  the  results  obtained  in  the  mock  serum  of  90%  FBS  (Figure  80A).    
  
















































Figure  80:  Temperature-­‐‑regulated  turbidimetry  was  attempted  in  mouse  serum  to  
approximate  CPP-­‐‑ELPBC  behavior  in  vivo.  The  first  attempt  (A)  and  modified  second  
attempt  (B)  both  supported  the  expected  micelle  assembly  of  Arg5-­‐‑ELPBC  and  ELPBC,  
but  neither  attempt  provided  sufficient  support  that  Arg8-­‐‑ELPBC  would  exhibit  
temperature-­‐‑triggered  aggregation  in  blood.  
Upon  further  reflection,  it  was  questionable  whether  several  aspects  of  this  
protocol  could  have  contributed  to  this  unexpected  result  for  Arg8-­‐‑ELPBC.  First,  the  
addition  of  heparin  to  these  samples  may  have  interacted  with  the  positively  charged  
CPP-­‐‑ELPBCs,  removing  some  fraction  of  material  along  with  the  cells  and  coagulation  
factors  in  the  centrifugation  step.  Second,  the  dilution  of  samples  to  meet  the  volume  
requirements  of  turbidimetry  measurements  may  have  reduced  the  concentration  of  
serum  proteins  to  the  extent  that  Arg8-­‐‑ELPBC  could  self-­‐‑assemble  in  this  diluted  serum.  
Third,  both  of  the  factors  above  may  have  resulted  in  the  decrease  of  Arg8-­‐‑ELPBC  to  a  
concentration  that  would  not  aggregate  at  the  temperatures  measured.  This  may  have  
contributed  to  the  CMT  of  all  constructs  at  temperatures  higher  than  what  is  preferable  
for  hyperthermia-­‐‑triggered  micelle  assembly  at  42  °C.  
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To  address  these  potentially  confounding  factors,  this  experiment  was  
reattempted  in  a  new  format.  Arg8-­‐‑ELPBC,  Arg5-­‐‑ELPBC,  and  ELPBC  were  intravenously  
injected,  this  time  into  nude  mice  due  to  their  apparent  increased  blood  volume,  as  
compared  to  balb/c  mice.  The  increased  blood  volume  of  this  mouse  strain  should  help  
prevent  the  need  for  dilution  for  turbidimetry  measurements.  The  blood  was  collected  
immediately  via  heart  puncture,  but  this  time  no  heparin  was  added  so  the  blood  was  
stored  on  ice  and  allowed  to  clot.  Again  the  blood  was  centrifuged  to  remove  cells  and  
clotted  factors.  The  fluorescence  of  the  supernatant  was  then  measured  to  back-­‐‑calculate  
the  concentration  of  the  ELPBC  based  on  standard  curves  of  each  treatment,  to  ensure  
that  a  significant  amount  of  the  constructs  was  not  lost  in  the  process  of  recovery  from  
the  blood  sample.  If  necessary,  the  samples  were  pooled  between  mice  receiving  the  
same  treatment  to  meet  the  volume  requirements  for  turbidimetry  measurements  and  
prevent  the  need  for  sample  dilution.    
In  this  modified  second  attempt  at  evaluating  the  thermal  behavior  of  CPP-­‐‑
ELPBCs  in  mouse  serum  the  turbidimetry  curves  exhibited  a  gradual  decrease  in  
absorbance  as  the  temperature  increased,  then  exhibited  an  inflection  point  near  the  
expected  CMT  of  40  °C,  based  on  their  back-­‐‑calculated  concentration,  and  increased  in  
absorbance  thereafter  as  temperature  continued  to  rise  (Figure  80B).  This  behavior,  
however,  was  less  evident  for  the  Arg8-­‐‑ELPBC,  as  compared  to  the  Arg5-­‐‑ELPBC  or  non-­‐‑
functionalized  ELPBC,  perhaps  suggesting  a  different  behavior  for  this  most  highly  
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charged  construct.  However,  Arg8-­‐‑ELPBC  more  closely  resembled  the  control  curve  from  
a  mouse  receiving  no  ELP  treatment,  which  did  not  change  absorbance  over  the  
temperatures  examined.  Still,  there  was  no  strong  evidence  from  the  mouse  serum  
experiments  that  supported  that  Arg8-­‐‑ELPBC  would  undergo  only  a  unimer-­‐‑to-­‐‑aggregate  
transition  in  blood.  It  thus  remained  unclear  what  approach  was  best  to  approximate  the  
behavior  in  vivo  using  ex  vivo  turbidimetry  measurements.  
5.3.5 Evaluation of fourth generation CPP-ELPBCs in vivo 
Fourth  generation  CPP-­‐‑ELPBCs  were  characterized  as  best  as  possible  ex  vivo  in  
attempts  of  creating  a  material  that  would  behave  predictably  in  the  in  vivo  setting.  
Further  characterization  of  these  constructs  was  then  attempted  by  means  of  evaluating  
their  functional  performance  as  carriers  in  vivo.  Pharmacokinetics  was  again  the  first  
parameter  to  be  tested  in  vivo  to  provide  insight  into  the  best  dosage  and  the  range  of  
concentration  that  could  be  maintained  in  the  blood  over  time.  
Mice  were  injected  intravenously  with  Alexa  Fluor  488-­‐‑labeled  fourth  generation  
CPP-­‐‑ELPBC  or  non-­‐‑functionalized  ELPBC  and  blood  was  sampled  from  the  tail  vein  over  
the  course  of  24  hours.  The  fluorescence  of  the  sampled  blood  at  each  time  point  was  
used  to  determine  the  blood  concentration  of  the  CPP-­‐‑ELPBC  based  on  standard  curves  
from  the  injected  construct.  Charge  played  an  important  factor  in  the  clearance  of  fourth  
generation  CPP-­‐‑ELPBCs  from  circulation.  The  ELPBC  control  exhibited  the  most  
prolonged  circulation,  while  in  comparison,  Arg5-­‐‑ELPBC  was  cleared  slightly  more  
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quickly  and  Arg8-­‐‑ELPBC  was  cleared  the  fastest  from  circulation  (Figure  81).    However,  
all  constructs  maintained  a  concentration  of  20  µμM  or  greater  over  the  course  of  2  hours,  
such  that  a  CMT  between  37  °C  and  42  °C  should  be  achieved  at  this  concentration  over  





















































Figure  81:  CPP-­‐‑functionalization  led  to  more  rapid  clearance  of  fourth  generation  
CPP-­‐‑ELPBCs,  where  Arg8-­‐‑ELPBC  was  cleared  the  fastest  from  circulation.  Yet  all  
constructs  maintained  a  blood  concentration  of  greater  than  20  µμM  over  the  course  of  
2  hours  (inset).  CPP-­‐‑ELPBCs  and  non-­‐‑functionalized  ELPBC  were  delivered  
intravenously  at  a  final  blood  concentration  of  100  µμM.  
Approximation  of  the  pharmacokinetic  parameters  supported  the  trend  
visualized  in  clearance  profiles,  whereby  non-­‐‑functionalized  ELPBC  achieved  the  greatest  
AUC  as  compared  to  Arg5-­‐‑ELPBC  or  Arg8-­‐‑ELPBC  (Table  17).  However,  Arg5-­‐‑ELPBC  was  
actually  approximated  to  have  a  longer  elimination  half-­‐‑life,  as  compared  to  ELPBC,  
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although  the  subtle  difference  in  this  parameter  suggested  that  the  Arg5-­‐‑
functionalization  was  not  detrimental  to  the  clearance  of  this  construct.  The  effect  of  
Arg8-­‐‑functionalization,  however,  was  much  greater  and  indeed  the  data  obtained  from  
this  pharmacokinetic  experiment  were  difficult  to  fit  to  pharmacokinetic  parameters,  
perhaps  due  to  their  rapid  decline  in  concentration  at  early  time  points.  Interestingly,  
fourth  generation  constructs  all  exhibited  faster  clearance,  as  determined  by  
approximated  pharmacokinetic  parameters,  as  compared  to  third  generation  constructs,  
despite  their  increased  molecular  weight.  This  was  likely  due  to  the  change  in  the  
quantification  of  data  between  these  experiments,  whereby  third  generation  constructs  
were  normalized  to  early  time  points  that  were  assumed  to  be  near  the  delivered  dose,  
whereas  fourth  generation  constructs  were  evaluated  by  actual  concentration  values  
back-­‐‑calculated  from  their  fluorescence.  The  later  approach  improved  the  quantitative  
validation  of  circulating  CPP-­‐‑ELPBCs  and  controls,  thus  suggesting  that  previous  data  for  
third  generation  carriers  more  than  likely  overestimated  the  pharmacokinetic  
performance.  
Table  17:  Pharmacokinetic  parameters  of  fourth  generation  CPP-­‐‑ELPBCs  and  control.  
*Arg8-­‐‑ELPBC  clearance  could  not  be  confidently  fit  to  determine  some  parameters,  the  
unreasonably  high  SD  suggested  they  should  be  used  only  for  qualitative  
comparison.  
Construct   α  t1/2  (minute)   β  t1/2  (hour)   AUC  (µμMh)  
ELPBC   7.5  ±  0.8   6.8  ±  0.1   377.4  ±  5.9  
Arg5-­‐‑ELPBC   9.4  ±  1.0   7.2  ±  0.2   325.9  ±  7.3  
Arg8-­‐‑ELPBC   0.6  *   5.8  ±  0.3   220.9*  
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Pharmacokinetics  suggested  that  all  constructs  would  maintain  the  necessary  
concentration  in  circulation  over  the  course  of  1  hour  to  exhibit  a  CMT  between  37  °C  
and  42  °C  and  thus  provide  hyperthermia-­‐‑triggered  self-­‐‑assembly  in  vivo.  The  effect  of  
hyperthermia-­‐‑triggered  micelle  assembly  was  first  evaluated  in  vivo  by  visualizing  the  
interaction  of  constructs  with  the  tumor  vascular  and  extravascular  space  using  
intravital  microscopy.  CPP-­‐‑ELPBC  was  injected  systemically  and  the  tumor  space  was  
imaged  over  the  course  of  1  hour  while  heated  to  37  °C  or  42  °C.  At  the  end  of  imaging,  
dextran  was  injected  to  mark  the  vascular  space  and  Hoechst  was  injected  to  locate  
cellular  nuclei.    
Non-­‐‑functionalized  ELPBC  administered  to  non-­‐‑heated  tumors  was  confined  to  
the  vascular  space  immediately  after  injection  (Figure  82).  Over  the  course  of  1  hour  the  
ELPBC  traversed  from  the  vascular  to  the  extravascular  space,  leading  to  fluorescence  
across  the  entire  imaging  window.  Dextran  labeling  confirmed  that  although  the  ELPBC  
did  extravasate,  a  portion  of  the  construct  did  still  remain  in  the  vasculature  at  1  hour.  
Hoechst  staining  demonstrated  that  the  fluorescence  in  the  extravascular  space  was  not  
localized  specifically  to  cells,  marked  by  their  nuclei,  in  the  tissue.  The  extravasation  
pattern  was  similar  for  ELPBC  in  a  tumor  heated  to  42  °C,  suggesting  that  the  
accumulation  of  ELPBC  in  the  extravascular  space  was  not  affected  significantly  by  tumor  
hyperthermia.  
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Figure  82:  Intravital  imaging  of  ELPBC  demonstrated  accumulation  in  the  extravascular  
space  over  the  course  of  1  hour  that  did  not  change  significantly  with  tumor  
hyperthermia.  Green—ELP;  red—vascular  mask;  blue—cell  nuclei;  acquired  at  20x.  
The  behavior  of  Arg5-­‐‑ELPBC  did  not  appear  to  be  distinctively  different  than  the  
control  non-­‐‑functionalized  ELPBC.  Similarly  to  that  seen  with  ELPBC,  Arg5-­‐‑ELPBC  was  at  
first  confined  to  the  vascular  space  and  extravasated  into  the  tumor  tissue  over  1  hour  
(Figure  83).  The  degree  or  specificity  of  extravasation  didn’t  seem  to  change  significantly  
with  tumor  hyperthermia,  suggesting  that  differences  between  unimer  and  micelle  Arg5-­‐‑
ELPBC,  if  any,  were  not  easily  visualized.  Subtle  differences  may,  however,  be  revealed  
by  more  thorough  image  processing  to  quantify  parameters  such  as  extravasation,  
permeability,  and  penetration  using  a  larger  sample  number  of  mice  for  each  treatment  
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condition.  Of  note  however,  were  distinct  areas  in  the  hyperthermia  treated  tumor  that  
strongly  excluded  the  Arg5-­‐‑ELPBC  in  the  extravascular  space.  The  shape  and  association  
of  these  areas  with  an  adjacent  nuclei  suggested  that  these  might  be  adipocytes  that  do  
not  take  up  Arg5-­‐‑ELPBC  into  their  fat  reservoirs.  
  
  
Figure  83:  Intravital  imaging  of  Arg5-­‐‑ELPBC  demonstrated  accumulation  in  the  
extravascular  space  over  the  course  of  1  hour  that  did  not  change  significantly  with  
tumor  hyperthermia.  The  extravasation,  with  time,  did  not  appear  to  differ  greatly  
from  the  non-­‐‑functionalized  ELPBC  control.  Green—ELP;  red—vascular  mask;  blue—
cell  nuclei;  acquired  at  20x.  
Intravital  imaging  of  Arg8-­‐‑ELPBC  in  a  hyperthermia  treated  tumor  demonstrated  
a  different  behavior  than  that  seen  with  Arg5-­‐‑ELPBC  or  ELPBC.  Arg8-­‐‑ELPBC  looked  similar  
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to  the  other  constructs  upon  injection,  with  relatively  homogenous  fluorescence  
confined  to  the  vascular  space.  However,  Arg8-­‐‑ELPBC  quickly  aggregated  in  the  heated  
tumor  as  indicated  by  the  formation  of  punctate  fluorescence  in  the  vasculature  at  20  
minutes  (Figure  84).  To  confirm  that  this  punctate  fluorescence  was  a  result  of  the  ELP  
aggregation,  and  not  an  interaction  of  the  construct  with  the  vasculature,  the  tumor  was  
cooled  to  below  37  °C.  The  punctate  fluorescence  disappeared  as  the  aggregated  ELP  
resolubilized  and  continued  to  circulate  in  the  vasculature.  Visualization  of  the  Arg8-­‐‑
ELPBC  therefore  finally  clarified  the  confounding  findings  made  in  trying  to  predict  the  
behavior  of  this  construct  in  vivo  and  confirmed  that  Arg8-­‐‑ELPBC  did  aggregate  in  
circulation.  Furthermore  this  validated  the  use  of  90%  FBS  as  a  mock  serum,  as  it  best  
predicted  the  behavior  of  Arg8-­‐‑ELPBC,  which  was  confirmed  by  intravital  imaging  in  a  
hyperthermia  treated  tumor.  
  
  
Figure  84:  Intravital  imaging  of  Arg8-­‐‑ELPBC  demonstrated  aggregation  in  a  
hyperthermia  treated  tumor.  Punctate  fluorescence  confirmed  that  Arg8-­‐‑ELPBC  
aggregated  in  hyperthermia-­‐‑treated  tumors  and  could  be  resolubilized  when  the  
tumor  was  cooled  below  37  °C.    Green—ELP;  blue—cell  nuclei;  acquired  at  20x.  
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Although  there  were  no  obvious  differences  between  the  behavior  of  Arg5-­‐‑ELPBC  
and  ELPBC  as  visualized  by  intravital  microscopy,  and  although  Arg8-­‐‑ELPBC  aggregated  
as  opposed  to  forming  micelles  in  response  to  hyperthermia  in  vivo,  the  biodistribution  
of  these  constructs  in  tumor  and  critical  organs  was  evaluated  as  an  alternative  approach  
to  identify  differences,  if  any,  between  the  in  vivo  behavior  of  these  constructs  that  could  
shed  light  on  their  potential  to  achieve  tumor-­‐‑targeted  accumulation  in  response  to  a  
hyperthermia  trigger.  
Biodistribution  was  evaluated  in  critical  organs  and  tumors,  treated  with  
hyperthermia  or  receiving  no  heat,  for  fourth  generation  Arg8-­‐‑ELPBC,  Arg5-­‐‑ELPBC,  and  
non-­‐‑functionalized  ELPBC  control.  In  one  group  of  animals  the  organs  were  collected  and  
the  dose  in  each  organ  was  quantified  at  approximately  2  hours  after  administration.  In  
a  second  group  of  animals  the  organs  were  collected  and  dose  in  each  organ  was  
quantified  at  approximately  24  hours  after  administration.  This  extended  time  point  was  
included  to  investigate  if  CPP-­‐‑ELPBCs  may  provide  an  advantage  of  prolonged  presence  
in  the  tumor,  as  compared  to  non-­‐‑functionalized  ELPBC,  by  means  of  their  intended  local  
internalization  with  hyperthermia-­‐‑triggered  micelle  assembly  in  the  tumor.  
Biodistribution  data  retrieved  2  hours  after  administration  revealed  several  
interesting  points  about  the  uptake  in  various  organs  of  these  fourth  generation  CPP-­‐‑
ELPBCs  (Figure  85A-­‐‑C).  First,  none  of  the  constructs  appeared  to  accumulate  significantly  
in  the  muscle,  heart,  lung,  or  spleen,  with  slightly  increased  accumulation  in  the  liver  in  
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all  cases.  Second,  despite  the  increased  size  of  these  fourth  generation  ELPBCs  there  was  
still  the  most  significant  amount  of  the  dose  present  in  the  kidney,  albeit  at  lower  levels  
than  was  observed  in  the  smaller  third  generation  constructs.  This  persistent  
accumulation  in  the  kidney,  despite  the  increased  molecular  weight  of  the  ELPBC,  may  
suggest  specific  interaction  of  the  CPP-­‐‑ELPBC  with  the  kidney  tissue.  Higher  salt  
concentration  in  the  kidney  tissue,  for  example,  could  induce  aggregation  of  CPP-­‐‑ELPBCs  
and  result  in  their  prolonged  presence  in  the  kidney.  Third,  all  constructs  showed  
accumulation  in  the  tumor  higher  than  the  muscle  at  either  thermal  condition,  
demonstrating  a  passive  mechanism  of  tumor  uptake  in  all  cases.  Finally,  accumulation  
in  the  tumor  followed  a  subtle  trend  dependent  on  carrier  and  tumor  heating  (Figure  
85D).  No  difference  in  tumor  accumulation  of  ELPBC  was  seen  between  hyperthermia  
treated  tumor  and  tumor  receiving  no  heat.  Arg5-­‐‑ELPBC  achieved  a  slight  increase  in  
accumulation  with  tumor  hyperthermia  and  temperature-­‐‑triggered  micelle  assembly.  
Arg8-­‐‑ELPBC  achieved  the  greatest  increase  in  accumulation  with  tumor  hyperthermia  
and  temperature-­‐‑triggered  aggregation,  although  this  effect  appears  exaggerated  due  to  
the  lowest  tumor  accumulation  in  non-­‐‑heated  tumor  with  this  construct.  This  increase  in  
tumor  accumulation  of  Arg8-­‐‑ELPBC  with  tumor  hyperthermia  was  statistically  significant  
(p<0.0167  between  thermal  conditions,  two-­‐‑way  ANOVA,  Bonferroni  posthoc  test  for  
multiple  comparisons).  These  trends  exhibit  modest  efficacy,  at  best,  of  a  targeted  carrier  
system  and  suggest  that  of  the  constructs  tested,  a  material  that  aggregates  as  opposed  
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to  assembles  into  predictable  nanoparticle  morphologies,  can  achieve  greater  tumor  
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Figure  85:  Biodistribution  of  fourth  generation  CPP-­‐‑ELPBCs  in  tumor  and  critical  
organs  collected  2  hours  after  administration.  Significant  percentage  of  the  dose  still  
accumulated  in  the  kidney,  despite  the  high  molecular  weight  of  these  constructs.  
Arg5-­‐‑ELPBC  and  Arg8-­‐‑ELPBC  achieved  modest  increase  of  accumulation  in  
hyperthermia-­‐‑treated  tumors,  as  compared  to  tumors  receiving  no  heat.  Data  
represents  mean  of  3-­‐‑4  mice  ±  SEM.  
Biodistribution  data  collected  24  hours  after  administration  confirmed  that  all  
constructs  were  significantly  cleared  from  the  muscle,  heart,  lung,  and  spleen  at  this  
longer  time  point  (Figure  86A-­‐‑C).  Surprisingly  the  high  dose  accumulated  in  the  kidney  
persisted,  as  did  a  lower  percentage  of  dose  in  the  liver.  Tumor  accumulation  at  24  hours  
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remained  higher  than  muscle  as  well,  confirming  the  retention  of  passively  accumulated  
constructs  in  the  tumor.  However,  no  trend  remained  in  tumor  accumulation  at  this  later  
time  point  for  CPP-­‐‑ELPBC  treatment  or  tumor  heating,  such  that  no  significant  difference  
was  detected  for  any  of  the  constructs  between  tumors  treated  with  hyperthermia  and  
those  treated  with  no  heat  (between  thermal  conditions,  two-­‐‑way  ANOVA,  Bonferroni  
posthoc  test  for  multiple  comparisons)  (Figure  86D).  This  suggested  that  constructs  were  
either  cleared  from  the  tumor  or  their  fluorescent  labels  were  destroyed  over  the  course  
of  24  hours  following  administration.  
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Figure  86:  Biodistribution  of  fourth  generation  CPP-­‐‑ELPBCs  in  tumor  and  critical  
organs  collected  24  hours  after  administration.  No  trends  were  evident  between  CPP-­‐‑
ELPBC  treatments  or  between  tumors  receiving  hyperthermia  and  those  receiving  no  
heat  at  this  later  time  point.  Data  represents  mean  of  4  mice  ±  SEM.  
5.4 Conclusions 
A  major  challenge  in  the  translation  of  CPP-­‐‑ELPBCs  for  use  as  stimulus-­‐‑
responsive  carriers  in  the  body  is  the  optimization  of  their  design  to  achieve  their  
intended  behavior  in  vivo.  Starting  from  the  characterization  of  third  generation  CPP-­‐‑
ELPBCs  in  vivo,  it  became  apparent  that  the  size  and  thermal  behavior  of  the  ELPBCs  
optimized  for  in  vitro  studies  were  not  appropriate  for  in  vivo  studies.  A  new  family  of  
CPP-­‐‑ELPBCs—the  fourth  generation  constructs—were  redesigned  in  such  a  way  to  have  
an  increased  molecular  weight,  in  hopes  of  avoiding  renal  clearance,  increased  
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hydrophilicity  in  the  corona,  to  encourage  stable  assembly  of  micelles  decorated  with  
positive  charge  in  the  presence  of  serum  proteins,  and  a  conserved  thermal  response  to  
hyperthermia,  such  that  unimers  at  37  °C  could  assemble  into  micelles  at  42  °C.    
With  an  optimized  family  of  CPP-­‐‑ELPBCs,  it  was  apparent  that  characterization  
should  be  performed  in  conditions  that  would  attempt  to  mimic  the  complex  
environment  that  the  carriers  would  be  exposed  to  upon  systemic  injection  in  a  living  
system.  FBS  and  mouse  serum  were  employed  to  best  choose  the  ELPBC  that  would  
perform  properly  and  predictively  in  vivo.  However,  confounding  results  between  these  
mock  serum  conditions  made  it  unclear  whether  or  not  the  most  heavily  charged  
construct,  Arg8-­‐‑ELPBC,  could  self-­‐‑assemble  into  micelles  in  blood  or  if  the  high  charge  
density  of  this  carrier  caused  it  to  transition  directly  from  unimer  to  aggregate  in  
circulation.  
The  ultimate  characterization  of  CPP-­‐‑ELPBCs  was  a  measurement  of  its  function  
based  on  circulation  time,  interaction  with  the  tumor  tissue,  and  biodistribution.  Not  
surprisingly,  increased  charge  led  to  decreased  circulation  time  as  measured  by  
pharmacokinetics,  but  all  constructs  appeared  to  maintain  a  blood  concentration  that  
was  sufficient  for  hyperthermia-­‐‑targeted  self-­‐‑assembly  over  the  required  1  hour  for  
hyperthermia  treatment  following  CPP-­‐‑ELPBC  administration.  Intravital  imaging  was  
used  to  visualize  the  interaction  of  CPP-­‐‑ELPBCs  with  the  tumor  vasculature  and  
extravascular  space.  No  significant  differences  in  extravascular  accumulation  or  
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localization  of  Arg5-­‐‑ELPBC  was  seen  as  compared  between  heated  and  non-­‐‑heated  
tumors  or  compared  to  the  ELPBC  control.  However,  intravital  imaging  did  elucidate  the  
thermal  behavior  of  Arg8-­‐‑ELPBC,  confirming  that  it  did  aggregate  in  hyperthermia  
treated  tumors  and  could  be  resolubilized  with  tumor  cooling.  
Biodistribution  studies  had  the  potential  to  reveal  information  about  the  bigger  
picture  of  tumor-­‐‑targeted  delivery  in  terms  of  quantifying  the  accumulation  in  the  
tumor  and  other  off-­‐‑target  organs.  Modest  trends  in  tumor  accumulation  suggested  that  
Arg5-­‐‑ELPBC  and  Arg8-­‐‑ELPBC  achieved  increased  accumulation  in  hyperthermia  treated  
tumors,  as  compared  to  non-­‐‑heated  tumors,  whereas  non-­‐‑functionalized  ELPBC  showed  
no  difference  in  accumulation  between  thermal  conditions.  From  the  biodistribution  
studies  of  fourth  generation  CPP-­‐‑ELPBCs  the  concern  remained  regarding  the  high  
percentage  of  dose  accumulating  in  the  kidney,  which  persisted  for  at  least  24  hours  
after  administration,  despite  the  increased  molecular  weight  of  these  constructs.  It  was  
unclear  if  these  results  suggested  that  free  fluorophore  was  easily  removed  from  the  
labeled  construct  in  vivo  and  if  this  signal  was  attributed  to  the  clearance  of  these  small  
molecules.  If  this  was  the  case,  it  is  unclear  why  this  signal  persisted  for  so  long,  as  
opposed  to  these  molecules  being  cleared  from  the  body.    
In  summary,  successful  tumor-­‐‑targeted  delivery  of  CPP-­‐‑ELPBCs  by  means  of  their  
hyperthermia-­‐‑triggered  micelle  assembly  was  not  achieved  with  the  generations  of  
constructs  that  progressively  improved  upon  the  qualities  and  functions  of  the  CPP-­‐‑
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ELPBC  platform.  Although  evidence  of  significantly  enhanced  tumor  accumulation  was  
not  found,  that  is  not  to  say  that  there  could  be  other  advantages  of  CPP-­‐‑ELPBC  delivery,  
for  example,  if  these  carriers  could  still  improve  upon  the  internalization,  beyond  
accumulation,  of  the  carrier  and  its  drug  cargo.  Optimized  CPP-­‐‑ELPBC  drug  carriers  with  
drug  cargo  and  conserved  thermal  properties  could  next  address  this  therapeutic  
measure  of  CPP-­‐‑ELPBC  function  in  vivo.  
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6. Conclusions and future directions 
6.1 Conclusions 
Although  this  dissertation  does  not  conclude  by  achieving  the  ultimate  goal  of  
targeted  drug  delivery,  a  great  deal  was  learned  along  the  way  about  the  design  and  
application  of  ELPBCs  as  stimulus-­‐‑responsive  carriers.  The  efforts  described  here  
contributed  to  the  synthesis,  characterization,  and  optimization  of  ELPBC  materials,  
shedding  light  on  the  parameters  that  can  assist  in  predictable  design  of  tunable  
stimulus-­‐‑responsive  ELPBC  self-­‐‑assembly.  Within  the  Chilkoti  Lab,  this  work  embodies  
the  first  application  of  ELPBCs  for  the  controlled  delivery  of  drug  cargo  manipulated  by  
the  clinically  relevant  stimulus  of  mild  hyperthermia.    
6.1.1 ELPBCs as tunable stimulus-responsive biopolymers 
The  LCST  phase  transition  behavior  of  ELPs  is  highly  tunable  by  both  intrinsic  
design  parameters  and  extrinsic  environmental  factors.  Large  libraries  of  homopolymer  
and  pseudorandom  ELPs  have  been  synthesized  and  characterized  to  build  models  that  
can  predict  the  ELP  transition  temperature  as  a  function  of  intrinsic  parameters  
including  ELP  length,  concentration,  and  sequence  [102,  187].  Predictive  design  of  
ELPBCs  with  desirable  thermal  properties,  such  as  CMT  and  micelle-­‐‑to-­‐‑aggregate  
transition  temperature,  is  a  more  complicated  problem.  Although  progress  is  being  
made  in  modeling  the  design  and  behavior  of  ELPBCs  [127],  to  create  a  ELPBC  with  novel  
functionalization  at  its  N-­‐‑  and  C-­‐‑terminus  while  achieving  precisely  defined  thermal  
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behavior  still  requires  a  great  deal  of  iterative  material  synthesis,  characterization,  and  
optimization.  Using  those  design  principles  known  for  homopolymer  and  
pseudorandom  ELPs,  characteristics  of  each  of  the  blocks  in  the  ELPBC  can  be  changed  to  
manipulate  the  thermal  properties  of  the  construct.  This  design  process  was  repeated  
several  times  to  achieve  ELPBCs  that  displayed  the  desired  thermal  properties,  existing  as  
soluble  unimers  at  37  °C,  while  self-­‐‑assembling  into  spherical  micelles  at  42  °C,  while  
accommodating  CPP  functionalization  at  the  C-­‐‑terminus  and  drug  loading  at  the  N-­‐‑
terminus  of  the  ELPBC.  
6.1.2 CPP-ELPBCs for controlled cellular uptake in vitro 
The  hypothesis  driving  the  design  of  the  CPP-­‐‑ELPBC  platform  was  that  
manipulation  of  CPP  density  with  micelle  assembly  could  control  cellular  uptake.  In  this  
case  of  ELPBCs,  this  self-­‐‑assembly  was  achieved  by  means  of  a  thermal  stimulus,  creating  
the  possibility  to  control  cellular  uptake  by  a  clinically  relevant  external  trigger.  
Successful  design  of  CPP-­‐‑ELPBCs  with  a  CMT  between  37  °C  and  42  °C  allowed  this  
hypothesis  to  be  tested  in  vitro  and  evaluated  by  the  internalization  of  fluorescently  
labeled  constructs.  As  hypothesized,  CPP-­‐‑ELPBCs  demonstrated  enhanced  cellular  
uptake  at  42  °C,  as  compared  to  37  °C,  demonstrating  the  effect  of  manipulating  CPP  
density  to  modulate  cellular  internalization.  Neither  non-­‐‑functionalized  ELPBC  or  soluble  
CPP-­‐‑ELP  unimer  controls  displayed  a  change  in  uptake  between  thermal  conditions,  
confirming  that  micelle  assembly  and  hyperthermia  alone  were  not  responsible  for  this  
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effect  of  amplified  cell  uptake  at  hyperthermic  conditions.  The  magnitude  of  uptake  at  
the  “off”  state  of  37  °C  and  the  magnitude  of  amplified  uptake  at  the  “on”  state  of  42  °C  
were  tunable  by  means  of  the  CPP-­‐‑functionalization  of  the  ELPBC.    
Although  the  mechanism  of  uptake  of  CPP-­‐‑ELPBCs  was  not  thoroughly  
characterized,  preliminary  analysis  suggested  that  these  materials  exploited  pathways  of  
macropinocytosis  or  caveolae-­‐‑mediated  endocytosis  more  so  than  that  of  clathrin-­‐‑
mediated  endocytosis,  typical  of  receptor-­‐‑mediated  internalization.  More  complete  
analysis  of  the  mechanism  of  uptake  and  intracellular  localization  of  CPP-­‐‑ELPBCs  could  
better  direct  their  design  as  drug  carriers  to  deliver  intact  drug  cargo  to  their  
intracellular  therapeutic  target.  
6.1.3 CPP-ELPBCs for controlled drug delivery in vitro 
The  controlled  cellular  uptake  of  CPP-­‐‑ELPBCs  suggested  that  any  drug  cargo  
associated  with  these  carriers  could  also  be  selectively  delivered  into  the  cell  and  thereby  
achieve  a  controlled  therapeutic  effect.  This  translation  of  controlled  cell  uptake  to  
controlled  drug  delivery  and  controlled  therapeutic  effect  was,  however,  complicated  by  
the  variable  effect  of  drug  conjugation  on  the  thermal  behavior  of  the  CPP-­‐‑ELPBC  carrier.  
Many  types  of  drugs  have  been  appended  to  homopolymer  and  pseudorandom  ELPs,  
including  small  molecules,  peptides,  and  proteins,  but  this  was  the  first  attempt  in  the  
Chilkoti  lab  to  attach  a  drug  at  the  hydrophobic  terminus  of  an  ELPBC  while  having  
minimal  tolerance  for  the  perturbation  of  temperature-­‐‑triggered  self-­‐‑assembly.  This  
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restriction  of  the  effect  of  drug  attachment  on  the  ELPBC  CMT  limited  the  choice  of  drug  
cargo.    
Preliminary  investigation  into  the  covalent  attachment  of  small  molecule  
chemotherapeutics  to  genetically  engineered  cysteine  residues  at  the  hydrophobic  block  
terminus  revealed  the  complexity  of  using  this  class  of  drug  with  CPP-­‐‑ELPBC  carriers.  A  
hydrophilic  small  molecule  drug  must  be  used  to  avoid  inducing  premature  self-­‐‑
assembly  of  the  CPP-­‐‑ELPBC  by  means  of  the  hydrophobic  effect.  However,  attachment  of  
hydrophilic  drugs  drives  up  the  CMT,  requiring  elevated  concentration  of  drug  carrier  
to  compensate  for  changes  in  thermal  behavior  such  that  unimer  and  micelle  conditions  
can  be  achieved  at  37  °C  and  42  °C,  respectively.  These  high  drug  concentrations  seemed  
to  be  overwhelmingly  cytotoxic  in  vitro,  obliterating  any  controlled  therapeutic  effect.  
Furthermore  the  pursuit  of  increased  drug  loading  with  this  approach  created  an  
opposite  problem,  whereby  an  increased  number  of  cysteine  residues  for  drug  loading  
induced  a  decrease  in  CMT  likely  due  to  inter-­‐‑ELP  disulfide  bonding  that  encouraged  
premature  self-­‐‑assembly.  Unfortunately  the  effects  of  attaching  the  hydrophilic  drug  did  
not  reverse  this  effect  significantly,  such  that  CPP-­‐‑ELPBCs  with  higher  drug  loading  
could  not  be  tested  for  hyperthermia-­‐‑targeted  drug  delivery.  An  extensive  amount  of  
CPP-­‐‑ELPBC  optimization  would  be  required  to  achieve  the  desired  thermal  properties  of  
CPP-­‐‑ELPBCs  covalently  loaded  with  small  molecule  drugs.  Therefore  an  alternative  drug  
cargo  was  selected  for  use  with  the  existing  CPP-­‐‑ELPBC  platform.  
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Peptide  therapeutics  proved  to  be  much  more  amenable  for  attachment  to  CPP-­‐‑
ELPBCs  without  significantly  perturbing  the  thermal  behavior  of  the  drug  carrier.  With  
peptide  drug  cargo  the  controlled  cellular  uptake  conferred  controlled  therapeutic  effect  
between  37  °C  and  42  °C.  Peptide  drug  cargo  also  provided  motivation  to  characterize  
the  parameters  of  successful  drug  carriers,  such  as  the  magnitude  of  intracellular  drug  
delivery  afforded  by  the  CPP-­‐‑ELPBCs  and  the  release  of  free  drug  within  the  cell  by  
cleavable  linkers.  Arg8-­‐‑ELPBC  provided  an  advantageous  balance  for  the  delivery  of  BH3  
peptide,  whereby  the  magnitude  of  intracellular  delivery  of  drug  at  42  °C  was  high  
enough  to  induce  significant  cytotoxicity  at  this  “on”  condition.  However,  the  
magnitude  of  intracellular  drug  delivery  at  37  °C  was  low  enough  to  spare  cells  and  
cause  minimal  cytotoxicity  at  this  “off”  condition.  This  was  the  idealized  behavior  in  
terms  of  controlled  therapeutic  effect.  However,  the  needs  of  ideal  “on”  and  “off”  state  
intracellular  delivery  is  likely  to  be  dependent  on  the  drug  cargo  and  its  potency,  
stability,  and  therapeutic  mechanism.  The  CPP-­‐‑ELPBC  platform  is  well  suited  to  meet  the  
needs  of  a  variety  of  peptide  drugs,  as  the  CPP-­‐‑functionalization  controls  the  “on”  and  
“off”  state  uptake  and  thus  far  has  been  shown  to  be  a  malleable  parameter  of  the  drug  
carrier  design  that  can  be  changed  without  perturbing  the  optimized  thermal  properties.  
The  CPPs  investigated  in  this  dissertation  provided  a  breadth  in  magnitude  of  “off”  and  
“on”  uptake,  but  the  family  of  CPP-­‐‑functionalized  ELPBCs  can  be  further  expanded  to  
explore  the  boundaries  of  amplified  uptake  at  42  °C  and  minimized  uptake  at  37  °C.  
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6.1.4 CPP-ELPBCs for targeted delivery in vivo 
With  successful  control  of  cellular  uptake,  control  of  drug  delivery,  and  control  
of  therapeutic  effect  in  vitro,  the  next  test  was  the  translation  of  CPP-­‐‑ELPBCs  in  vivo  as  
tumor-­‐‑targeted  carriers.  A  great  number  of  challenges  were  present  in  this  transition  
from  in  vitro  to  in  vivo  conditions.  The  preliminary  design  of  CPP-­‐‑ELPBCs,  based  on  
approximations  of  charge  density  of  TAT-­‐‑decorated  liposomes,  had  relatively  low  
charge  content  of  only  3  arginine  residues  per  ELPBC.  A  greater  number  of  arginine  
residues  were  found  to  be  necessary  to  achieve  meaningful  control  of  intracellular  
delivery  with  temperature-­‐‑triggered  micelle  assembly.  An  even  greater  number  of  
arginine  residues  were  found  to  be  necessary  to  achieve  meaningful  control  of  
therapeutic  effect  with  temperature-­‐‑triggered  micelle  assembly,  at  least  with  one  
example  of  peptide  drug  cargo.  The  family  of  optimized  CPP-­‐‑ELPBCs  therefore  had  
much  greater  charge  content  than  was  originally  envisioned  for  this  drug  carrier  
platform.  
This  high  cationic  charge  leads  to  a  multitude  of  complications  in  the  translation  
of  drug  carriers  from  the  cell  culture  environment  in  vitro  to  the  complex  environment  of  
blood  encountered  by  systemically  administered  carriers  in  vivo.  The  primary  concern  is  
non-­‐‑specific  interaction  of  the  cationic  CPP-­‐‑ELPBC  with  materials  in  the  body  that  are  
anywhere  but  the  desired  tumor  target.  These  non-­‐‑specific  interactions  can  have  
negative  effects  that  manifest  as  changes  in  clearance  of  the  CPP-­‐‑ELPBC  from  systemic  
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circulation,  changes  in  the  thermal  properties  of  the  CPP-­‐‑ELPBC,  and  changes  in  the  level  
of  cellular  uptake  of  CPP-­‐‑ELPBC  micelles.  Although  charge  did  appear  to  affect  the  
clearance  of  CPP-­‐‑ELPBCs,  whereby  greater  charge  lead  to  faster  clearance,  none  of  the  
CPP-­‐‑ELPBCs  investigated  in  vivo  demonstrated  pharmacokinetics  that  suggested  
clearance  was  happening  fast  enough  to  preclude  their  useful  concentration  over  the  
course  of  mild  clinical  hyperthermia  of  just  1  hour.  Changes  in  thermal  properties  were  
evident  for  all  ELPBCs  in  serum,  as  compared  to  PBS  or  SF-­‐‑media,  even  in  the  absence  of  
CPP  functionalization.  This  was  expected  as  most  ELPs  demonstrate  a  decreased  Tt  in  
serum.  For  ELPBCs  the  decrease  in  Tt  was  typically  more  apparent  for  the  micelle-­‐‑to-­‐‑
aggregate  transition  as  opposed  to  the  CMT.  For  highly  charged  Arg8-­‐‑ELPBC  the  
presence  of  serum  was  detrimental  to  temperature-­‐‑triggered  micelle  assembly,  and  this  
construct  would  transition  from  unimer-­‐‑to-­‐‑aggregate  in  serum.  The  effect  of  serum  on  
the  cellular  uptake  of  CPP-­‐‑ELPBCs  and  their  self-­‐‑assembled  micelles  was  less  clear  and  
measured  only  indirectly  by  visualization  of  the  interaction  of  drug  carrier  with  tumor  
tissue  using  intravital  microscopy  and  quantification  of  localization  within  the  body  by  
biodistribution  studies  of  the  tumor  and  select  organs.  CPP-­‐‑ELPBCs  did  not  achieve  
significantly  controlled  tumor  targeting  with  micelle  assembly  in  hyperthermia  treated  
tumors,  as  compared  to  tumors  that  were  not  heated,  suggesting  that  cellular  uptake  
was  not  robust  enough  in  this  in  vivo  setting  to  create  a  detectable  difference  in  the  
extrinsically  controlled  accumulation  of  drug  carrier.    
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6.2 Future directions 
Many  questions  remain  about  the  potential  of  CPP-­‐‑ELPBCs  to  function  
successfully  in  an  in  vivo  setting.  The  material  properties  of  new  ELPBCs  have  yet  to  be  
optimized  to  accommodate  a  variety  of  CPP-­‐‑functionalization  while  maintaining  
temperature-­‐‑triggered  micelle  assembly  in  blood.  Furthermore,  the  limitations  of  
cationic  CPPs,  which  were  not  overcome  in  this  dissertation,  could  be  circumvented  by  
investigation  of  alternative  CPP  moieties  with  decreased  cationic  content  but  equivalent  
potential  for  facilitating  the  internalization  of  self-­‐‑assembled  micelles.  
6.2.1 Investigation of alternative hydrophilic block copolymer 
domains 
The  effect  of  serum  on  the  thermal  behavior  of  ELPBCs  seems  to  be  exaggerated  
with  respect  to  the  micelle-­‐‑to-­‐‑aggregate  transition,  as  compared  to  the  unimer-­‐‑to-­‐‑micelle  
transition.  Furthermore,  the  CPPs  that  are  responsible  for  destruction  of  micelle  
assembly  in  serum  are  of  course  localized  to  the  terminus  of  the  hydrophilic  domain  of  
the  ELPBC.  It  is  thus  imaginable  that  it  is  ultimately  the  change  in  the  apparent  thermal  
behavior  of  this  hydrophilic  domain  that  causes  its  Tt  to  decrease  in  serum  to  a  point  at  
which  it  collapses  collectively  with  the  hydrophobic  domain,  in  effect  eliminating  the  
ability  of  the  ELPBC  to  self-­‐‑assemble  into  micelles.  Thus,  attention  was  put  on  
manipulation  of  the  hydrophilic  domain  of  the  ELPBC  in  an  attempt  to  alleviate  the  
negative  effects  of  serum  on  CPP-­‐‑ELPBC  self-­‐‑assembly.  A  new  hydrophilic  block,  
composed  with  the  guest  residue  serine,  was  therefore  created  in  an  attempt  to  increase  
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the  transition  temperature  of  the  hydrophilic  domain.  This  particular  change  in  the  
ELPBC  design  fixed  the  problem  for  Arg5-­‐‑functionalization,  but  not  Arg8-­‐‑
functionalization.  However,  this  approach  was  only  one  of  many  ways  in  which  the  
hydrophilic  domain  could  be  manipulated.  
Alternative  ELP  sequences  may  impart  qualities  on  the  ELPBC  that  could  produce  
temperature-­‐‑triggered  micelle  self-­‐‑assembly  in  serum,  even  when  presenting  high  
cationic  charge  density  on  the  micelle  corona.  A  modest  change  in  the  hydrophilic  ELP  
sequence  could  be  the  replacement  of  the  serine  guest  residue  with  a  glycine  guest  
reside.  Although  these  guest  residues  should  have  similar  hydrophilicity  based  on  
Urry’s  many  scales  [100,  101],  the  simple  chemistry  of  the  glycine  residue  may  reduce  
interactions  with  extraneous  materials  in  the  body  as  compared  to  serine  and  its  
hydroxyl  side  chain,  capable  of  interactions  such  as  hydrogen  bonding.  More  extreme  
changes  in  the  hydrophilic  block  could  be  the  use  of  anionic  guest  residues  to  help  offset  
undesirable  electrostatic  CPP  interactions  by  charge  repulsion.  Of  course  this  approach  
would  create  a  significant  risk  of  CPP  interaction  with  the  carrier  itself,  preoccupying  
the  CPP  from  its  intended  target  of  the  cancer  cell  surface.  A  zwitterionic  ELP  sequence  
may  provide  the  best  advantage,  avoiding  direct  interaction  with  the  CPP  while  serving  
to  decrease  extraneous  interactions  with  cells  and  proteins  prior  to  reaching  the  heated  
tumor  target.  
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6.2.2 Investigation of alternative hydrophobic block copolymer 
domains 
All  of  the  effort  thus  far  for  improving  the  ELPBC  design  for  triggered  micelle  
assembly  in  vivo  has  focused  on  manipulation  of  the  hydrophilic  domain  of  the  block  
copolymer.  However,  the  hydrophobic  domain  likely  also  plays  a  role  in  successful  
micelle  assembly  in  the  presence  of  serum,  as  the  genetic  fusion  of  hydrophobic  and  
hydrophilic  domains  in  the  ELPBC  causes  them  to  influence  each  other,  as  seen  in  their  
effects  on  the  CMT  and  micelle-­‐‑to-­‐‑aggregate  transition  as  compared  to  the  Tt  of  either  
block  alone.  Alternative  hydrophobic  blocks  may  therefore  improve  micelle  assembly  in  
serum.  For  instance,  others  have  incorporated  cysteine  residues  at  the  interface  of  the  
hydrophobic  and  hydrophilic  domains  to  encourage  stable  micelle  assembly  in  serum  by  
means  of  intra-­‐‑micelle  disulfide  bonding  upon  self-­‐‑assembly  [190].  
The  difficulty  in  exploring  alternative  hydrophobic  domains  is  that  the  CMT  is  
controlled  by  the  transition  of  this  block,  and  therefore  the  thermal  properties  of  the  
ELPBC  are  likely  to  be  perturbed  significantly  by  changes  in  this  design  parameter.  
However,  since  success  has  been  elusive  for  self-­‐‑assembly  of  highly  charged  CPP-­‐‑ELPBCs  
in  serum,  it  may  be  best  to  step  back  and  first  achieve  an  ELPBC  that  can  attain  the  goal  of  
self-­‐‑assembly  with  this  functionalization,  regardless  of  CMT.  From  there  the  possibility  
of  optimizing  the  thermal  properties  can  next  be  evaluated.  
An  advantage  may  emerge  from  pursuing  change  in  both  the  hydrophilic  and  
hydrophobic  domains,  in  that  new  ELP  materials  with  extremes  in  Tt  or  stability  may  
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combine  in  an  ELPBC  in  such  a  way  that  the  advantages  of  each  component  are  
maintained,  but  the  extreme  thermal  properties  are  neutralized  by  their  interaction  in  
the  genetic  fusion.  This  is  of  course  a  lofty  proposal,  but  nonetheless,  interesting  
parameters  in  ELPBC  design  and  behavior  would  surely  be  gleaned  from  exploring  the  
combination  of  new  hydrophobic  and  hydrophilic  ELP  domains  in  next  generation  
ELPBCs.  
6.2.3 Investigation of alternative CPP families 
Cationic  CPPs  were  the  primary  focus  of  this  dissertation,  based  on  our  
hypothesis  related  to  the  threshold  of  arginine  oligomers.  However,  alternative  CPPs  
may  also  provide  controlled  cellular  uptake  in  a  similar  manner  depending  on  their  
material  characteristics  and  their  mechanism  of  CPP  function.  Although  many  CPPs  are  
positively  charged,  not  all  rely  on  a  cationic  content  to  induce  cellular  uptake  by  
initiating  electrostatic  interactions  with  the  cell  surface.  Those  outlier  CPPs,  in  terms  of  
neutral  or  even  anionic  charge,  may  be  suitable  for  triggered  cellular  uptake  and  also  
circumvent  the  problems  in  vivo  that  largely  stem  from  the  cationic  nature  of  CPP-­‐‑
ELPBCs  investigated  in  this  dissertation.  Of  particular  interest  is  the  sweet  arrow  protein  
(SAP),  a  neutral  CPP  shown  to  achieve  efficient  uptake  of  functionalized  
oligonucleotides  [191],  lipid  nanoparticles  [192],  and  gold  nanoparticles  [193],  as  it  has  
been  genetically  mutated  to  incorporate  anionic  residues,  without  detrimental  effect  on  
its  CPP  functionality  [194].  As  such,  it  is  believed  to  be  the  first  anionic  CPP  of  its  kind.  
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These  CPPs  may  be  an  interesting  place  to  start  for  investigating  alternative  CPPs  that  
may  function  well  in  vitro  and  carry  their  function  over  into  an  in  vivo  environment.    
If  alternative  CPPs  are  pursued  as  a  solution  to  the  undesirable  thermal  behavior,  
seen  for  example  with  Arg8-­‐‑ELPBC,  to  would  be  wise  to  screen  for  both  in  vitro  and  in  
vivo  function  to  eliminate  immediately  those  CPPs  that  may  not  be  amenable  to  self-­‐‑
assembly  on  ELPBC  micelles  in  serum  but  also  to  not  overlook  those  CPPs  that  may  not  
have  stellar  function  in  vitro,  yet  can  perform  appropriately  in  an  animal  host.  Certainly  
this  would  be  a  cumbersome  task  to  screen  a  large  number  of  CPP  candidates,  but  
experience  with  arginine  oligomer  CPPs  has  shown  that  in  vitro  and  in  vivo  
environments  are  greatly  disparate  conditions  in  which  to  achieve  intracellular  delivery  
of  drug  carriers.  It  is  therefore  not  unreasonable  to  think  that  what  does  not  function  in  
one  condition  may  well  function  in  another.  
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Figure  87:  Extrinsically  controlled  intracellular  drug  delivery  
Intrinsic  targets  in  tumors  may  be  
Receptors  or  enzymes  or  acidity 
But  intrinsic  targets  in  tumors  are  tough 
Some  cancers  and  patients  just  don’t  have  enough 
To  deliver  drug  to  sites  of  disease 
Without  side  effects  just  wherever  you  please 
Instead  we  can  use  an  extrinsic  cue 
To  gain  some  control  from  an  external  view 
For  this  approach  we  can  use  ELPs 
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Reacting  to  heat  with  the  slightest  of  ease 
With  careful  design  these  can  assemble  
And  spherical  micelles  they  will  resemble 
This  just  occurs  in  conditions  of  heat 
Without  which  as  unimers  they  stay  discrete 
Add  an  internalization  domain 
Non-­‐‑specific  cell  uptake  this  will  obtain 
How  can  we  control  this  uptake  you  cry 
Change  the  density  from  low  levels  to  high 
High  density  (micelles)  -­‐‑  means  uptake  galore 
Low  density  (unimers)  -­‐‑  uptake  is  poor 
And  there  you  have  with  a  flip  of  a  switch 
A  toggle  from  low  to  the  density  rich 
Labeled  with  fluorophore  ELPs  glow 
To  see  in  the  microscope  or  count  with  flow 
Just  in  the  presence  of  heat  are  they  seen 
Inside  HeLa  cell  where  they  show  up  in  green 
Thus  it  is  in  vitro  we  can  portray 
That  cell  uptake  can  be  controlled  in  this  way 
What  we  can  propose  to  one  day  obtain 
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Is  delivery  control  on  in  vivo  terrain 
Here  we  inject  in  a  unimer  state 
Where  uptake  remains  at  a  diminished  rate 
If  tumor  alone  is  treated  with  heat 
The  micelle  assembly  will  here  be  replete 
Uptake  is  much  greater  here  where  it’s  hot 
Whereas  normal  cells  uptake  diddly-­‐‑squat 
Assembly  targets  the  tumor  you  see 
With  the  unheated  healthy  tissues  left  be 
Thus  tumor  target  we  successfully  meet 
With  an  external  trigger  that  is  simply  heat 
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1 2 3 4 5
1) Protein ladder
2) Lysate after sonication
3) Supernatant after centrifugation with PEI
4) Pellet after centrifugation with PEI
5) Supernatant after 1st hot spin
6) Supernatant after 1st cold spin
7) Supernatant after 2nd hot spin
8) Supernatant after 2nd cold spin
9) Supernatant after 3rd hot spin
10) Supernatant after 3rd cold spin






















Elastin-like polypeptides:  
Biopolymer applications in drug delivery 
  
Figure  88:  An  Ode  to  Biopolymers  
Polymers  are  swell  for  delivering  drugs 
Small  molecule,  biologics  they  are  happy  to  lug 
Throughout  your  body  with  the  greatest  of  ease 
Delivering  drug  to  the  site  of  disease 
Now  polymers  made  from  a  synthetic  route 
Won’t  have  the  same  qualities  day-­‐‑in  and  day-­‐‑out 
The  reactive  site  where  the  drug  can  attach 
May  vary  in  number  and  place  with  each  batch 
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RAFT,  ROMP,  ATRP 
Each  is  controlled,  but  to  what  degree? 
So  sometimes  you’ll  get  what  you  need  with  some  luck 
And  others  might  say  that  they  don’t  give  a 
Care  in  the  world  if  they  don’t  know  exactly 
Where  the  drug  is  attached  or  the  protein  is  actually 
But  I  will  still  say  it’s  important  to  know 
That  the  drug  is  right  here  and  the  protein  just  so 
And  the  way  to  achieve  this  perfect  precision 
Just  make  them  under  a  gene’s  supervision 
Biopolymers  born  from  a  plasmid  gene  template 
Are  exactly  the  same  in  their  sequence  and  weight 
Monodisperse,  each  one  the  same 
You  can  be  sure  they  will  meet  their  aim 
Predictable  in  their  biodistribution 
So  for  the  disease  they  will  be  your  solution 
They’re  each  time  the  same,  no  if,  ands  or  butt 
Made  your  first  year  or  seventh  –  seventh,  wait  what? 
Anyways,  they'ʹre  biocompatible  to  boot 
The  value  of  biopolymers  you  just  can’t  refute 
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